assay_id,tissue_id,doc_id,assay_tax_id,bao_format,assay_category,src_assay_id,cell_id,curated_by,src_id,assay_organism,assay_test_type,confidence_score,assay_subcellular_fraction,relationship_type,assay_strain,description,assay_type,assay_tissue
1,,11087,,BAO_0000019,,,,Autocuration,1,,,8,,H,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,B,
2,,684,,BAO_0000219,,,,Autocuration,1,,,0,,U,,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,F,
3,,15453,,BAO_0000019,,,,Autocuration,1,,,0,,U,,,B,
4,,17841,9913.0,BAO_0000249,,,,Autocuration,1,Bos taurus,,4,,H,,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,B,
5,,17430,9606.0,BAO_0000219,,,163.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),F,
6,,17430,9606.0,BAO_0000219,,,163.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),F,
7,,13799,10090.0,BAO_0000219,,,163.0,Intermediate,1,Mus musculus,,1,,N,,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,F,
8,,17774,9606.0,BAO_0000219,,,163.0,Expert,1,Homo sapiens,,1,,N,,In vitro cell cytotoxicity was determined against 143B cell line,F,
9,,3801,9606.0,BAO_0000219,,,163.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,F,
10,,17430,9606.0,BAO_0000219,,,163.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,F,
11,,17430,9606.0,BAO_0000219,,,163.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,F,
12,,17774,9606.0,BAO_0000219,,,163.0,Expert,1,Homo sapiens,,1,,N,,In vitro cell cytotoxicity was determined against 143B-LTK cell line,F,
13,,11324,1280.0,BAO_0000218,,,,Intermediate,1,Staphylococcus aureus,,1,,N,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,
14,,11324,1280.0,BAO_0000218,,,,Intermediate,1,Staphylococcus aureus,,1,,N,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,
15,,11324,1280.0,BAO_0000218,,,,Intermediate,1,Staphylococcus aureus,,1,,N,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,
16,,11324,1280.0,BAO_0000218,,,,Intermediate,1,Staphylococcus aureus,,1,,N,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,
17,,11347,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,A,
18,,16474,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),B,
19,,10091,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Inhibition of partially purified 15-lipoxygenase from human leukocytes,B,
20,,16474,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),B,
21,,16474,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),B,
22,,16474,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),B,
23,,16474,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,B,
24,,16474,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,B,
25,,14352,,BAO_0000219,,,,Autocuration,1,,,0,,U,,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",B,
26,,5646,9986.0,BAO_0000357,,,,Autocuration,1,Oryctolagus cuniculus,,8,,H,,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,B,
27,,5646,9986.0,BAO_0000357,,,,Autocuration,1,Oryctolagus cuniculus,,8,,H,,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),B,
28,,10997,,BAO_0000219,,,,Autocuration,1,,,8,,H,,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,B,
29,,6309,3847.0,BAO_0000357,,,,Autocuration,1,soya bean,,8,,H,,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,B,
30,,167,3847.0,BAO_0000357,,,,Autocuration,1,Glycine max,,8,,H,,Inhibitory activity against soybean 15-lipoxygenase was evaluated,B,
31,,167,3847.0,BAO_0000357,,,,Autocuration,1,Glycine max,,8,,H,,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,B,
32,,11087,3847.0,BAO_0000357,,,,Autocuration,1,Glycine max,,8,,H,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,B,
33,,11087,3847.0,BAO_0000357,,,,Autocuration,1,Glycine max,,8,,H,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,B,
34,,13622,3847.0,BAO_0000357,,,,Autocuration,1,Glycine max,,8,,H,,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,B,
35,,13622,3847.0,BAO_0000357,,,,Autocuration,1,Glycine max,,8,,H,,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,B,
36,,11347,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,0,,U,,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,A,
37,,5926,562.0,BAO_0000019,,,,Autocuration,1,Escherichia coli,,0,,U,,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,B,
38,,4567,,BAO_0000019,,,,Autocuration,1,,,0,,U,,Dissociation constant with dimeric 16S rRNA RNA construct B,B,
39,,3782,,BAO_0000225,,,,Intermediate,1,,,3,,M,,Dissociation constant towards 16S rRNA construct A,B,
40,,3782,,BAO_0000225,,,,Intermediate,1,,,3,,M,,Dissociation constant towards 16S rRNA construct B,B,
41,,4466,562.0,BAO_0000225,,,,Expert,1,Escherichia coli,,3,,M,,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,B,
42,,6592,562.0,BAO_0000225,,,,Expert,1,Escherichia coli,,3,,M,,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,B,
43,,898,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,
44,,898,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,
45,,13163,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,8,,H,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,B,
46,,13163,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,8,,H,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,B,
47,,10691,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",B,
48,,10691,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",B,
49,,10691,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",B,
50,,10691,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",B,
51,,898,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,
52,,912,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),B,
53,,912,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,B,
54,,912,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,B,
55,,15103,10116.0,BAO_0000249,,,,Autocuration,1,Rattus norvegicus,,5,Membranes,D,,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,B,
56,,5116,9606.0,BAO_0000219,,,506.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,F,
57,,14578,10116.0,BAO_0000219,,,,Autocuration,1,Rattus norvegicus,,7,,D,,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,F,
58,,14578,10116.0,BAO_0000219,,,,Autocuration,1,Rattus norvegicus,,7,,D,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,F,
59,,14578,10116.0,BAO_0000219,,,,Autocuration,1,Rattus norvegicus,,7,,D,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,F,
60,,4787,9606.0,BAO_0000219,,,506.0,Expert,1,Homo sapiens,,1,,N,,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,F,
61,,4787,9606.0,BAO_0000219,,,506.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,F,
62,,3547,9606.0,BAO_0000219,,,506.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxic activity against human ovarian cancer (1A9) cell line,F,
63,,3547,9606.0,BAO_0000219,,,506.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,F,
64,,6726,9606.0,BAO_0000219,,,506.0,Intermediate,1,Homo sapiens,,1,,N,,Effective dose of compound against replication of 1A9 cell line was evaluated,F,
65,,3455,9606.0,BAO_0000219,,,506.0,Expert,1,Homo sapiens,,1,,N,,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,F,
66,,5726,9606.0,BAO_0000219,,,506.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),F,
67,,5726,9606.0,BAO_0000219,,,506.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,F,
68,,5726,9606.0,BAO_0000219,,,506.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,F,
69,,3395,9606.0,BAO_0000219,,,506.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory activity against Taxol resistant 1A9 cell lines,F,
70,,3415,9606.0,BAO_0000219,,,506.0,Expert,1,Homo sapiens,,1,,N,,Cytotoxicity against human ovarian cancer (1A9) cell lines.,F,
71,,3415,9606.0,BAO_0000219,,,506.0,Expert,1,Homo sapiens,,1,,N,,Percentage inhibition of human ovarian cancer (1A9) cell lines.,F,
72,,17099,9606.0,BAO_0000219,,,506.0,Expert,1,Homo sapiens,,1,,N,,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,F,
73,,17099,9606.0,BAO_0000219,,,506.0,Intermediate,1,Homo sapiens,,1,,N,,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,F,
74,,17099,9606.0,BAO_0000219,,,506.0,Intermediate,1,Homo sapiens,,1,,N,,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,F,
75,,17099,9606.0,BAO_0000219,,,506.0,Intermediate,1,Homo sapiens,,1,,N,,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,F,
76,,17721,9606.0,BAO_0000219,,,503.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory concentration against Jurkat cells,F,
77,,1229,,BAO_0000019,,,,Intermediate,1,,,0,,U,,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,F,
78,,11347,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,A,
79,,17117,,BAO_0000357,,,,Expert,1,,,8,,H,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",B,
80,,17117,,BAO_0000357,,,,Expert,1,,,8,,H,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",B,
81,,17117,,BAO_0000357,,,,Expert,1,,,8,,H,,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",B,
82,,11375,5476.0,BAO_0000251,,,,Autocuration,1,Candida albicans,,8,Microsomes,H,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",B,
83,,11375,5476.0,BAO_0000251,,,,Autocuration,1,Candida albicans,,8,Microsomes,H,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",B,
84,,11375,4932.0,BAO_0000251,,,,Autocuration,1,Saccharomyces cerevisiae,,8,Microsomes,H,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",B,
85,,11375,4932.0,BAO_0000251,,,,Autocuration,1,Saccharomyces cerevisiae,,8,Microsomes,H,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",B,
86,2107.0,11375,9823.0,BAO_0000251,,,,Autocuration,1,Sus scrofa,,8,Microsomes,H,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",B,Liver
87,,791,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,8,,H,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",B,
88,,791,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,8,,H,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",B,
89,,791,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,8,,H,,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",B,
90,2107.0,11375,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,9,Microsomes,D,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",B,Liver
91,2107.0,11375,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,9,Microsomes,D,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",B,Liver
92,2107.0,153,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,9,Microsomes,D,,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",B,Liver
93,,8269,,BAO_0000357,,,,Expert,1,,,8,,H,,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),B,
94,,8269,,BAO_0000357,,,,Expert,1,,,8,,H,,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,B,
95,,17653,9606.0,BAO_0000219,,,726.0,Expert,1,Homo sapiens,,1,,N,,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,F,
96,,14277,9606.0,BAO_0000219,,,726.0,Intermediate,1,Homo sapiens,,1,,N,,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,F,
97,,1717,9606.0,BAO_0000219,,,726.0,Intermediate,1,Homo sapiens,,1,,N,,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,F,
98,,14091,9606.0,BAO_0000219,,,726.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,F,
99,,14091,9606.0,BAO_0000219,,,726.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,F,
100,,17653,10407.0,BAO_0000218,,,,Expert,1,Hepatitis B virus,,1,,N,,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,F,
101,,13105,9606.0,BAO_0000219,,,726.0,Intermediate,1,Homo sapiens,,1,,N,,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,F,
102,,1717,9606.0,BAO_0000219,,,726.0,Intermediate,1,Homo sapiens,,1,,N,,Concentration required to inhibit 50% of 2.2.15 cell line,F,
103,,13105,9606.0,BAO_0000219,,,726.0,Intermediate,1,Homo sapiens,,1,,N,,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,A,
104,,13600,9606.0,BAO_0000218,,,,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxic activity of compound against uninfected 2.2.15 cells.,F,
105,,13467,9606.0,BAO_0000218,,,,Intermediate,1,Homo sapiens,,1,,N,,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,F,
106,,17477,10407.0,BAO_0000218,,,,Expert,1,Hepatitis B virus,,1,,N,,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",F,
107,,1593,9606.0,BAO_0000218,,,,Intermediate,1,Homo sapiens,,1,,N,,In vitro anti-HBV activity in 2.2.15 cells,F,
108,,1593,9606.0,BAO_0000218,,,,Intermediate,1,Homo sapiens,,1,,N,,In vitro anti-HBV activity in 2.2.15 cells; Not determined,F,
109,,15089,9606.0,BAO_0000218,,,,Intermediate,1,Homo sapiens,,1,,N,,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,F,
110,,15089,9606.0,BAO_0000218,,,,Intermediate,1,Homo sapiens,,1,,N,,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,F,
111,,1593,9606.0,BAO_0000218,,,,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity in 2.2.15 cells,F,
112,,1593,9606.0,BAO_0000218,,,,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity in 2.2.15 cells; Not determined,F,
113,,13600,9606.0,BAO_0000218,,,,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,F,
114,,13467,9606.0,BAO_0000218,,,,Intermediate,1,Homo sapiens,,1,,N,,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,F,
115,,13467,9606.0,BAO_0000218,,,,Intermediate,1,Homo sapiens,,1,,N,,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,F,
116,,14764,9606.0,BAO_0000219,,,726.0,Intermediate,1,Homo sapiens,,1,,N,,Antiviral activity against HBV was determined in 2.215 cell line,F,
117,,6531,9606.0,BAO_0000251,,,,Autocuration,1,Homo sapiens,,0,Microsomes,U,,Inhibition of 20-HETE synthesis in human renal microsomes,B,
118,,17322,,BAO_0000019,,,,Autocuration,1,,,0,,U,,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,B,
119,,17072,9606.0,BAO_0000219,,,388.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory concentration against 2008 (ovarian) cells,F,
120,,16936,9606.0,BAO_0000219,,,388.0,Intermediate,1,Homo sapiens,,1,,N,,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,F,
121,,16936,9606.0,BAO_0000219,,,388.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),F,
122,,17146,9606.0,BAO_0000219,,,388.0,Intermediate,1,Homo sapiens,,1,,N,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,F,
123,,17146,9606.0,BAO_0000219,,,388.0,Intermediate,1,Homo sapiens,,1,,N,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,F,
124,,10797,9606.0,BAO_0000219,,,561.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro inhibition of 2008/R ovarian cancer cell line,F,
125,,10797,9606.0,BAO_0000219,,,561.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,F,
126,,10797,9606.0,BAO_0000219,,,389.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro inhibition of 2008/S ovarian cancer cell line,F,
127,,10797,9606.0,BAO_0000219,,,389.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,F,
128,,4823,9606.0,BAO_0000220,,,,Expert,1,Homo sapiens,,2,,S,,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,B,
129,,12912,9606.0,BAO_0000220,,,,Intermediate,1,Homo sapiens,,2,,S,,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,B,
130,,2957,,BAO_0000220,,,,Expert,1,,,2,,S,,Inhibition of chymotrypsin-like activity of 20S proteasome,B,
131,,2957,,BAO_0000220,,,,Expert,1,,,2,,S,,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,B,
132,,3260,,BAO_0000220,,,,Intermediate,1,,,2,,S,,Inhibitory activity against 20S proteosome,B,
133,,3451,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Compound was tested for inhibitory activity against tryptase,B,
134,,13885,9606.0,BAO_0000219,,,726.0,Intermediate,1,Homo sapiens,,1,,N,,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,F,
135,,13885,9606.0,BAO_0000219,,,726.0,Intermediate,1,Homo sapiens,,1,,N,,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,F,
136,,3676,,BAO_0000019,,,,Autocuration,1,,,0,,U,,Compound was tested for the inhibition of Alpha-glucosidase,B,
137,,6043,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory concentration against human neutrophil elastase (HNE),B,
138,948.0,11140,10116.0,BAO_0000218,,,,Autocuration,1,Rattus norvegicus,,0,,U,,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,F,Heart
139,,10543,,BAO_0000019,,,,Autocuration,1,,,8,,H,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,F,
140,,10543,,BAO_0000019,,,,Expert,1,,,8,,H,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,F,
141,,10543,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,B,
142,,10543,,BAO_0000019,,,,Expert,1,,,8,,H,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,F,
143,,11365,10090.0,BAO_0000219,,,524.0,Intermediate,1,Mus musculus,,1,,N,,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,F,
144,,11365,10090.0,BAO_0000219,,,524.0,Intermediate,1,Mus musculus,,1,,N,,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,F,
145,,11803,9606.0,BAO_0000219,,,554.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,F,
146,,11803,9940.0,BAO_0000019,,,,Autocuration,1,Ovis aries,,0,,U,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,F,
147,,11803,9940.0,BAO_0000019,,,,Autocuration,1,Ovis aries,,0,,U,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,F,
148,,12278,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),B,
149,,8249,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,F,
150,,8249,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,F,
151,,8249,9606.0,BAO_0000219,,,635.0,Autocuration,1,Homo sapiens,,0,,U,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,F,
152,,8249,9606.0,BAO_0000219,,,635.0,Autocuration,1,Homo sapiens,,0,,U,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,F,
153,,8249,9606.0,BAO_0000219,,,635.0,Autocuration,1,Homo sapiens,,0,,U,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,F,
154,,8249,9606.0,BAO_0000219,,,635.0,Autocuration,1,Homo sapiens,,0,,U,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,F,
155,,8249,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,F,
156,,8249,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,F,
157,,16992,,BAO_0000249,,,,Autocuration,1,,,6,,H,,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,B,
158,,10543,1314.0,BAO_0000218,,,,Intermediate,1,Streptococcus pyogenes,,1,,N,,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,F,
159,,17833,10335.0,BAO_0000218,,,,Intermediate,1,Human herpesvirus 3,,1,,N,,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),F,
160,,17290,10335.0,BAO_0000218,,,468.0,Expert,1,vericilla zoster virus,,1,,N,,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,F,
161,,17290,10335.0,BAO_0000218,,,,Intermediate,1,vericilla zoster virus,,1,,N,,Antiviral activity against 07/1 strain of VZV; ND: No data,F,
162,,17290,10335.0,BAO_0000218,,,,Intermediate,1,vericilla zoster virus,,1,,N,,Antiviral activity against 07/1 strain of VZV; ND=No data,F,
163,,10932,561.0,BAO_0000218,,,,Intermediate,1,escherichia cloac,,1,,N,,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",F,
164,,9707,,BAO_0000019,,,,Autocuration,1,,,0,,U,,Ratio of Ki at A2 to Ki at A1 receptors,B,
165,,2346,5476.0,BAO_0000249,,,,Expert,1,Candida albicans,,8,,H,,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",B,
166,,2205,284593.0,BAO_0000357,,,,Expert,1,Candida glabrata CBS 138,,8,,H,,"Inhibition of 1,3-beta-glucan synthase",B,
167,,11900,9606.0,BAO_0000219,,,832.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibition of growth of 1-87 human tumor cell line,F,
168,,14864,10116.0,BAO_0000219,,,,Expert,1,Rattus norvegicus,,9,,D,,Inhibition of 1-lipoxygenase (LOX)in RBL cells,B,
169,,16474,3847.0,BAO_0000357,,,,Autocuration,1,Glycine max,,9,,D,,Inhibitory activity against soybean 1-lipoxygenase (SLO),B,
170,,16474,3847.0,BAO_0000357,,,,Autocuration,1,Glycine max,,9,,D,,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,B,
171,,16474,3847.0,BAO_0000357,,,,Autocuration,1,Glycine max,,9,,D,,% inhibition against soybean 1-lipoxygenase (SLO),B,
172,,16474,3847.0,BAO_0000357,,,,Autocuration,1,Glycine max,,9,,D,,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,B,
173,,3094,3847.0,BAO_0000357,,,,Autocuration,1,Glycine max,,9,,D,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,B,
174,,3094,3847.0,BAO_0000357,,,,Autocuration,1,Glycine max,,9,,D,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,B,
175,,3094,3847.0,BAO_0000357,,,,Autocuration,1,Glycine max,,9,,D,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,B,
176,,3094,3847.0,BAO_0000357,,,,Autocuration,1,Glycine max,,9,,D,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,B,
177,,3094,3847.0,BAO_0000357,,,,Autocuration,1,Glycine max,,9,,D,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,B,
178,,3094,3847.0,BAO_0000357,,,,Autocuration,1,Glycine max,,9,,D,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,B,
179,,3094,3847.0,BAO_0000357,,,,Autocuration,1,Glycine max,,9,,D,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,B,
180,,3094,3847.0,BAO_0000357,,,,Autocuration,1,Glycine max,,9,,D,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,B,
181,,3094,3847.0,BAO_0000357,,,,Autocuration,1,Glycine max,,9,,D,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,B,
182,,3094,3847.0,BAO_0000357,,,,Autocuration,1,Glycine max,,9,,D,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,B,
183,,3094,3847.0,BAO_0000357,,,,Autocuration,1,Glycine max,,9,,D,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,B,
184,,10413,10090.0,BAO_0000019,,,,Autocuration,1,Mus musculus,,0,,U,,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,B,
185,,16929,10090.0,BAO_0000219,,,294.0,Intermediate,1,Mus musculus,,1,,N,,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),F,
186,,1229,,BAO_0000019,,,,Intermediate,1,,,0,,U,,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,F,
187,,16587,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),B,
188,,16587,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),B,
189,,16587,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,B,
190,,16587,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,B,
191,,16587,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,B,
192,,8058,9913.0,BAO_0000019,,,,Expert,1,Bos taurus,,9,,D,,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,F,
193,,9065,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,B,
194,2369.0,8865,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Inhibition of 11 beta-hydroxylase from rat adrenal gland,B,Adrenal gland
195,,9066,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Inhibition of rat adrenal 11-beta-hydroxylase,B,
196,,8394,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Inhibition of rat adrenal 11-beta-hydroxylase,B,
197,,8394,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,B,
198,,6431,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,B,
199,,6431,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,B,
200,,6431,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,B,
201,,9295,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for the percent of inhibition against 12-LO at 10 uM,F,
202,,10193,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,
203,,13622,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested in vitro for inhibition of 12-LO human platelet,B,
204,,12079,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Inhibitory concentration against human platelet 12-lipoxygenase,F,
205,,13622,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,B,
206,,12079,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,9,,D,,Inhibitory concentration against human platelet 12-lipoxygenase,F,
207,,13500,,BAO_0000019,,,,Expert,1,,,8,,H,,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,B,
208,,13723,,BAO_0000357,,,,Expert,1,,,8,,H,,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,B,
209,,16474,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),B,
210,,1630,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Inhibitory activity against human platelet 12-lipoxygenase,B,
211,,167,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,B,
212,,16474,,BAO_0000019,,,,Autocuration,1,,,8,,H,,% inhibition against human platelet 12-lipoxygenase (12-HLO),B,
213,,167,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,B,
214,,16474,,BAO_0000019,,,,Autocuration,1,,,8,,H,,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,B,
215,,10091,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory activity towards porcine 12-lipoxygenase,B,
216,,11966,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested for inhibition against porcine 12-LO,B,
217,,951,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,B,
218,,10997,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,B,
219,,10193,,BAO_0000019,,,,Expert,1,,,8,,H,,In vitro inhibition of rat platelet 12-lipoxygenase,B,
220,,10193,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,
221,,10193,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,B,
222,,10193,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,B,
223,,10193,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,
224,,10193,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro inhibitory activity against rat platelet 12-lipoxygenase,B,
225,,11087,,BAO_0000019,,,,Autocuration,1,,,8,,H,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,B,
226,,15569,9606.0,BAO_0000219,,,621.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,F,
227,,12989,9606.0,BAO_0000219,,,621.0,Expert,1,Homo sapiens,,1,,N,,In vitro antitumor activity against 41M cell line.,F,
228,,16745,9606.0,BAO_0000219,,,621.0,Intermediate,1,Homo sapiens,,1,,N,,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,F,
229,,15569,9606.0,BAO_0000219,,,621.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,F,
230,,12989,9606.0,BAO_0000219,,,621.0,Expert,1,Homo sapiens,,1,,N,,In vitro antitumor activity against 41McisR cell line.,F,
231,,12989,9606.0,BAO_0000219,,,621.0,Expert,1,Homo sapiens,,1,,N,,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,F,
232,,16745,9606.0,BAO_0000219,,,621.0,Intermediate,1,Homo sapiens,,1,,N,,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,F,
233,,6210,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),B,
234,,6210,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),B,
235,,6226,,BAO_0000357,,,,Expert,1,,,8,,H,,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),B,
236,,17855,,BAO_0000357,,,,Expert,1,,,8,,H,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,B,
237,,17855,,BAO_0000357,,,,Expert,1,,,8,,H,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,B,
238,,17855,,BAO_0000357,,,,Expert,1,,,8,,H,,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,B,
239,,10413,,BAO_0000357,,,,Autocuration,1,,,8,,H,,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",B,
240,,10413,562.0,BAO_0000357,,,,Autocuration,1,Escherichia coli,,8,,H,,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",B,
241,,10413,562.0,BAO_0000357,,,,Autocuration,1,Escherichia coli,,8,,H,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",B,
242,,10413,562.0,BAO_0000357,,,,Autocuration,1,Escherichia coli,,8,,H,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",B,
243,,10413,,BAO_0000357,,,,Autocuration,1,,,8,,H,,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",B,
244,,10413,,BAO_0000357,,,,Autocuration,1,,,8,,H,,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",B,
245,,7587,9823.0,BAO_0000357,,,,Autocuration,1,Sus scrofa,,8,,H,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,
246,,7587,9823.0,BAO_0000019,,,,Autocuration,1,Sus scrofa,,8,,H,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",B,
247,,7587,9823.0,BAO_0000357,,,,Autocuration,1,Sus scrofa,,8,,H,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",B,
248,,7587,9823.0,BAO_0000357,,,,Autocuration,1,Sus scrofa,,8,,H,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",B,
249,,7587,9823.0,BAO_0000357,,,,Autocuration,1,Sus scrofa,,8,,H,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,
250,,7587,9823.0,BAO_0000019,,,,Autocuration,1,Sus scrofa,,8,,H,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",B,
251,,7587,9823.0,BAO_0000019,,,,Autocuration,1,Sus scrofa,,8,,H,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",B,
252,,7587,9823.0,BAO_0000019,,,,Autocuration,1,Sus scrofa,,8,,H,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",B,
253,,7587,9823.0,BAO_0000019,,,,Autocuration,1,Sus scrofa,,8,,H,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",B,
254,,7587,9823.0,BAO_0000019,,,,Autocuration,1,Sus scrofa,,8,,H,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",B,
255,,7587,9823.0,BAO_0000357,,,,Autocuration,1,Sus scrofa,,8,,H,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,
256,,7587,9823.0,BAO_0000019,,,,Autocuration,1,Sus scrofa,,8,,H,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",B,
257,,7323,,BAO_0000357,,,,Autocuration,1,,,8,,H,,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",B,
258,,7587,9823.0,BAO_0000019,,,,Autocuration,1,Sus scrofa,,0,,U,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",B,
259,,7587,9823.0,BAO_0000019,,,,Autocuration,1,Sus scrofa,,0,,U,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",B,
260,,13750,4932.0,BAO_0000357,,,,Expert,1,Saccharomyces cerevisiae,,8,,H,,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,B,
261,,7662,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,0,,U,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,B,
262,,7662,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,0,,U,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,B,
263,,7662,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,0,,U,,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",B,
264,,12211,,BAO_0000019,,,,Autocuration,1,,,6,,H,,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",F,
265,,12211,,BAO_0000019,,,,Autocuration,1,,,6,,H,,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",F,
266,2116.0,12211,10141.0,BAO_0000221,,,,Intermediate,1,Cavia porcellus,,9,,D,,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,F,Ileum
267,,12211,,BAO_0000019,,,,Expert,1,,,8,,H,,Stimulatory activity of intragastric pressure was tested in the rat,F,
268,,15453,,BAO_0000357,,,,Autocuration,1,,,8,,H,,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,B,
269,,11884,10116.0,BAO_0000218,,,,Autocuration,1,Rattus norvegicus,,0,,U,,Dose to reduce neuronal firing against 5-HT cells in rats (iv),F,
270,,7185,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,F,
271,,6876,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,B,
272,,6876,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,B,
273,,11863,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,F,
274,,11863,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibition constant of high-affinity 5-HT uptake,B,
275,,11863,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Michaelis-Menten constant was reported for high affinity transport of 5-HT,F,
276,,11863,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Maximum rate was determined for high affinity transport of 5-HT,F,
277,,4639,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Compound was tested for agonistic activity against 5-HT uptake,F,
278,,15796,,BAO_0000019,,,,Expert,1,,,8,,H,,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,B,
279,,15796,9913.0,BAO_0000357,,,,Expert,1,Bos taurus,,8,,H,,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,B,
280,,12801,10116.0,BAO_0000224,,,,Autocuration,1,Rattus norvegicus,,5,,D,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,B,
281,,12801,,BAO_0000224,,,,Autocuration,1,,,4,,H,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,B,
282,,12120,,BAO_0000249,,,,Autocuration,1,,,4,Membranes,H,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,B,
283,,12120,,BAO_0000249,,,,Autocuration,1,,,4,Membranes,H,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,B,
284,,11963,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,
285,,11701,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,F,
286,10000000.0,9995,,BAO_0000221,,,,Autocuration,1,,,8,,H,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,Hippocampus
287,10000000.0,9995,,BAO_0000221,,,,Autocuration,1,,,8,,H,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,Hippocampus
288,10000000.0,9995,,BAO_0000221,,,,Autocuration,1,,,8,,H,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,Hippocampus
289,,16394,,BAO_0000218,,,,Autocuration,1,,In vivo,8,,H,,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),F,
290,,11574,10141.0,BAO_0000019,,,,Intermediate,1,Cavia porcellus,,9,,D,,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,F,
291,,15779,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,
292,,15363,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,B,
293,,15363,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Efficacy against 5-hydroxytryptamine 2A receptor,F,
294,,15329,,BAO_0000019,,,,Expert,1,,,8,,H,,Intrinsic activity towards 5-HT2A receptor of rat tail artery,F,
295,,15329,,BAO_0000019,,,,Expert,1,,,8,,H,,Relative potency towards 5-HT2A receptor of rat tail artery,F,
296,,15329,,BAO_0000019,,,,Expert,1,,,8,,H,,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,F,
297,,15329,,BAO_0000019,,,,Expert,1,,,8,,H,,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,F,
298,,15329,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,F,
299,,15329,,BAO_0000019,,,,Expert,1,,,8,,H,,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,F,
300,2116.0,273,10141.0,BAO_0000221,,,,Intermediate,1,Cavia porcellus,,9,,D,,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,F,Ileum
301,2116.0,273,10141.0,BAO_0000221,,,,Intermediate,1,Cavia porcellus,,9,,D,,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),F,Ileum
302,2116.0,273,10141.0,BAO_0000221,,,,Intermediate,1,Cavia porcellus,,9,,D,,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,F,Ileum
303,,12092,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,B,
304,,1317,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,F,
305,,12409,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 4 receptor,B,
306,,11126,9031.0,BAO_0000019,,,,Autocuration,1,Gallus gallus,,0,,U,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,B,
307,,11126,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,F,
308,,11126,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,F,
309,,11126,9606.0,BAO_0000219,,,649.0,Autocuration,1,Homo sapiens,,1,,N,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,B,
310,,11126,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,B,
311,,11126,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,B,
312,,17807,9606.0,BAO_0000219,,,,Autocuration,1,Homo sapiens,,7,,D,,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,B,
313,,16575,,BAO_0000220,,,,Intermediate,1,,,2,,S,,Chymotryptic inhibitory activity against 26S proteasome,F,
314,,15407,,BAO_0000220,,,,Intermediate,1,,,2,,S,,Inhibitory activity against 26S proteasome degradation of IkB,B,
315,,10797,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro inhibition of 2780/DOX ovarian cancer cell line,F,
316,,10797,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro inhibition of 2780/S ovarian cancer cell line,F,
317,,3469,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,F,
318,,16037,,BAO_0000225,,,,Intermediate,1,,,3,,M,,Association constant for binding to AATT 28-mer AATT hairpin,B,
319,,16037,,BAO_0000225,,,,Intermediate,1,,,3,,M,,Kinetically Defined Association Constant for 28-mer AATT hairpin.,B,
320,,16037,,BAO_0000225,,,,Intermediate,1,,,3,,M,,Reaction Rate Parameter for 28-mer AATT hairpin,B,
321,,16037,,BAO_0000225,,,,Intermediate,1,,,3,,M,,Reaction Rate Parameter for 28-mer AATT hairpin,B,
322,,16524,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),F,
323,,16524,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),F,
324,,16524,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,F,
325,,16758,10029.0,BAO_0000019,,,,Autocuration,1,Cricetulus griseus,,0,,U,,Cytotoxicity against cell line 2SC/20 determined by MTT test,F,
326,,16758,10029.0,BAO_0000019,,,,Autocuration,1,Cricetulus griseus,,0,,U,,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,F,
327,,16758,10029.0,BAO_0000019,,,,Autocuration,1,Cricetulus griseus,,0,,U,,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,F,
328,,14360,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,B,
329,,14360,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,B,
330,,9964,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,0,,U,,Selectivity ratio of ID50 in liver and heart,B,
331,,9964,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"Selectivity, ratio of relative ID50 in liver and heart",B,
332,,9964,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,B,
333,,9964,,BAO_0000218,,,,Autocuration,1,,,8,,H,,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,
334,,9964,,BAO_0000218,,,,Autocuration,1,,,8,,H,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,
335,,9964,,BAO_0000218,,,,Autocuration,1,,In vivo,8,,H,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,
336,,9964,,BAO_0000218,,,,Autocuration,1,,In vivo,8,,H,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",F,
337,,9964,,BAO_0000019,,,,Autocuration,1,,,0,,U,,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",B,
338,,9964,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,B,
339,,9964,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",B,
340,,9964,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,B,
341,,9964,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,F,
342,,9964,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",B,
343,,9964,10116.0,BAO_0000218,,,,Autocuration,1,Rattus norvegicus,,0,,U,,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",B,
344,,9964,,BAO_0000218,,,,Autocuration,1,,In vivo,8,,H,,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,B,
345,,9964,,BAO_0000218,,,,Autocuration,1,,,8,,H,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,
346,,9964,10116.0,BAO_0000218,,,,Autocuration,1,Rattus norvegicus,,0,,U,,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",B,
347,,9964,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",B,
348,,9964,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",F,
349,,3796,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,0,,U,,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",B,
350,,4251,562.0,BAO_0000357,,,,Autocuration,1,Escherichia coli,,8,,H,,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,B,
351,,4251,562.0,BAO_0000357,,,,Autocuration,1,Escherichia coli,,8,,H,,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,B,
352,,4251,562.0,BAO_0000357,,,,Autocuration,1,Escherichia coli,,8,,H,,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,B,
353,,4251,562.0,BAO_0000357,,,,Autocuration,1,Escherichia coli,,8,,H,,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,B,
354,,166,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,B,
355,,17861,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,B,
356,,166,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibition constant against 3-dehydroquinate synthase,B,
357,,166,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Association rate constant against 3-dehydroquinate synthase,B,
358,,166,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Rate constant against 3-dehydroquinate synthase,B,
359,,3548,,BAO_0000019,,,,Autocuration,1,,,0,,U,,Inhibitory activity against fuc-TVII,B,
360,2107.0,9877,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,9,Microsomes,D,,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,Liver
361,2107.0,9877,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,9,Microsomes,D,,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,Liver
362,2107.0,9877,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,9,Microsomes,D,,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,Liver
363,2107.0,9877,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,9,Microsomes,D,,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,Liver
364,2107.0,9877,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,9,Microsomes,D,,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,Liver
365,2107.0,9877,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,9,Microsomes,D,,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,B,Liver
366,2107.0,9877,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,9,Microsomes,D,,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,B,Liver
367,2107.0,9877,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,9,Microsomes,D,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,B,Liver
368,2107.0,9877,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,9,Microsomes,D,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,B,Liver
369,2107.0,9877,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,9,Microsomes,D,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,B,Liver
370,2107.0,9877,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,9,Microsomes,D,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,B,Liver
371,,3003,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Inhibitory activity against 3-phosphoglycerate kinase.,B,
372,,3003,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,B,
373,,3003,,BAO_0000224,,,,Autocuration,1,,,4,,H,,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",B,
374,,17185,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,B,
375,,6072,9606.0,BAO_0000219,,,844.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity on 3677 melanoma cells,F,
376,,6072,9606.0,BAO_0000219,,,844.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,F,
377,,5018,10090.0,BAO_0000219,,,700.0,Intermediate,1,Mus musculus,,1,,N,,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,F,
378,,2852,9606.0,BAO_0000019,,,,Intermediate,1,Homo sapiens,,0,,U,,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,F,
379,,8663,,BAO_0000218,,,798.0,Autocuration,1,,,0,,U,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,F,
380,,8663,,BAO_0000218,,,798.0,Autocuration,1,,,0,,U,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,F,
381,,3245,12131.0,BAO_0000019,,,,Expert,1,Human rhinovirus 14,,9,,D,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,F,
382,,3245,169066.0,BAO_0000218,,,,Intermediate,1,Human rhinovirus sp.,,1,,N,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,F,
383,,3877,169066.0,BAO_0000218,,,,Intermediate,1,human rhinovirus type 14,,1,,N,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,F,
384,,3877,169066.0,BAO_0000218,,,,Intermediate,1,human rhinovirus type 14,,1,,N,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,F,
385,,5861,12131.0,BAO_0000019,,,,Expert,1,Human rhinovirus 14,,9,,D,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,
386,,5861,12131.0,BAO_0000019,,,,Expert,1,Human rhinovirus 14,,9,,D,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,
387,,5861,12131.0,BAO_0000019,,,,Expert,1,Human rhinovirus 14,,9,,D,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,
388,,5861,12131.0,BAO_0000019,,,,Expert,1,Human rhinovirus 14,,9,,D,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,F,
389,,13748,12059.0,BAO_0000218,,,,Intermediate,1,Enterovirus,,1,,N,,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,F,
390,,13748,12059.0,BAO_0000218,,,,Intermediate,1,Enterovirus,,1,,N,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,F,
391,,13748,12059.0,BAO_0000218,,,,Intermediate,1,Enterovirus,,1,,N,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,F,
392,,13748,12059.0,BAO_0000218,,,,Intermediate,1,Enterovirus,,1,,N,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,F,
393,,13748,147712.0,BAO_0000357,,,,Expert,1,Human rhinovirus B,,8,,H,,Inhibition of human rhinovirus 3C protease,B,
394,,17699,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,B,
395,,7145,10090.0,BAO_0000218,,,833.0,Intermediate,1,Mus musculus,,1,,N,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),F,
396,,7145,10090.0,BAO_0000218,,,833.0,Intermediate,1,Mus musculus,,1,,N,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),F,
397,,7145,10090.0,BAO_0000218,,,833.0,Intermediate,1,Mus musculus,,1,,N,,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),F,
398,,7145,10090.0,BAO_0000218,,,833.0,Intermediate,1,Mus musculus,,1,,N,,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),F,
399,,7145,10090.0,BAO_0000218,,,833.0,Intermediate,1,Mus musculus,,1,,N,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,F,
400,,7145,10090.0,BAO_0000218,,,833.0,Intermediate,1,Mus musculus,,1,,N,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,F,
401,,5325,10090.0,BAO_0000218,,,847.0,Intermediate,1,Mus musculus,,1,,N,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,F,
402,,5325,10090.0,BAO_0000218,,,847.0,Intermediate,1,Mus musculus,,1,,N,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,F,
403,,5325,10090.0,BAO_0000218,,,847.0,Expert,1,Mus musculus,,1,,N,,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,F,
404,,16169,10090.0,BAO_0000219,,,847.0,Intermediate,1,Mus musculus,,1,,N,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,F,
405,,16169,10090.0,BAO_0000219,,,847.0,Intermediate,1,Mus musculus,,1,,N,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,F,
406,,16169,10090.0,BAO_0000219,,,847.0,Intermediate,1,Mus musculus,,1,,N,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,F,
407,,16169,10090.0,BAO_0000219,,,847.0,Intermediate,1,Mus musculus,,1,,N,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,F,
408,,16169,10090.0,BAO_0000219,,,847.0,Intermediate,1,Mus musculus,,1,,N,,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,F,
409,,16169,10090.0,BAO_0000219,,,847.0,Intermediate,1,Mus musculus,,1,,N,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,F,
410,,16169,10090.0,BAO_0000219,,,847.0,Intermediate,1,Mus musculus,,1,,N,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,F,
411,,16169,10090.0,BAO_0000219,,,847.0,Intermediate,1,Mus musculus,,1,,N,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,F,
412,,16169,10090.0,BAO_0000219,,,847.0,Intermediate,1,Mus musculus,,1,,N,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,F,
413,,16169,10090.0,BAO_0000219,,,847.0,Intermediate,1,Mus musculus,,1,,N,,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,F,
414,,16169,10090.0,BAO_0000219,,,847.0,Intermediate,1,Mus musculus,,1,,N,,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,F,
415,,16169,10090.0,BAO_0000219,,,847.0,Intermediate,1,Mus musculus,,1,,N,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,F,
416,,16169,10090.0,BAO_0000219,,,847.0,Intermediate,1,Mus musculus,,1,,N,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,F,
417,,16169,10090.0,BAO_0000219,,,847.0,Intermediate,1,Mus musculus,,1,,N,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,F,
418,,16169,10090.0,BAO_0000219,,,847.0,Intermediate,1,Mus musculus,,1,,N,,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,F,
419,,16169,10090.0,BAO_0000219,,,847.0,Intermediate,1,Mus musculus,,1,,N,,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,F,
420,,16169,10090.0,BAO_0000219,,,847.0,Intermediate,1,Mus musculus,,1,,N,,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,F,
421,,16169,10090.0,BAO_0000219,,,847.0,Intermediate,1,Mus musculus,,1,,N,,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,F,
422,,16169,10090.0,BAO_0000219,,,847.0,Intermediate,1,Mus musculus,,1,,N,,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,F,
423,,16169,10090.0,BAO_0000219,,,847.0,Intermediate,1,Mus musculus,,1,,N,,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,F,
424,,16169,10090.0,BAO_0000219,,,847.0,Intermediate,1,Mus musculus,,1,,N,,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,F,
425,,16169,10090.0,BAO_0000219,,,847.0,Intermediate,1,Mus musculus,,1,,N,,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,F,
426,,16169,10090.0,BAO_0000219,,,847.0,Intermediate,1,Mus musculus,,1,,N,,spermine levels in 3LL cells after the treatment of 1 uM of Compound,F,
427,,16169,10090.0,BAO_0000219,,,847.0,Intermediate,1,Mus musculus,,1,,N,,spermine levels in 3LL cells after the treatment of 10 uM of Compound,F,
428,,16169,10090.0,BAO_0000219,,,847.0,Intermediate,1,Mus musculus,,1,,N,,spermine levels in 3LL cells after the treatment of 250 uM of Compound,F,
429,,16169,10090.0,BAO_0000219,,,847.0,Intermediate,1,Mus musculus,,1,,N,,spermine levels in 3LL cells after the treatment of 50 uM of Compound,F,
430,,15547,9606.0,BAO_0000219,,,971.0,Intermediate,1,Homo sapiens,,1,,N,,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,F,
431,,8663,,BAO_0000218,,,,Autocuration,1,,,0,,U,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,F,
432,,8663,,BAO_0000218,,,,Autocuration,1,,,0,,U,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,F,
433,,8663,,BAO_0000218,,,,Autocuration,1,,,0,,U,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,F,
434,,8663,,BAO_0000218,,,,Autocuration,1,,,0,,U,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,F,
435,,4504,10090.0,BAO_0000219,,,723.0,Intermediate,1,Mus musculus,,1,,N,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,F,
436,,4504,10090.0,BAO_0000219,,,723.0,Intermediate,1,Mus musculus,,1,,N,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,F,
437,,12695,,BAO_0000219,,,723.0,Expert,1,,,8,,H,,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,F,
438,,12695,10090.0,BAO_0000219,,,723.0,Intermediate,1,Mus musculus,,1,,N,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,F,
439,,12695,10090.0,BAO_0000219,,,723.0,Intermediate,1,Mus musculus,,1,,N,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,F,
440,,17642,10090.0,BAO_0000219,,,723.0,Expert,1,Mus musculus,,1,,N,,Effective dose against murine 3T3 fibroblasts cells,F,
441,,17642,10090.0,BAO_0000219,,,723.0,Expert,1,Mus musculus,,1,,N,,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,F,
442,,12340,10090.0,BAO_0000219,,,723.0,Expert,1,Mus musculus,,1,,N,,Cytotoxic effect on 3T3 cells,F,
443,,12340,10090.0,BAO_0000219,,,723.0,Expert,1,Mus musculus,,1,,N,,Cytotoxic effect on 3T3 cells,F,
444,,12716,10090.0,BAO_0000219,,,723.0,Intermediate,1,Mus musculus,,1,,N,,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,F,
445,,6277,10090.0,BAO_0000219,,,723.0,Intermediate,1,Mus musculus,,1,,N,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,F,
446,,6277,10090.0,BAO_0000219,,,723.0,Intermediate,1,Mus musculus,,1,,N,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,F,
447,,6277,10090.0,BAO_0000219,,,723.0,Expert,1,Mus musculus,,1,,N,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,F,
448,,6277,10090.0,BAO_0000219,,,723.0,Expert,1,Mus musculus,,1,,N,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,F,
449,,6277,10090.0,BAO_0000219,,,723.0,Intermediate,1,Mus musculus,,1,,N,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,F,
450,,6277,10090.0,BAO_0000219,,,723.0,Expert,1,Mus musculus,,1,,N,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,F,
451,,6277,10090.0,BAO_0000219,,,723.0,Expert,1,Mus musculus,,1,,N,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,F,
452,,6277,10090.0,BAO_0000219,,,723.0,Intermediate,1,Mus musculus,,1,,N,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,F,
453,,17780,10090.0,BAO_0000218,,,723.0,Expert,1,Mus musculus,,1,,N,,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,F,
454,,12751,10090.0,BAO_0000219,,,,Autocuration,1,Mus musculus,,7,,D,,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,F,
455,,12380,10090.0,BAO_0000219,,,723.0,Expert,1,Mus musculus,,1,,N,,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,F,
456,,14892,10090.0,BAO_0000219,,,723.0,Intermediate,1,Mus musculus,,1,,N,,Inhibitory activity against 3T3 cell line,F,
457,,12695,10090.0,BAO_0000219,,,723.0,Intermediate,1,Mus musculus,,1,,N,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,F,
458,,12695,,BAO_0000019,,,,Expert,1,,,8,,H,,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,F,
459,,12695,10090.0,BAO_0000219,,,723.0,Intermediate,1,Mus musculus,,1,,N,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,F,
460,,12695,10090.0,BAO_0000219,,,723.0,Intermediate,1,Mus musculus,,1,,N,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,F,
461,,12695,,BAO_0000019,,,,Expert,1,,,8,,H,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,F,
462,,12695,,BAO_0000019,,,,Expert,1,,,8,,H,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,F,
463,,6277,10090.0,BAO_0000219,,,723.0,Intermediate,1,Mus musculus,,1,,N,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,F,
464,,6277,10090.0,BAO_0000219,,,723.0,Expert,1,Mus musculus,,1,,N,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,F,
465,,4959,9606.0,BAO_0000219,,,723.0,Expert,1,Homo sapiens,,9,,D,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,F,
466,,4959,9606.0,BAO_0000219,,,723.0,Expert,1,Homo sapiens,,9,,D,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),F,
467,,4959,9606.0,BAO_0000219,,,723.0,Expert,1,Homo sapiens,,9,,D,,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,F,
468,,4959,9606.0,BAO_0000219,,,723.0,Expert,1,Homo sapiens,,9,,D,,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),F,
469,,12082,10090.0,BAO_0000219,,,723.0,Intermediate,1,Mus musculus,,1,,N,,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,F,
470,,12082,10090.0,BAO_0000219,,,723.0,Intermediate,1,Mus musculus,,1,,N,,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,F,
471,,12082,10090.0,BAO_0000219,,,723.0,Intermediate,1,Mus musculus,,1,,N,,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,F,
472,,12082,10090.0,BAO_0000219,,,723.0,Intermediate,1,Mus musculus,,1,,N,,Inhibitory concentration was calculated on 3T3 cells by using growth assay,F,
473,,2643,10090.0,BAO_0000219,,,723.0,Intermediate,1,Mus musculus,,1,,N,,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,F,
474,,11926,10090.0,BAO_0000219,,,723.0,Expert,1,Mus musculus,,1,,N,,Inhibition of Swiss 3T3 mouse fibroblast proliferation,F,
475,,15204,10090.0,BAO_0000219,,,723.0,Intermediate,1,Mus musculus,,1,,N,,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,A,
476,,15992,10090.0,BAO_0000219,,,723.0,Expert,1,Mus musculus,,1,,N,,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,F,
477,,16279,10090.0,BAO_0000219,,,723.0,Intermediate,1,Mus musculus,,1,,N,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,F,
478,,16279,10090.0,BAO_0000219,,,723.0,Intermediate,1,Mus musculus,,1,,N,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,
479,,16279,10090.0,BAO_0000219,,,723.0,Intermediate,1,Mus musculus,,1,,N,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,
480,,16279,10090.0,BAO_0000219,,,723.0,Intermediate,1,Mus musculus,,1,,N,,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,
481,,16279,10090.0,BAO_0000219,,,723.0,Intermediate,1,Mus musculus,,1,,N,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,
482,,16279,10090.0,BAO_0000219,,,723.0,Intermediate,1,Mus musculus,,1,,N,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,
483,,12831,10090.0,BAO_0000219,,,723.0,Expert,1,Mus musculus,,1,,N,,Inhibition of swiss 3T3 mouse fibroblast proliferation,F,
484,,13497,10090.0,BAO_0000219,,,723.0,Intermediate,1,Mus musculus,,1,,N,,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,F,
485,,13715,,BAO_0000218,,,620.0,Intermediate,1,,,1,,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,
486,,13618,10090.0,BAO_0000219,,,620.0,Intermediate,1,Mus musculus,,1,,N,,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,F,
487,,11902,10090.0,BAO_0000219,,,620.0,Intermediate,1,Mus musculus,,1,,N,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,F,
488,,11902,10090.0,BAO_0000219,,,620.0,Intermediate,1,Mus musculus,,1,,N,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,F,
489,,11902,10090.0,BAO_0000219,,,620.0,Intermediate,1,Mus musculus,,1,,N,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,F,
490,,14840,10090.0,BAO_0000218,,,620.0,Intermediate,1,Mus musculus,,1,,N,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",F,
491,,14840,10090.0,BAO_0000218,,,620.0,Intermediate,1,Mus musculus,,1,,N,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",F,
492,,13715,,BAO_0000219,,,620.0,Intermediate,1,,,1,,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,F,
493,,13715,,BAO_0000219,,,620.0,Intermediate,1,,,1,,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,F,
494,,13715,,BAO_0000219,,,620.0,Intermediate,1,,,1,,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,
495,,13715,,BAO_0000219,,,620.0,Intermediate,1,,,1,,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,F,
496,,13715,,BAO_0000219,,,620.0,Intermediate,1,,,1,,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,
497,,13715,,BAO_0000218,,,620.0,Intermediate,1,,,1,,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,F,
498,,13715,,BAO_0000218,,,620.0,Intermediate,1,,,1,,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,F,
499,,13715,,BAO_0000218,,,620.0,Intermediate,1,,,1,,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,F,
500,,13715,,BAO_0000218,,,620.0,Intermediate,1,,,1,,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,
501,,13715,,BAO_0000218,,,620.0,Expert,1,,,1,,N,,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,F,
502,,13715,,BAO_0000218,,,620.0,Expert,1,,,1,,N,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,
503,,13715,,BAO_0000218,,,620.0,Intermediate,1,,,1,,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,F,
504,,13715,,BAO_0000218,,,620.0,Intermediate,1,,,1,,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,
505,,13715,,BAO_0000218,,,620.0,Intermediate,1,,,1,,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,F,
506,,13715,,BAO_0000218,,,620.0,Expert,1,,,1,,N,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,
507,,13715,,BAO_0000218,,,620.0,Expert,1,,,1,,N,,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,
508,,13715,,BAO_0000218,,,620.0,Expert,1,,,1,,N,,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,F,
509,,13715,,BAO_0000219,,,620.0,Intermediate,1,,,1,,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,F,
510,,13715,,BAO_0000219,,,620.0,Intermediate,1,,,1,,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,
511,,13715,,BAO_0000219,,,620.0,Intermediate,1,,,1,,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,F,
512,,13715,,BAO_0000218,,,620.0,Intermediate,1,,,1,,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,F,
513,,13715,,BAO_0000218,,,620.0,Intermediate,1,,,1,,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,
514,,13715,,BAO_0000218,,,620.0,Intermediate,1,,,1,,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,
515,,13715,,BAO_0000218,,,620.0,Intermediate,1,,,1,,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,
516,,13715,,BAO_0000218,,,620.0,Intermediate,1,,,1,,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,F,
517,,6411,,BAO_0000219,,,620.0,Expert,1,,,8,,H,,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,F,
518,,6411,10090.0,BAO_0000219,,,620.0,Intermediate,1,Mus musculus,,1,,N,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,F,
519,,6411,,BAO_0000219,,,620.0,Expert,1,,,8,,H,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,F,
520,,3966,10090.0,BAO_0000219,,,620.0,Expert,1,Mus musculus,,1,,N,,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,F,
521,,3966,10090.0,BAO_0000219,,,620.0,Intermediate,1,Mus musculus,,1,,N,,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,F,
522,,15556,10090.0,BAO_0000219,,,620.0,Expert,1,Mus musculus,,1,,N,,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,F,
523,,5845,10090.0,BAO_0000219,,,620.0,Expert,1,Mus musculus,,1,,N,,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,F,
524,,14422,10090.0,BAO_0000219,,,620.0,Expert,1,Mus musculus,,1,,N,,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,F,
525,,5845,10090.0,BAO_0000219,,,620.0,Expert,1,Mus musculus,,1,,N,,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,F,
526,,14508,10090.0,BAO_0000219,,,620.0,Expert,1,Mus musculus,,1,,N,,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,F,
527,,14508,10090.0,BAO_0000219,,,620.0,Expert,1,Mus musculus,,1,,N,,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,F,
528,,14508,10090.0,BAO_0000219,,,620.0,Expert,1,Mus musculus,,1,,N,,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,F,
529,,6349,10116.0,BAO_0000219,,,1118.0,Intermediate,1,Rattus norvegicus,,1,,N,,Inhibitory activity against rat fibroblast (3Y1) cell line,F,
530,,15899,10116.0,BAO_0000219,,,1118.0,Expert,1,Rattus norvegicus,,1,,N,,Mean concentration causing inhibition of cell growth in 3Y1 cells.,F,
531,,15899,10116.0,BAO_0000219,,,1118.0,Expert,1,Rattus norvegicus,,1,,N,,Cytotoxicity in 3Y1 cells.,F,
532,,15899,10116.0,BAO_0000219,,,1118.0,Expert,1,Rattus norvegicus,,1,,N,,Cytostatic effect in 3Y1 cells.,F,
533,,15899,10116.0,BAO_0000219,,,1118.0,Intermediate,1,Rattus norvegicus,,1,,N,,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",F,
534,,17038,10116.0,BAO_0000219,,,1118.0,Expert,1,Rattus norvegicus,,1,,N,,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,F,
535,,12421,,BAO_0000019,,,,Autocuration,1,,,0,,U,,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,B,
536,,12947,,BAO_0000019,,,,Autocuration,1,,,0,,U,,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,B,
537,,12947,,BAO_0000019,,,,Autocuration,1,,,0,,U,,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,B,
538,,4896,9823.0,BAO_0000019,,,,Expert,1,Sus scrofa,,9,,D,,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,B,
539,,6148,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,B,
540,,16432,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,B,
541,,4978,,BAO_0000019,,,,Expert,1,,,8,,H,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,B,
542,,4978,,BAO_0000019,,,,Expert,1,,,8,,H,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),B,
543,,3723,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,B,
544,,3518,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),B,
545,,4164,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,B,
546,,3518,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,B,
547,,4164,9823.0,BAO_0000019,,,,Expert,1,Sus scrofa,,9,,D,,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,B,
548,,3518,,BAO_0000019,,,,Autocuration,1,,,8,,H,,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,B,
549,,3518,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),B,
550,,4978,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,B,
551,,4978,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),B,
552,,6455,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Binding affinity against melatonin (MT1) receptor (pC1),B,
553,,2222,,BAO_0000019,,,,Autocuration,1,,,0,,U,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,B,
554,,13020,,BAO_0000019,,,,Autocuration,1,,,0,,U,,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,B,
555,,13021,,BAO_0000019,,,,Autocuration,1,,,0,,U,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,B,
556,,14532,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,B,
557,,14118,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,B,
558,10000000.0,11884,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,B,Hippocampus
559,,13969,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,B,
560,,13392,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity for 5-hydroxytryptamine 1A receptor,B,
561,,14430,,BAO_0000019,,,,Expert,1,,,8,,H,,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,B,
562,10000000.0,12248,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,Hippocampus
563,10000000.0,12249,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,Hippocampus
564,10000000.0,9995,,BAO_0000221,,,,Autocuration,1,,,8,,H,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,B,Hippocampus
565,10000000.0,9995,,BAO_0000221,,,,Autocuration,1,,,8,,H,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,Hippocampus
566,10000000.0,9995,,BAO_0000221,,,,Autocuration,1,,,8,,H,,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,B,Hippocampus
567,10000000.0,9995,,BAO_0000221,,,,Autocuration,1,,,8,,H,,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,B,Hippocampus
568,10000000.0,9995,,BAO_0000221,,,,Autocuration,1,,,8,,H,,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,Hippocampus
569,10000000.0,12249,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,Hippocampus
570,10000000.0,11799,,BAO_0000221,,,,Autocuration,1,,,8,,H,,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",B,Hippocampus
571,,14331,10116.0,BAO_0000249,,,,Expert,1,Rattus norvegicus,,9,Membranes,D,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,B,
572,10000000.0,11884,9913.0,BAO_0000221,,,,Expert,1,Bos taurus,,8,,H,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,B,Hippocampus
573,10000000.0,14331,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,B,Hippocampus
574,10000000.0,11701,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,B,Hippocampus
575,10000000.0,11701,,BAO_0000221,,,,Expert,1,,,8,,H,,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,B,Hippocampus
576,10000000.0,12248,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,B,Hippocampus
577,,12248,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,B,
578,10000000.0,12248,,BAO_0000221,,,,Expert,1,,,8,,H,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,Hippocampus
579,10000000.0,12249,,BAO_0000221,,,,Expert,1,,,8,,H,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,Hippocampus
580,,12248,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,
581,10000000.0,11799,,BAO_0000221,,,,Expert,1,,,8,,H,,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",B,Hippocampus
582,,634,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,B,
583,10000000.0,9995,,BAO_0000221,,,,Autocuration,1,,,8,,H,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,B,Hippocampus
584,10000000.0,9995,,BAO_0000221,,,,Autocuration,1,,,8,,H,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,Hippocampus
585,10000000.0,9995,,BAO_0000221,,,,Autocuration,1,,,8,,H,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,Hippocampus
586,10000000.0,9995,,BAO_0000221,,,,Autocuration,1,,,8,,H,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,Hippocampus
587,10000000.0,9995,,BAO_0000221,,,,Autocuration,1,,,8,,H,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,Hippocampus
588,10000000.0,12210,,BAO_0000218,,,,Expert,1,,,8,,H,,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,B,Hippocampus
589,10000000.0,13311,,BAO_0000221,,,,Expert,1,,,8,,H,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,Hippocampus
590,,2331,9606.0,BAO_0000219,,,449.0,Expert,1,Homo sapiens,,9,,D,,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",B,
591,,1375,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,8,,H,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,F,
592,,1375,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,8,,H,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,F,
593,10000000.0,11574,10141.0,BAO_0000221,,,,Autocuration,1,Cavia porcellus,,8,,H,,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,F,Hippocampus
594,2116.0,12867,10141.0,BAO_0000221,,,,Autocuration,1,Cavia porcellus,,8,,H,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,B,Ileum
595,2116.0,12867,10141.0,BAO_0000221,,,,Autocuration,1,Cavia porcellus,,8,,H,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,Ileum
596,2116.0,12867,10141.0,BAO_0000221,,,,Autocuration,1,Cavia porcellus,,8,,H,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,B,Ileum
597,2116.0,12867,10141.0,BAO_0000221,,,,Autocuration,1,Cavia porcellus,,8,,H,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,Ileum
598,2116.0,12867,10141.0,BAO_0000221,,,,Autocuration,1,Cavia porcellus,,8,,H,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,Ileum
599,2116.0,12867,10141.0,BAO_0000221,,,,Autocuration,1,Cavia porcellus,,8,,H,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,B,Ileum
600,,11574,10141.0,BAO_0000357,,,,Autocuration,1,Cavia porcellus,,8,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor,B,
601,,13114,10141.0,BAO_0000357,,,,Autocuration,1,Cavia porcellus,,8,,H,,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,B,
602,,13181,10141.0,BAO_0000357,,,,Autocuration,1,Cavia porcellus,,8,,H,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,B,
603,10000000.0,10639,10141.0,BAO_0000221,,,,Autocuration,1,Cavia porcellus,,8,,H,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,B,Hippocampus
604,10000000.0,10639,10141.0,BAO_0000221,,,,Autocuration,1,Cavia porcellus,,8,,H,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,F,Hippocampus
605,,11883,10029.0,BAO_0000218,,,449.0,Autocuration,1,Cricetulus griseus,,8,,H,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),B,
606,,17785,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,B,
607,,1558,,BAO_0000219,,,308.0,Autocuration,1,,,8,,H,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,F,
608,,1558,,BAO_0000219,,,308.0,Autocuration,1,,,8,,H,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,F,
609,,15740,,BAO_0000019,,,,Autocuration,1,,,8,,H,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,F,
610,,17624,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,F,
611,,17624,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,F,
612,,17624,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,F,
613,,17624,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,F,
614,,17624,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,
615,,17624,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,
616,,17624,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,B,
617,,14256,,BAO_0000219,,,,Autocuration,1,,,8,,H,,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,F,
618,,3445,9606.0,BAO_0000219,,,308.0,Expert,1,Homo sapiens,,9,,D,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,B,
619,,3445,9606.0,BAO_0000219,,,308.0,Expert,1,Homo sapiens,,9,,D,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,B,
620,,17200,9606.0,BAO_0000219,,,449.0,Expert,1,Homo sapiens,,9,,D,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,B,
621,,17200,9606.0,BAO_0000219,,,449.0,Expert,1,Homo sapiens,,9,,D,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,B,
622,,15180,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,F,
623,,15180,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,F,
624,,16026,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,
625,,2759,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,
626,,2759,9606.0,BAO_0000219,,,449.0,Expert,1,Homo sapiens,,9,,D,,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),F,
627,,2759,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),F,
628,,2759,9606.0,BAO_0000219,,,449.0,Expert,1,Homo sapiens,,9,,D,,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),F,
629,,2759,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,
630,,2759,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),F,
631,,2759,9606.0,BAO_0000219,,,449.0,Expert,1,Homo sapiens,,9,,D,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),F,
632,,2759,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),F,
633,,2759,9606.0,BAO_0000219,,,449.0,Expert,1,Homo sapiens,,9,,D,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),F,
634,,3445,9606.0,BAO_0000019,,,,Expert,1,Homo sapiens,,9,,D,,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,F,
635,,5272,9606.0,BAO_0000019,,,,Expert,1,Homo sapiens,,9,,D,,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,
636,,5272,9606.0,BAO_0000019,,,,Expert,1,Homo sapiens,,9,,D,,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",F,
637,,5272,9606.0,BAO_0000019,,,,Expert,1,Homo sapiens,,9,,D,,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",F,
638,,17624,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,
639,,17624,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,
640,,17624,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,F,
641,,17624,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,
642,,17624,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,F,
643,,17624,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,F,
644,,17624,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,
645,,17624,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,F,
646,,17624,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,
647,,17624,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,F,
648,,17624,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,
649,,17624,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,F,
650,,6563,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,
651,,6563,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,
652,,6563,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,F,
653,,17296,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,
654,,6876,9606.0,BAO_0000019,,,,Expert,1,Homo sapiens,,9,,D,,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",F,
655,,6876,,BAO_0000019,,,,Expert,1,,,8,,H,,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",F,
656,,5272,9606.0,BAO_0000019,,,,Expert,1,Homo sapiens,,9,,D,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,F,
657,,5272,9606.0,BAO_0000019,,,,Expert,1,Homo sapiens,,9,,D,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,F,
658,,5548,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,
659,,5548,,BAO_0000019,,,,Expert,1,,,8,,H,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",F,
660,,5548,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,
661,,5548,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,
662,,5929,,BAO_0000019,,,,Expert,1,,,8,,H,,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",F,
663,,5929,9606.0,BAO_0000019,,,,Expert,1,Homo sapiens,,9,,D,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",F,
664,,5929,9606.0,BAO_0000019,,,,Expert,1,Homo sapiens,,9,,D,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",F,
665,,16245,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",F,
666,,5640,,BAO_0000019,,,,Expert,1,,,8,,H,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",F,
667,,5640,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",F,
668,,14509,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,F,
669,,14509,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,F,
670,,15331,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,
671,,15331,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,
672,,6563,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,
673,,6563,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",F,
674,,6563,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,F,
675,,6563,9606.0,BAO_0000019,,,,Expert,1,Homo sapiens,,9,,D,,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,F,
676,,6563,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,
677,,5272,9606.0,BAO_0000019,,,,Expert,1,Homo sapiens,,9,,D,,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,F,
678,,5272,9606.0,BAO_0000019,,,,Expert,1,Homo sapiens,,9,,D,,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,
679,,5272,9606.0,BAO_0000019,,,,Expert,1,Homo sapiens,,9,,D,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",F,
680,,5272,9606.0,BAO_0000019,,,,Expert,1,Homo sapiens,,9,,D,,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,F,
681,,5272,9606.0,BAO_0000019,,,,Expert,1,Homo sapiens,,9,,D,,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,F,
682,,5272,9606.0,BAO_0000019,,,,Expert,1,Homo sapiens,,9,,D,,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,
683,,5272,9606.0,BAO_0000019,,,,Expert,1,Homo sapiens,,9,,D,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",F,
684,,5272,9606.0,BAO_0000019,,,,Expert,1,Homo sapiens,,9,,D,,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,F,
685,,16146,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Inhibition of human 5-hydroxytryptamine 1A receptor,B,
686,,17624,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,
687,,13706,,BAO_0000219,,,722.0,Expert,1,,,9,,D,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,B,
688,,15250,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,B,
689,,17624,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,
690,,6861,,BAO_0000357,,,,Expert,1,,,8,,H,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,B,
691,,17200,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,B,
692,,17624,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,B,
693,,17624,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,
694,,12058,10116.0,BAO_0000218,,,,Autocuration,1,Rattus norvegicus,In vivo,0,,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,F,
695,,12058,10116.0,BAO_0000218,,,,Autocuration,1,Rattus norvegicus,In vivo,0,,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,F,
696,,12058,10116.0,BAO_0000218,,,,Autocuration,1,Rattus norvegicus,In vivo,0,,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,F,
697,,12058,10116.0,BAO_0000218,,,,Autocuration,1,Rattus norvegicus,In vivo,0,,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,F,
698,,12058,10116.0,BAO_0000218,,,,Autocuration,1,Rattus norvegicus,In vivo,0,,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,F,
699,,12058,10116.0,BAO_0000218,,,,Autocuration,1,Rattus norvegicus,In vivo,0,,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,F,
700,,12058,10116.0,BAO_0000218,,,,Autocuration,1,Rattus norvegicus,In vivo,0,,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,F,
701,,12058,10116.0,BAO_0000218,,,,Autocuration,1,Rattus norvegicus,In vivo,0,,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,F,
702,,12058,10116.0,BAO_0000218,,,,Autocuration,1,Rattus norvegicus,In vivo,0,,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,F,
703,,12058,10116.0,BAO_0000218,,,,Autocuration,1,Rattus norvegicus,In vivo,0,,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,F,
704,,12058,10116.0,BAO_0000218,,,,Autocuration,1,Rattus norvegicus,In vivo,0,,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,F,
705,,12058,10116.0,BAO_0000218,,,,Autocuration,1,Rattus norvegicus,In vivo,0,,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,F,
706,,12058,10116.0,BAO_0000218,,,,Autocuration,1,Rattus norvegicus,In vivo,0,,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,F,
707,,12058,10116.0,BAO_0000218,,,,Autocuration,1,Rattus norvegicus,In vivo,0,,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,F,
708,,12058,10116.0,BAO_0000218,,,,Autocuration,1,Rattus norvegicus,In vivo,0,,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,F,
709,,12058,10116.0,BAO_0000218,,,,Autocuration,1,Rattus norvegicus,In vivo,0,,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,F,
710,,12058,10116.0,BAO_0000218,,,,Autocuration,1,Rattus norvegicus,In vivo,0,,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,F,
711,,12058,10116.0,BAO_0000218,,,,Autocuration,1,Rattus norvegicus,In vivo,0,,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,F,
712,,12058,10116.0,BAO_0000218,,,,Autocuration,1,Rattus norvegicus,In vivo,0,,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,F,
713,,11440,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,B,
714,1898.0,6238,,BAO_0000249,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,B,Hypothalamus
715,,10046,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,B,
716,,10046,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,B,
717,,10046,,BAO_0000019,,,,Expert,1,,,8,,H,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,B,
718,,167,,BAO_0000357,,,,Autocuration,1,,,8,,H,,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",B,
719,,167,,BAO_0000357,,,,Autocuration,1,,,8,,H,,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",B,
720,,11520,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),F,
721,,11520,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,
722,,11520,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,
723,,11520,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,
724,,135,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,8,,H,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,F,
725,,135,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,8,,H,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,F,
726,,11311,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,8,,H,,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,B,
727,,10193,10141.0,BAO_0000357,,,,Autocuration,1,Cavia porcellus,,8,,H,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,B,
728,,12281,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Inhibitory concentration against 5-lipoxygenase from human whole blood,B,
729,,11311,,BAO_0000219,,,,Autocuration,1,,,8,,H,,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],B,
730,,12576,,BAO_0000218,,,,Autocuration,1,,,8,,H,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,F,
731,,12281,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,B,
732,,12576,,BAO_0000218,,,,Autocuration,1,,,8,,H,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,F,
733,,11089,9823.0,BAO_0000019,,,,Expert,1,Sus scrofa,,8,,H,,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,B,
734,,11006,,BAO_0000357,,,,Expert,1,,,8,,H,,In vitro inhibition of rat 5-Lipoxygenase,B,
735,,11481,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Inhibitory activity against 5-Lipoxygenase,B,
736,,10864,,BAO_0000219,,,702.0,Expert,1,,,8,,H,,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,B,
737,,3595,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,
738,,11311,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,B,
739,,11311,,BAO_0000019,,,,Autocuration,1,,,8,,H,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,B,
740,,11311,,BAO_0000219,,,,Autocuration,1,,,8,,H,,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],B,
741,,11006,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,B,
742,,3595,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,B,
743,,11311,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The compound was tested for inhibition of isolated 5-Lipoxygenase,B,
744,,11481,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,0,,U,,Ratio of IC50 against 5-LO and COX,B,
745,,11006,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,B,
746,,11006,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,B,
747,,11311,,BAO_0000219,,,,Autocuration,1,,,8,,H,,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,B,
748,,11006,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,F,
749,2367.0,4288,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,B,Prostate gland
750,,7587,8932.0,BAO_0000019,,,,Autocuration,1,Columba livia,,0,,U,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,B,
751,,7587,8932.0,BAO_0000019,,,,Autocuration,1,Columba livia,,0,,U,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,B,
752,,7587,8932.0,BAO_0000019,,,,Autocuration,1,Columba livia,,0,,U,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,B,
753,,11249,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,B,
754,,8003,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,F,
755,,8003,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),F,
756,,8003,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),F,
757,10000000.0,12416,,BAO_0000221,,,,Expert,1,,,8,,H,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,B,Hippocampus
758,,16293,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards human 5-hydroxytryptamine 1 receptor,B,
759,,13047,9986.0,BAO_0000019,,,,Autocuration,1,Oryctolagus cuniculus,,0,,U,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,
760,,13047,9986.0,BAO_0000019,,,,Autocuration,1,Oryctolagus cuniculus,,0,,U,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,
761,,13047,9986.0,BAO_0000019,,,,Autocuration,1,Oryctolagus cuniculus,,0,,U,,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,B,
762,,13047,9986.0,BAO_0000019,,,,Autocuration,1,Oryctolagus cuniculus,,0,,U,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,B,
763,10000000.0,10085,,BAO_0000221,,,,Autocuration,1,,,4,,H,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,Hippocampus
764,10000000.0,10085,,BAO_0000221,,,,Autocuration,1,,,4,,H,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,Hippocampus
765,10000000.0,10085,,BAO_0000221,,,,Autocuration,1,,,4,,H,,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,Hippocampus
766,,9841,,BAO_0000249,,,,Autocuration,1,,,4,Membranes,H,,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,B,
767,,8822,10116.0,BAO_0000249,,,,Autocuration,1,Rattus norvegicus,,5,,D,,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,B,
768,,9806,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,5,,D,,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,B,
769,,9806,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,5,,D,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,B,
770,,8868,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,B,
771,10000000.0,9036,,BAO_0000221,,,,Autocuration,1,,,4,,H,,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,B,Hippocampus
772,10000000.0,11374,,BAO_0000221,,,,Autocuration,1,,,4,,H,,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,B,Hippocampus
773,,10881,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,B,
774,,8822,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,B,
775,,9806,10116.0,BAO_0000249,,,,Autocuration,1,Rattus norvegicus,,5,,D,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,B,
776,,15463,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,
777,,15463,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,
778,955.0,14542,,BAO_0000221,,,,Autocuration,1,,,4,,H,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,Brain
779,955.0,14542,,BAO_0000221,,,,Autocuration,1,,,4,,H,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,Brain
780,,8569,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,B,
781,,10062,10116.0,BAO_0000224,,,,Autocuration,1,Rattus norvegicus,,5,,D,,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,B,
782,,4771,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,B,
783,,10062,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,
784,,10062,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,
785,,10062,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,
786,,15463,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,B,
787,,15463,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,B,
788,,9098,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,B,
789,,3070,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,0,,U,,Affinity for 5-hydroxytryptamine 1 receptor,B,
790,955.0,14542,,BAO_0000221,,,,Autocuration,1,,,4,,H,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,B,Brain
791,955.0,14542,,BAO_0000221,,,,Autocuration,1,,,4,,H,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,Brain
792,,6398,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,B,
793,955.0,1344,,BAO_0000221,,,,Autocuration,1,,,4,,H,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,B,Brain
794,,11963,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,
795,,8908,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,0,,U,,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,B,
796,,9098,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,B,
797,,8841,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,5,,D,,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,B,
798,,8814,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,0,,U,,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,B,
799,,11752,,BAO_0000019,,,,Autocuration,1,,,4,,H,,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,B,
800,955.0,11642,,BAO_0000221,,,,Autocuration,1,,,4,,H,,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,B,Brain
801,,11642,,BAO_0000019,,,,Autocuration,1,,,4,,H,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,B,
802,955.0,9231,,BAO_0000220,,,,Autocuration,1,,,4,,H,,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,B,Brain
803,955.0,11351,,BAO_0000221,,,,Autocuration,1,,,4,,H,,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,B,Brain
804,,4639,,BAO_0000019,,,,Autocuration,1,,,0,,U,,Compound was tested for binding affinity against 5-HT1 receptor,B,
805,,1205,,BAO_0000019,,,,Autocuration,1,,,0,,U,,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,B,
806,,10025,,BAO_0000357,,,,Expert,1,,,8,,H,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,B,
807,,13241,,BAO_0000249,,,,Autocuration,1,,,8,,H,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",F,
808,,16245,,BAO_0000218,,,,Autocuration,1,,In vivo,8,,H,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,F,
809,,16245,,BAO_0000218,,,,Autocuration,1,,In vivo,8,,H,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,F,
810,,12438,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,F,
811,,16245,,BAO_0000218,,,,Autocuration,1,,In vivo,8,,H,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,F,
812,,16245,,BAO_0000218,,,,Autocuration,1,,In vivo,8,,H,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,F,
813,,15740,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,F,
814,,15535,,BAO_0000219,,,,Autocuration,1,,,8,,H,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,F,
815,,15535,,BAO_0000219,,,,Expert,1,,,8,,H,,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,F,
816,,15535,,BAO_0000219,,,,Autocuration,1,,,8,,H,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,F,
817,,9888,,BAO_0000249,,,,Expert,1,,,8,,H,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,B,
818,10000000.0,10085,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,B,Hippocampus
819,10000000.0,10085,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,B,Hippocampus
820,,17331,,BAO_0000249,,,,Expert,1,,,8,Membranes,H,,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,B,
821,10000000.0,10845,10116.0,BAO_0000221,,,,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,B,Hippocampus
822,10000000.0,10845,10116.0,BAO_0000221,,,,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,B,Hippocampus
823,10000000.0,10845,,BAO_0000221,,,,Expert,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,B,Hippocampus
824,10000000.0,10845,10116.0,BAO_0000221,,,,Expert,1,Rattus norvegicus,,9,,D,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,B,Hippocampus
825,10000000.0,10845,10116.0,BAO_0000221,,,,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,B,Hippocampus
826,,13730,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,B,
827,,13508,,BAO_0000249,,,,Expert,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,B,
828,10000000.0,13508,,BAO_0000249,,,,Expert,1,,,8,,H,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,B,Hippocampus
829,10000000.0,12073,,BAO_0000221,,,,Expert,1,,,8,,H,,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,Hippocampus
830,10000000.0,4671,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,B,Hippocampus
831,10000000.0,13631,,BAO_0000221,,,,Expert,1,,,8,,H,,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,B,Hippocampus
832,,12438,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,B,
833,,10483,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,B,
834,10000000.0,10483,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,B,Hippocampus
835,,12352,,BAO_0000249,,,,Intermediate,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,B,
836,10000000.0,14732,,BAO_0000249,,,,Autocuration,1,,,8,,H,,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,B,Hippocampus
837,,11049,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,B,
838,,11049,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,B,
839,,13657,,BAO_0000249,,,,Expert,1,,,8,,H,,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",B,
840,,11473,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,B,
841,,2014,,BAO_0000249,,,,Autocuration,1,,,8,,H,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,B,
842,10000000.0,3086,,BAO_0000221,,,,Expert,1,,,8,,H,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,Hippocampus
843,,15854,,BAO_0000019,,,,Expert,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,
844,10000000.0,10922,,BAO_0000221,,,,Expert,1,,,8,,H,,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,B,Hippocampus
845,10000000.0,13346,,BAO_0000221,,,,Expert,1,,,8,,H,,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,B,Hippocampus
846,,15311,,BAO_0000357,,,,Expert,1,,,8,,H,,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,B,
847,10000000.0,10922,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,B,Hippocampus
848,,10025,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,B,
849,,10025,,BAO_0000357,,,,Expert,1,,,8,,H,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,B,
850,,9742,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,B,
851,,9742,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,F,
852,,12304,,BAO_0000019,,,,Expert,1,,,8,,H,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,
853,10000000.0,15789,,BAO_0000221,,,,Autocuration,1,,,8,,H,,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,B,Hippocampus
854,,9912,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",B,
855,,9912,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",B,
856,,9912,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",B,
857,,16693,,BAO_0000019,,,,Expert,1,,,8,,H,,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,B,
858,,13276,,BAO_0000357,,,,Expert,1,,,8,,H,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,
859,10000000.0,12678,,BAO_0000221,,,,Autocuration,1,,,8,,H,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,B,Hippocampus
860,,11825,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,B,
861,,12443,,BAO_0000357,,,,Expert,1,,,8,,H,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,B,
862,,13830,,BAO_0000357,,,,Expert,1,,,8,,H,,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,
863,10000000.0,14286,,BAO_0000249,,,,Expert,1,,,8,,H,,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,B,Hippocampus
864,10000000.0,14356,10116.0,BAO_0000221,,,,Expert,1,Rattus norvegicus,,9,,D,,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,Hippocampus
865,,15306,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibition concentration against 5-hydroxytryptamine 1A receptor,B,
866,,15306,,BAO_0000357,,,,Expert,1,,,8,,H,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),B,
867,,16616,10116.0,BAO_0000249,,,,Expert,1,Rattus norvegicus,,9,,D,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",F,
868,10000000.0,3651,,BAO_0000221,,,,Autocuration,1,,,8,,H,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",B,Hippocampus
869,10000000.0,14331,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,F,Hippocampus
870,10000000.0,14331,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,F,Hippocampus
871,,14178,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,B,
872,,10639,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,B,
873,10000000.0,12306,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,Hippocampus
874,,1348,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,B,
875,10000000.0,13605,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,B,Hippocampus
876,,17624,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,
877,,17624,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,
878,,17624,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,
879,,15267,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,B,
880,,16532,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,B,
881,,6563,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,
882,,4751,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,B,
883,,15463,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,B,
884,,3805,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),B,
885,,5640,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,
886,,6563,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,B,
887,,5548,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,B,
888,,6347,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Percent binding affinity against 5-hydroxytryptamine 1A receptor,B,
889,,17296,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,
890,,13047,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,B,
891,,15740,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,B,
892,,5640,,BAO_0000019,,,,Expert,1,,,8,,H,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",F,
893,,5640,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",F,
894,,17211,,BAO_0000219,,,308.0,Expert,1,,,8,,H,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,B,
895,,4751,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,B,
896,,6491,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,B,
897,,4707,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,B,
898,,13910,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding affinity against 5-hydroxytryptamine 1A receptor,B,
899,,16190,,BAO_0000219,,,308.0,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,B,
900,,16633,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,
901,,11898,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,B,
902,,11898,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,
903,,14331,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against human 5-hydroxytryptamine 1A receptor,B,
904,,17624,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,B,
905,,17624,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,B,
906,,3307,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,B,
907,,6563,9606.0,BAO_0000219,,,449.0,Expert,1,Homo sapiens,,9,,D,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,B,
908,,14165,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,B,
909,,5732,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,B,
910,,13366,,BAO_0000357,,,,Expert,1,,,8,,H,,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,B,
911,,17626,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards human 5-hydroxytryptamine 1A receptor,B,
912,,6588,,BAO_0000219,,,308.0,Expert,1,,,8,,H,,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,B,
913,,16209,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,B,
914,,15463,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,
915,,15463,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,
916,,14770,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,B,
917,,16245,,BAO_0000219,,,1167.0,Autocuration,1,,,8,,H,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),B,
918,,16245,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),B,
919,,5548,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,B,
920,,5548,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,
921,,5548,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,
922,,6876,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,B,
923,,2598,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,
924,,17785,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,B,
925,,6013,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,
926,,5929,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,B,
927,,16633,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,
928,,1558,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,B,
929,,16026,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,
930,,12469,,BAO_0000219,,,,Autocuration,1,,,8,,H,,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,B,
931,,15874,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,
932,,15874,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,
933,,3935,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,B,
934,,15818,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,B,
935,,13706,,BAO_0000219,,,485.0,Autocuration,1,,,8,,H,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,B,
936,,13729,,BAO_0000219,,,485.0,Expert,1,,,8,,H,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,F,
937,,15413,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,B,
938,,15413,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),B,
939,,15413,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),B,
940,,15413,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,B,
941,,3445,9606.0,BAO_0000219,,,308.0,Expert,1,Homo sapiens,,9,,D,,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,B,
942,,15740,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,B,
943,,15740,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,B,
944,,17626,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,B,
945,,4234,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,B,
946,,5640,,BAO_0000357,,,,Expert,1,,,8,,H,,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,B,
947,,5272,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,8,,H,,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,B,
948,,4622,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,B,
949,,17085,,BAO_0000019,,,,Expert,1,,,8,,H,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,B,
950,,3025,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,B,
951,,15315,,BAO_0000357,,,,Expert,1,,,8,,H,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,B,
952,,15267,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,B,
953,,17158,,BAO_0000219,,,308.0,Autocuration,1,,,8,,H,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,B,
954,,14214,9606.0,BAO_0000219,,,308.0,Expert,1,Homo sapiens,,9,,D,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,B,
955,,17133,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,
956,,16532,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,B,
957,,2391,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Affinity for 5-hydroxytryptamine 1A receptor subtype,B,
958,,14447,,BAO_0000019,,,,Autocuration,1,,,8,,H,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,B,
959,,14447,,BAO_0000019,,,,Autocuration,1,,,8,,H,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,B,
960,,15086,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,B,
961,,13051,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,B,
962,,16026,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",F,
963,,17085,,BAO_0000019,,,,Expert,1,,,8,,H,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,B,
964,,17133,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,
965,,17133,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,B,
966,,17211,,BAO_0000219,,,308.0,Autocuration,1,,,8,,H,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,
967,,17211,,BAO_0000219,,,308.0,Autocuration,1,,,8,,H,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,B,
968,,17211,,BAO_0000219,,,308.0,Autocuration,1,,,8,,H,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,
969,,17211,,BAO_0000219,,,308.0,Autocuration,1,,,8,,H,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,
970,,16394,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,
971,,16394,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,
972,,16394,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,
973,,16394,,BAO_0000218,,,,Autocuration,1,,In vivo,8,,H,,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,F,
974,,16394,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,B,
975,,15740,,BAO_0000019,,,,Autocuration,1,,,8,,H,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,F,
976,,15740,,BAO_0000019,,,,Autocuration,1,,,8,,H,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,F,
977,,15740,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,B,
978,,17296,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,
979,,5640,,BAO_0000019,,,,Expert,1,,,8,,H,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",F,
980,,5640,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",F,
981,,5640,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",F,
982,,5640,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",F,
983,,2759,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,
984,,16394,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",F,
985,,16394,9606.0,BAO_0000019,,,,Expert,1,Homo sapiens,,9,,D,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",F,
986,,3445,9606.0,BAO_0000019,,,,Expert,1,Homo sapiens,,9,,D,,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,F,
987,,4316,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,B,
988,,4316,,BAO_0000019,,,,Expert,1,,,8,,H,,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,B,
989,,15180,9606.0,BAO_0000019,,,,Expert,1,Homo sapiens,,9,,D,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,F,
990,,15180,9606.0,BAO_0000019,,,,Expert,1,Homo sapiens,,9,,D,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,F,
991,,15042,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,
992,,15042,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,
993,,15042,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,F,
994,,15042,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,
995,,15042,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,
996,,15042,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,
997,,15042,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,F,
998,,15180,9606.0,BAO_0000219,,,308.0,Expert,1,Homo sapiens,,9,,D,,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,
999,,15180,9606.0,BAO_0000219,,,308.0,Expert,1,Homo sapiens,,9,,D,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,
1000,,15180,9606.0,BAO_0000219,,,308.0,Expert,1,Homo sapiens,,9,,D,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,
1001,,16245,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",F,
1002,,16026,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,
1003,,17296,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,
1004,,2759,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),F,
1005,,2759,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,F,
1006,,2759,9606.0,BAO_0000219,,,449.0,Expert,1,Homo sapiens,,9,,D,,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),F,
1007,,2759,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),F,
1008,,15419,,BAO_0000219,,,,Expert,1,,,8,,H,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,F,
1009,,15419,,BAO_0000219,,,,Autocuration,1,,,8,,H,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,F,
1010,,16026,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,
1011,,1414,,BAO_0000219,,,,Expert,1,,In vitro,8,,H,,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,B,
1012,,1414,,BAO_0000219,,,,Expert,1,,In vitro,8,,H,,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,B,
1013,,12861,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding activity radioligand.,B,
1014,,12861,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,
1015,,5104,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,B,
1016,,5105,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,B,
1017,,16312,,BAO_0000357,,,,Autocuration,1,,,8,,H,,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,B,
1018,,15180,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,B,
1019,,5033,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,B,
1020,,16909,9606.0,BAO_0000219,,,449.0,Expert,1,Homo sapiens,,9,,D,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,B,
1021,,2590,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,F,
1022,,2590,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,F,
1023,,16394,,BAO_0000019,,,,Expert,1,,,8,,H,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,B,
1024,,4540,9606.0,BAO_0000219,,,722.0,Expert,1,Homo sapiens,,9,,D,,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,B,
1025,,17296,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,B,
1026,,17296,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,B,
1027,,15779,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,B,
1028,,15779,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,B,
1029,,15779,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,B,
1030,,6166,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,B,
1031,,15779,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,B,
1032,,4199,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,B,
1033,,15316,,BAO_0000219,,,,Autocuration,1,,,8,,H,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,B,
1034,,14875,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,B,
1035,,14727,,BAO_0000219,,,308.0,Expert,1,,,8,,H,,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,B,
1036,,14727,,BAO_0000019,,,,Expert,1,,,8,,H,,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,B,
1037,,15146,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,B,
1038,,5213,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,B,
1039,,16429,,BAO_0000219,,,,Autocuration,1,,,8,,H,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,B,
1040,,15042,9606.0,BAO_0000219,,,308.0,Expert,1,Homo sapiens,,9,,D,,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,B,
1041,,14818,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,B,
1042,,4829,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",B,
1043,,17200,,BAO_0000357,,,,Expert,1,,,9,,D,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,B,
1044,,13051,9606.0,BAO_0000357,,,,Autocuration,1,Homo sapiens,,9,,D,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,B,
1045,,5486,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,B,
1046,,5254,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-HT1D receptor,B,
1047,,5254,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor,B,
1048,,15331,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,
1049,,13506,9606.0,BAO_0000357,,,,Autocuration,1,Homo sapiens,,8,,H,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,B,
1050,,15267,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,B,
1051,,16616,,BAO_0000218,,,,Autocuration,1,,In vivo,8,,H,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,F,
1052,,16616,,BAO_0000218,,,,Autocuration,1,,In vivo,8,,H,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,F,
1053,,16616,,BAO_0000218,,,,Autocuration,1,,In vivo,8,,H,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,F,
1054,,16616,10090.0,BAO_0000218,,,,Expert,1,Mus musculus,,9,,D,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,F,
1055,,16616,10090.0,BAO_0000218,,,,Expert,1,Mus musculus,,9,,D,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,F,
1056,,16616,10090.0,BAO_0000218,,,,Expert,1,Mus musculus,,9,,D,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,F,
1057,,16616,10090.0,BAO_0000218,,,,Expert,1,Mus musculus,,9,,D,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,F,
1058,,16616,10090.0,BAO_0000218,,,,Expert,1,Mus musculus,,9,,D,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,F,
1059,,16616,10090.0,BAO_0000218,,,,Expert,1,Mus musculus,,9,,D,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,F,
1060,10000000.0,10297,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,B,Hippocampus
1061,,13704,,BAO_0000357,,,,Expert,1,,,8,,H,,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,B,
1062,10000000.0,10297,10090.0,BAO_0000221,,,,Expert,1,Mus musculus,,9,,D,,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,B,Hippocampus
1063,10000000.0,10297,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,B,Hippocampus
1064,10000000.0,10297,10090.0,BAO_0000221,,,,Expert,1,Mus musculus,,9,,D,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,B,Hippocampus
1065,10000000.0,10297,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,B,Hippocampus
1066,,217,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,B,
1067,10000000.0,10297,10090.0,BAO_0000221,,,,Expert,1,Mus musculus,,9,,D,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,B,Hippocampus
1068,,4921,9823.0,BAO_0000357,,,,Autocuration,1,Sus scrofa,,8,,H,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,B,
1069,,4921,9823.0,BAO_0000357,,,,Autocuration,1,Sus scrofa,,8,,H,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,B,
1070,,4996,9823.0,BAO_0000019,,,,Autocuration,1,Sus scrofa,,8,,H,,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,B,
1071,,12918,9823.0,BAO_0000357,,,,Autocuration,1,Sus scrofa,,8,,H,,Compound was evaluated for the binding affinity at 5- HT1A receptor,B,
1072,,5333,9823.0,BAO_0000019,,,,Autocuration,1,Sus scrofa,,8,,H,,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,B,
1073,,4437,9823.0,BAO_0000019,,,,Autocuration,1,Sus scrofa,,8,,H,,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,B,
1074,,1742,9823.0,BAO_0000019,,,,Autocuration,1,Sus scrofa,,8,,H,,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,B,
1075,,16688,9823.0,BAO_0000357,,,,Expert,1,Sus scrofa,,8,,H,,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,B,
1076,,12861,9823.0,BAO_0000357,,,,Autocuration,1,Sus scrofa,,8,,H,,Binding activity radioligand.,B,
1077,,12861,9823.0,BAO_0000019,,,,Expert,1,Sus scrofa,,8,,H,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,B,
1078,,12861,9823.0,BAO_0000019,,,,Autocuration,1,Sus scrofa,,8,,H,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,B,
1079,,12490,,BAO_0000019,,,,Expert,1,,,8,,H,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,B,
1080,,11828,9823.0,BAO_0000019,,,,Expert,1,Sus scrofa,,8,,H,,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,B,
1081,10000000.0,11866,9823.0,BAO_0000221,,,,Autocuration,1,Sus scrofa,,8,,H,,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,B,Hippocampus
1082,,12827,9823.0,BAO_0000249,,,,Autocuration,1,Sus scrofa,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,B,
1083,,12918,9823.0,BAO_0000019,,,,Autocuration,1,Sus scrofa,,8,,H,,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,B,
1084,,12919,9823.0,BAO_0000019,,,,Expert,1,Sus scrofa,,8,,H,,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,F,
1085,,13047,9986.0,BAO_0000019,,,,Autocuration,1,Oryctolagus cuniculus,,8,,H,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,B,
1086,,15796,10116.0,BAO_0000249,,,,Expert,1,Rattus norvegicus,,9,,D,,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,B,
1087,10000000.0,3651,10116.0,BAO_0000221,,,,Expert,1,Rattus norvegicus,,9,,D,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",B,Hippocampus
1088,,188,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,B,
1089,,16616,10116.0,BAO_0000249,,,,Expert,1,Rattus norvegicus,,9,Membranes,D,,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",F,
1090,10000000.0,16616,10116.0,BAO_0000249,,,,Expert,1,Rattus norvegicus,,9,Membranes,D,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",F,Hippocampus
1091,10000000.0,12306,,BAO_0000221,,,,Autocuration,1,,,8,,H,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,Hippocampus
1092,10000000.0,17167,10116.0,BAO_0000221,,,,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,B,Hippocampus
1093,,14776,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,B,
1094,,12158,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,B,
1095,,13481,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,B,
1096,,13427,,BAO_0000219,,,,Autocuration,1,,In vitro,8,,H,,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,
1097,,10210,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,B,
1098,,10205,,BAO_0000249,,,,Autocuration,1,,,8,Membranes,H,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,B,
1099,,10205,,BAO_0000249,,,,Autocuration,1,,,8,Membranes,H,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,B,
1100,,10205,,BAO_0000249,,,,Expert,1,,,8,Membranes,H,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,B,
1101,,12280,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,B,
1102,,17386,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,B,
1103,,13654,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,B,
1104,10000000.0,14423,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,B,Hippocampus
1105,10000000.0,15412,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,B,Hippocampus
1106,10000000.0,12073,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,Hippocampus
1107,,4101,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,B,
1108,,10062,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,B,
1109,,6238,,BAO_0000249,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,B,
1110,,16273,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,
1111,,11139,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,B,
1112,,16796,,BAO_0000019,,,,Expert,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,B,
1113,955.0,9548,10116.0,BAO_0000221,,,,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,Brain
1114,955.0,10381,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,Brain
1115,,13408,,BAO_0000249,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,B,
1116,10000000.0,13825,10116.0,BAO_0000221,,,,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,B,Hippocampus
1117,10000000.0,11147,,BAO_0000221,,,,Expert,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,B,Hippocampus
1118,,10552,,BAO_0000249,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,B,
1119,2435.0,10552,,BAO_0000249,,,,Autocuration,1,,,8,,H,,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",B,Striatum
1120,,17136,10116.0,BAO_0000249,,,,Expert,1,Rattus norvegicus,,9,Membranes,D,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,B,
1121,,5778,10116.0,BAO_0000249,,,,Expert,1,Rattus norvegicus,,9,Membranes,D,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,B,
1122,10000000.0,13481,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,Hippocampus
1123,10000000.0,13481,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,B,Hippocampus
1124,10000000.0,13630,,BAO_0000221,,,,Intermediate,1,,,8,,H,,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,B,Hippocampus
1125,,16245,,BAO_0000249,,,,Expert,1,,,8,,H,,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,
1126,10000000.0,14509,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,B,Hippocampus
1127,10000000.0,14509,,BAO_0000221,,,,Expert,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,B,Hippocampus
1128,10000000.0,14509,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,B,Hippocampus
1129,10000000.0,14509,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,B,Hippocampus
1130,,14256,,BAO_0000019,,,,Expert,1,,,8,,H,,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,B,
1131,,11139,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,B,
1132,,11047,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,B,
1133,,11047,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,B,
1134,,11047,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,B,
1135,,2395,10116.0,BAO_0000219,,,485.0,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,B,
1136,,9699,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,
1137,10000000.0,12028,10116.0,BAO_0000221,,,,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,B,Hippocampus
1138,10000000.0,12028,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,B,Hippocampus
1139,,5815,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,
1140,,16616,,BAO_0000019,,,,Expert,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,B,
1141,,5815,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,B,
1142,10000000.0,2761,,BAO_0000221,,,,Autocuration,1,,,8,,H,,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",B,Hippocampus
1143,,13133,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,B,
1144,,10444,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,B,
1145,,13278,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,B,
1146,,15874,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,
1147,2435.0,10552,,BAO_0000249,,,,Autocuration,1,,,8,Membranes,H,,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",B,Striatum
1148,,11130,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),B,
1149,,11130,,BAO_0000218,,,,Autocuration,1,,In vivo,8,,H,,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),B,
1150,955.0,14542,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,B,Brain
1151,,13670,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,
1152,,9888,,BAO_0000249,,,,Expert,1,,,8,,H,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,B,
1153,,3678,10116.0,BAO_0000249,,,,Expert,1,Rattus norvegicus,,9,Membranes,D,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,B,
1154,10000000.0,11332,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,B,Hippocampus
1155,10000000.0,11332,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,B,Hippocampus
1156,,1185,,BAO_0000357,,,,Expert,1,,,8,,H,,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,B,
1157,,2014,,BAO_0000249,,,,Expert,1,,,8,,H,,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,B,
1158,,1185,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,B,
1159,,14429,,BAO_0000019,,,,Expert,1,,,8,,H,,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,B,
1160,,16288,,BAO_0000019,,,,Expert,1,,,8,,H,,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",B,
1161,,5432,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,B,
1162,,14429,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,B,
1163,,13672,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,B,
1164,10000000.0,11296,,BAO_0000221,,,,Expert,1,,,8,,H,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,Hippocampus
1165,,11296,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,B,
1166,,14749,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,B,
1167,,15086,,BAO_0000019,,,,Expert,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,B,
1168,10000000.0,13462,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,B,Hippocampus
1169,,15363,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,B,
1170,,15363,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,B,
1171,,10796,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,B,
1172,955.0,12816,,BAO_0000221,,,,Expert,1,,,8,,H,,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,B,Brain
1173,10000000.0,13542,,BAO_0000221,,,,Expert,1,,,8,,H,,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,Hippocampus
1174,,13308,,BAO_0000019,,,,Expert,1,,,8,,H,,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,B,
1175,10000000.0,13541,,BAO_0000221,,,,Expert,1,,,8,,H,,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,B,Hippocampus
1176,10000000.0,10058,,BAO_0000221,,,,Autocuration,1,,,8,,H,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,B,Hippocampus
1177,10000000.0,10058,,BAO_0000221,,,,Autocuration,1,,,8,,H,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,B,Hippocampus
1178,10000000.0,10058,,BAO_0000221,,,,Autocuration,1,,,8,,H,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,B,Hippocampus
1179,10000000.0,10058,,BAO_0000221,,,,Autocuration,1,,,8,,H,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,B,Hippocampus
1180,10000000.0,10058,,BAO_0000221,,,,Autocuration,1,,,8,,H,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,B,Hippocampus
1181,10000000.0,10058,,BAO_0000221,,,,Autocuration,1,,,8,,H,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,B,Hippocampus
1182,10000000.0,10058,,BAO_0000221,,,,Autocuration,1,,,8,,H,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,B,Hippocampus
1183,10000000.0,10058,,BAO_0000221,,,,Autocuration,1,,,8,,H,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,B,Hippocampus
1184,10000000.0,10058,,BAO_0000221,,,,Autocuration,1,,,8,,H,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,B,Hippocampus
1185,10000000.0,10058,,BAO_0000221,,,,Autocuration,1,,,8,,H,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,B,Hippocampus
1186,10000000.0,10058,,BAO_0000221,,,,Autocuration,1,,,8,,H,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,B,Hippocampus
1187,10000000.0,10058,,BAO_0000221,,,,Autocuration,1,,,8,,H,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,B,Hippocampus
1188,10000000.0,10058,,BAO_0000221,,,,Autocuration,1,,,8,,H,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,B,Hippocampus
1189,10000000.0,10058,10116.0,BAO_0000221,,,,Expert,1,Rattus norvegicus,,9,,D,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,B,Hippocampus
1190,10000000.0,10058,,BAO_0000221,,,,Autocuration,1,,,8,,H,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,B,Hippocampus
1191,10000000.0,10058,,BAO_0000221,,,,Autocuration,1,,,8,,H,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,B,Hippocampus
1192,,12879,,BAO_0000019,,,,Expert,1,,,8,,H,,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,B,
1193,,11964,,BAO_0000019,,,,Expert,1,,,8,,H,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,B,
1194,,11964,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),B,
1195,,11964,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),B,
1196,955.0,9548,,BAO_0000221,,,,Expert,1,,,8,,H,,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,Brain
1197,,9098,,BAO_0000019,,,,Expert,1,,,8,,H,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,B,
1198,,9098,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,B,
1199,,9098,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,B,
1200,,13248,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,B,
1201,,3147,,BAO_0000249,,,,Expert,1,,,8,,H,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,B,
1202,,13949,,BAO_0000019,,,,Expert,1,,,8,,H,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,B,
1203,,11883,,BAO_0000218,,,449.0,Autocuration,1,,,8,,H,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),B,
1204,,11883,,BAO_0000218,,,,Autocuration,1,,,8,,H,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),B,
1205,,11883,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,B,
1206,,15535,,BAO_0000249,,,,Expert,1,,,8,Membranes,H,,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,
1207,,15535,,BAO_0000249,,,,Autocuration,1,,,8,,H,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,B,
1208,,15535,,BAO_0000249,,,,Autocuration,1,,,8,,H,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,B,
1209,,16372,9606.0,BAO_0000219,,,449.0,Expert,1,Homo sapiens,,9,,D,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,B,
1210,,14608,,BAO_0000249,,,,Expert,1,,,8,,H,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,B,
1211,10000000.0,4795,10116.0,BAO_0000221,,,,Expert,1,Rattus norvegicus,,9,,D,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,B,Hippocampus
1212,,13863,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,
1213,,13863,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,B,
1214,,13863,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,B,
1215,,13863,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,B,
1216,,13863,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,B,
1217,,13863,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,B,
1218,,13863,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,B,
1219,,13863,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,B,
1220,,13863,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,B,
1221,,13863,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,B,
1222,,13863,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,B,
1223,,13863,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,B,
1224,,13863,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,B,
1225,,13863,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,B,
1226,,13863,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,B,
1227,,9742,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,B,
1228,,12073,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,B,
1229,,4101,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,B,
1230,,15360,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,B,
1231,10000000.0,11576,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,Hippocampus
1232,,5834,,BAO_0000019,,,,Expert,1,,,8,,H,,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,B,
1233,,2395,10116.0,BAO_0000219,,,485.0,Expert,1,Rattus norvegicus,,9,,D,,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,B,
1234,,1375,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,B,
1235,,1375,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,B,
1236,,3967,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),B,
1237,,12884,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,B,
1238,,2343,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,B,
1239,,11511,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",B,
1240,,11511,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",B,
1241,,16394,,BAO_0000218,,,,Autocuration,1,,In vivo,8,,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,F,
1242,,16394,,BAO_0000218,,,,Autocuration,1,,In vivo,8,,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),F,
1243,,16394,,BAO_0000218,,,,Autocuration,1,,In vivo,8,,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),F,
1244,,16394,,BAO_0000218,,,,Autocuration,1,,In vivo,8,,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),F,
1245,,16394,,BAO_0000218,,,,Autocuration,1,,In vivo,8,,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),F,
1246,,16394,,BAO_0000218,,,,Autocuration,1,,In vivo,8,,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),F,
1247,,16394,,BAO_0000218,,,,Autocuration,1,,In vivo,8,,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),F,
1248,,16394,,BAO_0000218,,,,Autocuration,1,,In vivo,8,,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),F,
1249,,16394,,BAO_0000218,,,,Autocuration,1,,In vivo,8,,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),F,
1250,,16394,,BAO_0000218,,,,Autocuration,1,,In vivo,8,,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),F,
1251,,16394,,BAO_0000218,,,,Autocuration,1,,In vivo,8,,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),F,
1252,,16394,,BAO_0000218,,,,Autocuration,1,,In vivo,8,,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),F,
1253,,16394,,BAO_0000218,,,,Autocuration,1,,In vivo,8,,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),F,
1254,,16394,,BAO_0000218,,,,Autocuration,1,,In vivo,8,,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),F,
1255,,16394,,BAO_0000218,,,,Autocuration,1,,In vivo,8,,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,F,
1256,,16616,10116.0,BAO_0000249,,,,Expert,1,Rattus norvegicus,,9,Membranes,D,,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",F,
1257,,16796,,BAO_0000019,,,,Autocuration,1,,,8,,H,,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,B,
1258,,16796,,BAO_0000019,,,,Autocuration,1,,,8,,H,,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,B,
1259,,15629,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,B,
1260,,13241,,BAO_0000249,,,,Autocuration,1,,,8,,H,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",F,
1261,10000000.0,12073,,BAO_0000221,,,,Expert,1,,,8,,H,,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,Hippocampus
1262,10000000.0,14286,,BAO_0000249,,,,Autocuration,1,,,8,,H,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,B,Hippocampus
1263,955.0,14542,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,B,Brain
1264,,13630,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,F,
1265,,13630,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,F,
1266,,13630,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,F,
1267,,13630,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,F,
1268,,13630,,BAO_0000019,,,,Expert,1,,,8,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,F,
1269,,13630,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,F,
1270,,13630,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,F,
1271,,13630,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,F,
1272,,13630,,BAO_0000019,,,,Expert,1,,,8,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,F,
1273,,13630,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,F,
1274,,13630,,BAO_0000019,,,,Expert,1,,,8,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,F,
1275,,13630,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,F,
1276,,13630,,BAO_0000019,,,,Expert,1,,,8,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,F,
1277,,13630,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,F,
1278,,13630,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,F,
1279,,13630,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,F,
1280,,13630,,BAO_0000019,,,,Expert,1,,,8,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,F,
1281,,13630,,BAO_0000019,,,,Expert,1,,,8,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,F,
1282,,13630,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,F,
1283,,13630,,BAO_0000019,,,,Expert,1,,,8,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,F,
1284,,13630,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,F,
1285,,13630,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,F,
1286,,13630,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,F,
1287,,13630,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,F,
1288,10000000.0,9783,,BAO_0000221,,,,Autocuration,1,,,8,,H,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,B,Hippocampus
1289,10000000.0,9783,,BAO_0000221,,,,Expert,1,,,8,,H,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,B,Hippocampus
1290,,14331,10116.0,BAO_0000249,,,,Expert,1,Rattus norvegicus,,9,Membranes,D,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,B,
1291,10000000.0,15260,,BAO_0000221,,,,Expert,1,,,8,,H,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,B,Hippocampus
1292,10000000.0,15260,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,B,Hippocampus
1293,10000000.0,15260,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,B,Hippocampus
1294,,16616,10116.0,BAO_0000249,,,,Expert,1,Rattus norvegicus,,9,,D,,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",F,
1295,,15629,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,B,
1296,,15086,,BAO_0000019,,,,Autocuration,1,,,8,,H,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,B,
1297,,5717,,BAO_0000019,,,,Expert,1,,,8,,H,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,F,
1298,,12652,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,B,
1299,10000000.0,14608,,BAO_0000221,,,,Autocuration,1,,,8,,H,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,B,Hippocampus
1300,10000000.0,12306,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,Hippocampus
1301,10000000.0,12306,,BAO_0000221,,,,Autocuration,1,,,8,,H,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,Hippocampus
1302,,15247,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,
1303,10000000.0,17529,,BAO_0000221,,,,Expert,1,,,8,,H,,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,B,Hippocampus
1304,10000000.0,14826,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,B,Hippocampus
1305,10000000.0,14826,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,B,Hippocampus
1306,10000000.0,13241,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,Hippocampus
1307,10000000.0,14093,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,B,Hippocampus
1308,10000000.0,14093,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,B,Hippocampus
1309,955.0,14442,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,B,Brain
1310,,9919,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Affinity for 5-hydroxytryptamine 1A receptor site,B,
1311,,9919,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Affinity for 5-hydroxytryptamine 1A receptor site,B,
1312,10000000.0,11440,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,B,Hippocampus
1313,,11257,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,B,
1314,,10330,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,B,
1315,10000000.0,17331,10116.0,BAO_0000221,,,,Expert,1,Rattus norvegicus,,9,,D,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,B,Hippocampus
1316,,16567,,BAO_0000249,,,,Expert,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,B,
1317,,12058,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",B,
1318,10000000.0,9699,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,B,Hippocampus
1319,,9547,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,B,
1320,,10330,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,B,
1321,,14331,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,B,
1322,,14060,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,B,
1323,10000000.0,14744,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,B,Hippocampus
1324,,13506,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,B,
1325,955.0,10862,,BAO_0000221,,,,Expert,1,,,8,,H,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,Brain
1326,955.0,10862,,BAO_0000221,,,,Expert,1,,,8,,H,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,Brain
1327,,10062,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,B,
1328,,12073,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,B,
1329,,14875,,BAO_0000357,,,,Autocuration,1,,,8,,H,,GTPgammaS radioligand binding assay,B,
1330,,2391,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,B,
1331,,2391,,BAO_0000019,,,,Autocuration,1,,,8,,H,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,F,
1332,,2391,,BAO_0000019,,,,Autocuration,1,,,8,,H,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,F,
1333,,2391,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,B,
1334,,2391,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,B,
1335,,2391,,BAO_0000019,,,,Autocuration,1,,,8,,H,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,F,
1336,,17211,,BAO_0000219,,,308.0,Expert,1,,,8,,H,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,B,
1337,,17211,,BAO_0000219,,,308.0,Autocuration,1,,,8,,H,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,B,
1338,,6491,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,B,
1339,,16190,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,B,
1340,,14165,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,B,
1341,,14165,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,B,
1342,,4234,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,B,
1343,,6328,,BAO_0000219,,,,Expert,1,,,8,,H,,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,B,
1344,,14770,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,
1345,,2598,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,B,
1346,,6897,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,B,
1347,,6897,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,B,
1348,,6013,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1B receptor,B,
1349,,5843,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,B,
1350,,14454,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,B,
1351,,16209,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,B,
1352,,3935,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,B,
1353,,13729,,BAO_0000219,,,485.0,Expert,1,,,8,,H,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,F,
1354,,14251,,BAO_0000019,,,,Expert,1,,,8,,H,,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,F,
1355,,17085,,BAO_0000019,,,,Expert,1,,,8,,H,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,B,
1356,,3025,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,B,
1357,,15315,,BAO_0000357,,,,Expert,1,,,8,,H,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,B,
1358,,14214,9606.0,BAO_0000219,,,,Expert,1,Homo sapiens,,9,,D,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,B,
1359,,3804,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,B,
1360,,2391,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Affinity for 5-hydroxytryptamine 1B receptor subtype,B,
1361,,4175,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding affinity for human 5-hydroxytryptamine 1B receptor,B,
1362,,17296,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,B,
1363,,17085,,BAO_0000019,,,,Expert,1,,,8,,H,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,B,
1364,,17211,,BAO_0000219,,,308.0,Autocuration,1,,,8,,H,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,B,
1365,,17211,,BAO_0000219,,,308.0,Autocuration,1,,,8,,H,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,B,
1366,,17211,,BAO_0000219,,,308.0,Autocuration,1,,,8,,H,,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,B,
1367,,15926,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,B,
1368,,16312,,BAO_0000219,,,485.0,Autocuration,1,,,8,,H,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,B,
1369,,5843,,BAO_0000357,,,,Expert,1,,,8,,H,,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,B,
1370,,5843,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,B,
1371,,16312,,BAO_0000219,,,485.0,Expert,1,,,8,,H,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,B,
1372,,15926,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding activity against human 5-hydroxytryptamine 1B receptor,B,
1373,,15926,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding activity against human 5-hydroxytryptamine 1B receptor,B,
1374,,4540,9606.0,BAO_0000219,,,449.0,Expert,1,Homo sapiens,,9,,D,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,B,
1375,,6166,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,B,
1376,,17296,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,B,
1377,,17296,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,B,
1378,,17296,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,B,
1379,,15779,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,
1380,,15779,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,
1381,,15779,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,B,
1382,,4199,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,B,
1383,,14875,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding affinity for human 5-hydroxytryptamine 1B receptor,B,
1384,,15146,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,B,
1385,,5213,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,B,
1386,,14818,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,B,
1387,,4829,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",B,
1388,,14454,,BAO_0000019,,,,Expert,1,,,8,,H,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,F,
1389,,14454,,BAO_0000019,,,,Expert,1,,,8,,H,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,F,
1390,,14875,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",F,
1391,,14875,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",F,
1392,,15250,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",F,
1393,,15250,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,B,
1394,,15086,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,B,
1395,,3025,9986.0,BAO_0000019,,,,Autocuration,1,Oryctolagus cuniculus,,8,,H,,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,F,
1396,,14998,9986.0,BAO_0000019,,,,Autocuration,1,Oryctolagus cuniculus,,8,,H,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,B,
1397,,14998,9986.0,BAO_0000019,,,,Intermediate,1,Oryctolagus cuniculus,,8,,H,,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",B,
1398,,14998,9986.0,BAO_0000019,,,,Autocuration,1,Oryctolagus cuniculus,,8,,H,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,B,
1399,,13969,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,B,
1400,,13392,,BAO_0000357,,,,Intermediate,1,,,9,,D,,Binding affinity for 5-hydroxytryptamine 1B receptor,B,
1401,2435.0,3651,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,B,Striatum
1402,,10025,,BAO_0000357,,,,Expert,1,,,8,,H,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,B,
1403,,13863,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,B,
1404,,13863,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,B,
1405,,13863,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,B,
1406,,13863,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,B,
1407,,13863,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,B,
1408,,13863,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,B,
1409,10000000.0,4622,,BAO_0000249,,,,Autocuration,1,,,8,,H,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,B,Hippocampus
1410,,14911,,BAO_0000019,,,,Intermediate,1,,,8,,H,,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,B,
1411,10000000.0,12678,,BAO_0000221,,,,Autocuration,1,,,8,,H,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,B,Hippocampus
1412,10000000.0,12678,,BAO_0000221,,,,Expert,1,,,8,,H,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,B,Hippocampus
1413,10000000.0,14235,,BAO_0000221,,,,Expert,1,,,8,,H,,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,Hippocampus
1414,10000000.0,14949,,BAO_0000221,,,,Expert,1,,,8,,H,,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,B,Hippocampus
1415,10000000.0,14949,,BAO_0000221,,,,Expert,1,,,8,,H,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,B,Hippocampus
1416,10000000.0,14949,,BAO_0000221,,,,Expert,1,,,8,,H,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,B,Hippocampus
1417,10000000.0,14949,,BAO_0000221,,,,Expert,1,,,8,,H,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,B,Hippocampus
1418,10000000.0,14949,,BAO_0000221,,,,Expert,1,,,8,,H,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,B,Hippocampus
1419,,16118,,BAO_0000249,,,,Expert,1,,,8,,H,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,B,
1420,,3268,,BAO_0000249,,,,Autocuration,1,,,8,,H,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,B,
1421,,3268,,BAO_0000249,,,,Autocuration,1,,,8,,H,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,B,
1422,,16117,,BAO_0000357,,,,Expert,1,,,8,,H,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,B,
1423,10000000.0,9783,,BAO_0000221,,,,Expert,1,,,8,,H,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,B,Hippocampus
1424,10000000.0,9783,,BAO_0000221,,,,Autocuration,1,,,8,,H,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,B,Hippocampus
1425,10000000.0,14356,10116.0,BAO_0000221,,,,Expert,1,Rattus norvegicus,,9,,D,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,B,Hippocampus
1426,,15740,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,F,
1427,10000000.0,12306,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,Hippocampus
1428,10000000.0,13348,10116.0,BAO_0000221,,,,Expert,1,Rattus norvegicus,,9,,D,,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,B,Hippocampus
1429,,10394,,BAO_0000249,,,,Autocuration,1,,,8,,H,,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,B,
1430,10000000.0,15260,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,B,Hippocampus
1431,10000000.0,10046,,BAO_0000221,,,,Expert,1,,,8,,H,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,Hippocampus
1432,10000000.0,15260,,BAO_0000221,,,,Intermediate,1,,,8,,H,,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,F,Hippocampus
1433,,12851,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,B,
1434,10000000.0,2148,10116.0,BAO_0000221,,,,Expert,1,Rattus norvegicus,,9,,D,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,B,Hippocampus
1435,,13134,,BAO_0000357,,,,Expert,1,,,8,,H,,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,B,
1436,,12462,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,B,
1437,,12462,,BAO_0000019,,,,Expert,1,,,8,,H,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,B,
1438,,12462,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,B,
1439,,11933,,BAO_0000357,,,,Expert,1,,,8,,H,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,B,
1440,,11933,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,B,
1441,10000000.0,403,10116.0,BAO_0000221,,,,Expert,1,Rattus norvegicus,,9,,D,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,B,Hippocampus
1442,10000000.0,15538,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,B,Hippocampus
1443,10000000.0,15538,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,B,Hippocampus
1444,10000000.0,15538,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,B,Hippocampus
1445,,12464,,BAO_0000019,,,,Intermediate,1,,,8,,H,,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,B,
1446,,1455,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,B,
1447,,12652,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,B,
1448,10000000.0,12639,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,B,Hippocampus
1449,,13949,,BAO_0000249,,,,Expert,1,,,8,,H,,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,B,
1450,,12463,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,B,
1451,10000000.0,14829,,BAO_0000221,,,,Expert,1,,,8,,H,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,B,Hippocampus
1452,10000000.0,14829,,BAO_0000221,,,,Autocuration,1,,,8,,H,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,B,Hippocampus
1453,,12092,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,B,
1454,,403,,BAO_0000249,,,,Autocuration,1,,,8,,H,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,B,
1455,,403,,BAO_0000249,,,,Autocuration,1,,,8,,H,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,B,
1456,,3967,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,B,
1457,,12771,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,B,
1458,,15086,,BAO_0000019,,,,Autocuration,1,,,8,,H,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,B,
1459,10000000.0,14909,,BAO_0000221,,,,Autocuration,1,,,8,,H,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,B,Hippocampus
1460,10000000.0,14949,,BAO_0000221,,,,Expert,1,,,8,,H,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,B,Hippocampus
1461,10000000.0,2309,10116.0,BAO_0000221,,,,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,B,Hippocampus
1462,,4170,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,
1463,10000000.0,11642,10116.0,BAO_0000221,,,,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,B,Hippocampus
1464,10000000.0,11642,,BAO_0000221,,,,Autocuration,1,,,8,,H,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,B,Hippocampus
1465,10000000.0,12953,,BAO_0000221,,,,Autocuration,1,,,8,,H,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,B,Hippocampus
1466,10000000.0,12953,,BAO_0000221,,,,Autocuration,1,,,8,,H,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,B,Hippocampus
1467,10000000.0,12953,,BAO_0000221,,,,Expert,1,,,8,,H,,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,B,Hippocampus
1468,,12903,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",B,
1469,,12536,,BAO_0000357,,,,Expert,1,,,8,,H,,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,
1470,,10058,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The inhibition activity of 5-HT1A at 1 uM,B,
1471,,12902,,BAO_0000219,,,485.0,Expert,1,,,8,,H,,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",B,
1472,,14057,,BAO_0000249,,,,Expert,1,,,8,,H,,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,B,
1473,,11296,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,B,
1474,10000000.0,11296,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,Hippocampus
1475,10000000.0,11296,,BAO_0000221,,,,Expert,1,,,8,,H,,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,Hippocampus
1476,,16616,10116.0,BAO_0000249,,,,Expert,1,Rattus norvegicus,,9,Membranes,D,,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,F,
1477,10000000.0,16616,10116.0,BAO_0000249,,,,Expert,1,Rattus norvegicus,,9,Membranes,D,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",F,Hippocampus
1478,,16567,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,B,
1479,,16567,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,B,
1480,,16567,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,B,
1481,,16567,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,B,
1482,,17136,,BAO_0000249,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,B,
1483,,17136,,BAO_0000249,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,B,
1484,,16616,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,B,
1485,10000000.0,17331,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,B,Hippocampus
1486,10000000.0,17331,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,B,Hippocampus
1487,10000000.0,17167,10116.0,BAO_0000221,,,,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,B,Hippocampus
1488,,15740,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,F,
1489,,15740,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,F,
1490,,4671,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Ratio of binding affinity to 5-HT 1A and D2 receptor,B,
1491,10000000.0,10058,,BAO_0000221,,,,Autocuration,1,,,8,,H,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,B,Hippocampus
1492,10000000.0,10058,,BAO_0000221,,,,Autocuration,1,,,8,,H,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,B,Hippocampus
1493,10000000.0,10058,,BAO_0000221,,,,Autocuration,1,,,8,,H,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,B,Hippocampus
1494,,12073,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Percentage inhibition against 5-hydroxytryptamine 1A receptor,B,
1495,,2759,,BAO_0000249,,,,Autocuration,1,,,8,,H,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),B,
1496,,2759,,BAO_0000249,,,,Autocuration,1,,,8,,H,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),F,
1497,,2759,,BAO_0000249,,,,Autocuration,1,,,8,,H,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),B,
1498,,2759,,BAO_0000249,,,,Autocuration,1,,,8,,H,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),F,
1499,,2759,,BAO_0000249,,,,Autocuration,1,,,8,,H,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,F,
1500,955.0,9737,,BAO_0000249,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,Brain
1501,,9737,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,B,
1502,,5717,,BAO_0000019,,,,Expert,1,,,8,,H,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,F,
1503,10000000.0,12253,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,Hippocampus
1504,,14025,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,B,
1505,,10425,,BAO_0000249,,,,Expert,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,B,
1506,,14998,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,B,
1507,10000000.0,13694,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,B,Hippocampus
1508,10000000.0,13694,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,B,Hippocampus
1509,,4342,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,B,
1510,,12936,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,B,
1511,,13144,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,B,
1512,,13343,,BAO_0000019,,,,Expert,1,,,8,,H,,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,B,
1513,,12132,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,
1514,,15419,,BAO_0000019,,,,Expert,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,B,
1515,10000000.0,1479,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,Hippocampus
1516,,14287,,BAO_0000019,,,,Expert,1,,,8,,H,,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,B,
1517,,13116,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity at 5-hydroxytryptamine 1A receptor,B,
1518,,2759,10116.0,BAO_0000249,,,,Expert,1,Rattus norvegicus,,9,Membranes,D,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,B,
1519,,2759,,BAO_0000249,,,,Autocuration,1,,,8,,H,,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,B,
1520,,14748,,BAO_0000019,,,,Expert,1,,,8,,H,,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",B,
1521,,12304,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,
1522,10000000.0,12409,10116.0,BAO_0000221,,,,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,B,Hippocampus
1523,10000000.0,12409,10116.0,BAO_0000221,,,,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,B,Hippocampus
1524,10000000.0,13267,,BAO_0000221,,,,Autocuration,1,,,8,,H,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,B,Hippocampus
1525,,15194,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,
1526,,14256,,BAO_0000357,,,,Expert,1,,,8,,H,,pKi value against rat 5-hydroxytryptamine 1A receptor.,B,
1527,,16567,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,B,
1528,,15740,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,F,
1529,,13278,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,B,
1530,,1970,,BAO_0000249,,,,Expert,1,,,8,Membranes,H,,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,
1531,955.0,10034,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,B,Brain
1532,,13348,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,8,,H,,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,B,
1533,,13630,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,F,
1534,955.0,10862,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,Brain
1535,,12058,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",B,
1536,,4639,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,B,
1537,,15453,,BAO_0000357,,,,Expert,1,,,8,,H,,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,B,
1538,,4820,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,
1539,,1089,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,B,
1540,,386,,BAO_0000249,,,,Autocuration,1,,,8,Brain membranes,H,,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,B,
1541,,6011,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,B,
1542,,5014,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,B,
1543,,4402,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,B,
1544,,17066,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,
1545,,17515,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,B,
1546,,2474,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor,B,
1547,,4775,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,B,
1548,,14294,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,B,
1549,,14294,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,B,
1550,,12249,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,
1551,,11376,,BAO_0000219,,,,Expert,1,,,8,,H,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,B,
1552,,2474,,BAO_0000218,,,,Autocuration,1,,In vivo,8,,H,,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,
1553,10000000.0,13311,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,Hippocampus
1554,,4373,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,B,
1555,,1633,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,B,
1556,,11866,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,B,
1557,,4373,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,B,
1558,,4687,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,B,
1559,,16946,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,
1560,,13291,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,B,
1561,,14159,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,B,
1562,,10812,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,B,
1563,,3032,10090.0,BAO_0000219,,,449.0,Expert,1,Mus musculus,,9,,D,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,B,
1564,,16655,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,
1565,,14532,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,B,
1566,,13944,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor,B,
1567,,13033,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against serotonergic 5-HT1a receptor,B,
1568,,10321,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,B,
1569,,2968,10090.0,BAO_0000357,,,,Expert,1,Mus musculus,,9,,D,,Binding affinity for 5-hydroxytryptamine 1A receptor,B,
1570,,13964,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity at 5-hydroxytryptamine 1A receptor,B,
1571,,15527,,BAO_0000357,,,,Autocuration,1,,,8,,H,,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",B,
1572,,12248,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,
1573,,12249,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,
1574,,15120,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,B,
1575,,13313,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,B,
1576,,2613,,BAO_0000218,,,,Autocuration,1,,,8,,H,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,B,
1577,,16700,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,B,
1578,,2201,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,B,
1579,,1274,10090.0,BAO_0000357,,,,Expert,1,Mus musculus,,9,,D,,Binding affinity against 5-hydroxytryptamine 1A receptor,B,
1580,,1317,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,B,
1581,,12146,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested against 5-hydroxytryptamine 1A receptor,B,
1582,,14059,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,B,
1583,,14025,9986.0,BAO_0000019,,,,Expert,1,Oryctolagus cuniculus,,8,,H,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,B,
1584,,14025,9986.0,BAO_0000019,,,,Autocuration,1,Oryctolagus cuniculus,,8,,H,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,B,
1585,,14447,9593.0,BAO_0000219,,,722.0,Intermediate,1,Gorilla gorilla,,9,,D,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,B,
1586,,3025,10141.0,BAO_0000218,,,,Autocuration,1,Cavia porcellus,In vivo,8,,H,,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,F,
1587,,3025,10141.0,BAO_0000218,,,,Autocuration,1,Cavia porcellus,In vivo,8,,H,,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,F,
1588,,15329,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,8,,H,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,F,
1589,,15329,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,8,,H,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,F,
1590,,15847,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,8,,H,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,F,
1591,,15847,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,8,,H,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,F,
1592,,14165,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,F,
1593,,14214,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),F,
1594,,14214,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),F,
1595,,14214,9606.0,BAO_0000019,,,,Expert,1,Homo sapiens,,9,,D,,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,F,
1596,,13729,9606.0,BAO_0000219,,,485.0,Expert,1,Homo sapiens,,9,,D,,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,F,
1597,,3025,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,F,
1598,,2391,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,B,
1599,,2391,,BAO_0000019,,,,Autocuration,1,,,8,,H,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,F,
1600,,14956,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",F,
1601,,2598,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,F,
1602,,2598,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,F,
1603,,2598,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,F,
1604,,2598,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,F,
1605,,14956,,BAO_0000019,,,,Expert,1,,,8,,H,,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",F,
1606,,14956,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",F,
1607,,14214,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,B,
1608,,3463,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,B,
1609,,15331,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,B,
1610,,16146,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding affinity against 5-hydroxytryptamine 1B receptor,B,
1611,,14159,9606.0,BAO_0000219,,,449.0,Expert,1,Homo sapiens,,9,,D,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,B,
1612,,14158,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,B,
1613,,14159,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,B,
1614,,15250,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,B,
1615,,15250,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,B,
1616,,15331,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,B,
1617,,15332,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,B,
1618,,14956,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,B,
1619,,3805,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),B,
1620,,14875,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,B,
1621,,14454,9986.0,BAO_0000019,,,,Autocuration,1,Oryctolagus cuniculus,,8,,H,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),F,
1622,,14454,9986.0,BAO_0000019,,,,Expert,1,Oryctolagus cuniculus,,8,,H,,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),F,
1623,,16288,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),B,
1624,,16288,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),B,
1625,,16312,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,B,
1626,,1348,9913.0,BAO_0000357,,,,Expert,1,Bos taurus,,8,,H,,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,B,
1627,,5834,9913.0,BAO_0000357,,,,Autocuration,1,Bos taurus,,8,,H,,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,B,
1628,2435.0,13366,9913.0,BAO_0000019,,,,Autocuration,1,Bos taurus,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,B,Striatum
1629,,1414,9913.0,BAO_0000357,,,,Expert,1,Bos taurus,,8,,H,,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,B,
1630,,14998,9913.0,BAO_0000019,,,,Autocuration,1,Bos taurus,,8,,H,,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,B,
1631,,11473,9913.0,BAO_0000357,,,,Autocuration,1,Bos taurus,,8,,H,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,B,
1632,,11473,9913.0,BAO_0000357,,,,Autocuration,1,Bos taurus,,8,,H,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,B,
1633,,10639,9913.0,BAO_0000357,,,,Autocuration,1,Bos taurus,,8,,H,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,B,
1634,,10639,9913.0,BAO_0000357,,,,Autocuration,1,Bos taurus,,8,,H,,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,B,
1635,,1375,9913.0,BAO_0000357,,,,Autocuration,1,Bos taurus,,8,,H,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,B,
1636,,1375,9913.0,BAO_0000357,,,,Autocuration,1,Bos taurus,,8,,H,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,B,
1637,,16532,9913.0,BAO_0000357,,,,Autocuration,1,Bos taurus,,8,,H,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,B,
1638,,11147,9913.0,BAO_0000357,,,,Autocuration,1,Bos taurus,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,B,
1639,2435.0,13366,9913.0,BAO_0000019,,,,Autocuration,1,Bos taurus,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,B,Striatum
1640,,10444,9913.0,BAO_0000019,,,,Autocuration,1,Bos taurus,,8,,H,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,B,
1641,,16532,9913.0,BAO_0000357,,,,Autocuration,1,Bos taurus,,8,,H,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,B,
1642,,16532,9913.0,BAO_0000357,,,,Autocuration,1,Bos taurus,,8,,H,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,B,
1643,,12827,9913.0,BAO_0000249,,,,Autocuration,1,Bos taurus,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,B,
1644,,12827,9913.0,BAO_0000249,,,,Autocuration,1,Bos taurus,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,B,
1645,,12919,9913.0,BAO_0000019,,,,Expert,1,Bos taurus,,8,,H,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,
1646,,14025,9913.0,BAO_0000019,,,,Autocuration,1,Bos taurus,,8,,H,,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,B,
1647,,12919,9913.0,BAO_0000019,,,,Expert,1,Bos taurus,,8,,H,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,
1648,,12919,9913.0,BAO_0000019,,,,Expert,1,Bos taurus,,8,,H,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,
1649,,12919,9913.0,BAO_0000019,,,,Expert,1,Bos taurus,,8,,H,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,
1650,,14447,9593.0,BAO_0000219,,,722.0,Autocuration,1,Gorilla gorilla,,8,,H,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,B,
1651,,1375,10141.0,BAO_0000019,,,,Intermediate,1,Cavia porcellus,,9,,D,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,B,
1652,,1375,10141.0,BAO_0000019,,,,Intermediate,1,Cavia porcellus,,9,,D,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,B,
1653,,12409,10141.0,BAO_0000019,,,,Intermediate,1,Cavia porcellus,,9,,D,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,F,
1654,,12409,10141.0,BAO_0000019,,,,Intermediate,1,Cavia porcellus,,9,,D,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,
1655,,12409,10141.0,BAO_0000019,,,,Intermediate,1,Cavia porcellus,,9,,D,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,F,
1656,,12409,10141.0,BAO_0000019,,,,Intermediate,1,Cavia porcellus,,9,,D,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,F,
1657,,12409,10141.0,BAO_0000019,,,,Intermediate,1,Cavia porcellus,,9,,D,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,F,
1658,,11574,10141.0,BAO_0000357,,,,Intermediate,1,Cavia porcellus,,9,,D,,Binding affinity against 5-hydroxytryptamine 1D receptor,B,
1659,,1558,10141.0,BAO_0000357,,,,Intermediate,1,Cavia porcellus,,9,,D,,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,B,
1660,,12409,10141.0,BAO_0000218,,,,Intermediate,1,Cavia porcellus,,9,,D,,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,
1661,,12409,10141.0,BAO_0000218,,,,Intermediate,1,Cavia porcellus,,9,,D,,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,
1662,,12409,10141.0,BAO_0000218,,,,Intermediate,1,Cavia porcellus,,9,,D,,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,
1663,,12409,10141.0,BAO_0000218,,,,Intermediate,1,Cavia porcellus,,9,,D,,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,F,
1664,,12253,10141.0,BAO_0000019,,,,Intermediate,1,Cavia porcellus,,9,,D,,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,B,
1665,,12936,10141.0,BAO_0000357,,,,Intermediate,1,Cavia porcellus,,9,,D,,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,B,
1666,,13181,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,8,,H,,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,B,
1667,2435.0,12409,10141.0,BAO_0000357,,,,Intermediate,1,Cavia porcellus,,9,,D,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,B,Striatum
1668,,10639,10141.0,BAO_0000357,,,,Intermediate,1,Cavia porcellus,,9,,D,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,B,
1669,,5254,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1D receptor,B,
1670,,13051,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,B,
1671,,3463,,BAO_0000019,,,,Expert,1,,,8,,H,,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,F,
1672,,15315,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,F,
1673,,6011,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,F,
1674,,14159,9606.0,BAO_0000219,,,449.0,Expert,1,Homo sapiens,,9,,D,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",F,
1675,,14159,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",F,
1676,,15250,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,B,
1677,,15250,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,B,
1678,,15331,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",F,
1679,,15332,9606.0,BAO_0000219,,,449.0,Expert,1,Homo sapiens,,9,,D,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",F,
1680,,15332,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",F,
1681,,3294,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",F,
1682,,14158,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",F,
1683,,14956,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",F,
1684,,12469,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,F,
1685,,3463,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,F,
1686,,15250,9606.0,BAO_0000219,,,449.0,Expert,1,Homo sapiens,,9,,D,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",F,
1687,,15250,9606.0,BAO_0000219,,,449.0,Expert,1,Homo sapiens,,9,,D,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",F,
1688,,14956,,BAO_0000019,,,,Expert,1,,,8,,H,,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",F,
1689,,14159,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",F,
1690,,14159,9606.0,BAO_0000019,,,,Expert,1,Homo sapiens,,9,,D,,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",F,
1691,,14499,9606.0,BAO_0000219,,,449.0,Expert,1,Homo sapiens,,9,,D,,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,F,
1692,,15315,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Intrinsic activity for 5-hydroxytryptamine 1D receptor,F,
1693,,3294,,BAO_0000219,,,,Autocuration,1,,In vitro,8,,H,,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),B,
1694,,3463,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,B,
1695,,15331,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,B,
1696,,14159,9606.0,BAO_0000219,,,449.0,Expert,1,Homo sapiens,,9,,D,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,
1697,,14158,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,B,
1698,,14159,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,B,
1699,,15250,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,B,
1700,,15250,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,
1701,,15331,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,
1702,,15332,9606.0,BAO_0000219,,,449.0,Expert,1,Homo sapiens,,9,,D,,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,
1703,,14499,9606.0,BAO_0000219,,,449.0,Expert,1,Homo sapiens,,9,,D,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,
1704,,15332,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,
1705,,14956,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,
1706,,3805,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),B,
1707,,6011,9606.0,BAO_0000219,,,449.0,Expert,1,Homo sapiens,,9,,D,,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,B,
1708,,16190,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,B,
1709,,14165,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,B,
1710,,4234,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,B,
1711,,15527,,BAO_0000357,,,,Autocuration,1,,,8,,H,,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",B,
1712,,6328,,BAO_0000219,,,,Expert,1,,,8,,H,,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,B,
1713,,16209,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,B,
1714,,14770,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,B,
1715,,2598,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,B,
1716,,6897,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,B,
1717,,6013,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1D receptor,B,
1718,,5843,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,B,
1719,,14454,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,B,
1720,,14454,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,B,
1721,,14454,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,B,
1722,,15818,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,B,
1723,,13729,,BAO_0000219,,,485.0,Expert,1,,,8,,H,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,F,
1724,,6011,9606.0,BAO_0000219,,,,Expert,1,Homo sapiens,In vitro,9,,D,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),B,
1725,,4234,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,B,
1726,,17085,,BAO_0000019,,,,Expert,1,,,8,,H,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,B,
1727,,3025,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,B,
1728,,15315,,BAO_0000357,,,,Expert,1,,,8,,H,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,B,
1729,,14214,9606.0,BAO_0000219,,,,Expert,1,Homo sapiens,,9,,D,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,B,
1730,,3804,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,
1731,,16700,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,B,
1732,,2391,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Affinity for 5-hydroxytryptamine 1D receptor subtype,B,
1733,,4175,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,
1734,,17085,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,B,
1735,,17085,,BAO_0000019,,,,Expert,1,,,8,,H,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,B,
1736,,15926,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,B,
1737,,16312,,BAO_0000219,,,485.0,Autocuration,1,,,8,,H,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,B,
1738,,16312,,BAO_0000219,,,485.0,Autocuration,1,,,8,,H,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,B,
1739,,14956,,BAO_0000219,,,449.0,Autocuration,1,,,4,,H,,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,B,
1740,,3294,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",F,
1741,,12861,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding activity radioligand.,B,
1742,,12861,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,
1743,,16312,,BAO_0000219,,,485.0,Expert,1,,,8,,H,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,B,
1744,,5104,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,B,
1745,,5105,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,B,
1746,,14499,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,B,
1747,,15926,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding activity against human 5-hydroxytryptamine 1D receptor,B,
1748,,4540,9606.0,BAO_0000219,,,449.0,Expert,1,Homo sapiens,,9,,D,,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,B,
1749,,15779,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,B,
1750,,15779,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,
1751,,6166,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,B,
1752,,15779,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,B,
1753,,15779,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,B,
1754,,17451,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,B,
1755,,17451,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,B,
1756,,17451,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,B,
1757,,4199,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,B,
1758,,14875,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,
1759,,15146,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,B,
1760,,5213,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,B,
1761,,14818,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,B,
1762,,4829,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",B,
1763,,14454,,BAO_0000019,,,,Expert,1,,,8,,H,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,F,
1764,,14454,,BAO_0000019,,,,Expert,1,,,8,,H,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,F,
1765,,5254,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-HT2C receptor,B,
1766,,5254,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1D receptor,B,
1767,,10639,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,B,
1768,,10639,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,F,
1769,,12352,,BAO_0000019,,,,Expert,1,,,8,,H,,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",B,
1770,,9098,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-HT1B was determined,B,
1771,,14430,,BAO_0000019,,,,Expert,1,,,8,,H,,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,B,
1772,,13657,,BAO_0000019,,,,Expert,1,,,8,,H,,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",B,
1773,,13657,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",B,
1774,,15854,,BAO_0000019,,,,Expert,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,
1775,,10639,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,B,
1776,,10025,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,B,
1777,,10025,,BAO_0000357,,,,Autocuration,1,,,8,,H,,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",B,
1778,,14286,,BAO_0000249,,,,Autocuration,1,,,8,,H,,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,B,
1779,2435.0,3651,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,B,Striatum
1780,,14178,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,B,
1781,,10639,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,B,
1782,2435.0,13605,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,B,Striatum
1783,2435.0,5834,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,B,Striatum
1784,2435.0,10922,,BAO_0000357,,,,Autocuration,1,,,8,,H,,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,B,Striatum
1785,,14286,,BAO_0000249,,,,Autocuration,1,,,8,,H,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,B,
1786,,11825,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,B,
1787,2435.0,14826,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,B,Striatum
1788,2435.0,9699,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-HT1B serotonin receptor in rat striatum,B,Striatum
1789,,14423,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,B,
1790,,10062,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,B,
1791,,10062,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,B,
1792,,12280,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,B,
1793,2435.0,15412,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,B,Striatum
1794,2435.0,15412,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,B,Striatum
1795,,10062,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,B,
1796,,11147,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,B,
1797,,9547,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,B,
1798,,10444,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,B,
1799,2435.0,12469,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,B,Striatum
1800,,9098,,BAO_0000019,,,,Expert,1,,,8,,H,,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,B,
1801,,9098,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,B,
1802,,9699,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,B,
1803,,10394,,BAO_0000249,,,,Autocuration,1,,,8,,H,,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,B,
1804,,12092,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,B,
1805,,16700,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,B,
1806,,403,10116.0,BAO_0000249,,,,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,B,
1807,,12771,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity towards 5-hydroxytryptamine 1B receptor,B,
1808,,11642,,BAO_0000019,,,,Autocuration,1,,,8,,H,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,B,
1809,,12953,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,B,
1810,,12953,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,B,
1811,2435.0,12953,,BAO_0000019,,,,Expert,1,,,8,,H,,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,B,Striatum
1812,,12953,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,B,
1813,955.0,9737,,BAO_0000249,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,Brain
1814,,9737,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,B,
1815,955.0,9737,,BAO_0000249,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,Brain
1816,,12827,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,B,
1817,,5033,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,B,
1818,,9786,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,B,
1819,,13116,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity at 5-hydroxytryptamine 1B receptor,B,
1820,,16429,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,B,
1821,,12409,10116.0,BAO_0000249,,,,Expert,1,Rattus norvegicus,,9,,D,,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,B,
1822,,15194,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,B,
1823,,15194,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,
1824,,5486,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,B,
1825,,4639,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,B,
1826,,386,,BAO_0000249,,,,Autocuration,1,,,8,Brain membranes,H,,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,B,
1827,,2474,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,B,
1828,,6011,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,B,
1829,,5014,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,B,
1830,,17515,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,B,
1831,,4373,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,B,
1832,,1633,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,B,
1833,,1633,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,B,
1834,,4373,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,B,
1835,,4687,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,B,
1836,,11574,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1B receptor,B,
1837,,10321,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,B,
1838,,15527,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,
1839,,17200,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,B,
1840,,14423,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,B,
1841,,5834,9913.0,BAO_0000357,,,,Autocuration,1,Bos taurus,,8,,H,,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,B,
1842,,11473,9823.0,BAO_0000357,,,,Autocuration,1,Sus scrofa,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,B,
1843,,11473,9823.0,BAO_0000357,,,,Autocuration,1,Sus scrofa,,8,,H,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,B,
1844,,10639,9823.0,BAO_0000357,,,,Autocuration,1,Sus scrofa,,8,,H,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,B,
1845,,10639,9823.0,BAO_0000357,,,,Autocuration,1,Sus scrofa,,8,,H,,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,B,
1846,,14331,9823.0,BAO_0000357,,,,Autocuration,1,Sus scrofa,,8,,H,,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,B,
1847,,10796,9823.0,BAO_0000357,,,,Autocuration,1,Sus scrofa,,8,,H,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,B,
1848,,9098,9823.0,BAO_0000357,,,,Expert,1,Sus scrofa,,8,,H,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,B,
1849,,14331,9823.0,BAO_0000357,,,,Expert,1,Sus scrofa,,8,,H,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,B,
1850,,11828,9823.0,BAO_0000019,,,,Expert,1,Sus scrofa,,8,,H,,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,B,
1851,,11866,9823.0,BAO_0000357,,,,Autocuration,1,Sus scrofa,,8,,H,,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,B,
1852,,13047,9986.0,BAO_0000019,,,,Autocuration,1,Oryctolagus cuniculus,,8,,H,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,B,
1853,,188,10116.0,BAO_0000357,,,,Autocuration,1,Rattus norvegicus,,9,,D,,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,B,
1854,,11825,10116.0,BAO_0000357,,,,Autocuration,1,Rattus norvegicus,,9,,D,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,B,
1855,,11825,10116.0,BAO_0000357,,,,Autocuration,1,Rattus norvegicus,,9,,D,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,B,
1856,,11624,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,B,
1857,,11139,10116.0,BAO_0000357,,,,Autocuration,1,Rattus norvegicus,,9,,D,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,B,
1858,,11147,10116.0,BAO_0000357,,,,Autocuration,1,Rattus norvegicus,,9,,D,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,B,
1859,,10444,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,9,,D,,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,B,
1860,,11624,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity against 5-hydroxytryptamine 1C receptor,B,
1861,,11662,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,9,,D,,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,
1862,,11662,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,9,,D,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,
1863,,11662,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,
1864,,11662,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,9,,D,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,
1865,,9098,10116.0,BAO_0000357,,,,Autocuration,1,Rattus norvegicus,,9,,D,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,B,
1866,,10394,10116.0,BAO_0000249,,,,Autocuration,1,Rattus norvegicus,,9,,D,,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,B,
1867,,11933,,BAO_0000357,,,,Expert,1,,,8,,H,,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,B,
1868,,12092,10116.0,BAO_0000357,,,,Autocuration,1,Rattus norvegicus,,9,,D,,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,B,
1869,,12253,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,9,,D,,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,B,
1870,,12253,10116.0,BAO_0000219,,,722.0,Autocuration,1,Rattus norvegicus,,9,,D,,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,B,
1871,,1558,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,B,
1872,,2474,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,B,
1873,,2474,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,B,
1874,,11574,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1C receptor,B,
1875,,1558,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,B,
1876,,13944,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1C receptor,B,
1877,,13033,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against serotonergic 5-HT1c receptor,B,
1878,,10321,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,B,
1879,,11866,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,B,
1880,,14454,9986.0,BAO_0000019,,,,Autocuration,1,Oryctolagus cuniculus,,8,,H,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),B,
1881,,11574,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,B,
1882,,11574,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,B,
1883,,13631,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,B,
1884,,9630,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,5,,D,,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,B,
1885,,8822,10116.0,BAO_0000249,,,,Autocuration,1,Rattus norvegicus,,5,,D,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,B,
1886,955.0,9064,10116.0,BAO_0000221,,,,Autocuration,1,Rattus norvegicus,,5,,D,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,B,Brain
1887,,8868,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,B,
1888,,9064,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,B,
1889,,9806,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,B,
1890,,9098,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,
1891,,8868,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,B,
1892,,12765,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,B,
1893,,11049,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,
1894,,11049,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,
1895,,11049,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,B,
1896,,11049,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,B,
1897,,11049,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,
1898,,11473,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,B,
1899,,11473,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,B,
1900,,3086,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,B,
1901,,11049,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,
1902,,11049,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,
1903,,10639,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,B,
1904,,10922,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,B,
1905,955.0,9064,10116.0,BAO_0000221,,,,Autocuration,1,Rattus norvegicus,,5,,D,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,B,Brain
1906,955.0,10748,,BAO_0000221,,,,Autocuration,1,,,4,,H,,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,B,Brain
1907,,11614,,BAO_0000249,,,,Autocuration,1,,,4,Membranes,H,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,B,
1908,,11615,,BAO_0000249,,,,Autocuration,1,,,4,Membranes,H,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,B,
1909,,11615,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,B,
1910,,11614,,BAO_0000249,,,,Autocuration,1,,,4,Membranes,H,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,B,
1911,,11702,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,B,
1912,,11702,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,B,
1913,,11702,10116.0,BAO_0000224,,,,Autocuration,1,Rattus norvegicus,,5,,D,,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,B,
1914,,11702,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,B,
1915,,13346,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,B,
1916,,10025,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,B,
1917,,10025,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,B,
1918,,10025,,BAO_0000224,,,,Autocuration,1,,,4,,H,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",B,
1919,,9036,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,B,
1920,,9036,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,B,
1921,,9161,,BAO_0000019,,,,Autocuration,1,,,4,,H,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,B,
1922,,12304,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,B,
1923,,13276,,BAO_0000224,,,,Autocuration,1,,,4,,H,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,B,
1924,,11825,,BAO_0000224,,,,Autocuration,1,,,4,,H,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,B,
1925,,12443,,BAO_0000224,,,,Autocuration,1,,,4,,H,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,B,
1926,,13830,,BAO_0000224,,,,Autocuration,1,,,4,,H,,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,B,
1927,,9592,,BAO_0000249,,,,Autocuration,1,,,4,Membranes,H,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,B,
1928,,9592,,BAO_0000249,,,,Autocuration,1,,,4,Membranes,H,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,B,
1929,,10881,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,B,
1930,,13605,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,B,
1931,,11624,10116.0,BAO_0000224,,,,Autocuration,1,Rattus norvegicus,,5,,D,,Inhibitory activity against 5-hydroxytryptamine 2 receptor,B,
1932,,4101,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,B,
1933,,4101,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,B,
1934,,15360,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,B,
1935,,11576,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,B,
1936,,5834,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,B,
1937,,2395,10116.0,BAO_0000219,,,485.0,Autocuration,1,Rattus norvegicus,,5,,D,,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,
1938,,11965,,BAO_0000249,,,,Autocuration,1,,,4,Membranes,H,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,B,
1939,,3967,,BAO_0000224,,,,Autocuration,1,,,4,,H,,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),B,
1940,,11130,,BAO_0000249,,,,Autocuration,1,,,4,Brain membranes,H,,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),B,
1941,,13427,,BAO_0000219,,,,Autocuration,1,,In vitro,4,,H,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,
1942,,9443,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,
1943,,9443,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,B,
1944,,11825,,BAO_0000224,,,,Autocuration,1,,,4,,H,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,B,
1945,,12120,,BAO_0000249,,,,Autocuration,1,,,4,Membranes,H,,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,B,
1946,,12120,,BAO_0000249,,,,Autocuration,1,,,4,Membranes,H,,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,B,
1947,1515.0,11963,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,F,Thoracic aorta
1948,,9069,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,B,
1949,,8868,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,B,
1950,,17200,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,B,
1951,,17200,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,B,
1952,,13969,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,B,
1953,,13392,,BAO_0000357,,,,Expert,1,,,9,,D,,Binding affinity for 5-hydroxytryptamine 1D receptor,B,
1954,,1742,,BAO_0000249,,,,Autocuration,1,,,8,,H,,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,
1955,,1742,,BAO_0000249,,,,Autocuration,1,,,8,,H,,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,
1956,2435.0,14331,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,B,Striatum
1957,,12861,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,F,
1958,,12861,,BAO_0000019,,,,Expert,1,,,8,,H,,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,B,
1959,,12861,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding activity radioligand.,B,
1960,,12861,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,
1961,,12861,,BAO_0000019,,,,Expert,1,,,8,,H,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,
1962,,12861,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,B,
1963,,675,,BAO_0000249,,,,Autocuration,1,,,8,,H,,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,
1964,,12490,,BAO_0000019,,,,Expert,1,,,8,,H,,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,B,
1965,,11828,,BAO_0000249,,,,Expert,1,,,8,,H,,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,B,
1966,,11866,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,B,
1967,,773,9823.0,BAO_0000357,,,,Autocuration,1,Sus scrofa,,8,,H,,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,B,
1968,,13047,9986.0,BAO_0000357,,,,Expert,1,Oryctolagus cuniculus,,8,,H,,The compound was tested for intrinsic activity against 5-HT1D receptor,B,
1969,,13047,9986.0,BAO_0000019,,,,Autocuration,1,Oryctolagus cuniculus,,8,,H,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,
1970,,13047,9986.0,BAO_0000357,,,,Expert,1,Oryctolagus cuniculus,,8,,H,,The compound was tested for binding affinity against 5-HT1D receptor,B,
1971,,188,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,B,
1972,,10639,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,F,
1973,,12438,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,F,
1974,,12438,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,B,
1975,,15854,,BAO_0000019,,,,Expert,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,
1976,,10394,,BAO_0000249,,,,Autocuration,1,,,8,,H,,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,B,
1977,,12092,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,B,
1978,,3389,,BAO_0000019,,,,Expert,1,,,8,,H,,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,B,
1979,,6011,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,B,
1980,,4639,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,B,
1981,,2474,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,B,
1982,,5014,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,B,
1983,,17515,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,B,
1984,,11866,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,B,
1985,,4687,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,B,
1986,,12146,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested against 5-hydroxytryptamine 1D receptor,B,
1987,,10321,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,B,
1988,,13267,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,B,
1989,,1274,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding affinity against 5-Hydroxytryptamine 1D receptor,B,
1990,,15250,,BAO_0000357,,,,Autocuration,1,,,8,,H,,,B,
1991,,13706,,BAO_0000219,,,485.0,Autocuration,1,,,8,,H,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,
1992,,13706,,BAO_0000219,,,485.0,Autocuration,1,,,8,,H,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,
1993,,13706,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,B,
1994,,13706,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,B,
1995,,13047,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,B,
1996,,13366,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,B,
1997,,13366,,BAO_0000357,,,,Expert,1,,,8,,H,,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,B,
1998,,1558,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,B,
1999,,12902,,BAO_0000219,,,485.0,Expert,1,,,8,,H,,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",B,
2000,,13706,,BAO_0000219,,,485.0,Autocuration,1,,,8,,H,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,
2001,,13706,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,F,
2002,,13706,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,
2003,,14251,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,
2004,,14251,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,
2005,,14251,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,
2006,,13313,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,B,
2007,,13313,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,B,
2008,,13366,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,B,
2009,,13051,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,B,
2010,,12903,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",B,
2011,,12469,9606.0,BAO_0000219,,,,Autocuration,1,Homo sapiens,,9,,D,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,B,
2012,,5619,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,B,
2013,,13047,9986.0,BAO_0000019,,,,Autocuration,1,Oryctolagus cuniculus,,8,,H,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,B,
2014,,16633,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,B,
2015,,16633,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,B,
2016,,16633,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,B,
2017,,16633,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,B,
2018,,3269,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Affinity against 5-hydroxytryptamine 1D receptor alpha,B,
2019,,12409,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,B,
2020,,13706,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,
2021,,13706,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,B,
2022,,13706,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,B,
2023,,12903,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",B,
2024,,13047,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,B,
2025,,13366,,BAO_0000357,,,,Expert,1,,,9,,D,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,
2026,,13366,,BAO_0000357,,,,Expert,1,,,9,,D,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,
2027,,13366,,BAO_0000357,,,,Expert,1,,,9,,D,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,
2028,,13366,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,B,
2029,,13366,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,B,
2030,,12469,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,B,
2031,,13706,,BAO_0000219,,,485.0,Autocuration,1,,,8,,H,,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,B,
2032,,13706,,BAO_0000219,,,485.0,Autocuration,1,,,8,,H,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,B,
2033,,13706,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,
2034,,12902,,BAO_0000219,,,485.0,Expert,1,,,8,,H,,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",B,
2035,,13051,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,B,
2036,,12903,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",B,
2037,,1558,,BAO_0000219,,,485.0,Autocuration,1,,,8,,H,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,F,
2038,,1558,,BAO_0000219,,,485.0,Autocuration,1,,,8,,H,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,F,
2039,,1558,,BAO_0000219,,,485.0,Autocuration,1,,,8,,H,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,F,
2040,,1558,,BAO_0000219,,,485.0,Autocuration,1,,,8,,H,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,F,
2041,,1558,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,B,
2042,,13047,9986.0,BAO_0000019,,,,Autocuration,1,Oryctolagus cuniculus,,8,,H,,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,B,
2043,,13313,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,B,
2044,,13313,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,B,
2045,,12409,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1D receptor beta,B,
2046,,15250,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,B,
2047,,1348,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,B,
2048,,1348,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,B,
2049,,4234,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,B,
2050,,16209,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,B,
2051,,10444,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,B,
2052,,3935,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,B,
2053,,15818,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,B,
2054,,17085,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,B,
2055,,12936,9606.0,BAO_0000219,,,449.0,Expert,1,Homo sapiens,,9,,D,,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,B,
2056,,6166,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,B,
2057,,15779,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,
2058,,15779,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,B,
2059,,15779,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,B,
2060,,13181,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,B,
2061,,4199,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,B,
2062,,14875,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,B,
2063,,15146,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,B,
2064,,5213,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,B,
2065,,12146,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,B,
2066,,13267,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,B,
2067,,14818,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,B,
2068,,4829,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",B,
2069,,4373,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,B,
2070,,4373,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,B,
2071,,14159,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,B,
2072,,16633,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1E receptor,B,
2073,,17085,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",F,
2074,,17085,,BAO_0000019,,,,Expert,1,,,8,,H,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",F,
2075,,16209,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,F,
2076,,16209,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,F,
2077,,17085,,BAO_0000019,,,,Expert,1,,,8,,H,,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",F,
2078,,14159,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,B,
2079,,15250,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,B,
2080,,3805,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),B,
2081,,16190,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,B,
2082,,16190,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,B,
2083,,16209,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards human 5-hydroxytryptamine 1F receptor,B,
2084,,16209,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,B,
2085,,16209,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,B,
2086,,6866,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,B,
2087,,17085,,BAO_0000019,,,,Expert,1,,,8,,H,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,B,
2088,,16312,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,B,
2089,,6166,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,B,
2090,,15779,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,
2091,,4199,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,B,
2092,,14875,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,B,
2093,,15146,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,B,
2094,,5213,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,B,
2095,,14818,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,B,
2096,,4829,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",B,
2097,,4829,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",B,
2098,,4373,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,B,
2099,,4373,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,B,
2100,,5014,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,B,
2101,,11662,,BAO_0000019,,,,Autocuration,1,,,4,,H,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",B,
2102,,11662,,BAO_0000019,,,,Autocuration,1,,,4,,H,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",B,
2103,,11662,,BAO_0000019,,,,Autocuration,1,,,4,,H,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,
2104,,14093,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,B,
2105,,11200,,BAO_0000218,,,,Autocuration,1,,In vivo,4,,H,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",F,
2106,,11200,,BAO_0000019,,,,Autocuration,1,,,4,,H,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,
2107,,12352,,BAO_0000019,,,,Intermediate,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,B,
2108,,13657,9913.0,BAO_0000019,,,,Autocuration,1,Bos taurus,,0,,U,,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",B,
2109,,14331,9913.0,BAO_0000019,,,,Autocuration,1,Bos taurus,,0,,U,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,B,
2110,,14331,9913.0,BAO_0000019,,,,Autocuration,1,Bos taurus,,0,,U,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,B,
2111,,14331,,BAO_0000019,,,,Autocuration,1,,,0,,U,,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,B,
2112,,12685,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,4,,H,,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,B,
2113,,14389,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,4,,H,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,B,
2114,,14386,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,4,,H,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,B,
2115,,5732,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,B,
2116,,16293,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,
2117,,2078,,BAO_0000224,,,,Autocuration,1,,,4,,H,,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,B,
2118,,5486,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,B,
2119,,11820,,BAO_0000218,,,,Autocuration,1,,In vivo,4,,H,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,B,
2120,,10297,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,B,
2121,,13704,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,B,
2122,,10297,10090.0,BAO_0000019,,,,Autocuration,1,Mus musculus,,5,,D,,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,B,
2123,,11820,,BAO_0000218,,,,Autocuration,1,,In vivo,4,,H,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,B,
2124,,10297,10090.0,BAO_0000019,,,,Autocuration,1,Mus musculus,,5,,D,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,B,
2125,,11555,,BAO_0000224,,,,Autocuration,1,,,4,,H,,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,B,
2126,,11555,,BAO_0000224,,,,Autocuration,1,,,4,,H,,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,B,
2127,,11555,,BAO_0000224,,,,Autocuration,1,,,4,,H,,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,B,
2128,,10297,10090.0,BAO_0000019,,,,Autocuration,1,Mus musculus,,5,,D,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,B,
2129,,16688,9823.0,BAO_0000224,,,,Autocuration,1,Sus scrofa,,4,,H,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,B,
2130,,16688,9823.0,BAO_0000224,,,,Autocuration,1,Sus scrofa,,4,,H,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,B,
2131,,5333,,BAO_0000221,,,,Autocuration,1,,,0,,U,,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,B,
2132,,4437,,BAO_0000221,,,,Autocuration,1,,,0,,U,,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,B,
2133,,5033,9823.0,BAO_0000357,,,,Autocuration,1,Sus scrofa,,8,,H,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,B,
2134,,15267,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,B,
2135,,15267,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,B,
2136,,11820,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,B,
2137,,9069,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,B,
2138,,9162,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,5,,D,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,B,
2139,,9162,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,B,
2140,,9162,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,B,
2141,,10428,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,F,
2142,,9628,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,B,
2143,,12704,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,B,
2144,,15453,10116.0,BAO_0000224,,,,Autocuration,1,Rattus norvegicus,,5,,D,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,B,
2145,,188,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,B,
2146,,10349,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,B,
2147,,10349,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,B,
2148,,8868,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,B,
2149,,10025,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,B,
2150,,10025,,BAO_0000224,,,,Autocuration,1,,,4,,H,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",B,
2151,,11702,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,B,
2152,,11702,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,B,
2153,,11702,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,B,
2154,,11702,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Compound was tested for the inhibition of quipazine induced head twitches in rats,F,
2155,,11702,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,F,
2156,10000000.0,10085,,BAO_0000221,,,,Autocuration,1,,,4,,H,,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,B,Hippocampus
2157,10000000.0,10085,,BAO_0000221,,,,Autocuration,1,,,4,,H,,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,B,Hippocampus
2158,955.0,9630,10116.0,BAO_0000221,,,,Autocuration,1,Rattus norvegicus,,5,,D,,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,B,Brain
2159,,11070,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,B,
2160,,9841,,BAO_0000249,,,,Autocuration,1,,,4,Membranes,H,,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,B,
2161,,9841,,BAO_0000249,,,,Autocuration,1,,,4,Membranes,H,,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,B,
2162,,13291,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,B,
2163,,10590,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,F,
2164,955.0,9064,10116.0,BAO_0000221,,,,Autocuration,1,Rattus norvegicus,,5,,D,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,B,Brain
2165,,12268,10116.0,BAO_0000249,,,,Autocuration,1,Rattus norvegicus,,5,Membranes,D,,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,B,
2166,955.0,13508,,BAO_0000221,,,,Autocuration,1,,,4,,H,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,B,Brain
2167,,11279,,BAO_0000019,,,,Autocuration,1,,,4,,H,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,F,
2168,,11200,,BAO_0000019,,,,Autocuration,1,,,4,,H,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,F,
2169,,11200,,BAO_0000019,,,,Autocuration,1,,,4,,H,,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,
2170,,11200,,BAO_0000019,,,,Autocuration,1,,,4,,H,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,F,
2171,,11200,,BAO_0000019,,,,Autocuration,1,,,4,,H,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,F,
2172,,11200,,BAO_0000019,,,,Autocuration,1,,,4,,H,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,
2173,955.0,9231,,BAO_0000220,,,,Autocuration,1,,,4,,H,,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,B,Brain
2174,,9737,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,B,
2175,955.0,9737,,BAO_0000249,,,,Autocuration,1,,,4,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,Brain
2176,,9737,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,B,
2177,,9737,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,B,
2178,,11828,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,5,,D,,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,B,
2179,,12253,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,B,
2180,,12253,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,B,
2181,,11279,,BAO_0000019,,,,Autocuration,1,,,4,,H,,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",F,
2182,,11866,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,B,
2183,,14424,10116.0,BAO_0000224,,,,Autocuration,1,Rattus norvegicus,,5,,D,,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,B,
2184,,15180,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,5,,D,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,B,
2185,,15180,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,5,,D,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,B,
2186,,9786,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,5,,D,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,B,
2187,,12132,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,B,
2188,,5486,,BAO_0000249,,,,Autocuration,1,,,4,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,B,
2189,,15316,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,B,
2190,,16429,,BAO_0000019,,,,Autocuration,1,,,4,,H,,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,B,
2191,,14617,,BAO_0000224,,,,Autocuration,1,,,4,,H,,pKi value for 5-hydroxytryptamine 2 receptor binding site,B,
2192,955.0,11351,,BAO_0000221,,,,Autocuration,1,,,4,,H,,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,B,Brain
2193,,11279,,BAO_0000019,,,,Autocuration,1,,,4,,H,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,F,
2194,,9523,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,
2195,,9523,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,
2196,,9523,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,
2197,,9523,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,
2198,,9523,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,
2199,,9523,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,
2200,,9523,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Hill coefficient of compound was determined,B,
2201,,4771,,BAO_0000019,,,,Autocuration,1,,,0,,U,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,B,
2202,,5033,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,5,,D,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,B,
2203,,10845,,BAO_0000019,,,,Expert,1,,,8,,H,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,B,
2204,,10845,,BAO_0000019,,,,Expert,1,,,8,,H,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,B,
2205,,16288,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),B,
2206,,16288,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),B,
2207,,16190,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,B,
2208,,12463,10116.0,BAO_0000224,,,,Autocuration,1,Rattus norvegicus,,5,,D,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,B,
2209,,9699,,BAO_0000224,,,,Autocuration,1,,,4,,H,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",B,
2210,,9699,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,B,
2211,,11662,,BAO_0000019,,,,Autocuration,1,,,4,,H,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,
2212,,1205,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,B,
2213,,11376,,BAO_0000219,,,,Autocuration,1,,,0,,U,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,B,
2214,,11376,,BAO_0000219,,,,Autocuration,1,,,4,,H,,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",B,
2215,,4639,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,B,
2216,,2222,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,B,
2217,,1558,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,B,
2218,,1089,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,B,
2219,,386,,BAO_0000249,,,,Autocuration,1,,,4,Brain membranes,H,,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,B,
2220,,2474,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,B,
2221,,17066,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Binding affinity towards 5-HT2 receptor,B,
2222,,959,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,
2223,,6398,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,B,
2224,,11889,,BAO_0000224,,,,Autocuration,1,,,4,,H,,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,B,
2225,,4221,,BAO_0000224,,,,Autocuration,1,,,4,,H,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,
2226,,11026,,BAO_0000224,,,,Autocuration,1,,,4,,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,B,
2227,,11866,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,B,
2228,,4221,,BAO_0000224,,,,Autocuration,1,,,4,,H,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,
2229,,13950,,BAO_0000019,,,,Autocuration,1,,,0,,U,,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,
2230,,1263,,BAO_0000224,,,,Autocuration,1,,,4,,H,,5-hydroxytryptamine 2 receptor binding affinity,B,
2231,,13291,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,B,
2232,,10812,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,B,
2233,,13020,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,B,
2234,,13021,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,B,
2235,,13020,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,B,
2236,,14532,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,B,
2237,,13944,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 2 receptor,B,
2238,,14331,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 2 receptor,B,
2239,,14118,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,B,
2240,,13033,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against serotonergic 5-HT2 receptor,B,
2241,,10321,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,B,
2242,,12918,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for the binding affinity at 5- HT2 receptor,B,
2243,,15120,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,B,
2244,,2613,,BAO_0000218,,,,Autocuration,1,,,8,,H,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,B,
2245,,13378,9606.0,BAO_0000224,,,,Autocuration,1,Homo sapiens,,5,,D,,Inhibitory activity against cloned human 5-HT2 receptor,B,
2246,,2331,9606.0,BAO_0000219,,,449.0,Autocuration,1,Homo sapiens,,5,,D,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",B,
2247,,2331,9606.0,BAO_0000219,,,449.0,Autocuration,1,Homo sapiens,,5,,D,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",B,
2248,,2331,9606.0,BAO_0000219,,,449.0,Autocuration,1,Homo sapiens,,5,,D,,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",B,
2249,,2331,9606.0,BAO_0000219,,,449.0,Autocuration,1,Homo sapiens,,5,,D,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",B,
2250,,4170,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,
2251,,15453,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,B,
2252,,1479,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,
2253,,11139,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,B,
2254,,13969,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,B,
2255,,13392,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,
2256,,14430,,BAO_0000019,,,,Expert,1,,,8,,H,,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,B,
2257,,13181,10141.0,BAO_0000357,,,,Autocuration,1,Cavia porcellus,,8,,H,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,B,
2258,,17200,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,
2259,,17200,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,
2260,,17200,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,
2261,,13463,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,B,
2262,,6347,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,B,
2263,,6857,9606.0,BAO_0000219,,,449.0,Expert,1,Homo sapiens,,9,,D,,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,F,
2264,,4176,,BAO_0000219,,,,Autocuration,1,,,8,,H,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,F,
2265,,4176,,BAO_0000219,,,,Autocuration,1,,,8,,H,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,F,
2266,,4176,,BAO_0000219,,,,Autocuration,1,,,8,,H,,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,F,
2267,,6347,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",B,
2268,,6347,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",B,
2269,,15331,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,B,
2270,,16146,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Inhibition of human 5-hydroxytryptamine 2A receptor,B,
2271,,15250,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,
2272,,13631,,BAO_0000219,,,,Expert,1,,,8,,H,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,B,
2273,,3805,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),B,
2274,,4011,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,B,
2275,,4012,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,B,
2276,,6366,,BAO_0000219,,,307.0,Expert,1,,,8,,H,,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,B,
2277,,15949,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,
2278,,14093,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,F,
2279,,13481,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,F,
2280,,6347,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,B,
2281,,6347,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,B,
2282,,14093,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,F,
2283,,14093,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,F,
2284,,13481,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,F,
2285,,14442,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,B,
2286,,14442,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,
2287,,14755,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,B,
2288,,16441,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,B,
2289,,14744,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,B,
2290,,16659,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,
2291,,3307,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,B,
2292,,6857,9606.0,BAO_0000019,,,,Expert,1,Homo sapiens,,9,,D,,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,B,
2293,,5635,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,B,
2294,,4234,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,B,
2295,,15527,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,B,
2296,,6588,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,B,
2297,,13631,,BAO_0000219,,,,Expert,1,,,8,,H,,Binding affinity towards human 5-HT2A receptor in BEK cells,B,
2298,,17723,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,B,
2299,,14770,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,B,
2300,,16293,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding affinity for human 5-hydroxytryptamine 2A receptor,B,
2301,,16209,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,
2302,,12469,,BAO_0000219,,,,Autocuration,1,,,8,,H,,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,B,
2303,,15363,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,B,
2304,,15363,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,B,
2305,,16441,,BAO_0000019,,,,Expert,1,,,8,,H,,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",B,
2306,,8,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,B,
2307,,4176,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,B,
2308,,17085,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,B,
2309,,17200,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,
2310,,17200,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,
2311,,4013,9606.0,BAO_0000219,,,449.0,Expert,1,Homo sapiens,,9,,D,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,B,
2312,,5088,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,B,
2313,,5088,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,B,
2314,,5088,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,B,
2315,,5088,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,B,
2316,,5088,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,B,
2317,,5088,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,
2318,,9786,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,B,
2319,,9205,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,5,,D,,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,B,
2320,,11257,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,B,
2321,,9362,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,B,
2322,,9362,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,B,
2323,,10590,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,B,
2324,,10468,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,B,
2325,,13050,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,B,
2326,,11624,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,B,
2327,,10468,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,B,
2328,,10330,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,B,
2329,,10062,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,B,
2330,,11642,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,B,
2331,,10062,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,B,
2332,,13427,,BAO_0000219,,,,Autocuration,1,,In vitro,4,,H,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,
2333,,12280,10116.0,BAO_0000224,,,,Autocuration,1,Rattus norvegicus,,5,,D,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,
2334,,4101,10116.0,BAO_0000224,,,,Autocuration,1,Rattus norvegicus,,5,,D,,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,B,
2335,,10062,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,B,
2336,,11147,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,B,
2337,,2395,10116.0,BAO_0000219,,,485.0,Autocuration,1,Rattus norvegicus,,5,,D,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,
2338,,2395,10116.0,BAO_0000219,,,485.0,Autocuration,1,Rattus norvegicus,,5,,D,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,
2339,,9098,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,5,,D,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,B,
2340,,9098,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,B,
2341,,9098,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,5,,D,,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,B,
2342,,9443,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,
2343,,9443,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,B,
2344,,9699,,BAO_0000019,,,,Autocuration,1,,,4,,H,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",B,
2345,,9699,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,B,
2346,,9098,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,
2347,,3070,10116.0,BAO_0000224,,,,Autocuration,1,Rattus norvegicus,,5,,D,,Affinity for 5-hydroxytryptamine 2 receptor,B,
2348,,9547,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,B,
2349,,10444,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,B,
2350,,14617,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,B,
2351,,14617,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,B,
2352,,11130,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),B,
2353,,11130,,BAO_0000218,,,,Autocuration,1,,In vivo,4,,H,,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),B,
2354,955.0,14542,,BAO_0000221,,,,Autocuration,1,,,4,,H,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,B,Brain
2355,,2797,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,B,
2356,,11332,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,B,
2357,,11332,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,B,
2358,1870.0,10752,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,B,Frontal cortex
2359,,1185,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,B,
2360,,1185,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,B,
2361,,11624,10116.0,BAO_0000224,,,,Autocuration,1,Rattus norvegicus,,5,,D,,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,B,
2362,,1344,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,B,
2363,2435.0,15453,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,5,,D,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,B,Striatum
2364,,11662,,BAO_0000019,,,,Autocuration,1,,,4,,H,,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",B,
2365,,11662,,BAO_0000019,,,,Autocuration,1,,,4,,H,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,
2366,,10796,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,B,
2367,,9069,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,B,
2368,,8814,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,5,,D,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,B,
2369,,8908,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,5,,D,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,B,
2370,,9098,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,B,
2371,,9098,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,B,
2372,,9098,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,B,
2373,,9098,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,B,
2374,,9098,,BAO_0000249,,,,Autocuration,1,,,4,,H,,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,B,
2375,,9098,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,B,
2376,,9098,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,B,
2377,,9161,,BAO_0000019,,,,Autocuration,1,,,4,,H,,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,B,
2378,,9161,,BAO_0000019,,,,Autocuration,1,,,4,,H,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,B,
2379,,9161,,BAO_0000019,,,,Autocuration,1,,,4,,H,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,B,
2380,,9161,,BAO_0000019,,,,Autocuration,1,,,4,,H,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,B,
2381,,9161,,BAO_0000019,,,,Autocuration,1,,,4,,H,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,B,
2382,,9161,,BAO_0000019,,,,Autocuration,1,,,4,,H,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,B,
2383,,9161,,BAO_0000019,,,,Autocuration,1,,,4,,H,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,B,
2384,,9161,,BAO_0000019,,,,Autocuration,1,,,4,,H,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,B,
2385,,9161,,BAO_0000019,,,,Autocuration,1,,,4,,H,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,B,
2386,,9161,,BAO_0000019,,,,Autocuration,1,,,4,,H,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,B,
2387,,9161,,BAO_0000019,,,,Autocuration,1,,,4,,H,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,B,
2388,,9161,,BAO_0000019,,,,Autocuration,1,,,4,,H,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,B,
2389,,12094,,BAO_0000019,,,,Autocuration,1,,,4,,H,,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,B,
2390,,12018,,BAO_0000249,,,,Autocuration,1,,,4,,H,,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,B,
2391,,10394,,BAO_0000249,,,,Autocuration,1,,,4,,H,,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,B,
2392,,15260,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,B,
2393,,11624,10116.0,BAO_0000224,,,,Autocuration,1,Rattus norvegicus,,5,,D,,Inhibitory constant against 5-hydroxytryptamine 2 receptor,B,
2394,,13654,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,B,
2395,,9541,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,B,
2396,,11933,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,B,
2397,,15538,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,B,
2398,,15538,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,B,
2399,,15538,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,B,
2400,,8841,,BAO_0000019,,,,Autocuration,1,,,5,,D,,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,B,
2401,,1455,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,B,
2402,,1455,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,B,
2403,,11752,,BAO_0000019,,,,Autocuration,1,,,4,,H,,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,B,
2404,955.0,11642,,BAO_0000221,,,,Autocuration,1,,,4,,H,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,B,Brain
2405,,12092,,BAO_0000224,,,,Autocuration,1,,,4,,H,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,B,
2406,,3967,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,B,
2407,,12771,10116.0,BAO_0000224,,,,Autocuration,1,Rattus norvegicus,,5,,D,,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,
2408,,11642,,BAO_0000019,,,,Autocuration,1,,,4,,H,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,B,
2409,,11628,,BAO_0000224,,,,Autocuration,1,,,4,,H,,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,B,
2410,,13654,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,
2411,,11200,,BAO_0000019,,,,Autocuration,1,,,4,,H,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,
2412,,11200,,BAO_0000019,,,,Autocuration,1,,,4,,H,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,
2413,,11200,,BAO_0000218,,,,Autocuration,1,,In vivo,4,,H,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",F,
2414,,11200,,BAO_0000218,,,,Autocuration,1,,In vivo,4,,H,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",F,
2415,,11200,,BAO_0000218,,,,Autocuration,1,,In vivo,4,,H,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",F,
2416,,11200,,BAO_0000218,,,,Autocuration,1,,In vivo,4,,H,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",F,
2417,955.0,15436,,BAO_0000221,,,,Expert,1,,,8,,H,,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,B,Brain
2418,,15436,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,
2419,,14025,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,B,
2420,,4342,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,B,
2421,,13735,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,B,
2422,,5816,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,B,
2423,,14287,,BAO_0000019,,,,Expert,1,,,8,,H,,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,B,
2424,,15738,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,B,
2425,,15738,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,B,
2426,,15026,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,B,
2427,,16647,,BAO_0000019,,,,Expert,1,,,8,,H,,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,B,
2428,,16647,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,B,
2429,,13345,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,B,
2430,,1543,,BAO_0000249,,,,Autocuration,1,,,8,Membranes,H,,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,B,
2431,,12444,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,B,
2432,,16404,,BAO_0000019,,,,Expert,1,,,8,,H,,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,B,
2433,,16404,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,B,
2434,,15577,,BAO_0000357,,,,Expert,1,,,8,,H,,Kinetic inhibition constant evaluated by measuring serotonergic activity,B,
2435,,15577,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Serotonergic activity of the compound.,B,
2436,,2495,,BAO_0000249,,,,Autocuration,1,,,8,,H,,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,B,
2437,,15042,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,B,
2438,,15026,,BAO_0000249,,,,Expert,1,,,8,,H,,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,B,
2439,,12919,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,
2440,,12919,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,
2441,,12919,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,
2442,,15194,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,
2443,,15194,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,B,
2444,,4820,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,
2445,,6736,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,B,
2446,,5163,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,B,
2447,,5163,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,B,
2448,,6011,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,B,
2449,,14294,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,B,
2450,,5014,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,B,
2451,,17066,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,
2452,,17515,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,B,
2453,,6736,,BAO_0000357,,,,Expert,1,,,8,,H,,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,B,
2454,,5163,,BAO_0000357,,,,Expert,1,,,8,,H,,Affinity for 5-hydroxytryptamine 2A receptor,B,
2455,,16911,,BAO_0000219,,,723.0,Expert,1,,,8,,H,,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,B,
2456,,6841,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,B,
2457,,6119,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,B,
2458,,3962,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,B,
2459,,4373,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,B,
2460,,4373,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,B,
2461,,3962,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,F,
2462,,1633,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,B,
2463,,4373,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,B,
2464,,6576,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,B,
2465,,4687,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,B,
2466,,16946,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,B,
2467,,14159,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,B,
2468,,3032,10090.0,BAO_0000219,,,449.0,Expert,1,Mus musculus,,8,,H,,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,B,
2469,,16655,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,B,
2470,,13964,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity at 5-hydroxytryptamine 2A receptor,B,
2471,,16989,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,B,
2472,,16117,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,B,
2473,,16700,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,B,
2474,,3269,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Affinity against 5-hydroxytryptamine 2A receptor,B,
2475,,1274,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding affinity against 5-Hydroxytryptamine 2A receptor,B,
2476,,1317,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,B,
2477,,12146,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested against 5-hydroxytryptamine 2A receptor,B,
2478,,12652,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,B,
2479,,12652,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,B,
2480,,12652,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,B,
2481,,12652,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,B,
2482,,16647,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),B,
2483,,15851,9606.0,BAO_0000219,,,722.0,Expert,1,Homo sapiens,,9,,D,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,B,
2484,,6857,9606.0,BAO_0000219,,,449.0,Expert,1,Homo sapiens,,9,,D,,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,F,
2485,,3805,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),B,
2486,,6491,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,B,
2487,,14093,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,F,
2488,,13481,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,F,
2489,,14093,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,F,
2490,,14093,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,F,
2491,,14093,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,F,
2492,,13481,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,F,
2493,,14442,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,B,
2494,,14442,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,B,
2495,,14442,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,B,
2496,,12369,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,B,
2497,,12369,,BAO_0000357,,,,Expert,1,,,8,,H,,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,B,
2498,,12369,,BAO_0000357,,,,Expert,1,,,8,,H,,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,B,
2499,,14447,,BAO_0000019,,,,Autocuration,1,,,8,,H,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,B,
2500,,14447,,BAO_0000019,,,,Autocuration,1,,,8,,H,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,B,
2501,,17451,,BAO_0000219,,,723.0,Autocuration,1,,,8,,H,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,
2502,,6857,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,
2503,,6857,9606.0,BAO_0000219,,,449.0,Expert,1,Homo sapiens,,9,,D,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,
2504,,5635,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,B,
2505,,12861,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding activity radioligand.,B,
2506,,12861,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,
2507,,5105,,BAO_0000219,,,307.0,Autocuration,1,,,8,,H,,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,B,
2508,,5104,,BAO_0000219,,,307.0,Expert,1,,,8,,H,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,B,
2509,,5105,,BAO_0000219,,,307.0,Expert,1,,,8,,H,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,B,
2510,,5105,,BAO_0000219,,,307.0,Autocuration,1,,,8,,H,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,B,
2511,,5254,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-HT2A receptor,B,
2512,,5254,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 2A receptor,B,
2513,,13267,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,B,
2514,,13267,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,B,
2515,,14157,9606.0,BAO_0000219,,,722.0,Expert,1,Homo sapiens,,9,,D,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,B,
2516,,12936,9606.0,BAO_0000219,,,722.0,Expert,1,Homo sapiens,,9,,D,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,
2517,,14068,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,B,
2518,,12936,9606.0,BAO_0000219,,,722.0,Expert,1,Homo sapiens,,9,,D,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,
2519,,12936,9606.0,BAO_0000219,,,722.0,Expert,1,Homo sapiens,,9,,D,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,
2520,,4540,9606.0,BAO_0000219,,,722.0,Expert,1,Homo sapiens,,9,,D,,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,B,
2521,,6166,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,B,
2522,,17296,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,B,
2523,,17296,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,B,
2524,,17296,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,B,
2525,,15779,9606.0,BAO_0000219,,,722.0,Expert,1,Homo sapiens,,9,,D,,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,B,
2526,,14391,,BAO_0000219,,,722.0,Expert,1,,,8,,H,,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,B,
2527,,15851,,BAO_0000219,,,722.0,Expert,1,,,8,,H,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",B,
2528,,15851,9606.0,BAO_0000219,,,722.0,Expert,1,Homo sapiens,,9,,D,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,B,
2529,,3832,,BAO_0000219,,,722.0,Expert,1,,,8,,H,,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,B,
2530,,3833,,BAO_0000219,,,722.0,Expert,1,,,8,,H,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,B,
2531,,12936,9606.0,BAO_0000219,,,722.0,Expert,1,Homo sapiens,,9,,D,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,
2532,,17451,,BAO_0000219,,,723.0,Autocuration,1,,,8,,H,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,B,
2533,,17451,,BAO_0000219,,,723.0,Autocuration,1,,,8,,H,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,
2534,,17451,,BAO_0000219,,,723.0,Autocuration,1,,,8,,H,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,
2535,,4199,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,B,
2536,,1883,,BAO_0000219,,,485.0,Autocuration,1,,,8,,H,,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,B,
2537,,1883,,BAO_0000219,,,485.0,Expert,1,,,8,,H,,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,B,
2538,,14875,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding affinity for human 5-hydroxytryptamine 2A receptor,B,
2539,,15146,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,B,
2540,,5213,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,B,
2541,,16404,9606.0,BAO_0000219,,,449.0,Expert,1,Homo sapiens,,9,,D,,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,B,
2542,,14818,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,B,
2543,,4829,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",B,
2544,,12652,,BAO_0000219,,,723.0,Autocuration,1,,,8,,H,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,F,
2545,,4682,,BAO_0000219,,,723.0,Expert,1,,,8,,H,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,B,
2546,,12652,,BAO_0000019,,,,Autocuration,1,,,8,,H,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,F,
2547,,4921,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,B,
2548,,4921,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,B,
2549,,16312,9986.0,BAO_0000357,,,,Autocuration,1,Oryctolagus cuniculus,,8,,H,,Binding affinity against rabbit aorta 5-HT2A receptor,B,
2550,,14998,9986.0,BAO_0000357,,,,Expert,1,Oryctolagus cuniculus,,8,,H,,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,B,
2551,,14025,9986.0,BAO_0000357,,,,Expert,1,Oryctolagus cuniculus,,8,,H,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,B,
2552,,13047,9986.0,BAO_0000019,,,,Autocuration,1,Oryctolagus cuniculus,,8,,H,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,B,
2553,,13047,9986.0,BAO_0000357,,,,Expert,1,Oryctolagus cuniculus,,8,,H,,The compound was tested for binding affinity against 5-HT2A receptor,B,
2554,,1883,,BAO_0000219,,,485.0,Autocuration,1,,,8,,H,,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,B,
2555,,13463,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity analysed towards 5-HT 2A in rat jugular vein,B,
2556,,13463,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,B,
2557,945.0,13463,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,B,Stomach
2558,945.0,13463,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity for 5-HT 2A in rat stomach fundus,B,Stomach
2559,,13463,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,B,
2560,,16326,,BAO_0000219,,,723.0,Expert,1,,,8,,H,,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,B,
2561,,14093,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,F,
2562,,14093,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,F,
2563,,15740,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,B,
2564,,16633,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,B,
2565,,17200,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,F,
2566,,17133,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,
2567,,17133,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,
2568,,17133,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,
2569,,17200,,BAO_0000219,,,,Autocuration,1,,,8,,H,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,
2570,,15363,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Efficacy at 5-hydroxytryptamine 2A receptor,F,
2571,,17200,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),B,
2572,,17200,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),B,
2573,,17200,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),B,
2574,,17200,10116.0,BAO_0000219,,,,Expert,1,Rattus norvegicus,,9,,D,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,
2575,,17200,,BAO_0000219,,,,Autocuration,1,,,8,,H,,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,
2576,,17211,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,B,
2577,,17331,,BAO_0000019,,,,Expert,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,B,
2578,,13565,,BAO_0000249,,,,Expert,1,,,8,,H,,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,B,
2579,,13730,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,B,
2580,,12416,,BAO_0000019,,,,Expert,1,,,8,,H,,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,B,
2581,,15295,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,B,
2582,,1742,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,B,
2583,,15295,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,B,
2584,,14970,,BAO_0000019,,,,Expert,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,B,
2585,,16693,,BAO_0000019,,,,Expert,1,,,8,,H,,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,B,
2586,,14776,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,B,
2587,,14286,,BAO_0000249,,,,Autocuration,1,,,8,,H,,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,
2588,,17200,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,B,
2589,,15306,,BAO_0000357,,,,Expert,1,,,8,,H,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),B,
2590,,14178,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,B,
2591,,14229,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,B,
2592,,12884,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,B,
2593,,13149,,BAO_0000357,,,,Expert,1,,,8,,H,,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",B,
2594,,15295,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,B,
2595,,15740,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,B,
2596,,15185,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",B,
2597,,15185,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",B,
2598,,17529,,BAO_0000019,,,,Expert,1,,,8,,H,,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,B,
2599,,14826,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,B,
2600,,17211,,BAO_0000019,,,,Expert,1,,,8,,H,,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,B,
2601,,14826,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,B,
2602,,14093,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,B,
2603,,14093,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,B,
2604,,13246,,BAO_0000219,,,723.0,Expert,1,,,8,,H,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,B,
2605,,13246,,BAO_0000357,,,,Expert,1,,,8,,H,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,B,
2606,,15436,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,
2607,,15436,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,
2608,955.0,14442,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,B,Brain
2609,,12457,,BAO_0000357,,,,Expert,1,,,8,,H,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,B,
2610,,12457,,BAO_0000219,,,723.0,Expert,1,,,8,,H,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,B,
2611,,14755,,BAO_0000221,,,,Autocuration,1,,,8,,H,,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",F,
2612,,4707,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,B,
2613,,13297,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 2A receptor,B,
2614,,17331,,BAO_0000019,,,,Expert,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,B,
2615,,4664,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,B,
2616,,16633,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,
2617,,4664,10116.0,BAO_0000219,,,723.0,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,B,
2618,,16133,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,
2619,,16133,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,
2620,,14060,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,B,
2621,,16326,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,
2622,,16659,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,
2623,,14776,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,B,
2624,,13481,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,B,
2625,,17386,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,B,
2626,,6611,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity for 5-hydroxytryptamine 2A receptor,B,
2627,,14423,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,B,
2628,,15412,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,B,
2629,,15412,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,B,
2630,,6238,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,B,
2631,,6648,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,B,
2632,,5667,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,B,
2633,,6611,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,B,
2634,,13481,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,
2635,,13481,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,B,
2636,,15558,,BAO_0000219,,,723.0,Expert,1,,,8,,H,,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,B,
2637,,6013,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,
2638,,16633,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,
2639,,6013,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,B,
2640,,6013,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,B,
2641,,6013,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,B,
2642,,6013,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,B,
2643,,6013,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,B,
2644,,6013,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,B,
2645,,16293,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,B,
2646,,17175,,BAO_0000219,,,723.0,Expert,1,,,8,,H,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,B,
2647,,13278,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,B,
2648,5383.0,3682,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,B,Caudate-putamen
2649,,2014,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,B,
2650,,2014,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,B,
2651,,4932,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,B,
2652,,4932,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,B,
2653,,3935,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,B,
2654,10000000.0,5432,10116.0,BAO_0000221,,,,Expert,1,Rattus norvegicus,,9,,D,,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,B,Hippocampus
2655,,15818,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,B,
2656,,13672,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,B,
2657,,13672,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,B,
2658,,14749,,BAO_0000219,,,723.0,Expert,1,,,8,,H,,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,B,
2659,,13462,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,B,
2660,,15740,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,B,
2661,,16647,,BAO_0000019,,,,Expert,1,,,8,,H,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,B,
2662,955.0,13345,,BAO_0000221,,,,Autocuration,1,,,8,,H,,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,B,Brain
2663,,16740,,BAO_0000249,,,,Autocuration,1,,,8,,H,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,
2664,,16740,,BAO_0000249,,,,Autocuration,1,,,8,,H,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,
2665,,15535,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,B,
2666,,16740,,BAO_0000249,,,,Expert,1,,,8,,H,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,
2667,,16740,,BAO_0000249,,,,Autocuration,1,,,8,,H,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,
2668,,16740,,BAO_0000249,,,,Autocuration,1,,,8,,H,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,
2669,,4795,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,B,
2670,,8,,BAO_0000019,,,,Expert,1,,,8,,H,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,B,
2671,,8,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,B,
2672,,17200,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,B,
2673,,2148,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,B,
2674,,13345,10116.0,BAO_0000224,,,,Expert,1,Rattus norvegicus,,5,,D,,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",B,
2675,,5088,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,
2676,,5088,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,
2677,,17133,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,B,
2678,,17133,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,B,
2679,,16532,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,B,
2680,,15086,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,B,
2681,,2309,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,B,
2682,,12953,,BAO_0000019,,,,Expert,1,,,8,,H,,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,B,
2683,,12953,,BAO_0000019,,,,Autocuration,1,,,8,,H,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,B,
2684,,12953,,BAO_0000019,,,,Autocuration,1,,,8,,H,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,B,
2685,,16659,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,B,
2686,,16740,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,B,
2687,,16740,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,B,
2688,,17133,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,B,
2689,,17211,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,B,
2690,,17331,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,B,
2691,,16633,,BAO_0000218,,,,Autocuration,1,,,8,,H,,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,B,
2692,,16633,,BAO_0000218,,,,Autocuration,1,,,8,,H,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,B,
2693,,16633,,BAO_0000218,,,,Autocuration,1,,,8,,H,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,B,
2694,,15026,,BAO_0000357,,,,Expert,1,,,8,,H,,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,B,
2695,,15026,,BAO_0000357,,,,Expert,1,,,8,,H,,Ratio of pKi of 5-HT2A to that of D2 receptor,B,
2696,,16404,,BAO_0000224,,,,Expert,1,,,4,,H,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,B,
2697,,16404,,BAO_0000224,,,,Expert,1,,,4,,H,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,B,
2698,,16404,,BAO_0000224,,,,Expert,1,,,4,,H,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,B,
2699,,16404,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,B,
2700,,16326,,BAO_0000357,,,,Expert,1,,,8,,H,,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,B,
2701,,15847,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,F,
2702,,15847,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,F,
2703,,15329,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,F,
2704,1515.0,16404,,BAO_0000019,,,,Expert,1,,,8,,H,,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,F,Thoracic aorta
2705,1515.0,16404,,BAO_0000019,,,,Expert,1,,,8,,H,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,F,Thoracic aorta
2706,1515.0,16404,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,F,Thoracic aorta
2707,,12861,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding activity radioligand.,B,
2708,,12861,,BAO_0000019,,,,Expert,1,,,8,,H,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,
2709,,12861,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,B,
2710,,12490,,BAO_0000019,,,,Expert,1,,,8,,H,,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,B,
2711,,12827,,BAO_0000219,,,339.0,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,B,
2712,,12827,,BAO_0000219,,,339.0,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,B,
2713,,12918,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,B,
2714,,12919,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,F,
2715,,17723,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,B,
2716,,6013,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,
2717,,16293,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards human 5-hydroxytryptamine 2C receptor,B,
2718,,3857,,BAO_0000019,,,,Expert,1,,,8,,H,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,B,
2719,,3857,,BAO_0000019,,,,Expert,1,,,8,,H,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,B,
2720,,3857,,BAO_0000019,,,,Expert,1,,,8,,H,,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,B,
2721,,15363,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,B,
2722,,15363,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,B,
2723,,16441,,BAO_0000019,,,,Expert,1,,,8,,H,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,B,
2724,,16441,,BAO_0000019,,,,Expert,1,,,8,,H,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,B,
2725,,4176,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,B,
2726,,17085,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,B,
2727,,17200,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,B,
2728,,5088,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,B,
2729,,5088,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,B,
2730,,5088,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,
2731,,5088,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,B,
2732,,16659,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,
2733,,16659,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,B,
2734,,17451,,BAO_0000219,,,723.0,Autocuration,1,,,8,,H,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,
2735,,6857,9606.0,BAO_0000219,,,449.0,Expert,1,Homo sapiens,,9,,D,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,
2736,,3857,,BAO_0000019,,,,Expert,1,,,8,,H,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,B,
2737,,12861,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding activity radioligand.,B,
2738,,12861,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,
2739,,5104,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,B,
2740,,5105,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,B,
2741,,5105,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,B,
2742,,5254,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-HT2C receptor,B,
2743,,13267,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,B,
2744,,14157,9606.0,BAO_0000219,,,722.0,Expert,1,Homo sapiens,,9,,D,,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,B,
2745,,12936,9606.0,BAO_0000219,,,722.0,Expert,1,Homo sapiens,,9,,D,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,B,
2746,,14068,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,B,
2747,,12936,9606.0,BAO_0000219,,,722.0,Expert,1,Homo sapiens,,9,,D,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,B,
2748,,4540,9606.0,BAO_0000219,,,722.0,Expert,1,Homo sapiens,,9,,D,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,B,
2749,,4540,9606.0,BAO_0000219,,,722.0,Expert,1,Homo sapiens,,9,,D,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,B,
2750,,6166,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,B,
2751,,17296,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,B,
2752,,17296,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,B,
2753,,15779,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,
2754,,15779,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,
2755,,14391,,BAO_0000219,,,722.0,Expert,1,,,8,,H,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,B,
2756,,15779,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",B,
2757,,15851,,BAO_0000219,,,722.0,Expert,1,,,8,,H,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",B,
2758,,15851,9606.0,BAO_0000219,,,722.0,Expert,1,Homo sapiens,,9,,D,,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,B,
2759,,15779,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",B,
2760,,3832,,BAO_0000219,,,722.0,Expert,1,,,8,,H,,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,B,
2761,,3833,,BAO_0000219,,,722.0,Expert,1,,,8,,H,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,B,
2762,,17451,,BAO_0000219,,,723.0,Autocuration,1,,,8,,H,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,B,
2763,,4199,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,B,
2764,,1883,,BAO_0000219,,,485.0,Expert,1,,,8,,H,,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,B,
2765,,4321,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding affinity against 5-hydroxytryptamine 2C receptor,B,
2766,,14875,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,B,
2767,,15146,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,B,
2768,,5213,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,B,
2769,,16404,,BAO_0000219,,,308.0,Autocuration,1,,,8,,H,,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,B,
2770,,13267,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,F,
2771,10000000.0,13267,,BAO_0000221,,,,Autocuration,1,,,8,,H,,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,F,Hippocampus
2772,,14818,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,B,
2773,,4829,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",B,
2774,,13463,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,B,
2775,945.0,13463,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity analysed on 5-HT 2C in rat stomach fundus,B,Stomach
2776,945.0,13463,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,B,Stomach
2777,,12652,,BAO_0000219,,,625.0,Autocuration,1,,,8,,H,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,F,
2778,,4682,,BAO_0000219,,,723.0,Autocuration,1,,,8,,H,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,B,
2779,,4682,,BAO_0000219,,,723.0,Autocuration,1,,,8,,H,,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,B,
2780,,4682,,BAO_0000219,,,723.0,Autocuration,1,,,8,,H,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,B,
2781,,12652,,BAO_0000019,,,,Autocuration,1,,,8,,H,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,F,
2782,945.0,13463,10090.0,BAO_0000019,,,,Autocuration,1,Mus musculus,,8,,H,,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,B,Stomach
2783,945.0,13463,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,B,Stomach
2784,,13969,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,B,
2785,,13392,9823.0,BAO_0000357,,,,Expert,1,Sus scrofa,,8,,H,,Binding affinity for 5-hydroxytryptamine 2C receptor,B,
2786,,13392,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,
2787,,14430,,BAO_0000019,,,,Expert,1,,,8,,H,,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,B,
2788,,1742,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,B,
2789,,14286,,BAO_0000249,,,,Autocuration,1,,,8,,H,,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,B,
2790,,5619,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,B,
2791,,15086,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,B,
2792,,12861,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding activity radioligand.,B,
2793,,12861,,BAO_0000019,,,,Expert,1,,,8,,H,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,
2794,,12861,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,B,
2795,,12827,,BAO_0000249,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,B,
2796,,12827,,BAO_0000249,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,B,
2797,,12919,9823.0,BAO_0000019,,,,Expert,1,Sus scrofa,,8,,H,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,F,
2798,,12919,9823.0,BAO_0000019,,,,Expert,1,Sus scrofa,,8,,H,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,F,
2799,,16429,9823.0,BAO_0000357,,,,Autocuration,1,Sus scrofa,,8,,H,,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,B,
2800,,773,9823.0,BAO_0000019,,,,Autocuration,1,Sus scrofa,,8,,H,,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,B,
2801,,5033,9823.0,BAO_0000357,,,,Autocuration,1,Sus scrofa,,8,,H,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,B,
2802,,12861,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,
2803,,14093,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,F,
2804,,14970,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,B,
2805,,14970,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,B,
2806,,14970,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,B,
2807,,14178,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,B,
2808,,14178,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,B,
2809,,14229,10116.0,BAO_0000249,,,,Expert,1,Rattus norvegicus,,9,Brain membranes,D,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,B,
2810,,16532,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,B,
2811,,14826,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,B,
2812,,17211,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,B,
2813,,17211,,BAO_0000219,,,,Expert,1,,In vitro,8,,H,,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,B,
2814,,13246,,BAO_0000219,,,723.0,Expert,1,,,8,,H,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,B,
2815,,13246,,BAO_0000357,,,,Expert,1,,,8,,H,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,B,
2816,,12457,,BAO_0000357,,,,Expert,1,,,8,,H,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,B,
2817,,12457,,BAO_0000219,,,723.0,Expert,1,,,8,,H,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,B,
2818,,4707,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,B,
2819,,13297,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 2C receptor,B,
2820,,16633,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,B,
2821,,16133,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,
2822,,16326,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,B,
2823,,14423,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,B,
2824,,15412,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,B,
2825,,15412,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,B,
2826,,15558,,BAO_0000219,,,625.0,Expert,1,,,8,,H,,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,B,
2827,,16633,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,B,
2828,,6013,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,B,
2829,,17175,,BAO_0000219,,,,Expert,1,,In vitro,8,,H,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,B,
2830,,12469,,BAO_0000219,,,,Autocuration,1,,,8,,H,,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,B,
2831,5383.0,3682,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,B,Caudate-putamen
2832,,4932,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,B,
2833,,4932,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,B,
2834,,3935,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,B,
2835,,15818,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,B,
2836,,15818,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,B,
2837,,14749,,BAO_0000219,,,,Expert,1,,,8,,H,,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,B,
2838,,15740,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,B,
2839,,17133,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,B,
2840,,16532,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,B,
2841,,12369,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,B,
2842,,12369,,BAO_0000219,,,,Expert,1,,,8,,H,,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,B,
2843,,2309,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,B,
2844,,12953,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,B,
2845,,12953,,BAO_0000019,,,,Autocuration,1,,,8,,H,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,B,
2846,,12953,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,B,
2847,,12953,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity for 5-hydroxytryptamine 2C receptor,B,
2848,,17133,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,B,
2849,,17211,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,B,
2850,,17211,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,B,
2851,,14025,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,B,
2852,,14998,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,B,
2853,,4342,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,B,
2854,,13735,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,B,
2855,,13181,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,B,
2856,,1883,,BAO_0000219,,,485.0,Autocuration,1,,,8,,H,,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,B,
2857,,15194,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,
2858,,15194,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,B,
2859,,14579,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,F,
2860,,4639,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,B,
2861,,4820,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,
2862,,14442,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,B,
2863,,14755,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,B,
2864,,14744,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,B,
2865,,6857,9606.0,BAO_0000019,,,,Expert,1,Homo sapiens,,9,,D,,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,B,
2866,,16209,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,B,
2867,,15363,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,B,
2868,,15363,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,B,
2869,,15363,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,B,
2870,,17085,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,B,
2871,,17200,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,B,
2872,,15851,9606.0,BAO_0000219,,,722.0,Expert,1,Homo sapiens,,9,,D,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,B,
2873,,15851,9606.0,BAO_0000219,,,722.0,Expert,1,Homo sapiens,,9,,D,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,B,
2874,,6857,9606.0,BAO_0000219,,,449.0,Expert,1,Homo sapiens,,9,,D,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,
2875,,6857,9606.0,BAO_0000219,,,449.0,Expert,1,Homo sapiens,,9,,D,,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,
2876,,15779,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,
2877,,15851,,BAO_0000219,,,722.0,Expert,1,,,8,,H,,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,B,
2878,,15779,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",B,
2879,,14157,9606.0,BAO_0000219,,,722.0,Expert,1,Homo sapiens,,9,,D,,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,B,
2880,,4540,9606.0,BAO_0000219,,,722.0,Expert,1,Homo sapiens,,9,,D,,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,B,
2881,,6166,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,B,
2882,,15779,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,B,
2883,,14391,,BAO_0000219,,,722.0,Expert,1,,,8,,H,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,B,
2884,,3832,,BAO_0000219,,,722.0,Expert,1,,,8,,H,,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,B,
2885,,3833,,BAO_0000219,,,722.0,Expert,1,,,8,,H,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,B,
2886,,15851,9606.0,BAO_0000219,,,722.0,Expert,1,Homo sapiens,,9,,D,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,B,
2887,,15851,9606.0,BAO_0000219,,,722.0,Expert,1,Homo sapiens,,9,,D,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,B,
2888,,4199,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,B,
2889,,1883,,BAO_0000219,,,485.0,Expert,1,,,8,,H,,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,B,
2890,,4321,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 2B receptor,B,
2891,,15146,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,B,
2892,,5213,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,B,
2893,,14818,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,B,
2894,,4829,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,
2895,,4829,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,
2896,,14025,9986.0,BAO_0000019,,,,Autocuration,1,Oryctolagus cuniculus,,8,,H,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,B,
2897,945.0,13463,,BAO_0000019,,,,Expert,1,,,8,,H,,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,B,Stomach
2898,945.0,7259,,BAO_0000357,,,,Expert,1,,,8,,H,,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,B,Stomach
2899,945.0,7259,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Affinity against serotonergic receptor in the isolated rat stomach fundus,B,Stomach
2900,945.0,7185,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,F,Stomach
2901,,7185,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Antagonistic against 5-hydroxytryptamine 2B receptor,F,
2902,945.0,13267,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,F,Stomach
2903,945.0,13735,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,B,Stomach
2904,,15738,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,F,
2905,,15738,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,F,
2906,,15738,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,F,
2907,945.0,12936,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,Stomach
2908,945.0,12936,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,Stomach
2909,945.0,12936,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,Stomach
2910,945.0,12936,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,Stomach
2911,945.0,16404,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,Stomach
2912,945.0,16404,,BAO_0000019,,,,Expert,1,,,8,,H,,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,Stomach
2913,945.0,16404,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,F,Stomach
2914,945.0,16404,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,F,Stomach
2915,945.0,16404,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,F,Stomach
2916,1515.0,16404,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,F,Thoracic aorta
2917,,7483,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,B,
2918,,7483,,BAO_0000357,,,,Expert,1,,,8,,H,,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,B,
2919,,7483,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,B,
2920,,7483,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,B,
2922,945.0,16404,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,9,,D,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,Stomach
2923,,6347,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor,B,
2924,,4373,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,B,
2925,,4373,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,B,
2926,,4687,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Evaluated for the binding affinity to 5-HT 2B receptor,B,
2927,,16946,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,B,
2928,,16633,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinities against 5-hydroxytryptamine 2B receptor,B,
2929,,16633,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinities towards 5-hydroxytryptamine 2B receptor,B,
2930,,16633,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,B,
2931,,15026,,BAO_0000357,,,,Expert,1,,,8,,H,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,B,
2932,,15738,9913.0,BAO_0000357,,,,Autocuration,1,Bos taurus,,8,,H,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,B,
2933,,15738,9913.0,BAO_0000357,,,,Autocuration,1,Bos taurus,,8,,H,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,B,
2934,,15738,9913.0,BAO_0000357,,,,Autocuration,1,Bos taurus,,8,,H,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,B,
2935,,15738,9913.0,BAO_0000357,,,,Autocuration,1,Bos taurus,,8,,H,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,B,
2936,,16404,9913.0,BAO_0000357,,,,Expert,1,Bos taurus,,8,,H,,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,B,
2937,,15026,9913.0,BAO_0000357,,,,Expert,1,Bos taurus,,8,,H,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,B,
2938,,15738,9913.0,BAO_0000357,,,,Autocuration,1,Bos taurus,,8,,H,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,B,
2939,,16312,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,8,,H,,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,B,
2940,2435.0,5486,10141.0,BAO_0000357,,,,Intermediate,1,Cavia porcellus,,9,,D,,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,B,Striatum
2941,,5254,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-HT1A receptor,B,
2942,,3857,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,F,
2943,,6857,9606.0,BAO_0000219,,,449.0,Expert,1,Homo sapiens,,9,,D,,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,F,
2944,,4176,,BAO_0000219,,,,Autocuration,1,,,8,,H,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,F,
2945,,6347,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,B,
2946,,6347,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",B,
2947,,16146,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Inhibition of human 5-hydroxytryptamine 2C receptor,B,
2948,,3805,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),B,
2949,,3857,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,B,
2950,,5635,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,B,
2951,,5635,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,B,
2952,,5635,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,B,
2953,,4012,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,B,
2954,,6366,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,B,
2955,,15949,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,
2956,,17211,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,B,
2957,,6491,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,B,
2958,,14093,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,F,
2959,,13481,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,F,
2960,,6347,10116.0,BAO_0000219,,,449.0,Expert,1,Rattus norvegicus,,8,,H,,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,B,
2961,,14093,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,F,
2962,,14093,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,F,
2963,,13481,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,F,
2964,,14442,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,B,
2965,,14442,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,B,
2966,,14442,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,B,
2967,,14755,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,B,
2968,,14744,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,B,
2969,,16659,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,
2970,,6857,9606.0,BAO_0000019,,,,Expert,1,Homo sapiens,,9,,D,,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,B,
2971,,5635,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,B,
2972,,4234,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,B,
2973,,16209,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,B,
2974,,5778,10116.0,BAO_0000249,,,,Autocuration,1,Rattus norvegicus,,7,Membranes,D,,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,B,
2975,,5094,,BAO_0000223,,,,Autocuration,1,,,6,,H,,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,B,
2976,,809,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,7,,D,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,B,
2977,,1578,,BAO_0000019,,,,Autocuration,1,,,6,,H,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,B,
2978,,809,,BAO_0000019,,,,Autocuration,1,,,6,,H,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,B,
2979,,12469,,BAO_0000219,,,,Autocuration,1,,,6,,H,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,B,
2980,,14290,,BAO_0000019,,,,Autocuration,1,,,6,,H,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,B,
2981,,14290,,BAO_0000019,,,,Autocuration,1,,,6,,H,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,B,
2982,,10609,,BAO_0000223,,,,Autocuration,1,,,6,,H,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,B,
2983,,10609,,BAO_0000223,,,,Autocuration,1,,,6,,H,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,B,
2984,,10609,,BAO_0000223,,,,Autocuration,1,,,6,,H,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,B,
2985,,15253,,BAO_0000249,,,,Autocuration,1,,,6,,H,,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",B,
2986,,15253,,BAO_0000249,,,,Autocuration,1,,,6,,H,,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",B,
2987,,11683,,BAO_0000249,,,,Autocuration,1,,,6,Membranes,H,,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,B,
2988,,12092,,BAO_0000223,,,,Autocuration,1,,,6,,H,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,B,
2989,,1946,,BAO_0000019,,,,Autocuration,1,,,6,,H,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,B,
2990,,11623,,BAO_0000223,,,,Autocuration,1,,,6,,H,,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,B,
2991,,11623,,BAO_0000223,,,,Autocuration,1,,,6,,H,,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,B,
2992,,14788,,BAO_0000019,,,,Autocuration,1,,,6,,H,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,B,
2993,,5432,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,7,,D,,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,B,
2994,,14826,,BAO_0000249,,,,Autocuration,1,,,6,,H,,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,
2995,,2222,,BAO_0000223,,,,Autocuration,1,,,6,,H,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,B,
2996,,11963,,BAO_0000019,,,,Autocuration,1,,,6,,H,,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,B,
2997,,14145,,BAO_0000019,,,,Autocuration,1,,,6,,H,,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,B,
2998,,17819,,BAO_0000019,,,,Autocuration,1,,,6,,H,,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,B,
2999,,10394,,BAO_0000249,,,,Autocuration,1,,,6,,H,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,B,
3000,,10394,,BAO_0000249,,,,Autocuration,1,,,6,,H,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,B,
3001,,15034,,BAO_0000019,,,,Autocuration,1,,,6,,H,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,B,
3002,,691,,BAO_0000019,,,,Autocuration,1,,,6,,H,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,B,
3003,,12092,,BAO_0000249,,,,Autocuration,1,,,6,Membranes,H,,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,B,
3004,,11752,10116.0,BAO_0000223,,,,Autocuration,1,Rattus norvegicus,,7,,D,,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,B,
3005,955.0,11752,,BAO_0000221,,,,Autocuration,1,,,6,,H,,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,B,Brain
3006,,301,,BAO_0000019,,,,Autocuration,1,,,6,,H,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,B,
3007,,16532,,BAO_0000223,,,,Autocuration,1,,,6,,H,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,B,
3008,,16532,,BAO_0000223,,,,Autocuration,1,,,6,,H,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,B,
3009,,12092,,BAO_0000223,,,,Autocuration,1,,,6,,H,,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,B,
3010,,11684,,BAO_0000223,,,,Autocuration,1,,,6,,H,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,B,
3011,,11684,,BAO_0000223,,,,Autocuration,1,,,6,,H,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,B,
3012,,12953,,BAO_0000019,,,,Autocuration,1,,,6,,H,,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,B,
3013,,12953,,BAO_0000019,,,,Autocuration,1,,,6,,H,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,B,
3014,,12953,,BAO_0000223,,,,Autocuration,1,,,6,,H,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,B,
3015,,12861,,BAO_0000019,,,,Autocuration,1,,,6,,H,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,B,
3016,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,F,
3017,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,F,
3018,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,F,
3019,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,F,
3020,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,F,
3021,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,F,
3022,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,F,
3023,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,F,
3024,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,F,
3025,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,F,
3026,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,F,
3027,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,F,
3028,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,F,
3029,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,F,
3030,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,F,
3031,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,F,
3032,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,F,
3033,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,F,
3034,,10609,,BAO_0000019,,,,Autocuration,1,,,6,,H,,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,F,
3035,,12861,,BAO_0000019,,,,Autocuration,1,,,6,,H,,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,B,
3036,,12861,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,7,,D,,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,B,
3037,,12861,,BAO_0000223,,,,Autocuration,1,,,6,,H,,Binding activity radioligand.,B,
3038,,10728,,BAO_0000249,,,,Autocuration,1,,,6,Brain membranes,H,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,B,
3039,,10728,,BAO_0000249,,,,Autocuration,1,,,6,Brain membranes,H,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,B,
3040,,5163,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,B,
3041,,5163,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,B,
3042,,6011,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,B,
3043,,5014,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,B,
3044,,5635,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,B,
3045,,5163,,BAO_0000357,,,,Expert,1,,,8,,H,,Affinity for 5-hydroxytryptamine 2C receptor,B,
3046,,6841,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,
3047,,6119,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,B,
3048,,4373,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,B,
3049,,1633,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,B,
3050,,1633,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,B,
3051,,4373,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,B,
3052,,6576,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,B,
3053,,4687,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,B,
3054,,12146,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,B,
3055,,12146,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,B,
3056,,16946,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,B,
3057,,14159,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,B,
3058,,16700,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,B,
3059,,3269,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Affinity against 5-hydroxytryptamine 2C receptor,B,
3060,,1274,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding affinity against 5-hydroxytryptamine 2C receptor,B,
3061,,1317,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,B,
3062,,5834,9913.0,BAO_0000357,,,,Autocuration,1,Bos taurus,,8,,H,,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,B,
3063,,11147,9913.0,BAO_0000357,,,,Autocuration,1,Bos taurus,,8,,H,,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,B,
3064,,14145,10141.0,BAO_0000019,,,,Expert,1,Cavia porcellus,,4,,H,,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,F,
3065,2116.0,10561,10141.0,BAO_0000221,,,,Autocuration,1,Cavia porcellus,,4,,H,,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,B,Ileum
3066,,15847,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,4,,H,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,F,
3067,,15847,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,4,,H,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,F,
3068,2116.0,10561,10141.0,BAO_0000221,,,,Autocuration,1,Cavia porcellus,,4,,H,,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,B,Ileum
3069,2116.0,11454,10141.0,BAO_0000221,,,,Autocuration,1,Cavia porcellus,,4,,H,,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,B,Ileum
3070,,4639,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,4,,H,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,F,
3071,,4639,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,4,,H,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,F,
3072,,4639,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,4,,H,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,F,
3073,,4639,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,4,,H,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,F,
3074,,4639,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,4,,H,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,F,
3075,,4639,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,4,,H,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,F,
3076,2116.0,15253,10141.0,BAO_0000221,,,,Autocuration,1,Cavia porcellus,,4,,H,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",F,Ileum
3077,2116.0,15253,10141.0,BAO_0000221,,,,Autocuration,1,Cavia porcellus,,4,,H,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",F,Ileum
3078,2116.0,11963,10141.0,BAO_0000221,,,,Autocuration,1,Cavia porcellus,,4,,H,,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,F,Ileum
3079,2116.0,1946,10141.0,BAO_0000221,,,,Autocuration,1,Cavia porcellus,,4,,H,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,B,Ileum
3080,2116.0,1946,10141.0,BAO_0000221,,,,Autocuration,1,Cavia porcellus,,4,,H,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,B,Ileum
3081,,12045,10141.0,BAO_0000223,,,,Autocuration,1,Cavia porcellus,,4,,H,,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,B,
3082,2116.0,1559,10141.0,BAO_0000221,,,,Autocuration,1,Cavia porcellus,,4,,H,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,Ileum
3083,2116.0,273,10141.0,BAO_0000221,,,,Autocuration,1,Cavia porcellus,,4,,H,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,Ileum
3084,2116.0,273,10141.0,BAO_0000221,,,,Autocuration,1,Cavia porcellus,,4,,H,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),F,Ileum
3085,2116.0,188,10141.0,BAO_0000221,,,,Autocuration,1,Cavia porcellus,,4,,H,,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,F,Ileum
3086,2116.0,12919,10141.0,BAO_0000221,,,,Autocuration,1,Cavia porcellus,,4,,H,,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,F,Ileum
3087,2116.0,12918,10141.0,BAO_0000221,,,,Autocuration,1,Cavia porcellus,,4,,H,,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,F,Ileum
3088,2116.0,1559,10141.0,BAO_0000221,,,,Autocuration,1,Cavia porcellus,,4,,H,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,Ileum
3089,2116.0,273,10141.0,BAO_0000221,,,,Autocuration,1,Cavia porcellus,,4,,H,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,Ileum
3090,2116.0,1559,10141.0,BAO_0000221,,,,Autocuration,1,Cavia porcellus,,4,,H,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,Ileum
3091,2116.0,1559,10141.0,BAO_0000221,,,,Autocuration,1,Cavia porcellus,,4,,H,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,B,Ileum
3092,2116.0,1559,10141.0,BAO_0000221,,,,Autocuration,1,Cavia porcellus,,4,,H,,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,B,Ileum
3093,2116.0,14424,10141.0,BAO_0000221,,,,Autocuration,1,Cavia porcellus,,4,,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,B,Ileum
3094,,13181,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,0,,U,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,B,
3095,,5486,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,B,
3096,,6491,9606.0,BAO_0000223,,,,Expert,1,Homo sapiens,,5,,D,,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,B,
3097,,6013,,BAO_0000223,,,,Autocuration,1,,,4,,H,,Binding affinity towards 5-HT3 receptor,B,
3098,,12861,,BAO_0000223,,,,Autocuration,1,,,4,,H,,Binding activity radioligand.,B,
3099,,12861,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,B,
3100,,5104,,BAO_0000223,,,,Autocuration,1,,,4,,H,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,B,
3101,,5105,,BAO_0000223,,,,Autocuration,1,,,4,,H,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,B,
3102,,5104,,BAO_0000223,,,,Autocuration,1,,,4,,H,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,B,
3103,,3935,,BAO_0000019,,,,Autocuration,1,,,0,,U,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,B,
3104,,13657,,BAO_0000219,,,433.0,Expert,1,,,4,,H,,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,B,
3105,,10369,,BAO_0000218,,,,Autocuration,1,,In vivo,4,,H,,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",B,
3106,,10369,,BAO_0000019,,,,Autocuration,1,,,4,,H,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),B,
3107,,12918,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,B,
3108,,12918,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Compound was evaluated for the binding affinity at 5- HT3 receptor,B,
3109,,10369,,BAO_0000019,,,,Autocuration,1,,,4,,H,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),B,
3110,,773,,BAO_0000019,,,,Autocuration,1,,,4,,H,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,B,
3111,,12918,,BAO_0000218,,,,Autocuration,1,,,4,,H,,5-hydroxytryptamine 3 receptor agonism in mouse,F,
3112,,10561,,BAO_0000219,,,,Autocuration,1,,,4,,H,,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,B,
3113,,12827,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,B,
3114,,12827,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,B,
3115,,12918,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,B,
3116,,273,,BAO_0000219,,,,Autocuration,1,,,4,,H,,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,B,
3117,,273,,BAO_0000219,,,,Autocuration,1,,,4,,H,,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,B,
3118,,10561,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,B,
3119,,5033,,BAO_0000219,,,,Autocuration,1,,In vitro,4,,H,,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,B,
3120,,16429,,BAO_0000219,,,339.0,Autocuration,1,,,4,,H,,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,B,
3121,,10322,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,B,
3122,,14331,,BAO_0000219,,,,Autocuration,1,,,8,,H,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,B,
3123,,13462,10090.0,BAO_0000357,,,,Autocuration,1,Mus musculus,,9,,D,,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,B,
3124,,12861,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,
3125,,15086,9823.0,BAO_0000357,,,,Autocuration,1,Sus scrofa,,8,,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,B,
3126,,12861,9823.0,BAO_0000357,,,,Autocuration,1,Sus scrofa,,8,,H,,Binding activity radioligand.,B,
3127,,10561,9986.0,BAO_0000223,,,,Autocuration,1,Oryctolagus cuniculus,,4,,H,,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,B,
3128,,10561,9986.0,BAO_0000223,,,,Autocuration,1,Oryctolagus cuniculus,,4,,H,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,B,
3129,,10561,9986.0,BAO_0000223,,,,Autocuration,1,Oryctolagus cuniculus,,4,,H,,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,B,
3130,,10561,9986.0,BAO_0000019,,,,Autocuration,1,Oryctolagus cuniculus,,4,,H,,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,B,
3131,,273,9986.0,BAO_0000019,,,,Autocuration,1,Oryctolagus cuniculus,,4,,H,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,
3132,,273,9986.0,BAO_0000019,,,,Autocuration,1,Oryctolagus cuniculus,,4,,H,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,
3133,2116.0,273,9986.0,BAO_0000221,,,,Autocuration,1,Oryctolagus cuniculus,,4,,H,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,Ileum
3134,,273,9986.0,BAO_0000019,,,,Autocuration,1,Oryctolagus cuniculus,,4,,H,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,
3135,,273,9986.0,BAO_0000019,,,,Autocuration,1,Oryctolagus cuniculus,,4,,H,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,
3136,,273,9986.0,BAO_0000019,,,,Autocuration,1,Oryctolagus cuniculus,,4,,H,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,
3137,,273,9986.0,BAO_0000019,,,,Autocuration,1,Oryctolagus cuniculus,,4,,H,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,
3138,,13047,9986.0,BAO_0000219,,,449.0,Autocuration,1,Oryctolagus cuniculus,,4,,H,,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,B,
3139,,1650,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,7,,D,,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,B,
3140,,16288,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),B,
3141,,16288,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),B,
3142,,10254,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,7,,D,,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,B,
3143,,14532,,BAO_0000019,,,,Autocuration,1,,,6,,H,,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",B,
3144,948.0,13392,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",F,Heart
3145,948.0,13392,,BAO_0000019,,,,Autocuration,1,,,6,,H,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",F,Heart
3146,948.0,13392,,BAO_0000019,,,,Autocuration,1,,,6,,H,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",F,Heart
3147,948.0,13392,,BAO_0000019,,,,Autocuration,1,,,6,,H,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",F,Heart
3148,948.0,13392,,BAO_0000019,,,,Autocuration,1,,,6,,H,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",F,Heart
3149,,13392,,BAO_0000019,,,,Autocuration,1,,,6,,H,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",F,
3150,,13392,,BAO_0000019,,,,Autocuration,1,,,6,,H,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",F,
3151,,13392,,BAO_0000019,,,,Autocuration,1,,,6,,H,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",F,
3152,,13392,,BAO_0000019,,,,Autocuration,1,,,6,,H,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",F,
3153,,1089,10116.0,BAO_0000218,,,,Autocuration,1,Rattus norvegicus,In vivo,7,,D,,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),F,
3154,,1089,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),F,
3155,,11454,10116.0,BAO_0000218,,,,Autocuration,1,Rattus norvegicus,In vivo,7,,D,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,F,
3156,,11454,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,7,,D,,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,F,
3157,,12205,10116.0,BAO_0000218,,,,Autocuration,1,Rattus norvegicus,In vivo,7,,D,,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,F,
3158,,1089,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,7,,D,,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),F,
3159,,5094,,BAO_0000019,,,,Autocuration,1,,,6,,H,,Binding affinity towards 5-HT3 receptor in rat was evaluated,B,
3160,,2622,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,7,,D,,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,B,
3161,,245,,BAO_0000223,,,,Autocuration,1,,,6,,H,,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,B,
3162,,14788,,BAO_0000019,,,,Autocuration,1,,,6,,H,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,B,
3163,,14788,,BAO_0000019,,,,Autocuration,1,,,6,,H,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,B,
3164,,3020,,BAO_0000249,,,,Autocuration,1,,,6,,H,,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,B,
3165,,1742,,BAO_0000019,,,,Autocuration,1,,,6,,H,,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,B,
3166,955.0,17394,,BAO_0000249,,,,Autocuration,1,,,6,,H,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,B,Brain
3167,955.0,17394,,BAO_0000221,,,,Autocuration,1,,,6,,H,,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,B,Brain
3168,,17394,,BAO_0000249,,,,Autocuration,1,,,6,,H,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,
3169,,14286,,BAO_0000249,,,,Autocuration,1,,,6,,H,,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,
3170,,14178,,BAO_0000019,,,,Autocuration,1,,,6,,H,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,B,
3171,,14178,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,7,,D,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,B,
3172,,14178,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,7,,D,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,B,
3173,,14178,10116.0,BAO_0000223,,,,Autocuration,1,Rattus norvegicus,,7,,D,,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,B,
3174,,15034,,BAO_0000019,,,,Autocuration,1,,,6,,H,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,B,
3175,,1089,,BAO_0000249,,,,Autocuration,1,,,6,Membranes,H,,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",B,
3176,,1089,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,7,,D,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,B,
3177,,16532,,BAO_0000223,,,,Autocuration,1,,,6,,H,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,B,
3178,,12801,10116.0,BAO_0000223,,,,Autocuration,1,Rattus norvegicus,,7,,D,,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,B,
3179,,15194,,BAO_0000219,,,433.0,Autocuration,1,,,6,,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),B,
3180,,15194,,BAO_0000219,,,433.0,Autocuration,1,,,6,,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,B,
3181,,15194,,BAO_0000019,,,,Autocuration,1,,,6,,H,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,B,
3182,,15194,,BAO_0000019,,,,Autocuration,1,,,6,,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,B,
3183,,15194,,BAO_0000019,,,,Autocuration,1,,,6,,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,B,
3184,,15194,,BAO_0000019,,,,Autocuration,1,,,6,,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,B,
3185,,10610,,BAO_0000019,,,,Autocuration,1,,,6,,H,,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,F,
3186,,10355,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,7,,D,,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,F,
3187,,691,,BAO_0000019,,,,Autocuration,1,,,6,,H,,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",F,
3188,,10611,,BAO_0000218,,,,Autocuration,1,,,6,,H,,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,F,
3189,,12801,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,F,
3190,,10609,,BAO_0000218,,,,Autocuration,1,,,6,,H,,Inhibition of 5-HT evoked reflex bradycardia in rat.,F,
3191,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,
3192,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,F,
3193,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),F,
3194,,11454,10116.0,BAO_0000218,,,,Autocuration,1,Rattus norvegicus,In vivo,7,,D,,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,F,
3195,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,
3196,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,F,
3197,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,F,
3198,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,F,
3199,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,F,
3200,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,F,
3201,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,F,
3202,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,F,
3203,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,F,
3204,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,
3205,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,F,
3206,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,F,
3207,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,F,
3208,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,F,
3209,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,F,
3210,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,F,
3211,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,F,
3212,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,F,
3213,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,F,
3214,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,F,
3215,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,F,
3216,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,F,
3217,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,F,
3218,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,F,
3219,,11454,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,F,
3220,,670,,BAO_0000218,,,,Autocuration,1,,,6,,H,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",F,
3221,,670,,BAO_0000218,,,,Autocuration,1,,,6,,H,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",F,
3222,,10321,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,F,
3223,,10321,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,F,
3224,,10321,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,F,
3225,,10321,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,F,
3226,,10321,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,F,
3227,,10322,,BAO_0000218,,,,Autocuration,1,,In vivo,6,,H,,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),F,
3228,,15412,,BAO_0000019,,,,Autocuration,1,,,6,,H,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,F,
3229,,15412,,BAO_0000019,,,,Autocuration,1,,,6,,H,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,F,
3230,,15412,10116.0,BAO_0000223,,,,Autocuration,1,Rattus norvegicus,,7,,D,,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,B,
3231,,15412,,BAO_0000019,,,,Autocuration,1,,,6,,H,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,F,
3232,10000000.0,15412,,BAO_0000221,,,,Intermediate,1,,,7,,D,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,B,Hippocampus
3233,,15412,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,7,,D,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,B,
3234,,17394,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,7,,D,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,B,
3235,,12457,,BAO_0000223,,,,Autocuration,1,,,6,,H,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,B,
3236,,12457,,BAO_0000019,,,,Autocuration,1,,,6,,H,,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,B,
3237,,12205,,BAO_0000019,,,,Autocuration,1,,,6,,H,,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,B,
3238,,14532,,BAO_0000019,,,,Autocuration,1,,,6,,H,,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,B,
3239,,1122,,BAO_0000019,,,,Autocuration,1,,,6,,H,,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,B,
3240,,5094,,BAO_0000019,,,,Autocuration,1,,,6,,H,,Binding affinity towards 5-HT3 receptor in rat was evaluated,B,
3241,2116.0,809,10141.0,BAO_0000221,,,,Intermediate,1,Cavia porcellus,,9,,D,,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,F,Ileum
3242,2116.0,809,10141.0,BAO_0000221,,,,Intermediate,1,Cavia porcellus,,9,,D,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,F,Ileum
3243,2116.0,14290,10141.0,BAO_0000221,,,,Intermediate,1,Cavia porcellus,,9,,D,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",F,Ileum
3244,2116.0,14290,10141.0,BAO_0000221,,,,Intermediate,1,Cavia porcellus,,9,,D,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",F,Ileum
3245,2116.0,14290,10141.0,BAO_0000221,,,,Intermediate,1,Cavia porcellus,,9,,D,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",F,Ileum
3246,2116.0,14290,10141.0,BAO_0000221,,,,Intermediate,1,Cavia porcellus,,9,,D,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",F,Ileum
3247,2116.0,14290,10141.0,BAO_0000221,,,,Intermediate,1,Cavia porcellus,,9,,D,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",F,Ileum
3248,2116.0,13961,10141.0,BAO_0000221,,,,Intermediate,1,Cavia porcellus,,9,,D,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,F,Ileum
3249,2116.0,13961,10141.0,BAO_0000221,,,,Intermediate,1,Cavia porcellus,,9,,D,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,F,Ileum
3250,2116.0,809,10141.0,BAO_0000221,,,,Intermediate,1,Cavia porcellus,,9,,D,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,F,Ileum
3251,2116.0,809,10141.0,BAO_0000221,,,,Intermediate,1,Cavia porcellus,,9,,D,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,F,Ileum
3252,2116.0,809,10141.0,BAO_0000221,,,,Intermediate,1,Cavia porcellus,,9,,D,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,F,Ileum
3253,2116.0,14290,10141.0,BAO_0000221,,,,Intermediate,1,Cavia porcellus,,9,,D,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",F,Ileum
3254,2116.0,14290,10141.0,BAO_0000221,,,,Intermediate,1,Cavia porcellus,,9,,D,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",F,Ileum
3255,2116.0,14290,10141.0,BAO_0000221,,,,Intermediate,1,Cavia porcellus,,9,,D,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",F,Ileum
3256,2116.0,14290,10141.0,BAO_0000221,,,,Intermediate,1,Cavia porcellus,,9,,D,,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,F,Ileum
3257,2116.0,14290,10141.0,BAO_0000221,,,,Intermediate,1,Cavia porcellus,,9,,D,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",F,Ileum
3258,2116.0,14290,10141.0,BAO_0000221,,,,Intermediate,1,Cavia porcellus,,9,,D,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",F,Ileum
3259,,15034,10141.0,BAO_0000357,,,,Intermediate,1,Cavia porcellus,,9,,D,,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,B,
3260,2435.0,5094,10141.0,BAO_0000249,,,,Intermediate,1,Cavia porcellus,,9,,D,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,B,Striatum
3261,2435.0,5094,10141.0,BAO_0000249,,,,Intermediate,1,Cavia porcellus,,9,,D,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,B,Striatum
3262,2435.0,5399,10141.0,BAO_0000357,,,,Intermediate,1,Cavia porcellus,,9,,D,,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,B,Striatum
3263,2435.0,17394,10141.0,BAO_0000357,,,,Intermediate,1,Cavia porcellus,,9,,D,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,B,Striatum
3264,2435.0,17394,10141.0,BAO_0000357,,,,Intermediate,1,Cavia porcellus,,9,,D,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,B,Striatum
3265,2435.0,17394,10141.0,BAO_0000357,,,,Intermediate,1,Cavia porcellus,,9,,D,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,B,Striatum
3266,2116.0,13961,10141.0,BAO_0000221,,,,Intermediate,1,Cavia porcellus,,9,,D,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,F,Ileum
3267,2116.0,13961,10141.0,BAO_0000221,,,,Intermediate,1,Cavia porcellus,,9,,D,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,F,Ileum
3268,2116.0,13961,10141.0,BAO_0000221,,,,Intermediate,1,Cavia porcellus,,9,,D,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,F,Ileum
3269,,16946,10141.0,BAO_0000357,,,,Intermediate,1,Cavia porcellus,,9,,D,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,B,
3270,,16946,10141.0,BAO_0000357,,,,Intermediate,1,Cavia porcellus,,9,,D,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,B,
3271,,15034,10141.0,BAO_0000019,,,,Intermediate,1,Cavia porcellus,,9,,D,,Agonistic activity against 5-hydroxytryptamine 4 receptor,F,
3272,,15034,10141.0,BAO_0000019,,,,Intermediate,1,Cavia porcellus,,9,,D,,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,F,
3273,,12918,10141.0,BAO_0000019,,,,Intermediate,1,Cavia porcellus,,9,,D,,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,F,
3274,,16946,10141.0,BAO_0000357,,,,Intermediate,1,Cavia porcellus,,9,,D,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,B,
3275,2435.0,17394,10141.0,BAO_0000357,,,,Intermediate,1,Cavia porcellus,,9,,D,,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,B,Striatum
3276,2435.0,15034,10141.0,BAO_0000357,,,,Intermediate,1,Cavia porcellus,,9,,D,,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,B,Striatum
3277,2435.0,5094,10141.0,BAO_0000249,,,,Intermediate,1,Cavia porcellus,,9,,D,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,B,Striatum
3278,2435.0,5094,10141.0,BAO_0000249,,,,Intermediate,1,Cavia porcellus,,9,,D,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,B,Striatum
3279,2116.0,17358,10141.0,BAO_0000221,,,,Intermediate,1,Cavia porcellus,,9,,D,,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,B,Ileum
3280,,12953,10141.0,BAO_0000357,,,,Expert,1,Cavia porcellus,,9,,D,,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,B,
3281,,12953,10141.0,BAO_0000357,,,,Intermediate,1,Cavia porcellus,,9,,D,,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,B,
3282,,12953,10141.0,BAO_0000357,,,,Intermediate,1,Cavia porcellus,,9,,D,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,B,
3283,,12953,10141.0,BAO_0000357,,,,Intermediate,1,Cavia porcellus,,9,,D,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,B,
3284,2116.0,273,10141.0,BAO_0000221,,,,Intermediate,1,Cavia porcellus,,9,,D,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,F,Ileum
3285,2116.0,12918,10141.0,BAO_0000221,,,,Intermediate,1,Cavia porcellus,,9,,D,,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,F,Ileum
3286,2116.0,12919,10141.0,BAO_0000221,,,,Intermediate,1,Cavia porcellus,,9,,D,,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,F,Ileum
3287,2116.0,273,10141.0,BAO_0000221,,,,Intermediate,1,Cavia porcellus,,9,,D,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,F,Ileum
3288,2116.0,273,10141.0,BAO_0000221,,,,Intermediate,1,Cavia porcellus,,9,,D,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,F,Ileum
3289,,13181,10141.0,BAO_0000357,,,,Intermediate,1,Cavia porcellus,,9,,D,,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,B,
3290,,13181,10141.0,BAO_0000357,,,,Autocuration,1,Cavia porcellus,,8,,H,,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,B,
3291,,15034,10141.0,BAO_0000019,,,,Intermediate,1,Cavia porcellus,,9,,D,,Antagonistic activity against 5-hydroxytryptamine 4 receptor,F,
3292,,5033,10141.0,BAO_0000357,,,,Intermediate,1,Cavia porcellus,,9,,D,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,B,
3293,,1980,10141.0,BAO_0000019,,,,Intermediate,1,Cavia porcellus,,9,,D,,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,B,
3294,,13181,10141.0,BAO_0000219,,,722.0,Autocuration,1,Cavia porcellus,,8,,H,,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,B,
3295,,14287,10141.0,BAO_0000019,,,,Intermediate,1,Cavia porcellus,,9,,D,,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,B,
3296,,1317,10141.0,BAO_0000357,,,,Intermediate,1,Cavia porcellus,,9,,D,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,B,
3297,,15316,10141.0,BAO_0000357,,,,Intermediate,1,Cavia porcellus,,9,,D,,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,B,
3298,2435.0,16429,10141.0,BAO_0000357,,,,Intermediate,1,Cavia porcellus,,9,,D,,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,B,Striatum
3299,10000000.0,14818,10141.0,BAO_0000221,,,,Intermediate,1,Cavia porcellus,,9,,D,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,B,Hippocampus
3300,,15194,10141.0,BAO_0000357,,,,Intermediate,1,Cavia porcellus,,9,,D,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,B,
3301,,15194,10141.0,BAO_0000357,,,,Intermediate,1,Cavia porcellus,,9,,D,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,B,
3302,2116.0,13961,10141.0,BAO_0000221,,,,Intermediate,1,Cavia porcellus,,9,,D,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,F,Ileum
3303,,5486,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,B,
3304,,16209,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,B,
3305,,17085,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,B,
3306,,4199,,BAO_0000219,,,308.0,Autocuration,1,,,8,,H,,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,B,
3307,,15146,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,B,
3308,,5213,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,B,
3309,,4829,,BAO_0000219,,,308.0,Autocuration,1,,,8,,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",B,
3310,,17358,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,B,
3311,,17358,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,B,
3312,,16946,,BAO_0000219,,,,Autocuration,1,,,8,,H,,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,B,
3313,,17358,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,B,
3314,2081.0,268,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,F,Cardiac atrium
3315,2081.0,268,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,F,Cardiac atrium
3316,,15086,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,B,
3317,10000000.0,14875,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,B,Hippocampus
3318,10000000.0,13267,9823.0,BAO_0000221,,,,Autocuration,1,Sus scrofa,,8,,H,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,B,Hippocampus
3319,,13047,9986.0,BAO_0000019,,,,Autocuration,1,Oryctolagus cuniculus,,8,,H,,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,B,
3320,,1650,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,B,
3321,,567,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,F,
3322,,17358,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,B,
3323,,188,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,B,
3324,,670,,BAO_0000019,,,,Autocuration,1,,,8,,H,,lntrinsic activity relative to 5-HT receptor,F,
3325,,204,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,F,
3326,,1946,,BAO_0000019,,,,Expert,1,,,8,,H,,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,F,
3327,,6398,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,F,
3328,,6398,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,F,
3329,,17358,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,F,
3330,,6398,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,F,
3331,,11752,,BAO_0000357,,,,Expert,1,,,8,,H,,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,B,
3332,,809,,BAO_0000019,,,,Autocuration,1,,,8,,H,,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,F,
3333,,14178,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,B,
3334,,567,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,B,
3335,,1946,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,B,
3336,,1946,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,B,
3337,,13961,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,B,
3338,2435.0,6238,,BAO_0000249,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,B,Striatum
3339,,14290,,BAO_0000249,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,B,
3340,,14290,,BAO_0000249,,,,Expert,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,B,
3341,2435.0,809,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,B,Striatum
3342,2435.0,1578,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,B,Striatum
3343,2435.0,16709,,BAO_0000249,,,,Expert,1,,,8,,H,,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,B,Striatum
3344,2435.0,1946,,BAO_0000019,,,,Expert,1,,,8,,H,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,B,Striatum
3345,2435.0,15253,,BAO_0000249,,,,Expert,1,,,8,,H,,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,B,Striatum
3346,2435.0,4535,,BAO_0000249,,,,Expert,1,,,8,,H,,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,B,Striatum
3347,,13961,,BAO_0000249,,,,Expert,1,,,8,,H,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,B,
3348,955.0,17358,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,F,Brain
3349,,15847,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,F,
3350,,15847,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,F,
3351,,670,,BAO_0000019,,,,Autocuration,1,,,8,,H,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,F,
3352,,670,,BAO_0000019,,,,Autocuration,1,,,8,,H,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,F,
3353,,1317,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,F,
3354,,12936,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity against rat 5-hydroxytryptamine 4 receptor,B,
3355,2435.0,4535,,BAO_0000249,,,,Expert,1,,,8,,H,,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,B,Striatum
3356,,14424,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,F,
3357,,14424,,BAO_0000019,,,,Expert,1,,,8,,H,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,F,
3358,,14424,,BAO_0000019,,,,Expert,1,,,8,,H,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,F,
3359,,14424,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,F,
3360,,14424,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,F,
3361,,14424,,BAO_0000019,,,,Expert,1,,,8,,H,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,F,
3362,,14424,,BAO_0000218,,,,Expert,1,,,8,,H,,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),F,
3363,,14424,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,F,
3364,,1980,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,8,,H,,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,F,
3365,,4639,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,F,
3366,,17358,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested for affinity towards 5-hydroxytryptamine 4 receptor,B,
3367,,17358,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,B,
3368,,17358,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for 5-hydroxytryptamine 4 binding affinity,B,
3369,,1558,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,B,
3370,,17358,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,
3371,,16117,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity towards 5-HT4 receptor was determined,B,
3372,,17358,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,
3373,,17358,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,F,
3374,,17358,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested for selectivity for 5-hydroxytryptamine 4 receptor,B,
3375,,17358,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,B,
3376,,17358,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,B,
3377,,17358,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,B,
3378,,1274,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity against 5-Hydroxytryptamine 4 receptor,B,
3379,,10728,,BAO_0000249,,,,Autocuration,1,,,6,Brain membranes,H,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,B,
3380,,11695,,BAO_0000249,,,,Autocuration,1,,,6,Brain membranes,H,,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,B,
3381,,11695,,BAO_0000249,,,,Autocuration,1,,,6,Brain membranes,H,,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,B,
3382,,12490,,BAO_0000019,,,,Autocuration,1,,,6,,H,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,B,
3383,,11828,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,7,,D,,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,B,
3384,10000000.0,12253,,BAO_0000221,,,,Autocuration,1,,,6,,H,,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,B,Hippocampus
3385,,10561,,BAO_0000019,,,,Autocuration,1,,,6,,H,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,B,
3386,,10561,,BAO_0000019,,,,Autocuration,1,,,6,,H,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,B,
3387,,14432,,BAO_0000019,,,,Autocuration,1,,,6,,H,,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,F,
3388,,12936,10116.0,BAO_0000223,,,,Autocuration,1,Rattus norvegicus,,7,,D,,Binding affinity against rat 5-hydroxytryptamine 3 receptor,B,
3389,,1274,10116.0,BAO_0000223,,,,Autocuration,1,Rattus norvegicus,,7,,D,,Binding affinity against 5-Hydroxytryptamine 3 receptor,B,
3390,,1980,,BAO_0000019,,,,Autocuration,1,,,6,,H,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,B,
3391,,670,,BAO_0000249,,,,Autocuration,1,,,6,,H,,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,B,
3392,,968,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,7,,D,,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,B,
3393,,14287,,BAO_0000019,,,,Autocuration,1,,,6,,H,,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,B,
3394,,567,,BAO_0000019,,,,Autocuration,1,,,6,,H,,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,B,
3395,,13267,,BAO_0000019,,,,Autocuration,1,,,6,,H,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,B,
3396,,14826,,BAO_0000249,,,,Autocuration,1,,,6,,H,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,B,
3397,,15194,,BAO_0000223,,,,Autocuration,1,,,6,,H,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,B,
3398,,15194,,BAO_0000223,,,,Autocuration,1,,,6,,H,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,B,
3399,,10394,10116.0,BAO_0000223,,,,Autocuration,1,Rattus norvegicus,,7,,D,,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,B,
3400,,13657,,BAO_0000249,,,,Expert,1,,,9,,D,,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",B,
3401,955.0,1879,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,F,Brain
3402,,1879,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,F,
3403,,1879,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,F,
3404,,204,,BAO_0000218,,,,Autocuration,1,,In vivo,8,,H,,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,F,
3405,,1879,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,B,
3406,,1879,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,
3407,,1879,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,B,
3408,,1879,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,B,
3409,,10641,,BAO_0000019,,,,Autocuration,1,,,6,,H,,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",B,
3410,,773,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,B,
3411,,11952,,BAO_0000249,,,,Autocuration,1,,,6,,H,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,B,
3412,,14145,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,9,,D,,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,F,
3413,,17066,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,
3414,,6398,,BAO_0000223,,,,Autocuration,1,,,4,,H,,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,B,
3415,,10321,,BAO_0000019,,,,Autocuration,1,,,0,,U,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,B,
3416,,511,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,F,
3417,,4639,,BAO_0000223,,,,Autocuration,1,,,4,,H,,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,B,
3418,,4639,,BAO_0000223,,,,Autocuration,1,,,4,,H,,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,
3419,,4639,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,4,,H,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,F,
3420,,4639,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,4,,H,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,F,
3421,,4639,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,4,,H,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,F,
3422,,1558,,BAO_0000223,,,,Autocuration,1,,,4,,H,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,B,
3423,,268,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,F,
3424,,2474,,BAO_0000223,,,,Autocuration,1,,,4,,H,,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,B,
3425,,5067,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,F,
3426,,5067,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,F,
3427,,5067,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,F,
3428,,5067,,BAO_0000223,,,,Autocuration,1,,,4,,H,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,B,
3429,,5067,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,F,
3430,,5067,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,F,
3431,,5067,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,F,
3432,,5067,,BAO_0000223,,,,Autocuration,1,,,4,,H,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,B,
3433,,5067,,BAO_0000223,,,,Autocuration,1,,,4,,H,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,B,
3434,,5067,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,F,
3435,,5067,,BAO_0000223,,,,Autocuration,1,,,4,,H,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,B,
3436,,5067,,BAO_0000223,,,,Autocuration,1,,,4,,H,,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,
3437,,14331,,BAO_0000219,,,,Autocuration,1,,,4,,H,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,B,
3438,,5067,,BAO_0000223,,,,Autocuration,1,,,4,,H,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,B,
3439,,6179,,BAO_0000219,,,433.0,Autocuration,1,,,4,,H,,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,B,
3440,,4265,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,B,
3441,,4265,,BAO_0000219,,,433.0,Autocuration,1,,,4,,H,,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,B,
3442,,17358,,BAO_0000223,,,,Autocuration,1,,,4,,H,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,B,
3443,,17358,,BAO_0000223,,,,Autocuration,1,,,4,,H,,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,B,
3444,,13628,,BAO_0000219,,,,Autocuration,1,,In vitro,4,,H,,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,B,
3445,,4612,,BAO_0000223,,,,Autocuration,1,,,4,,H,,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,B,
3446,,17358,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,F,
3447,,4639,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,4,,H,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,F,
3448,,4639,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,4,,H,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,F,
3449,,4639,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,4,,H,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,F,
3450,,4639,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,4,,H,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,F,
3451,,511,,BAO_0000223,,,,Autocuration,1,,,4,,H,,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,B,
3452,,1479,,BAO_0000223,,,,Autocuration,1,,,4,,H,,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,
3453,,1317,,BAO_0000223,,,,Autocuration,1,,,4,,H,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,B,
3454,,12146,,BAO_0000223,,,,Autocuration,1,,,4,,H,,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,B,
3455,,12146,,BAO_0000223,,,,Autocuration,1,,,4,,H,,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,B,
3456,,13969,,BAO_0000223,,,,Autocuration,1,,,4,,H,,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,B,
3457,,13392,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity for 5-hydroxytryptamine 2C receptor,B,
3458,,13392,,BAO_0000223,,,,Autocuration,1,,,6,,H,,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,
3459,,14159,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,B,
3460,,1558,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,B,
3461,,16655,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,B,
3462,,13020,,BAO_0000223,,,,Autocuration,1,,,4,,H,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,B,
3463,,13021,,BAO_0000223,,,,Autocuration,1,,,4,,H,,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,B,
3464,,13020,,BAO_0000223,,,,Autocuration,1,,,4,,H,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,B,
3465,,10321,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,B,
3466,,15818,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,
3467,,15818,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,
3468,,17358,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,B,
3469,,2222,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,B,
3470,,10322,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,B,
3471,,16117,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,B,
3472,,17200,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,B,
3473,,17358,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Tested for 5-hydroxytryptamine 3 receptor agonist activity,F,
3474,,16700,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,B,
3475,,1980,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,B,
3476,,1980,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,B,
3477,,12409,,BAO_0000223,,,,Autocuration,1,,,4,,H,,Binding affinity against the 5-hydroxytryptamine 3 receptor,B,
3478,,4365,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against human 5-hydroxytryptamine 3A receptor,B,
3479,,4365,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Percent efficacy against 5-hydroxytryptamine 3A receptor,F,
3480,,4365,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against human 5-hydroxytryptamine 3A receptor,B,
3481,,6769,10116.0,BAO_0000219,,,,Expert,1,Rattus norvegicus,,9,,D,,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,F,
3482,,6769,10116.0,BAO_0000219,,,,Expert,1,Rattus norvegicus,,9,,D,,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,F,
3483,,6769,10116.0,BAO_0000219,,,,Expert,1,Rattus norvegicus,,9,,D,,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,F,
3484,2116.0,809,10141.0,BAO_0000221,,,,Intermediate,1,Cavia porcellus,,9,,D,,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,F,Ileum
3485,2116.0,809,10141.0,BAO_0000221,,,,Intermediate,1,Cavia porcellus,,9,,D,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,F,Ileum
3486,,14290,10141.0,BAO_0000019,,,,Intermediate,1,Cavia porcellus,,9,,D,,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,F,
3487,2116.0,17358,10141.0,BAO_0000221,,,,Intermediate,1,Cavia porcellus,,9,,D,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,B,Ileum
3488,,17358,10141.0,BAO_0000357,,,,Intermediate,1,Cavia porcellus,,9,,D,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,B,
3489,2116.0,17358,10141.0,BAO_0000221,,,,Intermediate,1,Cavia porcellus,,9,,D,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,B,Ileum
3490,2116.0,17386,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,B,Ileum
3491,,3269,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Affinity against 5-hydroxytryptamine 7 receptor,B,
3492,,7721,10141.0,BAO_0000224,,,,Autocuration,1,Cavia porcellus,,4,,H,,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,B,
3493,,7721,10141.0,BAO_0000224,,,,Autocuration,1,Cavia porcellus,,4,,H,,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,B,
3494,2116.0,9117,10141.0,BAO_0000221,,,,Autocuration,1,Cavia porcellus,,4,,H,,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,B,Ileum
3495,,7721,10141.0,BAO_0000224,,,,Autocuration,1,Cavia porcellus,,4,,H,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",B,
3496,,7721,10141.0,BAO_0000224,,,,Autocuration,1,Cavia porcellus,,4,,H,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",B,
3497,,15796,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,4,,H,,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,F,
3498,,15796,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,4,,H,,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,F,
3499,2081.0,15650,9606.0,BAO_0000219,,,,Expert,1,Homo sapiens,,9,,D,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,B,Cardiac atrium
3500,2081.0,15650,9606.0,BAO_0000219,,,,Expert,1,Homo sapiens,,9,,D,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,B,Cardiac atrium
3501,,6866,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,5,,D,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",F,
3502,2081.0,15650,9606.0,BAO_0000219,,,,Expert,1,Homo sapiens,,9,,D,,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",F,Cardiac atrium
3503,,10063,10090.0,BAO_0000019,,,,Autocuration,1,Mus musculus,,0,,U,,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,B,
3504,,12665,10090.0,BAO_0000019,,,,Autocuration,1,Mus musculus,,0,,U,,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,B,
3505,,7504,,BAO_0000019,,,,Autocuration,1,,,4,,H,,5-hydroxytryptamine receptor binding affinity was determined in rats,B,
3506,,7504,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Binding affinity at rat 5-hydroxytryptamine receptor.,B,
3507,,7038,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Affinity against 5-hydroxytryptamine receptors in rat fundus model,B,
3508,,7626,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,B,
3509,,7626,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,B,
3510,945.0,7185,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,F,Stomach
3511,945.0,7185,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,F,Stomach
3512,,7185,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,F,
3513,,6960,,BAO_0000224,,,,Autocuration,1,,,4,,H,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,B,
3514,,6960,,BAO_0000224,,,,Autocuration,1,,,4,,H,,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",B,
3515,10000000.0,12416,,BAO_0000221,,,,Autocuration,1,,,8,,H,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,B,Hippocampus
3516,,15753,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity for rat 5-hydroxytryptamine transporter.,B,
3517,,8062,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,B,
3518,,9036,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,5,,D,,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,B,
3519,,15067,10116.0,BAO_0000224,,,,Autocuration,1,Rattus norvegicus,,5,,D,,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,B,
3520,955.0,15753,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,F,Brain
3521,2037.0,15753,10116.0,BAO_0000221,,,,Expert,1,Rattus norvegicus,,9,,D,,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,F,Cerebellum
3522,,15295,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,5,,D,,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,B,
3523,,6347,10116.0,BAO_0000224,,,,Autocuration,1,Rattus norvegicus,,5,,D,,Percent binding affinity against 5-hydroxytryptamine receptor,B,
3524,,6763,,BAO_0000019,,,,Autocuration,1,,,0,,U,,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,B,
3525,,12092,10116.0,BAO_0000224,,,,Autocuration,1,Rattus norvegicus,,5,,D,,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,B,
3526,,1579,10116.0,BAO_0000224,,,,Autocuration,1,Rattus norvegicus,,5,,D,,Affinity against 5-hydroxytryptamine receptor was determined,B,
3527,945.0,1579,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,5,,D,,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,B,Stomach
3528,,5963,9606.0,BAO_0000219,,,,Expert,1,Homo sapiens,In vitro,9,,D,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,B,
3529,,5963,9606.0,BAO_0000219,,,,Expert,1,Homo sapiens,In vitro,9,,D,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,B,
3530,,5030,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,B,
3531,,15796,,BAO_0000357,,,,Expert,1,,,8,,H,,Inhibition of 5-hydroxytryptamine reuptake,B,
3532,,15413,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",F,
3533,,15413,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",F,
3534,,15413,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",F,
3535,,12409,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Tested for 5-hydroxytryptamine receptor uptake,F,
3536,,16909,9606.0,BAO_0000219,,,449.0,Expert,1,Homo sapiens,,9,,D,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,B,
3537,,16909,9606.0,BAO_0000019,,,,Expert,1,Homo sapiens,,9,,D,,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,F,
3538,,15629,9606.0,BAO_0000249,,,,Autocuration,1,Homo sapiens,,8,,H,,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,B,
3539,,15629,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,B,
3540,,15629,,BAO_0000249,,,,Expert,1,,,8,,H,,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,B,
3541,2435.0,10034,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,F,Striatum
3542,2435.0,10034,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,F,Striatum
3543,2435.0,10034,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,F,Striatum
3544,2435.0,10034,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,F,Striatum
3545,2435.0,10034,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,F,Striatum
3546,2435.0,10034,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,F,Striatum
3547,2435.0,10034,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,F,Striatum
3548,2435.0,10034,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,F,Striatum
3549,2435.0,10034,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,F,Striatum
3550,2435.0,10034,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,F,Striatum
3551,2435.0,10034,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,F,Striatum
3552,349.0,10034,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,F,Limbic system
3553,349.0,10034,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,F,Limbic system
3554,349.0,10034,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,F,Limbic system
3555,349.0,10034,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,F,Limbic system
3556,349.0,10034,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,F,Limbic system
3557,349.0,10034,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,F,Limbic system
3558,349.0,10034,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,F,Limbic system
3559,,1274,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 4 receptor,B,
3560,,17358,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,
3561,,14532,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,B,
3562,,16989,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,B,
3563,,17200,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,B,
3564,,15779,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 4 receptor,B,
3565,,15779,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,B,
3566,,15779,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,B,
3567,,15650,,BAO_0000219,,,643.0,Autocuration,1,,,8,,H,,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,B,
3568,,15650,,BAO_0000219,,,643.0,Autocuration,1,,,8,,H,,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,B,
3569,,15650,,BAO_0000219,,,643.0,Autocuration,1,,,8,,H,,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,B,
3570,,15650,,BAO_0000219,,,643.0,Autocuration,1,,,8,,H,,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,B,
3571,,17046,,BAO_0000219,,,673.0,Autocuration,1,,,8,,H,,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,B,
3572,,17046,,BAO_0000219,,,673.0,Expert,1,,,8,,H,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,B,
3573,,15650,,BAO_0000219,,,673.0,Expert,1,,,8,,H,,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,B,
3574,,17046,,BAO_0000219,,,673.0,Expert,1,,,8,,H,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,B,
3575,,17066,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 5 receptor,B,
3576,,17200,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,B,
3577,,16146,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding affinity against 5-hydroxytryptamine 5A receptor,B,
3578,,15250,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,B,
3579,,6491,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,B,
3580,,17066,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding affinity towards human 5-hydroxytryptamine 5A receptor,B,
3581,,17066,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,B,
3582,,4234,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,B,
3583,,6013,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-HT5A receptor,B,
3584,,17175,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,B,
3585,,15818,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,B,
3586,,6166,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards cloned human 5-HT5A receptor was determined,B,
3587,,15779,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,
3588,,15779,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,B,
3589,,5213,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),B,
3590,,17066,10090.0,BAO_0000357,,,,Expert,1,Mus musculus,,9,,D,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,B,
3591,,17066,10090.0,BAO_0000357,,,,Expert,1,Mus musculus,,9,,D,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,B,
3592,,17066,10090.0,BAO_0000357,,,,Expert,1,Mus musculus,,9,,D,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,B,
3593,,17066,10090.0,BAO_0000357,,,,Expert,1,Mus musculus,,9,,D,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,B,
3594,,17066,10090.0,BAO_0000357,,,,Expert,1,Mus musculus,,9,,D,,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,B,
3595,,17175,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,B,
3596,,16190,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,B,
3597,,16190,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,B,
3598,,4820,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards 5-HT5a receptor,B,
3599,,17066,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding affinity towards 5-hydroxytryptamine 5A receptor,B,
3600,,17066,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,B,
3601,,17175,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,B,
3602,,16633,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinities against 5-hydroxytryptamine 5A receptor,B,
3603,,16633,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinities towards 5-hydroxytryptamine 5A receptor,B,
3604,,16700,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,B,
3605,,4639,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,4,,H,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,F,
3606,,5486,,BAO_0000223,,,,Autocuration,1,,,4,,H,,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,B,
3607,,16146,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Inhibition of human 5-hydroxytryptamine 6 receptor,B,
3608,,17273,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,B,
3609,,17687,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibition against human 5-hydroxytryptamine 6 receptor,B,
3610,,6491,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,B,
3611,,16190,,BAO_0000219,,,308.0,Expert,1,,,8,,H,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,B,
3612,,17066,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,B,
3613,,17066,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,
3614,,17066,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,B,
3615,,17066,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,B,
3616,,3555,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding affinity against 5-hydroxytryptamine 6 receptor,B,
3617,,5808,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,
3618,,6013,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,
3619,,15818,,BAO_0000219,,,722.0,Expert,1,,,8,,H,,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",B,
3620,,16209,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,B,
3621,,3935,,BAO_0000219,,,722.0,Expert,1,,,8,,H,,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,B,
3622,,15818,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,B,
3623,,3805,9606.0,BAO_0000219,,,722.0,Expert,1,Homo sapiens,,9,,D,,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,B,
3624,,16441,,BAO_0000019,,,,Expert,1,,,8,,H,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,B,
3625,,16441,,BAO_0000019,,,,Expert,1,,,8,,H,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,B,
3626,,6786,,BAO_0000219,,,643.0,Expert,1,,,8,,H,,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,B,
3627,,4234,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,B,
3628,,17085,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,B,
3629,,17200,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,B,
3630,,17451,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,B,
3631,,3935,,BAO_0000019,,,,Autocuration,1,,,8,,H,,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,F,
3632,,5033,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,B,
3633,,4540,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity against human 5-hydroxytryptamine 6 receptor,B,
3634,,4540,9606.0,BAO_0000219,,,308.0,Expert,1,Homo sapiens,,9,,D,,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,B,
3635,,4540,9606.0,BAO_0000219,,,308.0,Expert,1,Homo sapiens,,9,,D,,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,B,
3636,,17296,,BAO_0000219,,,308.0,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,B,
3637,,17296,,BAO_0000219,,,308.0,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,B,
3638,,17296,,BAO_0000219,,,308.0,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,B,
3639,,15779,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,
3640,,15779,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,
3641,,15779,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,B,
3642,,15779,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,B,
3643,,15779,,BAO_0000219,,,308.0,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,B,
3644,,6166,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,
3645,,17451,,BAO_0000219,,,308.0,Autocuration,1,,,8,,H,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,B,
3646,,15316,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,B,
3647,,4199,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity against human 5-hydroxytryptamine 6 receptor,B,
3648,,15146,,BAO_0000219,,,308.0,Expert,1,,,8,,H,,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,B,
3649,,5213,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),B,
3650,,16429,,BAO_0000219,,,,Autocuration,1,,,8,,H,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,B,
3651,,14818,,BAO_0000219,,,308.0,Autocuration,1,,,8,,H,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,B,
3652,,4829,,BAO_0000219,,,308.0,Autocuration,1,,,8,,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",B,
3653,,4829,,BAO_0000219,,,308.0,Autocuration,1,,,8,,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",B,
3654,,4829,,BAO_0000219,,,308.0,Autocuration,1,,,8,,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",B,
3655,,15250,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,B,
3656,,14423,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,B,
3657,,15086,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,B,
3658,,4342,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,B,
3659,,16190,9606.0,BAO_0000219,,,308.0,Autocuration,1,Homo sapiens,,9,,D,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,B,
3660,,4820,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,
3661,,4639,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,B,
3662,,17066,9606.0,BAO_0000019,,,,Expert,1,Homo sapiens,,9,,D,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,F,
3663,,6011,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,B,
3664,,17066,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,
3665,,17515,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,B,
3666,,5014,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,B,
3667,,4373,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,B,
3668,,17066,,BAO_0000019,,,,Expert,1,,,8,,H,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,F,
3669,,17066,,BAO_0000019,,,,Expert,1,,,8,,H,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,F,
3670,,4373,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,B,
3671,,4687,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,B,
3672,,16946,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,B,
3673,,16946,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,B,
3674,,16633,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinities against 5-hydroxytryptamine 6 receptor,B,
3675,,16633,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinities towards 5-hydroxytryptamine 6 receptor,B,
3676,,17066,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding affinity towards 5-hydroxytryptamine 6 receptor,B,
3677,,16700,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,B,
3678,,3269,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Affinity against 5-hydroxytryptamine 6 receptor,B,
3679,,5486,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],B,
3680,,16146,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Inhibition of human 5-hydroxytryptamine 7 receptor,B,
3681,,5014,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,B,
3682,,15463,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,B,
3683,,3805,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),B,
3684,,5014,,BAO_0000219,,,722.0,Expert,1,,,8,,H,,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,B,
3685,,6491,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,B,
3686,,16190,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,B,
3687,,17066,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,B,
3688,,17066,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,B,
3689,,3555,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding affinity against 5-hydroxytryptamine 7 receptor,B,
3690,,6588,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,B,
3691,,15463,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,B,
3692,,6013,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,
3693,,16209,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,B,
3694,,3935,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,B,
3695,,15818,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,B,
3696,,5014,,BAO_0000219,,,722.0,Expert,1,,,8,,H,,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,B,
3697,,16441,,BAO_0000019,,,,Expert,1,,,8,,H,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,B,
3698,,16441,,BAO_0000019,,,,Expert,1,,,8,,H,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,B,
3699,,4234,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,B,
3700,,17085,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,B,
3701,,17200,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,B,
3702,,17451,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,B,
3703,,17085,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,B,
3704,,5104,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,B,
3705,,5104,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,B,
3706,,5033,9606.0,BAO_0000219,,,643.0,Expert,1,Homo sapiens,,9,,D,,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,B,
3707,,5486,,BAO_0000219,,,643.0,Autocuration,1,,,8,,H,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,B,
3708,,4540,9606.0,BAO_0000219,,,722.0,Expert,1,Homo sapiens,,9,,D,,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,B,
3709,,6166,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,B,
3710,,17342,,BAO_0000219,,,722.0,Expert,1,,,8,,H,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,B,
3711,,17342,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,B,
3712,,17296,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 7 human receptors,B,
3713,,16429,,BAO_0000219,,,,Expert,1,,,8,,H,,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,B,
3714,,15779,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,B,
3715,,15779,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,
3716,,15779,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,
3717,,15779,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,
3718,,15779,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,B,
3719,,17451,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,B,
3720,,4199,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),B,
3721,,4199,,BAO_0000219,,,722.0,Expert,1,,,9,,D,,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,B,
3722,,4199,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),B,
3723,,3680,,BAO_0000219,,,722.0,Intermediate,1,,,9,,D,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,B,
3724,,3680,,BAO_0000357,,,,Intermediate,1,,,9,,D,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,B,
3725,,15316,,BAO_0000219,,,643.0,Autocuration,1,,,8,,H,,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,B,
3726,,15146,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,B,
3727,,5213,,BAO_0000219,,,722.0,Expert,1,,,8,,H,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,B,
3728,,5213,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),B,
3729,,14818,9606.0,BAO_0000219,,,722.0,Expert,1,Homo sapiens,,9,,D,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,B,
3730,,14818,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,B,
3731,,14818,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,B,
3732,,4829,,BAO_0000219,,,722.0,Autocuration,1,,,8,,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",B,
3733,,17200,9606.0,BAO_0000357,,,,Autocuration,1,Homo sapiens,,9,,D,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,B,
3734,,17066,10090.0,BAO_0000357,,,,Expert,1,Mus musculus,,9,,D,,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,B,
3735,,14025,9986.0,BAO_0000019,,,,Autocuration,1,Oryctolagus cuniculus,,8,,H,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,B,
3736,,15250,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,B,
3737,,16372,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,B,
3738,,16372,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,B,
3739,,16372,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,B,
3740,,16372,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,B,
3741,,16372,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,B,
3742,,16372,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,B,
3743,,16372,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,B,
3744,,16372,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,B,
3745,,16372,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,B,
3746,,16372,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,B,
3747,,16372,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,B,
3748,,16372,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,B,
3749,,17066,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,B,
3750,,17066,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,B,
3751,,17386,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,B,
3752,,14423,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,B,
3753,,15874,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,B,
3754,,15874,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,B,
3755,,16372,10116.0,BAO_0000219,,,449.0,Expert,1,Rattus norvegicus,,9,,D,,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,B,
3756,,4622,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,B,
3757,,15086,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,B,
3758,,16372,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",B,
3759,,16372,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",B,
3760,,16372,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,B,
3761,,16372,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,B,
3762,2116.0,17386,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,F,Ileum
3763,2116.0,17386,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,F,Ileum
3764,2116.0,17386,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,F,Ileum
3765,,5831,10116.0,BAO_0000249,,,,Expert,1,Rattus norvegicus,,9,Membranes,D,,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,B,
3766,,4342,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,B,
3767,,17319,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,B,
3768,1898.0,17342,,BAO_0000019,,,,Expert,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,B,Hypothalamus
3769,,17342,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,B,
3770,1898.0,3680,,BAO_0000249,,,,Expert,1,,,8,,H,,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,B,Hypothalamus
3771,,3680,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,
3772,,17319,10116.0,BAO_0000219,,,722.0,Expert,1,Rattus norvegicus,,9,,D,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,F,
3773,,17319,10116.0,BAO_0000219,,,722.0,Expert,1,Rattus norvegicus,,9,,D,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,F,
3774,,17319,10116.0,BAO_0000219,,,722.0,Autocuration,1,Rattus norvegicus,,9,,D,,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,F,
3775,,4820,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,
3776,,4639,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,B,
3777,,6011,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,B,
3778,,17066,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,B,
3779,,17066,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,B,
3780,,17515,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,B,
3781,,4373,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,B,
3782,,17066,,BAO_0000019,,,,Expert,1,,,8,,H,,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,F,
3783,,4373,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,B,
3784,,4373,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,B,
3785,,4687,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,B,
3786,,17342,,BAO_0000357,,,,Expert,1,,,8,,H,,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,B,
3787,,16946,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,B,
3788,,16946,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,B,
3789,,16633,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinities against 5-hydroxytryptamine 7 receptor,B,
3790,,16633,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinities towards 5-hydroxytryptamine 7 receptor,B,
3791,,17066,,BAO_0000357,,,,Expert,1,,,8,,H,,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,B,
3792,,16700,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,B,
3793,2116.0,17386,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,B,Ileum
3794,,14080,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,F,
3795,,14080,9606.0,BAO_0000019,,,,Expert,1,Homo sapiens,,9,,D,,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,F,
3796,,409,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,B,
3797,,409,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro inhibition of human recombinant lipoxygenase enzyme,B,
3798,,409,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,B,
3799,178.0,11090,,BAO_0000357,,,,Expert,1,,,8,,H,,Inhibition of 5-lipoxygenase in human whole blood.,B,Blood
3800,178.0,11090,,BAO_0000357,,,,Expert,1,,,8,,H,,Inhibition of 5-lipoxygenase in human whole blood.,B,Blood
3801,,948,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,B,
3802,,948,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),B,
3803,,13622,,BAO_0000219,,,,Expert,1,,,8,,H,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,F,
3804,178.0,13622,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,F,Blood
3805,,9637,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro inhibition of 5-lipoxygenase from human polymorphs,B,
3806,,11320,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),B,
3807,,11320,,BAO_0000357,,,,Expert,1,,,8,,H,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,B,
3808,,6838,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,B,
3809,178.0,17667,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),B,Blood
3810,,12703,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro potency against human 5-Lipoxygenase,B,
3811,,14312,9606.0,BAO_0000019,,,,Expert,1,Homo sapiens,,9,,D,,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,F,
3812,178.0,14312,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,F,Blood
3813,,5364,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,F,
3814,,951,,BAO_0000219,,,,Autocuration,1,,,8,,H,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,B,
3815,,951,,BAO_0000219,,,,Autocuration,1,,,8,,H,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,B,
3816,,951,,BAO_0000219,,,,Autocuration,1,,,8,,H,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,B,
3817,,951,,BAO_0000219,,,,Autocuration,1,,,8,,H,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,B,
3818,,12365,,BAO_0000219,,,,Autocuration,1,,,8,,H,,Inhibition of human 5-lipoxygenase in human cells,B,
3819,,10603,,BAO_0000357,,,,Expert,1,,,8,,H,,Inhibition of human neutrophil 5-lipoxygenase,B,
3820,,10501,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,B,
3821,178.0,12281,,BAO_0000357,,,,Expert,1,,,8,,H,,Inhibition of 5-lipoxygenase from human whole blood,B,Blood
3822,,2567,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,B,
3823,,2567,,BAO_0000219,,,,Autocuration,1,,,8,,H,,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,B,
3824,,10193,,BAO_0000357,,,,Expert,1,,,8,,H,,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,B,
3825,,10193,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,
3826,,13623,,BAO_0000357,,,,Expert,1,,,8,,H,,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,B,
3827,,12780,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested against 5-lipoxygenase,B,
3828,,12780,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested for activity against 5-Lipoxygenase (5-LO),B,
3829,,12780,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested for activity against 5-lipoxygenase,B,
3830,,11966,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested for inhibition of 5-HPETE production by human 5-LO,B,
3831,,5364,,BAO_0000019,,,,Autocuration,1,,,8,,H,,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,F,
3832,,13165,,BAO_0000357,,,,Expert,1,,,8,,H,,Inhibition of Human 5-lipoxygenase,B,
3833,,5364,,BAO_0000019,,,,Autocuration,1,,,8,,H,,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,B,
3834,,11311,,BAO_0000219,,,,Autocuration,1,,,8,,H,,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],B,
3835,,11311,,BAO_0000219,,,,Autocuration,1,,,8,,H,,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],B,
3836,,14863,,BAO_0000019,,,,Autocuration,1,,,8,,H,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,B,
3837,,14863,,BAO_0000019,,,,Autocuration,1,,,8,,H,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,B,
3838,178.0,11087,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),B,Blood
3839,,455,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,B,
3840,,13183,,BAO_0000357,,,,Autocuration,1,,,8,,H,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,
3841,,10319,,BAO_0000019,,,,Expert,1,,,8,,H,,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,B,
3842,,10193,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,
3843,,951,,BAO_0000219,,,,Autocuration,1,,,8,,H,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,B,
3844,,951,,BAO_0000219,,,,Autocuration,1,,,8,,H,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,B,
3845,,951,,BAO_0000219,,,,Autocuration,1,,,8,,H,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,B,
3846,,951,,BAO_0000219,,,,Autocuration,1,,,8,,H,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,B,
3847,,9859,,BAO_0000357,,,,Expert,1,,,8,,H,,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,B,
3848,,9859,,BAO_0000357,,,,Expert,1,,,8,,H,,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,B,
3849,,9859,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,B,
3850,,2567,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,B,
3851,,10193,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,B,
3852,,10193,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,
3853,,949,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,B,
3854,,949,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,B,
3855,,10603,,BAO_0000357,,,,Expert,1,,,8,,H,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,B,
3856,,10603,,BAO_0000357,,,,Expert,1,,,8,,H,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,B,
3857,,10603,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,F,
3858,,10603,,BAO_0000357,,,,Expert,1,,,8,,H,,Inhibition of lipoxygenase at the concentration of 0.1 uM,B,
3859,,10603,,BAO_0000357,,,,Expert,1,,,8,,H,,Inhibition of lipoxygenase at the concentration of 1 uM,B,
3860,,10193,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,B,
3861,,14580,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Inhibition of 5-Lipoxygenase (5-LOX),B,
3862,,11090,,BAO_0000357,,,,Expert,1,,,8,,H,,Inhibition of 5-lipoxygenase in mouse macrophages.,B,
3863,,11090,,BAO_0000357,,,,Expert,1,,,8,,H,,Inhibition of 5-lipoxygenase in mouse macrophages.,B,
3864,,6339,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory activity against lipoxygenase-2 in mice,B,
3865,,6339,,BAO_0000357,,,,Expert,1,,,8,,H,,Inhibitory activity against murine lipoxygenase-2.,B,
3866,,12281,10090.0,BAO_0000357,,,,Expert,1,Mus musculus,,9,,D,,Inhibition of 5-lipoxygenase from mouse macrophage,B,
3867,,11311,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,B,
3868,,11089,9823.0,BAO_0000019,,,,Autocuration,1,Sus scrofa,,8,,H,,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,B,
3869,,10091,9823.0,BAO_0000019,,,,Autocuration,1,Sus scrofa,,8,,H,,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,B,
3870,,14352,9986.0,BAO_0000019,,,,Autocuration,1,Oryctolagus cuniculus,,8,,H,,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,B,
3871,,13329,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,B,
3872,,13329,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",B,
3873,,13329,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",B,
3874,,13329,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",B,
3875,,13329,,BAO_0000019,,,,Expert,1,,,8,,H,,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),B,
3876,,13329,,BAO_0000019,,,,Expert,1,,,8,,H,,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",B,
3877,,13329,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,B,
3878,,11311,,BAO_0000019,,,,Autocuration,1,,,8,,H,,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),B,
3879,,11311,,BAO_0000019,,,,Autocuration,1,,,8,,H,,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,B,
3880,,105,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",B,
3881,,105,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",B,
3882,,9138,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),B,
3883,,9138,,BAO_0000357,,,,Autocuration,1,,,8,,H,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",B,
3884,,9138,,BAO_0000357,,,,Autocuration,1,,,8,,H,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",B,
3885,,14427,,BAO_0000357,,,,Autocuration,1,,,8,,H,,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,B,
3886,,13329,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",B,
3887,,13329,,BAO_0000019,,,,Autocuration,1,,,8,,H,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",B,
3888,,14427,10116.0,BAO_0000219,,,663.0,Expert,1,Rattus norvegicus,,9,,D,,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,B,
3889,,14427,,BAO_0000357,,,,Autocuration,1,,,8,,H,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,B,
3890,,14427,,BAO_0000357,,,,Autocuration,1,,,8,,H,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,B,
3891,,10293,,BAO_0000219,,,702.0,Expert,1,,,8,,H,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,B,
3892,,338,10116.0,BAO_0000219,,,702.0,Expert,1,Rattus norvegicus,,9,,D,,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,B,
3893,,303,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),B,
3894,,303,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,B,
3895,,9247,,BAO_0000219,,,702.0,Expert,1,,,8,,H,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,B,
3896,,9247,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,B,
3897,,137,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,B,
3898,,11481,,BAO_0000357,,,,Expert,1,,,8,,H,,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,B,
3899,,11481,,BAO_0000357,,,,Expert,1,,,8,,H,,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",B,
3900,,9029,,BAO_0000357,,,,Expert,1,,,8,,H,,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,B,
3901,,1701,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,B,
3902,,1701,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,B,
3903,,1701,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,B,
3904,,1701,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,B,
3905,,13358,,BAO_0000219,,,702.0,Expert,1,,,8,,H,,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,F,
3906,,1175,,BAO_0000219,,,702.0,Expert,1,,,8,,H,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,B,
3907,,8797,,BAO_0000219,,,702.0,Expert,1,,,8,,H,,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,B,
3908,,8797,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,B,
3909,,577,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,B,
3910,,9295,,BAO_0000219,,,702.0,Expert,1,,,8,,H,,In vitro inhibitory activity against RBL-1 5-LO,B,
3911,,9295,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),B,
3912,,9295,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),B,
3913,,9295,,BAO_0000218,,,,Autocuration,1,,,8,,H,,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,B,
3914,,9295,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,B,
3915,,216,,BAO_0000218,,,,Autocuration,1,,,8,,H,,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,B,
3916,,11090,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,B,
3917,178.0,11090,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,B,Blood
3918,,10091,,BAO_0000357,,,,Expert,1,,,8,,H,,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,B,
3919,,10274,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,F,
3920,,13622,,BAO_0000219,,,,Autocuration,1,,,8,,H,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,F,
3921,,12118,,BAO_0000219,,,702.0,Expert,1,,,8,,H,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,B,
3922,,12576,,BAO_0000357,,,,Expert,1,,,8,,H,,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,B,
3923,,9546,,BAO_0000219,,,702.0,Expert,1,,,8,,H,,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,B,
3924,,9521,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,B,
3925,,10626,,BAO_0000219,,,702.0,Expert,1,,,8,,H,,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,B,
3926,,9225,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,In vitro inhibition of RBL-1 5-lipoxygenase,B,
3927,,9225,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,B,
3928,,9225,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,B,
3929,,9225,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,B,
3930,,9225,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,B,
3931,,9225,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,B,
3932,,9225,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,B,
3933,,9225,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,B,
3934,,9225,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,B,
3935,,9225,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,B,
3936,,9225,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,B,
3937,,9225,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,B,
3938,,9225,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,B,
3939,,9225,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,B,
3940,,9225,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,B,
3941,,9225,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,B,
3942,,9225,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,B,
3943,,9225,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,B,
3944,,9225,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,B,
3945,,9225,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,B,
3946,,9225,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,B,
3947,,9225,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,B,
3948,,9225,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,B,
3949,,9225,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,B,
3950,,9401,,BAO_0000019,,,,Expert,1,,,8,,H,,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,B,
3951,,10325,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,B,
3952,,1556,,BAO_0000219,,,663.0,Expert,1,,,8,,H,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,F,
3953,,1556,,BAO_0000219,,,663.0,Expert,1,,,8,,H,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,F,
3954,,961,10116.0,BAO_0000219,,,702.0,Expert,1,Rattus norvegicus,,9,,D,,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,B,
3955,,6838,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,B,
3956,,10325,,BAO_0000019,,,,Expert,1,,,8,,H,,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),B,
3957,,9209,10116.0,BAO_0000219,,,702.0,Expert,1,Rattus norvegicus,,9,,D,,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,B,
3958,,11520,,BAO_0000219,,,702.0,Expert,1,,,8,,H,,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,B,
3959,,137,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro inhibitory activity against 5-lipoxygenase was determined,B,
3960,,4717,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,B,
3961,,10636,,BAO_0000219,,,702.0,Expert,1,,,8,,H,,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,B,
3962,,14312,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,F,
3963,,1203,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,B,
3964,,1203,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,B,
3965,,13622,,BAO_0000219,,,702.0,Expert,1,,,8,,H,,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,B,
3966,,9793,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,B,
3967,,1143,10116.0,BAO_0000219,,,702.0,Expert,1,Rattus norvegicus,,9,,D,,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,B,
3968,,11854,10116.0,BAO_0000219,,,702.0,Expert,1,Rattus norvegicus,,9,,D,,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,B,
3969,,3595,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,
3970,,3595,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),B,
3971,,10501,10116.0,BAO_0000219,,,702.0,Expert,1,Rattus norvegicus,,9,,D,,Inhibition of 5-lipoxygenase in rat RBL-1 cells,B,
3972,,12526,,BAO_0000219,,,702.0,Expert,1,,,8,,H,,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,
3973,349.0,10034,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,F,Limbic system
3974,349.0,10034,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,F,Limbic system
3975,,10034,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Approximate dose levels for a half maximal reduction of 5-HTP levels,F,
3976,10000000.0,10046,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,Hippocampus
3977,10000000.0,10046,,BAO_0000221,,,,Autocuration,1,,,8,,H,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,Hippocampus
3978,,10046,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,B,
3979,178.0,12079,9615.0,BAO_0000019,,,,Autocuration,1,Canis lupus familiaris,,8,,H,,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,F,Blood
3980,178.0,12079,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,F,Blood
3981,,11311,,BAO_0000219,,,,Autocuration,1,,,8,,H,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],B,
3982,,12338,,BAO_0000219,,,,Expert,1,,,8,,H,,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,B,
3983,,12143,,BAO_0000219,,,,Expert,1,,,8,,H,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,B,
3984,,12143,,BAO_0000219,,,,Autocuration,1,,,8,,H,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),B,
3985,,12143,,BAO_0000219,,,,Expert,1,,,8,,H,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,B,
3986,,12143,,BAO_0000219,,,,Autocuration,1,,,8,,H,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,B,
3987,,12365,,BAO_0000357,,,,Expert,1,,,8,,H,,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,B,
3988,,13500,,BAO_0000357,,,,Expert,1,,,8,,H,,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,B,
3989,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,Blood
3990,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,Blood
3991,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,Blood
3992,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,Blood
3993,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,Blood
3994,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,Blood
3995,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,Blood
3996,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,Blood
3997,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,Blood
3998,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,Blood
3999,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",F,Blood
4000,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",F,Blood
4001,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",F,Blood
4002,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,Blood
4003,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",F,Blood
4004,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",F,Blood
4005,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",F,Blood
4006,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,Blood
4007,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",F,Blood
4008,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",F,Blood
4009,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",F,Blood
4010,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,Blood
4011,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",F,Blood
4012,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",F,Blood
4013,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",F,Blood
4014,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,Blood
4015,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",F,Blood
4016,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",F,Blood
4017,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",F,Blood
4018,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,Blood
4019,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",F,Blood
4020,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",F,Blood
4021,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",F,Blood
4022,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,Blood
4023,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",F,Blood
4024,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",F,Blood
4025,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",F,Blood
4026,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,Blood
4027,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,Blood
4028,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,Blood
4029,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,Blood
4030,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,Blood
4031,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",F,Blood
4032,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,Blood
4033,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,Blood
4034,178.0,12832,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,8,,H,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,Blood
4035,,3595,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,,8,,H,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,B,
4036,,3595,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,,8,,H,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,B,
4037,,3595,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,,8,,H,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,B,
4038,,3595,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,,8,,H,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,B,
4039,,3595,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,,8,,H,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,B,
4040,,3595,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,,8,,H,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,B,
4041,,3595,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,,8,,H,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,B,
4042,,3595,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,,8,,H,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,B,
4043,,9203,10141.0,BAO_0000357,,,,Autocuration,1,Cavia porcellus,,8,,H,,Ability to inhibit 5-lipoxygenase in guinea pig,B,
4044,,82,10141.0,BAO_0000357,,,,Expert,1,Cavia porcellus,,8,,H,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),B,
4045,,11090,10141.0,BAO_0000357,,,,Autocuration,1,Cavia porcellus,,8,,H,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,B,
4046,178.0,12832,10141.0,BAO_0000218,,,,Autocuration,1,Cavia porcellus,,8,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",B,Blood
4047,,1065,10141.0,BAO_0000357,,,,Autocuration,1,Cavia porcellus,,8,,H,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,B,
4048,,1065,10141.0,BAO_0000357,,,,Autocuration,1,Cavia porcellus,,8,,H,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,B,
4049,,12832,10141.0,BAO_0000019,,,,Expert,1,Cavia porcellus,,8,,H,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,B,
4050,,12832,10141.0,BAO_0000019,,,,Expert,1,Cavia porcellus,,8,,H,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,B,
4051,,12832,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,8,,H,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,B,
4052,,10504,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,8,,H,,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,B,
4053,,7788,10141.0,BAO_0000357,,,,Autocuration,1,Cavia porcellus,,8,,H,,Inhibitory activity against 5-lipoxygenase,B,
4054,,10001,10141.0,BAO_0000357,,,,Autocuration,1,Cavia porcellus,,8,,H,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,B,
4055,,10193,10141.0,BAO_0000357,,,,Autocuration,1,Cavia porcellus,,8,,H,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,B,
4056,,13243,10141.0,BAO_0000357,,,,Autocuration,1,Cavia porcellus,,8,,H,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,B,
4057,,13243,10141.0,BAO_0000357,,,,Autocuration,1,Cavia porcellus,,8,,H,,Inhibitory activity uM,B,
4058,,969,10141.0,BAO_0000219,,,,Autocuration,1,Cavia porcellus,,8,,H,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,B,
4059,,10001,10141.0,BAO_0000357,,,,Autocuration,1,Cavia porcellus,,8,,H,,Inhibitory activity against 5-lipoxygenase at 10 uM,B,
4060,,7788,10141.0,BAO_0000357,,,,Autocuration,1,Cavia porcellus,,8,,H,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,B,
4061,,10001,10141.0,BAO_0000357,,,,Autocuration,1,Cavia porcellus,,8,,H,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,B,
4062,,10193,10141.0,BAO_0000357,,,,Autocuration,1,Cavia porcellus,,8,,H,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,B,
4063,,13243,10141.0,BAO_0000357,,,,Autocuration,1,Cavia porcellus,,8,,H,,Inhibitory activity uM,B,
4064,,13243,10141.0,BAO_0000357,,,,Autocuration,1,Cavia porcellus,,8,,H,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,B,
4065,,13243,10141.0,BAO_0000357,,,,Expert,1,Cavia porcellus,,8,,H,,Inhibitory activity uM,B,
4066,,13243,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,8,,H,,Inhibitory activity uM,F,
4067,,10504,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,8,,H,,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,B,
4068,,7788,10141.0,BAO_0000357,,,,Autocuration,1,Cavia porcellus,,8,,H,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,B,
4069,2116.0,10546,10141.0,BAO_0000221,,,,Expert,1,Cavia porcellus,,8,,H,,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,F,Ileum
4070,,13183,,BAO_0000357,,,,Autocuration,1,,,8,,H,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,
4071,,13183,,BAO_0000357,,,,Autocuration,1,,,8,,H,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,
4072,,2578,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),B,
4073,,12780,,BAO_0000357,,,,Expert,1,,,8,,H,,In vitro inhibition of human 5-Lipoxygenase.,B,
4074,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,B,Liver
4075,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,B,Liver
4076,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,B,Liver
4077,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,B,Liver
4078,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,B,Liver
4079,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,Liver
4080,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,Liver
4081,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,B,Liver
4082,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,B,Liver
4083,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,B,Liver
4084,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,B,Liver
4085,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,B,Liver
4086,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,B,Liver
4087,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,Liver
4088,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,B,Liver
4089,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,B,Liver
4090,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,Liver
4091,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,Liver
4092,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,B,Liver
4093,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,B,Liver
4094,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,B,Liver
4095,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,B,Liver
4096,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,B,Liver
4097,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,B,Liver
4098,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,B,Liver
4099,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,B,Liver
4100,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,B,Liver
4101,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,B,Liver
4102,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,B,Liver
4103,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,B,Liver
4104,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,B,Liver
4105,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,B,Liver
4106,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,B,Liver
4107,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,B,Liver
4108,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,Liver
4109,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,B,Liver
4110,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,B,Liver
4111,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,B,Liver
4112,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,B,Liver
4113,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,B,Liver
4114,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,Liver
4115,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,B,Liver
4116,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,B,Liver
4117,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,B,Liver
4118,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,B,Liver
4119,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,B,Liver
4120,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,Liver
4121,,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,B,
4122,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,Liver
4123,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,Liver
4124,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",B,Liver
4125,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,Liver
4126,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,Liver
4127,,10797,9606.0,BAO_0000219,,,741.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro inhibition of 7226/S myeloma cancer cell line,F,
4128,,6881,9606.0,BAO_0000219,,,993.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),F,
4129,,3838,9606.0,BAO_0000219,,,391.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,F,
4130,,3838,9606.0,BAO_0000219,,,391.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,F,
4131,,12981,10029.0,BAO_0000219,,,505.0,Expert,1,Cricetulus griseus,,1,,N,,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,F,
4132,,12981,10029.0,BAO_0000219,,,505.0,Expert,1,Cricetulus griseus,,1,,N,,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,F,
4133,,7653,10116.0,BAO_0000219,,,1119.0,Intermediate,1,Rattus norvegicus,,1,,N,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,F,
4134,,7653,10116.0,BAO_0000219,,,1119.0,Intermediate,1,Rattus norvegicus,,1,,N,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,F,
4135,,7653,10116.0,BAO_0000219,,,1119.0,Intermediate,1,Rattus norvegicus,,1,,N,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,F,
4136,,7653,10116.0,BAO_0000219,,,1119.0,Intermediate,1,Rattus norvegicus,,1,,N,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,F,
4137,,7653,10116.0,BAO_0000219,,,1119.0,Intermediate,1,Rattus norvegicus,,1,,N,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,F,
4138,,7653,10116.0,BAO_0000219,,,1119.0,Intermediate,1,Rattus norvegicus,,1,,N,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,F,
4139,,17229,9606.0,BAO_0000219,,,391.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro antitumor activity against renal 786-0 tumor cell lines,F,
4140,,12858,9606.0,BAO_0000219,,,391.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxic activity against 786-0 Renal cancer cell line,F,
4141,,16325,9606.0,BAO_0000219,,,391.0,Intermediate,1,Homo sapiens,,1,,N,,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,F,
4142,,16325,9606.0,BAO_0000219,,,391.0,Intermediate,1,Homo sapiens,,1,,N,,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,F,
4143,,5858,9606.0,BAO_0000219,,,391.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro antitumor activity against human renal 786-0 cell line,F,
4144,,16325,9606.0,BAO_0000219,,,391.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibition of Renal cancer in 786-0 cancer cell lines,F,
4145,,14696,9606.0,BAO_0000219,,,391.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,F,
4146,,3786,9606.0,BAO_0000219,,,391.0,Intermediate,1,Homo sapiens,,1,,N,,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,F,
4147,,14696,9606.0,BAO_0000219,,,391.0,Intermediate,1,Homo sapiens,,1,,N,,inhibition of the growth of renal cancer(786-0) cell line,F,
4148,,14769,9606.0,BAO_0000219,,,391.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),F,
4149,,15354,9606.0,BAO_0000219,,,391.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,F,
4150,,14255,9606.0,BAO_0000219,,,391.0,Intermediate,1,Homo sapiens,,1,,N,,The IC50 value was measured on 786-0 cell line in ovarian tumor,F,
4151,,14255,9606.0,BAO_0000219,,,391.0,Intermediate,1,Homo sapiens,,1,,N,,The IC50 value was measured on 786-0 cell line in ovarian tumor t,F,
4152,,14255,9606.0,BAO_0000219,,,391.0,Intermediate,1,Homo sapiens,,1,,N,,The IC50 value was measured on 786-0 cell line in renal tumor type.,F,
4153,,14696,9606.0,BAO_0000219,,,391.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,F,
4154,,12016,9606.0,BAO_0000219,,,391.0,Intermediate,1,Homo sapiens,,1,,N,,Tested for cytotoxic activity against renal cancer 786-0 cell line,F,
4155,,2597,9606.0,BAO_0000219,,,391.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for growth inhibitory activity against 786-0 cell line,F,
4156,,12526,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,B,
4157,,12526,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,B,
4158,,14799,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,B,
4159,,3595,,BAO_0000219,,,702.0,Expert,1,,,8,,H,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,
4160,,3595,,BAO_0000219,,,702.0,Expert,1,,,8,,H,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),B,
4161,,12767,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,B,
4162,,10997,,BAO_0000219,,,,Autocuration,1,,,8,,H,,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,B,
4163,,11388,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,B,
4164,,167,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,B,
4165,,167,,BAO_0000357,,,,Autocuration,1,,,8,,H,,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",B,
4166,,13744,,BAO_0000357,,,,Expert,1,,,8,,H,,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,B,
4167,,1630,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,B,
4168,,1630,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),B,
4169,,969,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",B,
4170,,13621,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,B,
4171,,10089,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,B,
4172,,10193,,BAO_0000357,,,,Expert,1,,,8,,H,,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,B,
4173,,11966,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,B,
4174,,12251,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,B,
4175,,211,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),B,
4176,,12251,,BAO_0000019,,,,Expert,1,,,8,,H,,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,F,
4177,,12495,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,B,
4178,,414,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested for its inhibitory activity against 5-lipoxygenase,B,
4179,,414,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,B,
4180,,10325,,BAO_0000019,,,,Expert,1,,,8,,H,,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",B,
4181,,11966,,BAO_0000019,,,,Expert,1,,,8,,H,,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,B,
4182,,165,,BAO_0000219,,,702.0,Expert,1,,,8,,H,,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,
4183,,165,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,B,
4184,,165,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,
4185,,165,,BAO_0000219,,,702.0,Expert,1,,,8,,H,,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,
4186,,11311,,BAO_0000218,,,,Autocuration,1,,,8,,H,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,B,
4187,,11311,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,B,
4188,,11311,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,B,
4189,,11311,,BAO_0000219,,,,Autocuration,1,,,8,,H,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],B,
4190,,11311,,BAO_0000219,,,,Autocuration,1,,,8,,H,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),B,
4191,,11311,,BAO_0000218,,,,Autocuration,1,,In vivo,8,,H,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),B,
4192,,11311,,BAO_0000219,,,663.0,Autocuration,1,,,8,,H,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,F,
4193,,11311,,BAO_0000219,,,663.0,Autocuration,1,,,8,,H,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,F,
4194,,11311,,BAO_0000019,,,,Autocuration,1,,,8,,H,,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],B,
4195,,11732,,BAO_0000019,,,,Autocuration,1,,,8,,H,,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,B,
4196,,11732,,BAO_0000019,,,,Expert,1,,,8,,H,,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,B,
4197,,11087,,BAO_0000019,,,,Expert,1,,,8,,H,,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,B,
4198,,11087,,BAO_0000019,,,,Autocuration,1,,,8,,H,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,B,
4199,,11087,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,B,
4200,,11087,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,B,
4201,,496,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,B,
4202,,13986,,BAO_0000219,,,702.0,Expert,1,,,8,,H,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,F,
4203,,11520,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for the inhibition of 5-lipoxygenase,B,
4204,,10293,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,B,
4205,,303,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,B,
4206,,303,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,B,
4207,,9247,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,B,
4208,,9247,10116.0,BAO_0000219,,,702.0,Expert,1,Rattus norvegicus,,9,,D,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,B,
4209,,9247,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,B,
4210,,9247,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,B,
4211,,9247,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,B,
4212,,9247,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,B,
4213,,9247,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,B,
4214,,9247,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,B,
4215,,11481,10116.0,BAO_0000357,,,,Expert,1,Rattus norvegicus,,9,,D,,Inhibitory activity against 5-lipoxygenase at 10 uM,B,
4216,,105,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,B,
4217,,9029,,BAO_0000357,,,,Expert,1,,,8,,H,,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,B,
4218,,1175,,BAO_0000219,,,702.0,Expert,1,,,8,,H,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,B,
4219,,12118,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,B,
4220,,12118,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,B,
4221,,12118,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,B,
4222,,9225,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,B,
4223,,9401,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,B,
4224,,137,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,B,
4225,,137,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,B,
4226,,4717,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,B,
4227,,3595,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,B,
4228,,10501,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,B,
4229,,10501,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,B,
4230,,10501,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,B,
4231,,12526,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,
4232,,14799,10116.0,BAO_0000219,,,702.0,Expert,1,Rattus norvegicus,,9,,D,,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,B,
4233,,14799,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,B,
4234,,3595,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,B,
4235,,3595,,BAO_0000219,,,702.0,Expert,1,,,8,,H,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,B,
4236,,12526,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,
4237,,12526,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,
4238,,10193,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,B,
4239,,10193,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,B,
4240,,10193,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,B,
4241,,10193,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,B,
4242,,9138,,BAO_0000357,,,,Expert,1,,,8,,H,,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),B,
4243,,9138,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,B,
4244,,11966,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,B,
4245,,165,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,B,
4246,,165,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,B,
4247,,11311,,BAO_0000219,,,663.0,Autocuration,1,,,8,,H,,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,B,
4248,,11311,,BAO_0000219,,,663.0,Autocuration,1,,,8,,H,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,B,
4249,,11311,,BAO_0000219,,,663.0,Autocuration,1,,,8,,H,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,F,
4250,,11311,,BAO_0000019,,,,Autocuration,1,,,8,,H,,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,F,
4251,,11311,,BAO_0000357,,,,Autocuration,1,,,8,,H,,The compound was tested for inhibition of isolated 5-lipoxygenase,B,
4252,,11311,,BAO_0000219,,,663.0,Autocuration,1,,,8,,H,,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,F,
4253,,11087,,BAO_0000019,,,,Autocuration,1,,,8,,H,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,B,
4254,,11087,,BAO_0000019,,,,Autocuration,1,,,8,,H,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,B,
4255,,11087,,BAO_0000019,,,,Autocuration,1,,,8,,H,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,B,
4256,,11087,,BAO_0000019,,,,Autocuration,1,,,8,,H,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,B,
4257,,11087,,BAO_0000019,,,,Autocuration,1,,,8,,H,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,B,
4258,,496,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,B,
4259,,496,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,B,
4260,,13986,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,F,
4261,,13986,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,F,
4262,,13986,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,F,
4263,,13986,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,F,
4264,,13986,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,F,
4265,,13986,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,F,
4266,,13986,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,F,
4267,,13986,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,F,
4268,,13986,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,F,
4269,,13986,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,F,
4270,,10193,,BAO_0000357,,,,Autocuration,1,,,8,,H,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,B,
4271,,9295,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for the percent of inhibition against 5-LO at 10 uM,B,
4272,,4717,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,B,
4273,,4717,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,B,
4274,,11854,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,B,
4275,,11854,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,B,
4276,,11854,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,B,
4277,,10193,,BAO_0000019,,,,Autocuration,1,,,8,,H,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,B,
4278,,9295,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,B,
4279,,9295,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,B,
4280,,9295,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,B,
4281,,9295,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,B,
4282,,165,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,B,
4283,,11311,,BAO_0000219,,,,Autocuration,1,,,8,,H,,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,B,
4284,,10489,9606.0,BAO_0000219,,,702.0,Expert,1,Homo sapiens,,8,,H,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),B,
4285,,10489,10116.0,BAO_0000219,,,702.0,Expert,1,Rattus norvegicus,,9,,D,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),B,
4286,,10489,10116.0,BAO_0000219,,,702.0,Expert,1,Rattus norvegicus,,9,,D,,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),B,
4287,,14799,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,9,,D,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,B,
4288,,9295,3847.0,BAO_0000357,,,,Autocuration,1,Glycine max,,8,,H,,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),B,
4289,,16811,,BAO_0000019,,,,Autocuration,1,,,0,,U,,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",B,
4290,,168,,BAO_0000357,,,,Expert,1,,,8,,H,,In vitro inhibition of 5-Lipoxygenase; Inactive.,B,
4291,,6309,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,B,
4292,,6309,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory concentration against 5-lipoxygenase; No inhibition,B,
4293,,3092,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,B,
4294,,168,,BAO_0000357,,,,Expert,1,,,8,,H,,Inhibitory activity against 5-lipoxygenase.,B,
4295,,168,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,B,
4296,,168,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,B,
4297,,168,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,B,
4298,,12338,,BAO_0000019,,,,Expert,1,,,8,,H,,Inhibitory concentration against arachidonic acid 5-lipoxygenation,F,
4299,,4501,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested for the inhibitory activity against 5-lipoxygenase,B,
4300,,1132,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for its inhibitory activity against 5-lipoxygenase,B,
4301,,2117,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,B,
4302,,168,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,B,
4303,,168,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,B,
4304,,13575,,BAO_0000219,,,702.0,Autocuration,1,,,8,,H,,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,B,
4305,,11089,,BAO_0000357,,,,Autocuration,1,,,8,,H,,,B,
4306,,216,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),B,
4307,,13165,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,B,
4308,,3278,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,B,
4309,,3278,,BAO_0000357,,,,Expert,1,,,8,,H,,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,B,
4310,,11966,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,B,
4311,,175,,BAO_0000357,,,,Autocuration,1,,,8,,H,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",B,
4312,,175,,BAO_0000357,,,,Autocuration,1,,,8,,H,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",B,
4313,,13449,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,B,
4314,,12014,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,B,
4315,,12014,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),B,
4316,,12014,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),B,
4317,,99,,BAO_0000220,,,,Intermediate,1,,,2,,S,,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,B,
4318,,4349,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,The dark toxicity against 543 human galactophore carcinoma cells,F,
4319,,4071,9606.0,BAO_0000219,,,390.0,Expert,1,Homo sapiens,,1,,N,,Tested in vitro for cytotoxicity against 56 human tumor cell lines,F,
4320,,17589,9606.0,BAO_0000219,,,345.0,Expert,1,Homo sapiens,,1,,N,,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,F,
4321,,15002,9606.0,BAO_0000219,,,345.0,Intermediate,1,Homo sapiens,,1,,N,,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,F,
4322,,13958,9606.0,BAO_0000219,,,345.0,Intermediate,1,Homo sapiens,,1,,N,,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",F,
4323,,17589,9606.0,BAO_0000219,,,345.0,Expert,1,Homo sapiens,,1,,N,,Growth inhibition against human 5637 cell lines,F,
4324,,16748,9606.0,BAO_0000219,,,345.0,Expert,1,Homo sapiens,,1,,N,,Antitumor activity against human bladder carcinoma 5637 cells.,F,
4325,,16747,9606.0,BAO_0000219,,,345.0,Intermediate,1,Homo sapiens,,1,,N,,Antitumor activity against human bladder carcinoma 5637 cells,F,
4326,,16747,9606.0,BAO_0000219,,,345.0,Intermediate,1,Homo sapiens,,1,,N,,Antitumor activity against human bladder carcinoma 5637 cells,F,
4327,,15285,9913.0,BAO_0000357,,,,Expert,1,Bos taurus,,9,,D,,In vitro inhibition of bovine trypsin(Trp).,B,
4328,,3726,9527.0,BAO_0000219,,,407.0,Expert,1,Cercopithecidae,,8,,H,,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,B,
4329,,5033,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,B,
4330,,11756,,BAO_0000019,,,,Autocuration,1,,,6,,H,,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,F,
4331,,11953,,BAO_0000218,,,,Autocuration,1,,In vivo,0,,U,,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,F,
4332,,5033,10141.0,BAO_0000357,,,,Intermediate,1,Cavia porcellus,,9,,D,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,B,
4333,,11347,10116.0,BAO_0000251,,,,Expert,1,Rattus norvegicus,,8,Microsomes,H,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,A,
4334,,11347,10116.0,BAO_0000251,,,,Expert,1,Rattus norvegicus,,8,Microsomes,H,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,A,
4335,,1229,,BAO_0000019,,,,Intermediate,1,,,0,,U,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,F,
4336,,1229,,BAO_0000019,,,,Intermediate,1,,,0,,U,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,F,
4337,,17588,5691.0,BAO_0000019,,,,Expert,1,Trypanosoma brucei,,8,,H,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,B,
4338,,17588,5691.0,BAO_0000019,,,,Autocuration,1,Trypanosoma brucei,,8,,H,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,B,
4339,,17588,9940.0,BAO_0000019,,,,Expert,1,Ovis aries,,8,,H,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,B,
4340,,17588,9940.0,BAO_0000019,,,,Autocuration,1,Ovis aries,,8,,H,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,B,
4341,,16485,,BAO_0000357,,,,Autocuration,1,,,8,,H,,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,B,
4342,,4337,9606.0,BAO_0000019,,,,Intermediate,1,Homo sapiens,,0,,U,,Average inhibitory concentration against 60 human cell lines was reported,F,
4343,,4112,9606.0,BAO_0000019,,,,Expert,1,Homo sapiens,,0,,U,,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,F,
4344,,16160,9606.0,BAO_0000219,,,542.0,Intermediate,1,Homo sapiens,,1,,N,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,F,
4345,,16160,9606.0,BAO_0000219,,,542.0,Intermediate,1,Homo sapiens,,1,,N,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,F,
4346,,17376,,BAO_0000219,,,542.0,Expert,1,,,1,,N,,In vitro mean growth inhibitory activity against 60-cell panel,F,
4347,,17376,,BAO_0000219,,,542.0,Expert,1,,,1,,N,,In vitro mean growth lethal concentration against 60-cell panel,F,
4348,,17376,,BAO_0000219,,,542.0,Expert,1,,,1,,N,,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,F,
4349,,17376,,BAO_0000219,,,542.0,Expert,1,,,1,,N,,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,F,
4350,,3241,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,F,
4351,,3241,,BAO_0000019,,,,Autocuration,1,,,4,,H,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,F,
4352,,3725,,BAO_0000357,,,,Expert,1,,,8,,H,,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,B,
4353,,10805,5833.0,BAO_0000218,,,,Expert,1,Plasmodium falciparum,,1,,N,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,F,
4354,,10805,5833.0,BAO_0000218,,,,Expert,1,Plasmodium falciparum,,1,,N,,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,F,
4355,,10805,5833.0,BAO_0000218,,,,Expert,1,Plasmodium falciparum,,1,,N,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,F,
4356,,10805,5833.0,BAO_0000218,,,,Expert,1,Plasmodium falciparum,,1,,N,,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,F,
4357,,10805,5833.0,BAO_0000218,,,,Intermediate,1,Plasmodium falciparum,,1,,N,,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,F,
4358,,10144,10090.0,BAO_0000218,,,850.0,Intermediate,1,Mus musculus,,1,,N,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,F,
4359,,10144,10090.0,BAO_0000218,,,850.0,Intermediate,1,Mus musculus,,1,,N,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,F,
4360,,10144,10090.0,BAO_0000218,,,850.0,Intermediate,1,Mus musculus,,1,,N,,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,F,
4361,,10144,10090.0,BAO_0000218,,,850.0,Intermediate,1,Mus musculus,,1,,N,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,F,
4362,,10144,10090.0,BAO_0000218,,,850.0,Intermediate,1,Mus musculus,,1,,N,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,F,
4363,,10144,10090.0,BAO_0000218,,,850.0,Intermediate,1,Mus musculus,,1,,N,,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,F,
4364,,10685,10090.0,BAO_0000218,,,,Autocuration,1,Mus musculus,In vivo,0,,U,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,F,
4365,,10685,10090.0,BAO_0000218,,,,Autocuration,1,Mus musculus,In vivo,0,,U,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,F,
4366,,10685,10090.0,BAO_0000218,,,,Autocuration,1,Mus musculus,In vivo,0,,U,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),F,
4367,,10685,10090.0,BAO_0000218,,,,Autocuration,1,Mus musculus,In vivo,0,,U,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,F,
4368,,10685,10090.0,BAO_0000218,,,,Autocuration,1,Mus musculus,In vivo,0,,U,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,F,
4369,,10685,10090.0,BAO_0000218,,,,Autocuration,1,Mus musculus,In vivo,0,,U,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,F,
4370,,10685,10090.0,BAO_0000218,,,,Autocuration,1,Mus musculus,In vivo,0,,U,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,F,
4371,,10685,10090.0,BAO_0000218,,,,Autocuration,1,Mus musculus,In vivo,0,,U,,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",F,
4372,,10685,10090.0,BAO_0000218,,,,Autocuration,1,Mus musculus,In vivo,0,,U,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),F,
4373,,10685,10090.0,BAO_0000218,,,,Autocuration,1,Mus musculus,In vivo,0,,U,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),F,
4374,,10685,10090.0,BAO_0000218,,,,Autocuration,1,Mus musculus,In vivo,0,,U,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,F,
4375,,10144,10090.0,BAO_0000218,,,,Autocuration,1,Mus musculus,,0,,U,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,F,
4376,,10144,10090.0,BAO_0000218,,,,Autocuration,1,Mus musculus,,0,,U,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,F,
4377,,10144,10090.0,BAO_0000218,,,,Autocuration,1,Mus musculus,,0,,U,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,F,
4378,,10144,10090.0,BAO_0000218,,,,Autocuration,1,Mus musculus,,0,,U,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,F,
4379,,10685,10090.0,BAO_0000218,,,,Autocuration,1,Mus musculus,,0,,U,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,F,
4380,,10685,10090.0,BAO_0000218,,,,Autocuration,1,Mus musculus,,0,,U,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,F,
4381,,10685,10090.0,BAO_0000218,,,,Autocuration,1,Mus musculus,,0,,U,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,F,
4382,,10685,10090.0,BAO_0000218,,,,Autocuration,1,Mus musculus,,0,,U,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,F,
4383,,10685,10090.0,BAO_0000218,,,,Autocuration,1,Mus musculus,,0,,U,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,A,
4384,,10685,10090.0,BAO_0000218,,,,Autocuration,1,Mus musculus,,0,,U,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,A,
4385,,10685,10090.0,BAO_0000218,,,,Autocuration,1,Mus musculus,,0,,U,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,A,
4386,,10685,10090.0,BAO_0000218,,,,Autocuration,1,Mus musculus,,0,,U,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,A,
4387,,8831,10090.0,BAO_0000218,,,850.0,Intermediate,1,Mus musculus,,1,,N,,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",F,
4388,,11704,,BAO_0000218,,,,Autocuration,1,,In vivo,0,,U,,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,F,
4389,,11704,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,A,
4390,,10685,10090.0,BAO_0000218,,,850.0,Intermediate,1,Mus musculus,In vivo,1,,N,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,F,
4391,,10685,10090.0,BAO_0000218,,,850.0,Intermediate,1,Mus musculus,In vivo,1,,N,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,F,
4392,,11368,10090.0,BAO_0000218,,,850.0,Expert,1,Mus musculus,,1,,N,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),F,
4393,,11368,10090.0,BAO_0000218,,,850.0,Intermediate,1,Mus musculus,,1,,N,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),F,
4394,,11368,10090.0,BAO_0000218,,,850.0,Expert,1,Mus musculus,,1,,N,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),F,
4395,,17763,1280.0,BAO_0000019,,,,Autocuration,1,Staphylococcus aureus,,0,,U,,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",B,
4396,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,B,Liver
4397,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,B,Liver
4398,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,B,Liver
4399,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,B,Liver
4400,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,B,Liver
4401,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,B,Liver
4402,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,B,Liver
4403,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,B,Liver
4404,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,B,Liver
4405,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,B,Liver
4406,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,B,Liver
4407,2107.0,7411,10116.0,BAO_0000251,,,,Autocuration,1,Rattus norvegicus,,0,Microsomes,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,B,Liver
4408,1969.0,347,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,The apparent total plasma clearance in monkey,A,Plasma
4409,,3341,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Compound was evaluated for Hepatic clearance in monkey,A,
4410,,17853,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Lower clearance in monkey (i.v.) at 0.5 mpk,A,
4411,,4514,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Plasma clearance in rhesus monkey,A,
4412,,6062,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,A,
4413,,6821,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Plasma clearance of compound was determined in monkey,A,
4414,,6057,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Plasma clearance was calculated in rhesus monkey,A,
4415,,5145,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Plasma clearance in rhesus monkey,A,
4416,,6641,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,
4417,,5472,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Plasma clearance was evaluated in rhesus,A,
4418,,4257,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,A,
4419,,5546,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,
4420,,5334,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,
4421,,5334,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,
4422,,17509,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Cmax 24 hr after 2 mg/kg oral administration in monkeys,A,
4423,,6535,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Cmax in monkey after administration of 1 mg/kg iv,A,
4424,,5668,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Cmax was determine after peroral administration at 10 mpk in Rhesus,A,
4425,,5922,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Cmax in cynomolgus monkey by iv administration,A,
4426,,5922,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Cmax in cynomolgus monkey by po administration,A,
4427,,6078,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Cmax value evaluated in monkey,A,
4428,,2661,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,
4429,1969.0,3249,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,A,Plasma
4430,1969.0,3249,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,A,Plasma
4431,1969.0,5553,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Maximal plasma concentration in squirrel monkeys,A,Plasma
4432,,1916,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,
4433,1969.0,6227,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,A,Plasma
4434,,4809,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,
4435,,5355,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,A,
4436,,5355,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,A,
4437,,5355,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,A,
4438,,5355,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,A,
4439,1969.0,6221,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,A,Plasma
4440,,167,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,,0,,U,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,A,
4441,,167,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,,0,,U,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,A,
4442,,4257,9443.0,BAO_0000218,,,,Autocuration,1,monkey,In vivo,0,,U,,Absolute bioavailability was evaluated in monkey,A,
4443,,6221,9443.0,BAO_0000218,,,,Autocuration,1,monkey,In vivo,0,,U,,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,A,
4444,,17667,9443.0,BAO_0000218,,,,Autocuration,1,monkey,In vivo,0,,U,,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,A,
4445,,17267,9544.0,BAO_0000218,,,,Autocuration,1,Macaca mulatta,In vivo,0,,U,,Bioavailability of compound was determined in rhesus monkey,A,
4446,,4256,38020.0,BAO_0000218,,,,Autocuration,1,marmosets,In vivo,0,,U,,Bioavailability determined after oral administration in marmoset,A,
4447,,4256,9541.0,BAO_0000218,,,,Autocuration,1,Macaca fascicularis,In vivo,0,,U,,Oral bioavailability in cynomolgus monkey,A,
4448,,17853,9443.0,BAO_0000218,,,,Autocuration,1,monkey,In vivo,0,,U,,Bioavailability in monkey (p.o.) at 2.0 mpk,A,
4449,,16365,9443.0,BAO_0000218,,,,Autocuration,1,monkey,In vivo,0,,U,,Bioavailability was evaluated after oral administration in monkey,A,
4450,,1916,9541.0,BAO_0000218,,,,Autocuration,1,Macaca fascicularis,In vivo,0,,U,,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,
4451,,5334,9544.0,BAO_0000218,,,,Autocuration,1,Macaca mulatta,In vivo,0,,U,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,
4452,,5334,9544.0,BAO_0000218,,,,Autocuration,1,Macaca mulatta,In vivo,0,,U,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,
4453,,17592,9443.0,BAO_0000218,,,,Autocuration,1,monkey,In vivo,0,,U,,Bioavailability of the compound was determined in monkey,A,
4454,,1399,9521.0,BAO_0000218,,,,Autocuration,1,Saimiri sciureus,In vivo,0,,U,,Bioavailability in squirrel monkey (dose 5 mg/kg),A,
4455,,4809,9443.0,BAO_0000218,,,,Autocuration,1,monkey,In vivo,0,,U,,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,
4456,,3341,9443.0,BAO_0000218,,,,Autocuration,1,monkey,In vivo,0,,U,,Oral bioavailability in monkey,A,
4457,,64,9521.0,BAO_0000218,,,,Autocuration,1,Saimiri sciureus,In vivo,0,,U,,Compound was tested for bioavailability in squirrel monkey,A,
4458,,5005,9544.0,BAO_0000218,,,,Autocuration,1,Macaca mulatta,In vivo,0,,U,,Oral bioavailability in Rhesus monkey,A,
4459,,5005,9544.0,BAO_0000218,,,,Autocuration,1,Macaca mulatta,In vivo,0,,U,,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),A,
4460,,5237,9541.0,BAO_0000218,,,,Autocuration,1,Macaca fascicularis,In vivo,0,,U,,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,A,
4461,,5237,9541.0,BAO_0000218,,,,Autocuration,1,Macaca fascicularis,In vivo,0,,U,,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,A,
4462,,5302,9443.0,BAO_0000218,,,,Autocuration,1,monkey,In vivo,0,,U,,Oral bioavailability in monkey (dose 5 mg/kg),A,
4463,,17667,9443.0,BAO_0000218,,,,Autocuration,1,monkey,In vivo,0,,U,,Oral bioavailability of compound at 5 mg/kg in monkey,A,
4464,,6161,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,A,
4465,,6161,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,A,
4466,1969.0,3854,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Plasma half life determined,A,Plasma
4467,1969.0,993,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Plasma half life in dog,A,Plasma
4468,1969.0,4514,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Plasma half-life in Beagle dogs,A,Plasma
4469,1969.0,5334,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,Plasma
4470,1969.0,5334,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),A,Plasma
4471,,1466,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,A,
4472,,1466,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,A,
4473,,5313,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Tested for the half life period in dog,A,
4474,,5313,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Tested for the half life period in dog at dosage of 10 mpk,A,
4475,,3880,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,The compound was tested for half life in dog,A,
4476,1969.0,3639,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",A,Plasma
4477,,3880,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,The half life was determined,A,
4478,1969.0,3918,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,The plasma half-life in dogs,A,Plasma
4479,1969.0,16452,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,A,Plasma
4480,,17796,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half life in dog,A,
4481,,5983,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,A,
4482,,1466,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,tmax upon peroral administration of 10.0 mg/Kg dose in dog,A,
4483,,16456,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,
4484,,6113,9669.0,BAO_0000218,,,,Expert,1,Mustela putorius furo,In vivo,1,,N,,Cmax in ferrets after 30 mg/kg oral dose,A,
4485,,6113,9669.0,BAO_0000218,,,,Expert,1,Mustela putorius furo,In vivo,1,,N,,Emesis in ferrets at 30 mg/kg oral dose,F,
4486,,17796,9541.0,BAO_0000218,,,,Autocuration,1,Macaca fascicularis,In vivo,0,,U,,Bioavailability in cynomolgus monkey,A,
4487,,17796,9541.0,BAO_0000218,,,,Intermediate,1,Macaca fascicularis,In vivo,1,,N,,Volume of distribution in cynomolgus,A,
4488,1969.0,5308,10141.0,BAO_0000218,,,,Autocuration,1,Cavia porcellus,,0,,U,,AUC tested in guinea pig when 3 mg/kg dose was given perorally,A,Plasma
4489,,4877,10141.0,BAO_0000218,,,,Autocuration,1,Cavia porcellus,,0,,U,,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,A,
4490,,4876,10141.0,BAO_0000218,,,,Autocuration,1,Cavia porcellus,,0,,U,,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",A,
4491,1969.0,4878,10141.0,BAO_0000218,,,,Autocuration,1,Cavia porcellus,In vivo,0,,U,,AUC in guinea pig after 3mg/kg oral dose,A,Plasma
4492,,5308,10141.0,BAO_0000218,,,,Autocuration,1,Cavia porcellus,In vivo,0,,U,,Bioavailability in guinea pig was tested,A,
4493,,4877,10141.0,BAO_0000218,,,,Autocuration,1,Cavia porcellus,In vivo,0,,U,,Tested for oral bioavailability in guinea pig at 5 mg/kg,A,
4494,,4876,10141.0,BAO_0000218,,,,Autocuration,1,Cavia porcellus,In vivo,0,,U,,Tested for the oral bioavailability of the compound,A,
4495,,4876,10141.0,BAO_0000218,,,,Autocuration,1,Cavia porcellus,In vivo,0,,U,,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,A,
4496,,5308,10141.0,BAO_0000218,,,,Autocuration,1,Cavia porcellus,In vivo,0,,U,,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,A,
4497,2048.0,4877,10141.0,BAO_0000218,,,,Autocuration,1,Cavia porcellus,In vivo,0,,U,,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,A,Lung
4498,,4878,10141.0,BAO_0000218,,,,Autocuration,1,Cavia porcellus,In vivo,0,,U,,Cmax in guinea pig after 3mg/kg oral dose,A,
4499,178.0,5689,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,0,,U,,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,A,Blood
4500,955.0,5689,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,0,,U,,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,A,Brain
4501,,5689,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,0,,U,,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,A,
4502,160.0,5689,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,0,,U,,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,A,Intestine
4503,2113.0,5689,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,0,,U,,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,A,Kidney
4504,2107.0,5689,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,0,,U,,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,A,Liver
4505,,5689,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,0,,U,,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,A,
4506,2106.0,5689,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,0,,U,,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,A,Spleen
4507,,14465,10141.0,BAO_0000218,,,,Autocuration,1,Cavia porcellus,In vivo,0,,U,,Elimination T1/2 in Guinea pig (PO dose),A,
4508,,5689,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,0,,U,,Partition coefficient was measured as -log (counts per min ),A,
4509,,611,10141.0,BAO_0000218,,,,Autocuration,1,Cavia porcellus,In vivo,0,,U,,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,A,
4510,,611,10141.0,BAO_0000218,,,,Autocuration,1,Cavia porcellus,In vivo,0,,U,,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,A,
4511,,14465,10141.0,BAO_0000218,,,,Autocuration,1,Cavia porcellus,In vivo,0,,U,,Elimination T1/2 in Guinea pig (PO dose),A,
4512,,4876,10141.0,BAO_0000218,,,,Autocuration,1,Cavia porcellus,In vivo,0,,U,,"Tested for the half life period of the compound, intravenously",A,
4513,,5689,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,0,,U,,Half-life was measured,A,
4514,,7515,10141.0,BAO_0000019,,,,Autocuration,1,Cavia porcellus,,0,,U,,The time required for onset of inotropy after addition of a single dose of delta F75,A,
4515,,17667,10141.0,BAO_0000218,,,,Autocuration,1,Cavia porcellus,In vivo,0,,U,,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,A,
4516,,17667,10141.0,BAO_0000218,,,,Autocuration,1,Cavia porcellus,In vivo,0,,U,,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,A,
4517,,4727,10029.0,BAO_0000218,,,,Autocuration,1,Cricetulus griseus,In vivo,0,,U,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,A,
4518,,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,
4519,,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,
4520,,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,
4521,,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,
4522,,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,A,
4523,,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,
4524,,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,
4525,178.0,3655,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,A,Blood
4526,178.0,3655,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,A,Blood
4527,178.0,3655,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,A,Blood
4528,10000001.0,3655,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,A,Bone
4529,10000001.0,3655,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,A,Bone
4530,10000001.0,3655,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,A,Bone
4531,955.0,3655,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,A,Brain
4532,955.0,3655,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,A,Brain
4533,955.0,3655,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,A,Brain
4534,948.0,3655,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,A,Heart
4535,948.0,3655,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,A,Heart
4536,948.0,3655,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,A,Heart
4537,160.0,3655,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,A,Intestine
4538,160.0,3655,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,A,Intestine
4539,160.0,3655,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,A,Intestine
4540,2113.0,3655,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,A,Kidney
4541,2113.0,3655,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,A,Kidney
4542,2113.0,3655,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,A,Kidney
4543,2107.0,3655,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,A,Liver
4544,2107.0,3655,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,A,Liver
4545,2107.0,3655,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,A,Liver
4546,2048.0,3655,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,A,Lung
4547,2048.0,3655,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,A,Lung
4548,2048.0,3655,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,A,Lung
4549,2385.0,3655,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,A,Muscle tissue
4550,2385.0,3655,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,A,Muscle tissue
4551,2385.0,3655,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,A,Muscle tissue
4552,2106.0,3655,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,A,Spleen
4553,2106.0,3655,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,A,Spleen
4554,2106.0,3655,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,A,Spleen
4555,945.0,3655,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,A,Stomach
4556,945.0,3655,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,A,Stomach
4557,945.0,3655,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,A,Stomach
4558,,16597,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,A,
4559,,16597,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,F,
4560,,16597,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,MRT value at a dose of 10 mg/kg intravenous administration in mice.,A,
4561,,16597,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,MRT value at a dose of 10 mg/kg peroral administration in mice.,A,
4562,,17764,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,A,
4563,,17764,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,F,
4564,,3830,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,F,
4565,,3829,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,F,
4566,,2040,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was evaluated for cytotoxicity against A2780 cell lines.,F,
4567,,15684,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,F,
4568,,15684,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,F,
4569,,15684,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,F,
4570,,15684,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,F,
4571,,15684,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,F,
4572,,15684,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,F,
4573,,2859,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was evaluated for cytotoxicity against A2780 cell line,F,
4574,,5618,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro inhibitory activity against human tumor cell line A2780,F,
4575,,15684,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,F,
4576,,15684,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,F,
4577,,15684,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,F,
4578,,15684,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,F,
4579,,2113,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,F,
4580,,2113,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,F,
4581,,16745,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,F,
4582,,16597,9606.0,BAO_0000218,,,478.0,Expert,1,Homo sapiens,,1,,N,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,
4583,,15684,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,F,
4584,,15684,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,F,
4585,,2040,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,F,
4586,,2040,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Relative resistance factor in A2780 cisplatin-resistant line,F,
4587,,16165,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,F,
4588,,16165,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,F,
4589,,16597,9606.0,BAO_0000218,,,478.0,Expert,1,Homo sapiens,,1,,N,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,
4590,,16597,9606.0,BAO_0000218,,,478.0,Expert,1,Homo sapiens,,1,,N,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,
4591,,3992,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,F,
4592,,10553,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,F,
4593,,15608,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,F,
4594,,15608,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,F,
4595,,15608,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,F,
4596,,15608,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,F,
4597,,15608,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,F,
4598,,15608,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,F,
4599,,15569,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,F,
4600,,17420,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Antiproliferative effect of compound on A2780/DX cell line,F,
4601,,17420,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,F,
4602,,15099,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),F,
4603,,15099,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),F,
4604,,17672,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,F,
4605,,17672,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,F,
4606,,17270,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against A2780ADR cell line,F,
4607,,17270,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against A2780CIS cell line,F,
4608,,5574,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,F,
4609,,2113,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,F,
4610,,16913,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",F,
4611,,16913,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",F,
4612,,17839,9544.0,BAO_0000218,,,,Autocuration,1,Macaca mulatta,In vivo,0,,U,,Oral bioavailability of compound in rhesus macaques,A,
4613,,6821,9443.0,BAO_0000218,,,,Autocuration,1,monkey,In vivo,0,,U,,Oral bioavailability in monkey,A,
4614,,6078,9443.0,BAO_0000218,,,,Autocuration,1,monkey,In vivo,0,,U,,Oral bioavailability evaluated in monkey,A,
4615,,6535,9443.0,BAO_0000218,,,,Autocuration,1,monkey,In vivo,0,,U,,Oral bioavailability in monkey (dose 1 mg/kg p.o.),A,
4616,,4449,9544.0,BAO_0000218,,,,Autocuration,1,Macaca mulatta,In vivo,0,,U,,Oral bioavailability in Rhesus monkey,A,
4617,,6057,9544.0,BAO_0000218,,,,Autocuration,1,Macaca mulatta,In vivo,0,,U,,Oral bioavailability was calculated in rhesus monkey,A,
4618,,5922,9541.0,BAO_0000218,,,,Autocuration,1,Macaca fascicularis,In vivo,0,,U,,Oral bioavailability in cynomolgus monkey,A,
4619,,5940,9443.0,BAO_0000218,,,,Autocuration,1,monkey,In vivo,0,,U,,Oral bioavailability in monkey,A,
4620,,6265,9443.0,BAO_0000218,,,,Autocuration,1,monkey,In vivo,0,,U,,Oral bioavailability in monkey,A,
4621,,6265,9443.0,BAO_0000218,,,,Autocuration,1,monkey,In vivo,0,,U,,Oral bioavailability in monkey (dose 1 mg/kg),A,
4622,,6265,9443.0,BAO_0000218,,,,Autocuration,1,monkey,In vivo,0,,U,,Oral bioavailability in monkey (dose 5 mg/kg),A,
4623,,5940,9443.0,BAO_0000218,,,,Autocuration,1,monkey,In vivo,0,,U,,Oral bioavailability in monkey,A,
4624,,5940,9443.0,BAO_0000218,,,,Autocuration,1,monkey,In vivo,0,,U,,Oral bioavailability in monkey,A,
4625,,4514,9544.0,BAO_0000218,,,,Autocuration,1,Macaca mulatta,In vivo,0,,U,,Oral bioavailability in rhesus monkey,A,
4626,,5546,9544.0,BAO_0000218,,,,Autocuration,1,Macaca mulatta,In vivo,0,,U,,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,A,
4627,,5553,9521.0,BAO_0000218,,,,Autocuration,1,Saimiri sciureus,In vivo,0,,U,,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,A,
4628,,6641,9443.0,BAO_0000218,,,,Autocuration,1,monkey,In vivo,0,,U,,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,
4629,,5472,9544.0,BAO_0000218,,,,Autocuration,1,Macaca mulatta,In vivo,0,,U,,Oral bioavailability in Rhesus monkey,A,
4630,,5668,9544.0,BAO_0000218,,,,Autocuration,1,Macaca mulatta,In vivo,0,,U,,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),A,
4631,,5711,9443.0,BAO_0000218,,,,Autocuration,1,monkey,In vivo,0,,U,,Oral bioavailability in monkey at 10 mg/kg of the compound,A,
4632,,5145,9544.0,BAO_0000218,,,,Autocuration,1,Macaca mulatta,In vivo,0,,U,,Bioavailability in Rhesus monkey,A,
4633,,3443,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,,0,,U,,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,
4634,,3443,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,,0,,U,,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,
4635,,3249,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,A,
4636,,3249,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,A,
4637,,5355,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Mean residence time was determined after intravenous administration in cynomolgus monkeys,A,
4638,,5355,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,A,
4639,,5355,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,A,
4640,,4809,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,
4641,,4809,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,
4642,,14294,9527.0,BAO_0000251,,,,Autocuration,1,Cercopithecidae,,0,Microsomes,U,,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),A,
4643,,14294,9527.0,BAO_0000251,,,,Autocuration,1,Cercopithecidae,,0,Microsomes,U,,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),A,
4644,,14294,9527.0,BAO_0000251,,,,Autocuration,1,Cercopithecidae,,0,Microsomes,U,,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),A,
4645,,14294,9527.0,BAO_0000251,,,,Autocuration,1,Cercopithecidae,,0,Microsomes,U,,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),A,
4646,,3443,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,
4647,,3443,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,
4648,,11271,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,A,
4649,,3443,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,,0,,U,,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,
4650,,3443,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,,0,,U,,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,
4651,,6821,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Elimination Half-life of compound was determined in monkey,A,
4652,,17267,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Half life of compound was determined in rhesus monkey,A,
4653,1969.0,5819,9527.0,BAO_0000366,,,,Autocuration,1,Cercopithecidae,,0,,U,,Half life in monkey plasma,A,Plasma
4654,1969.0,5819,9527.0,BAO_0000366,,,,Autocuration,1,Cercopithecidae,,0,,U,,Half life in monkey plasma; Not detected,A,Plasma
4655,,1916,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,
4656,,17509,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Half-life 24 hr after 2 mg/kg iv administration in monkeys,A,
4657,,1399,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Terminal half life of the compound.,A,
4658,,1916,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,
4659,,4809,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,
4660,,5546,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,,0,,U,,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,
4661,1088.0,3443,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,,0,,U,,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,Urine
4662,1088.0,3443,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,,0,,U,,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,Urine
4663,,4257,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,A,
4664,,6221,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,A,
4665,,5472,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Volume of distribution was evaluated in rhesus,A,
4666,,4727,10029.0,BAO_0000218,,,,Autocuration,1,Cricetulus griseus,In vivo,0,,U,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,A,
4667,,4727,10029.0,BAO_0000218,,,,Autocuration,1,Cricetulus griseus,In vivo,0,,U,,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,A,
4668,,4727,10029.0,BAO_0000218,,,,Autocuration,1,Cricetulus griseus,In vivo,0,,U,,Bioavailability in hamster was determined,A,
4669,,4727,10029.0,BAO_0000218,,,,Autocuration,1,Cricetulus griseus,In vivo,0,,U,,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,A,
4670,,4727,10029.0,BAO_0000218,,,,Autocuration,1,Cricetulus griseus,In vivo,0,,U,,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,A,
4671,178.0,4727,10029.0,BAO_0000221,,,,Autocuration,1,Cricetulus griseus,,0,,U,,Half life of compound was determined in hamster blood,A,Blood
4672,,1452,9823.0,BAO_0000019,,,,Autocuration,1,Sus scrofa,,0,,U,,Michaelis-Menten constant of the compound.,A,
4673,,1452,9823.0,BAO_0000019,,,,Autocuration,1,Sus scrofa,,0,,U,,Vmax value was measured at 0 uM concentration of silyl ether.,A,
4674,,1452,9823.0,BAO_0000019,,,,Autocuration,1,Sus scrofa,,0,,U,,Vmax value was measured at 10 uM concentration of silyl ether.,A,
4675,,1452,9823.0,BAO_0000019,,,,Autocuration,1,Sus scrofa,,0,,U,,Vmax value was measured at 5 uM concentration of silyl ether.,A,
4676,,11706,9606.0,BAO_0000357,,,,Expert,1,Homo sapiens,,9,,D,,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,B,
4677,,1916,9606.0,BAO_0000218,,,,Autocuration,1,Homo sapiens,,0,,U,,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,A,
4678,,17791,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Compound was evaluated for area under the curve expressed as (h*ug/ml),A,
4679,,7766,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Active metabolite of ifosfamide determined in humans; A-Active,A,
4680,,6567,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,A,
4681,,6567,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,A,
4682,,6567,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,A,
4683,,6567,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,A,
4684,,17791,9606.0,BAO_0000218,,,,Autocuration,1,Homo sapiens,,0,,U,,Compound was evaluated for oral bioavailability in human,A,
4685,1088.0,7766,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Metabolite of ifosfamide determined in urine; NF-Not found,A,Urine
4686,,6852,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),A,
4687,,6852,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,A,
4688,,6852,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,A,
4689,,6852,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,A,
4690,,6852,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,A,
4691,,6852,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),A,
4692,,6852,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Percent of compound in healthy individuals (Group D),A,
4693,2107.0,4397,9606.0,BAO_0000251,,,,Autocuration,1,Homo sapiens,,0,Microsomes,U,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,A,Liver
4694,,17409,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Binding towards human plasma protein at 10 uM,A,
4695,,17409,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Binding towards human plasma protein at 100 uM,A,
4696,,17176,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Human plasma protein binding activity was determined,A,
4697,,15444,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),A,
4698,,17267,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Percent binding of compound towards human plasma protein was determined,A,
4699,2107.0,5944,9606.0,BAO_0000251,,,,Autocuration,1,Homo sapiens,In vitro,0,Microsomes,U,,Plasma clearance in human liver microsomes,A,Liver
4700,2107.0,5668,9606.0,BAO_0000251,,,,Autocuration,1,Homo sapiens,In vitro,0,Microsomes,U,,In vitro intrinsic clearance in human liver microsome,A,Liver
4701,2107.0,5669,9606.0,BAO_0000251,,,,Autocuration,1,Homo sapiens,In vitro,0,Microsomes,U,,In vitro intrinsic clearance in human liver microsome,A,Liver
4702,,5041,9606.0,BAO_0000251,,,,Autocuration,1,Homo sapiens,In vitro,0,Microsomes,U,,In vitro microsome metabolism clearance in human was determined,A,
4703,,5041,9606.0,BAO_0000251,,,,Autocuration,1,Homo sapiens,In vitro,0,Microsomes,U,,In vitro microsome metabolism clearance in human was determined; High,A,
4704,,5041,9606.0,BAO_0000251,,,,Autocuration,1,Homo sapiens,In vitro,0,Microsomes,U,,In vitro microsome metabolism clearance in human was determined; ND denotes no data,A,
4705,2107.0,5676,9606.0,BAO_0000251,,,,Autocuration,1,Homo sapiens,In vitro,0,Microsomes,U,,Pharmacokinetic property (clearance) in human liver microsome,A,Liver
4706,2107.0,5944,9606.0,BAO_0000251,,,,Autocuration,1,Homo sapiens,In vitro,0,Microsomes,U,,Plasma clearance in human liver microsomes,A,Liver
4707,2107.0,17538,9606.0,BAO_0000251,,,,Autocuration,1,Homo sapiens,In vitro,0,Microsomes,U,,In vitro clearance in human liver microsomes,A,Liver
4708,2107.0,6331,9606.0,BAO_0000251,,,,Autocuration,1,Homo sapiens,In vitro,0,Microsomes,U,,Intrinsic clearance in human liver microsomes was determined,A,Liver
4709,2107.0,5948,9606.0,BAO_0000251,,,,Autocuration,1,Homo sapiens,In vitro,0,Microsomes,U,,Intrinsic clearance in human liver microsomes was determined,A,Liver
4710,,5965,9606.0,BAO_0000218,,,,Autocuration,1,Homo sapiens,In vivo,0,,U,,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,A,
4711,,1916,9606.0,BAO_0000218,,,,Autocuration,1,Homo sapiens,In vivo,0,,U,,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,A,
4712,,5965,9606.0,BAO_0000218,,,,Autocuration,1,Homo sapiens,,0,,U,,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,A,
4713,,1299,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Stability in human plasma 2 hr after incubation expressed as percent concentration,A,
4714,,1299,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Stability in human plasma 4 hr after incubation expressed as percent concentration,A,
4715,1088.0,7766,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,Urine
4716,1088.0,7766,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,Urine
4717,1088.0,7766,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,Urine
4718,1088.0,7766,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,Urine
4719,,17764,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,F,
4720,,17764,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,F,
4721,,17764,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,F,
4722,,17764,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,F,
4723,,14294,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),A,
4724,,14294,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),A,
4725,,14294,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),A,
4726,2107.0,6251,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,In vitro metabolic potential in mouse liver microsomes,A,Liver
4727,,17582,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Ability of compound to bind to plasma protein was evaluated in HSA cells,A,
4728,2369.0,17811,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),A,Adrenal gland
4729,955.0,17811,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,A,Brain
4730,955.0,17811,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,A,Brain
4731,,17811,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),A,
4732,2113.0,17811,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),A,Kidney
4733,,17811,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),A,
4734,,5288,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,A,
4735,1977.0,2717,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,A,Serum
4736,1977.0,2717,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,A,Serum
4737,1977.0,2717,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,A,Serum
4738,1969.0,17753,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Half life of compound was determined in plasma of mice at 24 mg/Kg,A,Plasma
4739,1969.0,17753,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Half life of compound was determined in plasma of mice at 40 mg/Kg,A,Plasma
4740,1969.0,17753,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Half life of compound was determined in plasma of mice at 5 mg/Kg,A,Plasma
4741,,17764,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Half life after intraperitoneal administration in mice at 18 uM/kg,F,
4742,,17764,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Half life after intraperitoneal administration in mice at 23 uM/kg,F,
4743,,17764,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Half life after intraperitoneal administration in mice at 25 uM/kg,F,
4744,,17764,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Half life after intraperitoneal administration in mice at 26 uM/kg,F,
4745,,17764,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Half life after intravenous administration in mice at 23 uM/kg,F,
4746,,17764,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Half life after intravenous administration in mice at 24 uM/kg,A,
4747,,16597,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,A,
4748,,2675,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,A,
4749,,2675,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Maximum time required to reach Cp max was evaluated in mice after oral administration,A,
4750,,16597,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),A,
4751,,4890,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",A,
4752,,429,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,A,
4753,178.0,17837,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,A,Blood
4754,,16597,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Half life at a dose of 10 mg/kg intravenous administration in mice.,A,
4755,,16597,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Half life at a dose of 10 mg/kg peroral administration in mice.,A,
4756,,6619,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Half life in ob/ob mice,A,
4757,,4066,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Half-life at a single subcutaneous administration of 40 mg/kg in mice,A,
4758,,4239,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Half-life was measured in mouse,A,
4759,,5969,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,A,
4760,,8999,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,A,
4761,,8999,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,A,
4762,955.0,17641,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,T2 in brain of mice at the oral dose of 50 mg/kg,A,Brain
4763,2113.0,17641,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,T2 in kidney of mice at the oral dose of 50 mg/kg,A,Kidney
4764,2107.0,17641,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,T2 in liver of mice at the oral dose of 50 mg/kg,A,Liver
4765,2048.0,17641,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,T2 in lungs of mice at the oral dose of 50 mg/kg,A,Lung
4766,2106.0,17641,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,T2 in spleen of mice at the oral dose of 50 mg/kg,A,Spleen
4767,,16597,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,A,
4768,,4890,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",A,
4769,,429,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,A,
4770,,429,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,A,
4771,,5969,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,A,
4772,,16913,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",F,
4773,,16913,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",F,
4774,,16913,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,
4775,,16913,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,
4776,,16913,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,
4777,,16913,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,
4778,,17270,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against A2780TAX cell line,F,
4779,,5618,9606.0,BAO_0000219,,,481.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro inhibitory activity against human tumor cell line A2780cis,F,
4780,,17777,9606.0,BAO_0000219,,,478.0,Expert,1,Homo sapiens,,1,,N,,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,F,
4781,,16112,9606.0,BAO_0000219,,,481.0,Intermediate,1,Homo sapiens,,1,,N,,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,F,
4782,,15748,9606.0,BAO_0000219,,,481.0,Intermediate,1,Homo sapiens,,1,,N,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),F,
4783,,6633,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,F,
4784,,16930,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,F,
4785,,17496,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,F,
4786,,12989,9606.0,BAO_0000219,,,478.0,Expert,1,Homo sapiens,,1,,N,,In vitro antitumor activity against A2780cisR cell line.,F,
4787,,4840,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),F,
4788,,12989,9606.0,BAO_0000219,,,478.0,Expert,1,Homo sapiens,,1,,N,,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,F,
4789,,16745,9606.0,BAO_0000219,,,481.0,Intermediate,1,Homo sapiens,,1,,N,,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,F,
4790,,16597,9606.0,BAO_0000219,,,478.0,Expert,1,Homo sapiens,,1,,N,,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,F,
4791,,16547,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,B,
4792,,16547,,BAO_0000019,,,,Expert,1,,,8,,H,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),F,
4793,,16547,10116.0,BAO_0000019,,,,Expert,1,Rattus norvegicus,,9,,D,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),F,
4794,,15856,9606.0,BAO_0000219,,,722.0,Expert,1,Homo sapiens,,9,,D,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,F,
4795,,15856,9606.0,BAO_0000219,,,722.0,Expert,1,Homo sapiens,,9,,D,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,F,
4796,,16547,10090.0,BAO_0000019,,,,Expert,1,Mus musculus,,9,,D,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,B,
4797,,16547,,BAO_0000019,,,,Expert,1,,,8,,H,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),F,
4798,,16547,10090.0,BAO_0000019,,,,Expert,1,Mus musculus,,9,,D,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),F,
4799,,17402,,BAO_0000357,,,,Expert,1,,,8,,H,,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,B,
4800,,11746,9606.0,BAO_0000219,,,574.0,Autocuration,1,Homo sapiens,,0,,U,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),F,
4801,,11746,9606.0,BAO_0000219,,,574.0,Autocuration,1,Homo sapiens,,0,,U,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,F,
4802,,5455,9606.0,BAO_0000219,,,455.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,F,
4803,,2068,9606.0,BAO_0000219,,,455.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,F,
4804,,2683,9606.0,BAO_0000219,,,455.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro antitumor activity against A375cell line extracted form melanoma,F,
4805,,15313,9606.0,BAO_0000219,,,455.0,Expert,1,Homo sapiens,,1,,N,,Inhibition of cell growth in (A375) melan cell line,F,
4806,,13739,9606.0,BAO_0000219,,,455.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,F,
4807,,13739,9606.0,BAO_0000219,,,455.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,F,
4808,,14750,9606.0,BAO_0000219,,,455.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,F,
4809,,14777,9606.0,BAO_0000219,,,797.0,Intermediate,1,Homo sapiens,,1,,N,,Antiproliferative activity measured against A427 human lung carcinoma,F,
4810,,14777,9606.0,BAO_0000219,,,797.0,Intermediate,1,Homo sapiens,,1,,N,,Antiproliferative activity measured against A427 human lung carcinoma,F,
4811,,17672,9606.0,BAO_0000219,,,797.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity against lung carcinoma A427 tumor cell lines,F,
4812,,14368,9606.0,BAO_0000219,,,797.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibition of large cell lung carcinoma (A427),F,
4813,,14368,9606.0,BAO_0000219,,,797.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,F,
4814,,13866,9606.0,BAO_0000219,,,797.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,F,
4815,,2545,9606.0,BAO_0000219,,,797.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory concentration in human lung carcinoma A427 cell line,F,
4816,,2545,9606.0,BAO_0000219,,,797.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory concentration in human lung carcinoma A427/VCR cell line,F,
4817,,6062,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,A,
4818,,4578,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Tested for volume of distribution upon iv administration to african green monkey,A,
4819,,17592,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Volume of distribution in monkey,A,
4820,,5005,9544.0,BAO_0000218,,,,Autocuration,1,Macaca mulatta,In vivo,0,,U,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,
4821,,5005,9544.0,BAO_0000218,,,,Autocuration,1,Macaca mulatta,In vivo,0,,U,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,A,
4822,,5922,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Pharmacokinetic property(Vdss) in cynomolgus monkey,A,
4823,,5355,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,The distribution volume after intravenous administration in cynomolgus monkeys,A,
4824,,5355,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,A,
4825,,5355,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,A,
4826,,6057,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Volume displacement was calculated in rhesus monkey,A,
4827,,5145,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Volume of distribution in steady state was determined in rhesus monkey,A,
4828,,6821,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Volume of distribution of compound was determined in monkey,A,
4829,,5334,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,
4830,,5334,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,
4831,,6641,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,
4832,,2661,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,
4833,,6535,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Volume distribution in monkey after administration of 1 mg/kg iv,A,
4834,,4809,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,
4835,,6062,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,A,
4836,,3443,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,
4837,,4578,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Oral systemic bioavailability upon iv administration to african green monkey,A,
4838,,4809,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,
4839,,11271,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Baboon plasma free fraction. ,A,
4840,,6057,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,,0,,U,,Area under the curve was calculated in rhesus monkey after iv administration,A,
4841,,6057,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Area under the curve was calculated in rhesus monkey after peroral administration,A,
4842,,17853,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,A,
4843,,5302,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Half life period in monkey after 5 mg/kg dose,A,
4844,,4257,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Half-life was determined in monkey after 3 mg/kg of i.v. dose,A,
4845,,4257,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,A,
4846,1969.0,13501,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,A,Plasma
4847,,5394,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,A,
4848,,2661,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,
4849,,3341,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Compound was evaluated for terminal half life in monkey,A,
4850,,3045,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,A,
4851,1969.0,5005,9544.0,BAO_0000218,,,,Autocuration,1,Macaca mulatta,In vivo,0,,U,,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,Plasma
4852,,4847,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Half life of compound was determined in squirrel monkey,A,
4853,,4256,9541.0,BAO_0000218,,,,Autocuration,1,Macaca fascicularis,In vivo,0,,U,,Half life after iv administration in cynomolgus monkey,A,
4854,1969.0,6535,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Half life in monkey plasma after administration of 1 mg/kg iv,A,Plasma
4855,,6057,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Half life was calculated in rhesus monkey,A,
4856,,17592,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Half life in monkey,A,
4857,,6641,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,
4858,,5472,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Half life was evaluated in rhesus,A,
4859,,6221,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Half life period after oral administration (2.5 mg/kg) in monkey was determined,A,
4860,,5668,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Half life period was determine after peroral administration at 10 mpk in Rhesus,A,
4861,,4809,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,
4862,,5546,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,
4863,,5553,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,A,
4864,,6078,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Half-life was calculated in monkey,A,
4865,,5147,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Half-life in Squirrel monkey,A,
4866,,5145,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Half-life in rhesus monkey,A,
4867,,6062,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Half-life was measured in monkey after an iv dose of 1 mg/kg,A,
4868,,5355,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Half-life period after intravenous administration in cynomolgus monkeys,A,
4869,,5355,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Half-life period after oral administration in cynomolgus monkeys,A,
4870,,5355,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,A,
4871,1088.0,7766,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,Urine
4872,1088.0,7766,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,Urine
4873,1088.0,7766,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,Urine
4874,1088.0,7766,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,Urine
4875,1088.0,7766,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,A,Urine
4876,1088.0,7766,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,A,Urine
4877,1088.0,7766,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,A,Urine
4878,1088.0,7766,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,A,Urine
4879,,1916,9606.0,BAO_0000218,,,,Autocuration,1,Homo sapiens,In vivo,0,,U,,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,A,
4880,,16643,9606.0,BAO_0000218,,,,Autocuration,1,Homo sapiens,In vivo,0,,U,,Oral bioavailability in human,A,
4881,,17248,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Compound was tested for human plasma protein binding,A,
4882,,17248,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Compound was tested for human plasma protein binding; Not determined,A,
4883,,6241,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Protein binding activity of compound in human plasma; % Free,A,
4884,,17716,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Unbound fraction (plasma),A,
4885,1969.0,17605,9606.0,BAO_0000366,,,,Autocuration,1,Homo sapiens,,0,,U,,Half life for the hydrolysis of compound in human blood serum,A,Plasma
4886,1969.0,17625,9606.0,BAO_0000366,,,,Autocuration,1,Homo sapiens,,0,,U,,Half life period in human plasma using phosphate buffer (0.08 M),A,Plasma
4887,1969.0,17625,9606.0,BAO_0000366,,,,Autocuration,1,Homo sapiens,,0,,U,,Half life period in human plasma using phosphate buffer (0.1 M),A,Plasma
4888,1969.0,17747,9606.0,BAO_0000366,,,,Autocuration,1,Homo sapiens,,0,,U,,Half-life in human plasma was determined,A,Plasma
4889,,15613,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,A,
4890,,354,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),A,
4891,,3741,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",A,
4892,,3741,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",A,
4893,,3741,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",A,
4894,,17599,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Partition coefficient (logP),A,
4895,,5486,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,In vitro metabolic stability in human was measured as pmol/min/mg/protein,A,
4896,,5600,9606.0,BAO_0000251,,,,Autocuration,1,Homo sapiens,,0,Microsomes,U,,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,A,
4897,,14294,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),A,
4898,,14294,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),A,
4899,,14294,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),A,
4900,,14294,9606.0,BAO_0000251,,,,Autocuration,1,Homo sapiens,,0,Microsomes,U,,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),A,
4901,,14294,9606.0,BAO_0000251,,,,Autocuration,1,Homo sapiens,,0,Microsomes,U,,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),A,
4902,,14294,9606.0,BAO_0000251,,,,Autocuration,1,Homo sapiens,,0,Microsomes,U,,Metabolism of compound in human microsomes; Trace,A,
4903,2107.0,6260,9606.0,BAO_0000251,,,,Autocuration,1,Homo sapiens,,0,Microsomes,U,,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,A,Liver
4904,,6187,9606.0,BAO_0000251,,,,Autocuration,1,Homo sapiens,,0,Microsomes,U,,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,A,
4905,2107.0,6251,9606.0,BAO_0000251,,,,Autocuration,1,Homo sapiens,,0,Microsomes,U,,In vitro metabolic potential in human liver microsomes,A,Liver
4906,,3246,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,A,
4907,,17313,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Tested for human plasma protein binding of the compound; Not tested,A,
4908,,6227,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Compound was tested for percent protein binding (PB) in human,A,
4909,1969.0,5530,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Protein binding in human plasma,A,Plasma
4910,,6108,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Permeability coefficient (B to A) in Caco-2 cell,A,
4911,,6108,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,A,
4912,,2774,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),A,
4913,,16643,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,In vitro rate of absorption observed as Caco-2 permeability in humans,A,
4914,,17582,9606.0,BAO_0000219,,,495.0,Autocuration,1,Homo sapiens,,0,,U,,Cellular permeability of compound was determined in Caco-2 cells; High,A,
4915,,6838,9606.0,BAO_0000219,,,495.0,Autocuration,1,Homo sapiens,,0,,U,,Permeability in Caco-2 cells of compound,A,
4916,,6108,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Permeability coefficient (A to B) in Caco-2 cell,A,
4917,,6108,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Permeability coefficient (B to A) in Caco-2 cell,A,
4918,,6108,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Permeability coefficient (Papp) (Caco-2 cell monolayer),A,
4919,,2146,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,A,
4920,,4514,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Compound was tested for protein binding in human plasma,A,
4921,,6108,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,A,
4922,1088.0,7766,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,A,Urine
4923,,5969,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,A,
4924,,3277,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,
4925,,3802,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,A,
4926,1969.0,2862,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Time taken to reach maximum concentration in plasma upon oral administration in mouse,A,Plasma
4927,1969.0,6348,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,Plasma
4928,,17764,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Tmax after intraperitoneal administration in mice at 23 uM/kg,F,
4929,,5781,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Tmax after oral administration at 30 mg/kg in ICR mouse,A,
4930,,17764,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Tmax after peroral administration in mice at 2.4 uM/kg,A,
4931,,4066,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Tmax at a single subcutaneous administration of 40 mg/kg in mice,A,
4932,955.0,17641,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Tmax in brain of mice at the oral dose of 50 mg/kg,A,Brain
4933,2113.0,17641,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Tmax in kidney of mice at the oral dose of 50 mg/kg,A,Kidney
4934,2107.0,17641,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Tmax in liver of mice at the oral dose of 50 mg/kg,A,Liver
4935,2048.0,17641,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Tmax in lungs of mice at the oral dose of 50 mg/kg,A,Lung
4936,,17764,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Tmax in mice at 18 uM/kg i.p. administration,F,
4937,,17764,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Tmax in mice at 23 uM/kg i.v. administration,F,
4938,,17764,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Tmax in mice at 25 uM/kg i.p. administration,F,
4939,,17764,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Tmax in mice at 26 uM/kg i.p. administration,F,
4940,2106.0,17641,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Tmax in spleen of mice at the oral dose of 50 mg/kg,A,Spleen
4941,,16597,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,A,
4942,,16597,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Tmax value at a dose of 10 mg/kg peroral administration in mice.,A,
4943,,5951,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Tmax value in IRC mice,A,
4944,,5506,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,A,
4945,,5506,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,A,
4946,1088.0,429,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),A,Urine
4947,1088.0,429,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),A,Urine
4948,1088.0,4066,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),A,Urine
4949,,17734,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,
4950,,17734,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,
4951,,6062,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,A,
4952,,5969,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,A,
4953,,5969,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,A,
4954,,5969,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,
4955,,5980,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Vd in mice,A,
4956,,17592,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Volume of distribution in mouse,A,
4957,,6348,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,
4958,,17753,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Volume of distribution of compound in plasma was determined at 24 mg/Kg,A,
4959,,17753,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Volume of distribution of compound in plasma was determined at 40 mg/Kg,A,
4960,,17753,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Volume of distribution of compound in plasma was determined at 5 mg/Kg,A,
4961,,4239,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Pharmacokinetic property (vdss) was measured in mouse,A,
4962,,2862,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Value distribution upon iv administration in mouse,A,
4963,,17734,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,
4964,,2675,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Volume of distribution was evaluated in mice after intravenous administration,A,
4965,,2675,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Volume of distribution was evaluated in mice after oral administration,A,
4966,,17837,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,A,
4967,,5727,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Steady state volume of distribution was determined in mice,A,
4968,,17852,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Volume distribution (steady state) of compound was determined in mouse,A,
4969,,17764,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,A,
4970,,16597,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Vss value at a dose of 10 mg/kg intravenous administration in mice.,A,
4971,,6062,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,A,
4972,2113.0,16438,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of compound (oxidized form) in in kidney tissue,A,Kidney
4973,178.0,16438,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,Blood
4974,178.0,16438,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,Blood
4975,178.0,16438,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,Blood
4976,,10708,9606.0,BAO_0000219,,,797.0,Intermediate,1,Homo sapiens,,1,,N,,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,F,
4977,,16597,9606.0,BAO_0000219,,,500.0,Expert,1,Homo sapiens,,1,,N,,Inhibition of A431 human squamous cell carcinoma cell proliferation,F,
4978,,16062,9606.0,BAO_0000219,,,500.0,Expert,1,Homo sapiens,,1,,N,,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,F,
4979,,16062,9606.0,BAO_0000219,,,500.0,Expert,1,Homo sapiens,,1,,N,,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,F,
4980,,16958,9606.0,BAO_0000219,,,500.0,Expert,1,Homo sapiens,,1,,N,,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,F,
4981,,6700,9606.0,BAO_0000219,,,500.0,Expert,1,Homo sapiens,,1,,N,,Inhibition of A431 human carcinoma cell proliferation,F,
4982,,17226,9606.0,BAO_0000219,,,500.0,Expert,1,Homo sapiens,,1,,N,,In vitro inhibition of A431 (human carcinoma) cell basal growth.,F,
4983,,6828,9606.0,BAO_0000219,,,500.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,F,
4984,,12314,9606.0,BAO_0000219,,,500.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against epidermoid carcinoma cell line,F,
4985,,13412,9606.0,BAO_0000218,,,500.0,Expert,1,Homo sapiens,,9,,D,,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",F,
4986,,13299,9606.0,BAO_0000219,,,500.0,Intermediate,1,Homo sapiens,,1,,N,,Antiproliferative activity of compound was measured on human tumor cell line A431.,F,
4987,,17420,9606.0,BAO_0000219,,,500.0,Intermediate,1,Homo sapiens,,1,,N,,Antiproliferative effect of compound on A431 cell line expressing mutant p53,F,
4988,,13678,9606.0,BAO_0000219,,,500.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,F,
4989,,14171,,BAO_0000219,,,500.0,Expert,1,,,8,,H,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,F,
4990,,6333,9606.0,BAO_0000219,,,500.0,Expert,1,Homo sapiens,,1,,N,,Tested for antiproliferative activity against human A431 cells,F,
4991,,2356,9606.0,BAO_0000219,,,500.0,Expert,1,Homo sapiens,,9,,D,,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,F,
4992,,15578,9606.0,BAO_0000219,,,500.0,Expert,1,Homo sapiens,,1,,N,,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,F,
4993,,5126,9606.0,BAO_0000219,,,500.0,Expert,1,Homo sapiens,,1,,N,,Inhibition of A431 cell proliferation,F,
4994,,6844,9606.0,BAO_0000219,,,500.0,Expert,1,Homo sapiens,,1,,N,,Cytotoxic effect on A431 human epidermoid carcinoma cells,F,
4995,,6844,9606.0,BAO_0000219,,,500.0,Expert,1,Homo sapiens,,1,,N,,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),F,
4996,,4925,9606.0,BAO_0000219,,,500.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,F,
4997,,4925,9606.0,BAO_0000219,,,500.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,F,
4998,,13978,9606.0,BAO_0000219,,,500.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,F,
4999,,16786,9606.0,BAO_0000219,,,500.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,F,
5000,,13412,,BAO_0000219,,,500.0,Expert,1,,,8,,H,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,F,
5001,,17824,9606.0,BAO_0000218,,,500.0,Intermediate,1,Homo sapiens,,1,,N,,In vivo antiproliferative activity against A431 cell line,F,
5002,,12751,9606.0,BAO_0000219,,,500.0,Expert,1,Homo sapiens,,9,,D,,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,F,
5003,,12380,9606.0,BAO_0000219,,,500.0,Expert,1,Homo sapiens,,1,,N,,Inhibition of A431 human epidermoid carcinoma cell proliferation,F,
5004,,4959,9606.0,BAO_0000219,,,500.0,Expert,1,Homo sapiens,,9,,D,,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,F,
5005,,6333,9606.0,BAO_0000219,,,500.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),F,
5006,,6333,9606.0,BAO_0000219,,,500.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),F,
5007,,6333,9606.0,BAO_0000219,,,500.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),F,
5008,,5296,9606.0,BAO_0000019,,,,Expert,1,Homo sapiens,,9,,D,,Inhibition of EGFR overexpressing A431 cell proliferation,F,
5009,,12624,9606.0,BAO_0000219,,,500.0,Expert,1,Homo sapiens,,1,,N,,Inhibition of A431 cell proliferation,F,
5010,,14926,9606.0,BAO_0000219,,,500.0,Expert,1,Homo sapiens,,9,,D,,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,F,
5011,,14926,9606.0,BAO_0000219,,,500.0,Expert,1,Homo sapiens,,9,,D,,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",F,
5012,,14926,,BAO_0000219,,,500.0,Expert,1,,,8,,H,,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),F,
5013,,15144,9606.0,BAO_0000219,,,500.0,Intermediate,1,Homo sapiens,,1,,N,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,F,
5014,,15144,9606.0,BAO_0000219,,,500.0,Intermediate,1,Homo sapiens,,1,,N,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,F,
5015,,5245,9606.0,BAO_0000219,,,500.0,Intermediate,1,Homo sapiens,,1,,N,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,F,
5016,,5245,9606.0,BAO_0000219,,,500.0,Intermediate,1,Homo sapiens,,1,,N,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,F,
5017,,5245,9606.0,BAO_0000219,,,500.0,Intermediate,1,Homo sapiens,,1,,N,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,F,
5018,,5245,9606.0,BAO_0000219,,,500.0,Intermediate,1,Homo sapiens,,1,,N,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,F,
5019,,5245,9606.0,BAO_0000219,,,500.0,Intermediate,1,Homo sapiens,,1,,N,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,F,
5020,,5922,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Half-life period in cynomolgus monkey,A,
5021,1969.0,1116,9527.0,BAO_0000366,,,,Autocuration,1,Cercopithecidae,In vitro,0,,U,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",A,Plasma
5022,,17853,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Longer half-life in monkey (i.v.) at 0.5 mpk,A,
5023,1969.0,993,9527.0,BAO_0000366,,,,Autocuration,1,Cercopithecidae,,0,,U,,Plasma half life in monkey,A,Plasma
5024,1969.0,4514,9527.0,BAO_0000366,,,,Autocuration,1,Cercopithecidae,,0,,U,,Plasma half-life in rhesus monkey,A,Plasma
5025,1969.0,5334,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,Plasma
5026,1969.0,5334,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,Plasma
5027,,4578,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Tested for half life upon iv administration to african green monkey,A,
5028,,2661,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,
5029,,5355,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,A,
5030,,5355,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,A,
5031,,5355,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,The time for peak concentration value after oral administration in cynomolgus monkeys,A,
5032,,11271,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,A,
5033,,11271,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,A,
5034,,11271,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,A,
5035,,11271,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,A,
5036,,11271,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,A,
5037,,11271,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,A,
5038,,11271,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,A,
5039,,11271,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,A,
5040,,11271,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,A,
5041,,11271,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,A,
5042,,11271,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,A,
5043,,11271,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,A,
5044,,11271,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,A,
5045,,11271,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,A,
5046,,11271,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,A,
5047,,11271,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,A,
5048,,5809,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,In vivo,1,,N,,Bioavailability in rat (cannulated) (dose 2 mg/kg),A,
5049,1969.0,17720,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,In vivo,1,,N,,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,A,Plasma
5050,1969.0,3546,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,,1,,N,,AUC value in rat after IV administration at a dose of 10 mg/kg,A,Plasma
5051,1969.0,3546,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,,1,,N,,AUC value in rat after oral administration at a dose of 10 mg/kg,A,Plasma
5052,,3546,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,In vivo,1,,N,,Cmax value in rat after oral administration at a dose of 10 mg/kg,A,
5053,,3546,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,In vivo,1,,N,,Bioavailability in rat after oral administration at a dose of 10 mg/kg,A,
5054,,3546,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,In vivo,1,,N,,Tmax value in rat after oral administration at a dose of 10 mg/kg,A,
5055,,3546,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,,1,,N,,Vc value in rat after IV administration at a dose of 10 mg/kg,A,
5056,,3546,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,In vivo,1,,N,,Half life period in rat after IV administration at a dose of 10 mg/kg,A,
5057,,10625,9557.0,BAO_0000019,,,,Autocuration,1,Papio hamadryas,,0,,U,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,A,
5058,,10625,9557.0,BAO_0000019,,,,Autocuration,1,Papio hamadryas,,0,,U,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),A,
5059,,10625,9557.0,BAO_0000019,,,,Autocuration,1,Papio hamadryas,,0,,U,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),A,
5060,,10625,9557.0,BAO_0000019,,,,Autocuration,1,Papio hamadryas,,0,,U,,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,A,
5061,,10625,9557.0,BAO_0000019,,,,Autocuration,1,Papio hamadryas,,0,,U,,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,A,
5062,,10625,9557.0,BAO_0000019,,,,Autocuration,1,Papio hamadryas,,0,,U,,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,A,
5063,,10625,9557.0,BAO_0000019,,,,Autocuration,1,Papio hamadryas,,0,,U,,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,A,
5064,,10625,9557.0,BAO_0000019,,,,Autocuration,1,Papio hamadryas,,0,,U,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,A,
5065,,3510,9615.0,BAO_0000019,,,,Autocuration,1,beagle,,0,,U,,Area under curve after 1 mpk peroral administration to beagles,A,
5066,,3510,9615.0,BAO_0000019,,,,Autocuration,1,beagle,,0,,U,,Area under curve after 2 mpk peroral administration to beagles,A,
5067,,3510,9615.0,BAO_0000218,,,,Autocuration,1,beagle,In vivo,0,,U,,Cmax value after 1 mpk peroral administration to beagles,A,
5068,1088.0,7766,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,A,Urine
5069,1088.0,7766,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,A,Urine
5070,1088.0,7766,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,A,Urine
5071,1088.0,7766,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,A,Urine
5072,1088.0,7766,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,A,Urine
5073,1088.0,7766,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,A,Urine
5074,1088.0,7766,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,A,Urine
5075,2107.0,16643,9606.0,BAO_0000251,,,,Autocuration,1,Homo sapiens,,0,Microsomes,U,,Metabolic stability observed at 30 min after administration in human liver microsomes,A,Liver
5076,,6852,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,A,
5077,,6852,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,A,
5078,,6852,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,A,
5079,2107.0,6567,9606.0,BAO_0000251,,,,Autocuration,1,Homo sapiens,,0,Microsomes,U,,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",A,Liver
5080,,6570,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Metabolic stability (% remaining at 30 mins) in human S9.,A,
5081,,6570,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,A,
5082,2107.0,5237,9606.0,BAO_0000251,,,,Autocuration,1,Homo sapiens,,0,Microsomes,U,,Percent parent compound remaining after 20 min incubation with human liver microsomes,A,Liver
5083,2107.0,5237,9606.0,BAO_0000251,,,,Autocuration,1,Homo sapiens,,0,Microsomes,U,,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,A,Liver
5084,2107.0,5237,9606.0,BAO_0000251,,,,Autocuration,1,Homo sapiens,,0,Microsomes,U,,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,A,Liver
5085,,5202,9606.0,BAO_0000218,,,,Autocuration,1,Homo sapiens,,0,,U,,First pass metabolism and metabolic bioavailability using human hepatic microsomes,A,
5086,,5481,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,A,
5087,,5481,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Percent remaining in human plasma after incubation for 60 min at 37 C.,A,
5088,,3956,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,The percent remaining in human plasma after 30 min was determined,A,
5089,1969.0,5074,9606.0,BAO_0000366,,,,Autocuration,1,Homo sapiens,,0,,U,,Conversion rate of the prodrug in human plasma,A,Plasma
5090,1969.0,5074,9606.0,BAO_0000366,,,,Autocuration,1,Homo sapiens,,0,,U,,Conversion rate of the prodrug in human plasma; ND means no data,A,Plasma
5091,178.0,4727,9606.0,BAO_0000221,,,,Autocuration,1,Homo sapiens,,0,,U,,Half life of compound was determined in human blood,A,Blood
5092,,5965,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Half life of compound was determined in man with once daily dosing,A,
5093,,5732,9606.0,BAO_0000251,,,,Autocuration,1,Homo sapiens,In vitro,0,Microsomes,U,,Half life in human microsomes,A,
5094,1969.0,5819,9606.0,BAO_0000366,,,,Autocuration,1,Homo sapiens,,0,,U,,Half life in human plasma,A,Plasma
5095,1969.0,5819,9606.0,BAO_0000366,,,,Autocuration,1,Homo sapiens,,0,,U,,Half life in human plasma; Not detected,A,Plasma
5096,,1916,9606.0,BAO_0000218,,,,Autocuration,1,Homo sapiens,In vivo,0,,U,,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,A,
5097,2107.0,6597,9606.0,BAO_0000251,,,,Autocuration,1,Homo sapiens,In vitro,0,Microsomes,U,,Half-life for oxidative metabolic stability was determined using rat liver microsomes,A,Liver
5098,1969.0,5229,9606.0,BAO_0000366,,,,Autocuration,1,Homo sapiens,,0,,U,,Half-life in human plasma,A,Plasma
5099,1969.0,5229,9606.0,BAO_0000366,,,,Autocuration,1,Homo sapiens,,0,,U,,Half-life of the parent prodrug in plasma,A,Plasma
5100,1969.0,2192,9606.0,BAO_0000366,,,,Autocuration,1,Homo sapiens,In vitro,0,,U,,In vitro half life in human plasma was determined,A,Plasma
5101,2107.0,3032,9606.0,BAO_0000251,,,,Autocuration,1,Homo sapiens,In vitro,0,Microsomes,U,,The compound was tested In Vitro for half life in human liver microsomes.,A,Liver
5102,,1916,9606.0,BAO_0000218,,,,Autocuration,1,Homo sapiens,In vivo,0,,U,,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,A,
5103,,17716,9606.0,BAO_0000218,,,,Autocuration,1,Homo sapiens,In vivo,0,,U,,Observed volume of distribution,A,
5104,,15778,9606.0,BAO_0000218,,,,Autocuration,1,Homo sapiens,In vivo,0,,U,,Oral bioavailability in human,A,
5105,,17313,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Tested for human plasma protein binding of the compound,A,
5106,,4231,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,"First order rate constant, k was determined in human plasma",A,
5107,,4755,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Observed rate constant in 80% human plasma at 37 degree Centigrade,A,
5108,,4755,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Observed rate constant in 80% human plasma at 37 degree Centigrade,A,
5109,2107.0,16907,9606.0,BAO_0000251,,,,Autocuration,1,Homo sapiens,,0,Microsomes,U,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,A,Liver
5110,,10839,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,The compound was tested for the plasma binding in human,A,
5111,,10839,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Plasma protein binding (human),A,
5112,2107.0,3199,9606.0,BAO_0000251,,,,Autocuration,1,Homo sapiens,In vitro,0,Microsomes,U,,Compound was evaluated for half-life in human liver microsomes,A,Liver
5113,178.0,1345,9606.0,BAO_0000221,,,,Autocuration,1,Homo sapiens,In vitro,0,,U,,Half life measured in vitro for its stability in human blood,A,Blood
5114,1977.0,4297,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Half life in human serum,A,Serum
5115,1977.0,4297,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Half life in human serum; ND=not determined,A,Serum
5116,,4297,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Half life were determined in CEM-SS cell extract in decomposition step 1,A,
5117,,4297,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Half life were determined in CEM-SS cell extract in decomposition step 2,A,
5118,1969.0,4231,9606.0,BAO_0000366,,,,Autocuration,1,Homo sapiens,,0,,U,,Half life of the in human plasma,A,Plasma
5119,,5633,9606.0,BAO_0000220,,,,Autocuration,1,Homo sapiens,In vitro,0,S9,U,,Half life period in human hepatic S9 fraction was determined,A,
5120,2107.0,5633,9606.0,BAO_0000251,,,,Autocuration,1,Homo sapiens,In vitro,0,Microsomes,U,,Half life period in human liver microsome was determined,A,Liver
5121,,17791,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Half life period was determined; 6-7,A,
5122,,17791,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Half life period was evaluated in human,A,
5123,1969.0,3160,9606.0,BAO_0000366,,,,Autocuration,1,Homo sapiens,,0,,U,,Half life time in human plasma,A,Plasma
5124,955.0,16438,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,Brain
5125,948.0,16438,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,Heart
5126,948.0,16438,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,Heart
5127,2113.0,16438,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,Kidney
5128,2113.0,16438,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,Kidney
5129,2113.0,16438,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,Kidney
5130,2107.0,16438,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,Liver
5131,2107.0,16438,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,Liver
5132,2107.0,16438,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,Liver
5133,2106.0,16438,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,Spleen
5134,2106.0,16438,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,Spleen
5135,2106.0,16438,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,Spleen
5136,955.0,16438,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,Brain
5137,178.0,16438,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of compound (oxidized form) in blood tissue,A,Blood
5138,178.0,16438,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,Blood
5139,178.0,16438,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,Blood
5140,178.0,16438,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,Blood
5141,178.0,16438,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,Blood
5142,178.0,16438,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,Blood
5143,955.0,16438,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of compound (oxidized form) in brain tissue of mice,A,Brain
5144,955.0,16438,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,Brain
5145,955.0,16438,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,Brain
5146,955.0,16438,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,Brain
5147,955.0,16438,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,Brain
5148,955.0,16438,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,Brain
5149,948.0,16438,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of compound (oxidized form) in heart tissue of mice,A,Heart
5150,948.0,16438,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,Heart
5151,948.0,16438,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,Heart
5152,948.0,16438,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,Heart
5153,948.0,16438,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,Heart
5154,948.0,16438,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,Heart
5155,2113.0,16438,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,Kidney
5156,2113.0,16438,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,Kidney
5157,2113.0,16438,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,Kidney
5158,2113.0,16438,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,Kidney
5159,2113.0,16438,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,Kidney
5160,2107.0,16438,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of compound (oxidized form) in liver tissue,A,Liver
5161,2107.0,16438,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,Liver
5162,2107.0,16438,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,Liver
5163,,5245,9606.0,BAO_0000219,,,500.0,Intermediate,1,Homo sapiens,,1,,N,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,F,
5164,,5245,9606.0,BAO_0000219,,,500.0,Intermediate,1,Homo sapiens,,1,,N,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,F,
5165,,16289,,BAO_0000218,,,500.0,Expert,1,,,1,,N,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",F,
5166,,16289,,BAO_0000218,,,500.0,Expert,1,,,1,,N,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",F,
5167,,16093,9606.0,BAO_0000219,,,500.0,Expert,1,Homo sapiens,,9,,D,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,F,
5168,,16825,9606.0,BAO_0000219,,,500.0,Intermediate,1,Homo sapiens,,1,,N,,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",F,
5169,,4848,9606.0,BAO_0000219,,,500.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,F,
5170,,14827,9606.0,BAO_0000219,,,500.0,Expert,1,Homo sapiens,,9,,D,,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,F,
5171,,14827,9606.0,BAO_0000219,,,500.0,Expert,1,Homo sapiens,,9,,D,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,F,
5172,,16289,,BAO_0000218,,,500.0,Expert,1,,,1,,N,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",F,
5173,,16289,,BAO_0000218,,,500.0,Expert,1,,,1,,N,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",F,
5174,,16289,,BAO_0000218,,,500.0,Expert,1,,,1,,N,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",F,
5175,,16289,,BAO_0000218,,,500.0,Expert,1,,,1,,N,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",F,
5176,,16289,,BAO_0000218,,,500.0,Expert,1,,,1,,N,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",F,
5177,,16289,9606.0,BAO_0000219,,,500.0,Expert,1,Homo sapiens,,9,,D,,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",F,
5178,,16289,,BAO_0000219,,,500.0,Expert,1,,,8,,H,,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,F,
5179,,16289,,BAO_0000218,,,500.0,Expert,1,,,1,,N,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",F,
5180,,16289,,BAO_0000218,,,500.0,Expert,1,,,1,,N,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",F,
5181,,16289,,BAO_0000218,,,500.0,Expert,1,,,1,,N,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",F,
5182,,14555,10090.0,BAO_0000218,,,500.0,Expert,1,Mus musculus,,1,,N,,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",F,
5183,,14555,10090.0,BAO_0000218,,,500.0,Expert,1,Mus musculus,,1,,N,,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",F,
5184,,14555,10090.0,BAO_0000218,,,500.0,Expert,1,Mus musculus,,1,,N,,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",F,
5185,,14555,10090.0,BAO_0000218,,,500.0,Expert,1,Mus musculus,,1,,N,,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",F,
5186,,1937,9606.0,BAO_0000219,,,500.0,Expert,1,Homo sapiens,,1,,N,,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,F,
5187,,13739,9606.0,BAO_0000219,,,500.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,F,
5188,,3558,9606.0,BAO_0000219,,,500.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,F,
5189,,3558,9606.0,BAO_0000219,,,500.0,Intermediate,1,Homo sapiens,,1,,N,,Dose giving a 50% decrease in the living cell number (A437 cells),F,
5190,,17686,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,In vitro inhibitory concentration against proliferation of A459 cell line.,F,
5191,,5305,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,F,
5192,,3614,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,F,
5193,,17229,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro antitumor activity against renal A498 tumor cell lines,F,
5194,,15935,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",F,
5195,,15935,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",F,
5196,,15560,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,F,
5197,,13891,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,F,
5198,,13891,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,F,
5199,,13788,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity on kidney carcinoma (A-498) cell line,F,
5200,,15403,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was evaluated against Human cell line renal A498,F,
5201,,1009,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for inhibition of A498 human renal cancer cell line,F,
5202,,1043,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,Growth inhibitory activity against A498 human cancer cell line,F,
5203,,5858,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro antitumor activity against human renal A498 cell line,F,
5204,,5958,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxic activity against renal (A498) cell line,F,
5205,,5506,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxic activity against human renal cancer (A498) cell line,F,
5206,,12781,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,Tested for cytostatic activity against renal A498 cell line,F,
5207,,14399,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,F,
5208,,5958,9606.0,BAO_0000219,,,624.0,Expert,1,Homo sapiens,,1,,N,,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,F,
5209,,3510,9615.0,BAO_0000218,,,,Autocuration,1,beagle,In vivo,0,,U,,Cmax value after 2 mpk peroral administration to beagles,A,
5210,,3510,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,0,,U,beagle,Bioavailability,A,
5211,,3510,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,0,,U,beagle,Bioavailability after 1 mpk peroral administration to beagles,A,
5212,,3510,9615.0,BAO_0000218,,,,Autocuration,1,Canis lupus familiaris,In vivo,0,,U,beagle,Bioavailability after 2 mpk peroral administration to beagles,A,
5213,,3085,9913.0,BAO_0000019,,,,Autocuration,1,Bos taurus,,0,,U,,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,A,
5214,,3085,9913.0,BAO_0000019,,,,Autocuration,1,Bos taurus,,0,,U,,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,A,
5215,,3085,9913.0,BAO_0000019,,,,Autocuration,1,Bos taurus,,0,,U,,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,A,
5216,,9372,9913.0,BAO_0000019,,,,Autocuration,1,Bos taurus,,0,,U,,Solubility against bovine alpha-chymotrypsin,A,
5217,,3085,9913.0,BAO_0000019,,,,Autocuration,1,Bos taurus,,0,,U,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,A,
5218,,3085,9913.0,BAO_0000019,,,,Autocuration,1,Bos taurus,,0,,U,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,A,
5219,2106.0,1469,9913.0,BAO_0000221,,,,Autocuration,1,Bos taurus,,0,,U,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,A,Spleen
5220,,4297,9913.0,BAO_0000019,,,,Autocuration,1,Bos taurus,,0,,U,,Half life in culture medium containing 10% of heat inactivated foetal calf serum,A,
5221,,4297,9913.0,BAO_0000019,,,,Autocuration,1,Bos taurus,,0,,U,,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,A,
5222,,17585,9913.0,BAO_0000019,,,,Autocuration,1,Bos taurus,,0,,U,,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,A,
5223,2106.0,1336,9913.0,BAO_0000221,,,,Autocuration,1,Bos taurus,,0,,U,,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,A,Spleen
5224,,3085,9913.0,BAO_0000019,,,,Autocuration,1,Bos taurus,,0,,U,,Half life in presence of 2 mg/mL BSA at pH 8.8,A,
5225,,2857,9913.0,BAO_0000019,,,,Autocuration,1,Bos taurus,,0,,U,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,A,
5226,,2857,9913.0,BAO_0000019,,,,Autocuration,1,Bos taurus,,0,,U,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,A,
5227,,2857,9913.0,BAO_0000019,,,,Autocuration,1,Bos taurus,,0,,U,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,A,
5228,,1540,9913.0,BAO_0000019,,,,Autocuration,1,Bos taurus,,0,,U,,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),A,
5229,1969.0,6316,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,A,Plasma
5230,1969.0,17594,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,AUC after administration at 100 mg/kg/day in dogs,A,Plasma
5231,1969.0,4953,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,AUC in dog at 0-24 hr by peroral administration at 3 mpk,A,Plasma
5232,1969.0,16907,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,AUC value after 15 mg/kg iv dose in Dogs,A,Plasma
5233,1969.0,16907,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,AUC value after 30 mg/kg po dose in Dogs,A,Plasma
5234,1969.0,2959,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,AUC value after administration of 4 mg/Kg oral dose in dog,A,Plasma
5235,1969.0,17594,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,A,Plasma
5236,,5356,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,A,
5237,,16807,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,A,
5238,,4527,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,A,
5239,,4527,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,A,
5240,,15660,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under curve determined in dogs after intravenous administration of 3 mg/kg,A,
5241,,15660,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under curve determined in dogs after oral administration of 10 mg/kg,A,
5242,,5802,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,
5243,,3598,9615.0,BAO_0000218,,,,Expert,1,Canis lupus familiaris,,1,,N,,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,A,
5244,,3598,9615.0,BAO_0000218,,,,Expert,1,Canis lupus familiaris,,1,,N,,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,A,
5245,,5944,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),A,
5246,,5944,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,A,
5247,,5944,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),A,
5248,,5944,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,A,
5249,,4186,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under curve in dog after administration of 20 mg/kg dose through peroral route,A,
5250,,5007,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,
5251,,5668,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under curve was determine after peroral administration at 10 mpk in dog,A,
5252,,5668,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under curve was determine after peroral administration at 5 mpk in dog,A,
5253,,5006,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under curve was determined,A,
5254,,5006,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under curve in dogs,A,
5255,,3771,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under curve in dogs at 10 mg/kg dose fo oral administration,A,
5256,,3771,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),A,
5257,,3771,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,A,
5258,,1916,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,
5259,,5302,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under curve value in dog at a dose of 5 mg/kg,A,
5260,,5600,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under curve was determined after 0.1 mg/kg iv administration in dog,A,
5261,,5600,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under curve was determined after 0.3 mg/kg po administration in dog,A,
5262,,17764,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,A,
5263,,4368,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,A,
5264,,5318,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,A,
5265,,5318,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,A,
5266,,5318,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,A,
5267,,5318,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,A,
5268,178.0,14518,9606.0,BAO_0000221,,,,Autocuration,1,Homo sapiens,,0,,U,,Time taken to reduce 50% of the concentration of compound in blood plasma,A,Blood
5269,1969.0,2209,9606.0,BAO_0000366,,,,Autocuration,1,Homo sapiens,,0,,U,,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",A,Plasma
5270,1969.0,6787,9606.0,BAO_0000366,,,,Autocuration,1,Homo sapiens,,0,,U,,Half life in human plasma,A,Plasma
5271,1969.0,4898,9606.0,BAO_0000366,,,,Autocuration,1,Homo sapiens,,0,,U,,Half life in human plasma was reported,A,Plasma
5272,1977.0,6072,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Half life in human serum,A,Serum
5273,1969.0,16907,9606.0,BAO_0000366,,,,Autocuration,1,Homo sapiens,,0,,U,,Half life upon exposure to human plasma,A,Plasma
5274,,5656,9606.0,BAO_0000251,,,,Autocuration,1,Homo sapiens,In vitro,0,Microsomes,U,,t1/2 in human microsomes,A,
5275,1969.0,4755,9606.0,BAO_0000366,,,,Autocuration,1,Homo sapiens,,0,,U,,Half life period in 80% human plasma at 37 degree Centigrade,A,Plasma
5276,14.0,17503,9606.0,BAO_0000221,,,,Autocuration,1,Homo sapiens,,0,,U,,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),A,Zone of skin
5277,1969.0,12357,9606.0,BAO_0000366,,,,Autocuration,1,Homo sapiens,In vitro,0,,U,,Half-life measured in in vitro Cathepsin B assay in human plasma,A,Plasma
5278,,3076,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,A,
5279,2107.0,6410,9606.0,BAO_0000251,,,,Autocuration,1,Homo sapiens,In vitro,0,Microsomes,U,,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,A,Liver
5280,1969.0,3741,9606.0,BAO_0000366,,,,Autocuration,1,Homo sapiens,,0,,U,,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",A,Plasma
5281,1969.0,3741,9606.0,BAO_0000366,,,,Autocuration,1,Homo sapiens,,0,,U,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",A,Plasma
5282,1969.0,3741,9606.0,BAO_0000366,,,,Autocuration,1,Homo sapiens,,0,,U,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",A,Plasma
5283,,1540,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Half-life in the CEM cell extracts,A,
5284,1969.0,2905,9606.0,BAO_0000366,,,,Autocuration,1,Homo sapiens,,0,,U,,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,A,Plasma
5285,1969.0,2905,9606.0,BAO_0000366,,,,Autocuration,1,Homo sapiens,,0,,U,,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,A,Plasma
5286,,5523,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Half-life was determined,A,
5287,178.0,1499,9606.0,BAO_0000221,,,,Autocuration,1,Homo sapiens,,0,,U,,Half-life (human blood stability),A,Blood
5288,178.0,1499,9606.0,BAO_0000221,,,,Autocuration,1,Homo sapiens,,0,,U,,Half-life (human blood stability); no data,A,Blood
5289,1969.0,17065,9606.0,BAO_0000366,,,,Autocuration,1,Homo sapiens,,0,,U,,Half-life in human plasma,A,Plasma
5290,,6861,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,CYP3A4 metabolism half-life (t1/2),A,
5291,178.0,1499,9606.0,BAO_0000221,,,,Autocuration,1,Homo sapiens,,0,,U,,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),A,Blood
5292,1969.0,530,9606.0,BAO_0000366,,,,Autocuration,1,Homo sapiens,In vitro,0,,U,,In vitro half life in human plasma,A,Plasma
5293,1969.0,1116,9606.0,BAO_0000366,,,,Autocuration,1,Homo sapiens,In vitro,0,,U,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",A,Plasma
5294,1969.0,6695,9606.0,BAO_0000366,,,,Autocuration,1,Homo sapiens,In vitro,0,,U,,In vitro hydrolysis in human plasma,A,Plasma
5295,1969.0,6695,9606.0,BAO_0000366,,,,Autocuration,1,Homo sapiens,In vitro,0,,U,,In vitro hydrolysis in human plasma; no data,A,Plasma
5296,2107.0,10,9606.0,BAO_0000251,,,,Autocuration,1,Homo sapiens,In vitro,0,Microsomes,U,,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,A,Liver
5297,1969.0,993,9606.0,BAO_0000366,,,,Autocuration,1,Homo sapiens,,0,,U,,Plasma half life in human,A,Plasma
5298,1969.0,15429,9606.0,BAO_0000366,,,,Autocuration,1,Homo sapiens,,0,,U,,Stability after incubation with human plasma (at 37 degree C),A,Plasma
5299,1969.0,1675,9606.0,BAO_0000366,,,,Autocuration,1,Homo sapiens,,0,,U,,T1/2 was evaluated in human plasma,A,Plasma
5300,1969.0,2209,9606.0,BAO_0000366,,,,Autocuration,1,Homo sapiens,,0,,U,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",A,Plasma
5301,1969.0,2209,9606.0,BAO_0000366,,,,Autocuration,1,Homo sapiens,,0,,U,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",A,Plasma
5302,,5318,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,A,
5303,,2412,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,In vitro,0,,U,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,A,
5304,,2412,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,In vitro,0,,U,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,A,
5305,1969.0,2906,9606.0,BAO_0000366,,,,Autocuration,1,Homo sapiens,,0,,U,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,A,Plasma
5306,1969.0,2906,9606.0,BAO_0000366,,,,Autocuration,1,Homo sapiens,,0,,U,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,A,Plasma
5307,,5495,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Time taken for 50% to be consumed by serum PON1 was determined,A,
5308,,5495,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,0,,U,,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,A,
5309,2107.0,4397,9606.0,BAO_0000251,,,,Autocuration,1,Homo sapiens,,0,Microsomes,U,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,A,Liver
5310,,2413,10095.0,BAO_0000218,,,,Autocuration,1,Mus sp.,,0,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,
5311,,2413,10095.0,BAO_0000218,,,,Autocuration,1,Mus sp.,,0,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,
5312,,2413,10095.0,BAO_0000218,,,,Autocuration,1,Mus sp.,,0,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,
5313,,2413,10095.0,BAO_0000218,,,,Autocuration,1,Mus sp.,,0,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,
5314,,2413,10095.0,BAO_0000218,,,,Autocuration,1,Mus sp.,,0,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,
5315,,2413,10095.0,BAO_0000218,,,,Autocuration,1,Mus sp.,,0,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,
5316,,6058,9606.0,BAO_0000219,,,391.0,Intermediate,1,Homo sapiens,,1,,N,,Compound tested for growth inhibition of renal cancer cell line 786-0,F,
5317,,17708,9606.0,BAO_0000219,,,391.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,F,
5318,,14017,9606.0,BAO_0000219,,,391.0,Expert,1,Homo sapiens,,1,,N,,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,F,
5319,,16818,9606.0,BAO_0000219,,,391.0,Intermediate,1,Homo sapiens,,1,,N,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",F,
5320,,16818,9606.0,BAO_0000219,,,391.0,Intermediate,1,Homo sapiens,,1,,N,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",F,
5321,,16818,9606.0,BAO_0000219,,,391.0,Intermediate,1,Homo sapiens,,1,,N,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",F,
5322,,11970,9606.0,BAO_0000219,,,391.0,Intermediate,1,Homo sapiens,,1,,N,,Tested for cytotoxicity against 786-0 cell lines in renal cancer,F,
5323,,12400,9606.0,BAO_0000219,,,391.0,Intermediate,1,Homo sapiens,,1,,N,,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,F,
5324,,12888,9606.0,BAO_0000219,,,391.0,Expert,1,Homo sapiens,,1,,N,,Cytotoxic effect on renal cancer line 786-0,F,
5325,,15300,9606.0,BAO_0000219,,,391.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,F,
5326,,14769,9606.0,BAO_0000219,,,391.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),F,
5327,,15895,9606.0,BAO_0000219,,,391.0,Intermediate,1,Homo sapiens,,1,,N,,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",F,
5328,,17376,9606.0,BAO_0000219,,,391.0,Intermediate,1,Homo sapiens,,1,,N,,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,F,
5329,,14882,9606.0,BAO_0000219,,,391.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,F,
5330,,14882,9606.0,BAO_0000219,,,391.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),F,
5331,,15176,9606.0,BAO_0000219,,,391.0,Intermediate,1,Homo sapiens,,1,,N,,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,F,
5332,,12696,9606.0,BAO_0000219,,,391.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,F,
5333,,2496,9606.0,BAO_0000219,,,391.0,Intermediate,1,Homo sapiens,,1,,N,,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),F,
5334,,11831,9606.0,BAO_0000219,,,972.0,Intermediate,1,Homo sapiens,,1,,N,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,F,
5335,,11831,9606.0,BAO_0000219,,,972.0,Intermediate,1,Homo sapiens,,1,,N,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),F,
5336,,11831,9606.0,BAO_0000219,,,972.0,Intermediate,1,Homo sapiens,,1,,N,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,F,
5337,,11831,9606.0,BAO_0000219,,,972.0,Intermediate,1,Homo sapiens,,1,,N,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),F,
5338,,11831,9606.0,BAO_0000219,,,972.0,Intermediate,1,Homo sapiens,,1,,N,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),F,
5339,,11831,9606.0,BAO_0000219,,,972.0,Intermediate,1,Homo sapiens,,1,,N,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,F,
5340,,11831,9606.0,BAO_0000219,,,972.0,Intermediate,1,Homo sapiens,,1,,N,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),F,
5341,,11831,9606.0,BAO_0000219,,,972.0,Intermediate,1,Homo sapiens,,1,,N,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),F,
5342,,11831,9606.0,BAO_0000219,,,972.0,Intermediate,1,Homo sapiens,,1,,N,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),F,
5343,,11831,9606.0,BAO_0000219,,,972.0,Intermediate,1,Homo sapiens,,1,,N,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,F,
5344,,12782,9606.0,BAO_0000219,,,391.0,Intermediate,1,Homo sapiens,,1,,N,,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,F,
5345,,1229,,BAO_0000019,,,,Intermediate,1,,,0,,U,,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,F,
5346,,15313,9606.0,BAO_0000219,,,741.0,Expert,1,Homo sapiens,,1,,N,,Inhibition of cell growth in drug resistant 8226 myeloma cell line,F,
5347,,15313,9606.0,BAO_0000219,,,741.0,Expert,1,Homo sapiens,,1,,N,,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,F,
5348,,11544,9606.0,BAO_0000219,,,741.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,F,
5349,,9424,9606.0,BAO_0000219,,,741.0,Intermediate,1,Homo sapiens,,1,,N,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,
5350,,9424,9606.0,BAO_0000219,,,741.0,Intermediate,1,Homo sapiens,,1,,N,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,
5351,,9424,9606.0,BAO_0000219,,,741.0,Intermediate,1,Homo sapiens,,1,,N,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,
5352,,9424,9606.0,BAO_0000219,,,741.0,Intermediate,1,Homo sapiens,,1,,N,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,
5353,,9424,9606.0,BAO_0000219,,,741.0,Intermediate,1,Homo sapiens,,1,,N,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,
5354,,9424,9606.0,BAO_0000219,,,741.0,Intermediate,1,Homo sapiens,,1,,N,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,
5355,,9424,9606.0,BAO_0000219,,,741.0,Intermediate,1,Homo sapiens,,1,,N,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,
5356,,9424,9606.0,BAO_0000219,,,741.0,Intermediate,1,Homo sapiens,,1,,N,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,
5357,,9424,9606.0,BAO_0000219,,,741.0,Intermediate,1,Homo sapiens,,1,,N,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,
5358,,14769,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),F,
5359,,15354,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for the growth inhibition of A498 renal tumor cell line,F,
5360,,17445,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),F,
5361,,4337,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro inhibitory concentration against renal cancer cell line A498,F,
5362,,15277,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity against A 498 tumor cell line,F,
5363,,4812,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro antitumor activity against A498 human cancer cell line,F,
5364,,4812,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),F,
5365,,4995,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory dose required against A498 human tumor cell lines,F,
5366,,5847,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,Anticancer activity against one renal cancer (A498 cell line),F,
5367,,6557,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against melanoma A498 cell line,F,
5368,,2597,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for growth inhibitory activity against A498 cell line,F,
5369,,6058,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,Compound tested for growth inhibition of renal cancer cell line A498,F,
5370,,17708,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,F,
5371,,15176,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,F,
5372,,15300,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,F,
5373,,11970,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,Tested for cytotoxicity against A498 cell lines in renal cancer,F,
5374,,12400,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,F,
5375,,12888,9606.0,BAO_0000219,,,624.0,Expert,1,Homo sapiens,,1,,N,,Cytotoxic effect on renal cancer lines A498,F,
5376,,3030,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,F,
5377,,14769,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),F,
5378,,17376,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,F,
5379,,16558,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,F,
5380,,5194,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity against human kidney carcinoma cell lines A4982LM,F,
5381,,10708,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,F,
5382,,16880,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,F,
5383,,10196,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Antitumor activity against A549 human lung carcinoma cell line,F,
5384,,10196,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,F,
5385,,10196,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,F,
5386,,12083,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",F,
5387,,16464,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,F,
5388,,16464,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,
5389,,16470,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,In vitro cytotoxic activity against human lung A549 cell line,F,
5390,,16470,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),F,
5391,,16470,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxic activity against human lung A549 cell line),F,
5392,,16470,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,F,
5393,,16582,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against human non small-cell-lung cell line A549.,F,
5394,,15935,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",F,
5395,,15935,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",F,
5396,,16597,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Inhibition of A549 human lung carcinoma cell proliferation,F,
5397,,17376,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory activity against A549 lung adenocarcinoma cell line,F,
5398,,16496,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,F,
5399,,16152,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,F,
5400,,16152,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,F,
5401,,16464,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,
5402,,2288,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,F,
5403,,17350,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,F,
5404,,4090,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Inhibition of A549 cancer cell proliferation,F,
5405,,4090,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Inhibition of A549 cancer cell proliferation (Not tested),F,
5406,,17350,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,F,
5407,,4197,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,F,
5408,,17072,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Antiproliferative potency determined as inhibitory concentration against A549 cells,F,
5409,,17072,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,F,
5410,,5194,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity against Renal cell lines A549 was determined,F,
5411,,4257,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under curve was determined in dog after a 3 mg/kg of oral dose,A,
5412,,6123,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under curve was determined in dog after oral administration at 1 mg/kg,A,
5413,,1337,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,
5414,,1337,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,
5415,,8833,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),A,
5416,,8833,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),A,
5417,,8833,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),A,
5418,,8833,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),A,
5419,1969.0,17657,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under plasma concentration time curve in dog upon oral administration,A,Plasma
5420,1969.0,17650,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,A,Plasma
5421,,1977,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,A,
5422,,1977,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,A,
5423,,3132,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under the curve for the compound was obtained when tested in dog,A,
5424,,5473,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under the curve at a dose of 1 mg/kg,A,
5425,,5474,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under the curve at a dose of 1 mg/kg (oral),A,
5426,,5474,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under the curve at i.v. dose of 0.2 mg/kg,A,
5427,,6062,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under the curve was measured in dog after an iv dose of 1 mg/kg,A,
5428,,4709,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,A,
5429,,2652,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,A,
5430,,2652,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,A,
5431,,2877,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Compound was evaluated for area under the curve in dog blood.,A,
5432,,5444,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,A,
5433,1969.0,5130,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,AUC in dog after oral dose (1 mg/kg),A,Plasma
5434,,6265,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,A,
5435,,4657,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",A,
5436,,16367,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Pharmacokinetic parameter AUC after intravenous administration to dogs,A,
5437,,16367,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Pharmacokinetic parameter AUC after oral administration to dogs,A,
5438,,9579,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,A,
5439,,9579,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,A,
5440,,5983,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,A,
5441,,6241,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,A,
5442,,5313,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",A,
5443,,5313,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",A,
5444,,6642,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,
5445,,6642,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,
5446,,6641,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Oral AUCN in dog (dosed at 0.5 mpk iv ),A,
5447,,6642,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Oral AUCN in dog (dosed at 0.5 mpk iv ),A,
5448,,17791,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Compound was evaluated for oral bioavailability in dog; 90-100,A,
5449,,17655,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,A,
5450,,17655,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,A,
5451,,6596,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,PAPP (membrane permeability) in dog kidney cell monolayer assay,A,
5452,,3880,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Oral bioavailability in dog,A,
5453,,16367,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Bioavailability administered orally at a dose of 10 mg/kg to dogs,A,
5454,1969.0,17409,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Plasma protein binding towards dog plasma at 10 uM,A,Plasma
5455,1969.0,17409,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Plasma protein binding towards dog plasma at 100 uM,A,Plasma
5456,,2959,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability in dog (dose 4 mg/kg p.o.),A,
5457,,13501,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,A,
5458,,4527,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,A,
5459,,15145,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability in dogs,A,
5460,,4219,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability,A,
5461,,17538,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog (dose 10 mg/kg),A,
5462,,17538,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,A,
5463,,1466,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability in dog (dose 10.0 mg/kg p.o.),A,
5464,,17650,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,A,
5465,,3132,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,A,
5466,,2413,10095.0,BAO_0000218,,,,Autocuration,1,Mus sp.,,0,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,
5467,2107.0,2413,10095.0,BAO_0000218,,,,Autocuration,1,Mus sp.,,0,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,Liver
5468,2107.0,2413,10095.0,BAO_0000218,,,,Autocuration,1,Mus sp.,,0,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,Liver
5469,2107.0,2413,10095.0,BAO_0000218,,,,Autocuration,1,Mus sp.,,0,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,Liver
5470,,2413,10095.0,BAO_0000218,,,,Autocuration,1,Mus sp.,,0,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,
5471,,2413,10095.0,BAO_0000218,,,,Autocuration,1,Mus sp.,,0,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,
5472,2385.0,2413,10095.0,BAO_0000218,,,,Autocuration,1,Mus sp.,,0,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,Muscle tissue
5473,2385.0,2413,10095.0,BAO_0000218,,,,Autocuration,1,Mus sp.,,0,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,Muscle tissue
5474,2385.0,2413,10095.0,BAO_0000218,,,,Autocuration,1,Mus sp.,,0,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,Muscle tissue
5475,2106.0,2413,10095.0,BAO_0000218,,,,Autocuration,1,Mus sp.,,0,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,Spleen
5476,2106.0,2413,10095.0,BAO_0000218,,,,Autocuration,1,Mus sp.,,0,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,Spleen
5477,,2413,10095.0,BAO_0000218,,,,Autocuration,1,Mus sp.,,0,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,
5478,,2413,10095.0,BAO_0000218,,,,Autocuration,1,Mus sp.,,0,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,
5479,,2413,10095.0,BAO_0000218,,,,Autocuration,1,Mus sp.,,0,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,
5480,,2413,10095.0,BAO_0000218,,,,Autocuration,1,Mus sp.,,0,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,
5481,,2413,10095.0,BAO_0000218,,,,Autocuration,1,Mus sp.,,0,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,
5482,,17827,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),A,
5483,2037.0,17827,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),A,Cerebellum
5484,1870.0,17827,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),A,Frontal cortex
5485,,17827,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),A,
5486,2435.0,17827,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),A,Striatum
5487,,17827,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),A,
5488,2037.0,17827,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),A,Cerebellum
5489,1870.0,17827,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),A,Frontal cortex
5490,,17827,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),A,
5491,2435.0,17827,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),A,Striatum
5492,,17791,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,,0,,U,,Compound was evaluated for oral bioavailability in rats,A,
5493,1969.0,17667,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,A,Plasma
5494,,17791,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Half life period was evaluated in monkey,A,
5495,,110,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Half-life in rhesus monkeys by intravenous administration of dose,A,
5496,1969.0,5781,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,A,Plasma
5497,1969.0,17734,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,AUC after intraperitoneal administration of 100 mg/kg in mice,A,Plasma
5498,1969.0,17718,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,AUC value was determined after oral administration,A,Plasma
5499,,4573,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,A,
5500,,3277,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,
5501,,2862,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Area under curve by ioral administration in mouse,A,
5502,,2862,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Area under curve by iv administration in mouse,A,
5503,,5951,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Area under curve at 0-8 hr in IRC mice after peroral administration,A,
5504,,17729,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,A,
5505,,17728,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,A,
5506,,17728,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,A,
5507,,17729,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,A,
5508,,9424,9606.0,BAO_0000219,,,741.0,Intermediate,1,Homo sapiens,,1,,N,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,
5509,,9424,9606.0,BAO_0000219,,,741.0,Intermediate,1,Homo sapiens,,1,,N,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,
5510,,9424,9606.0,BAO_0000219,,,741.0,Intermediate,1,Homo sapiens,,1,,N,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,
5511,,9424,9606.0,BAO_0000219,,,741.0,Intermediate,1,Homo sapiens,,1,,N,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,
5512,,9424,9606.0,BAO_0000219,,,741.0,Intermediate,1,Homo sapiens,,1,,N,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,
5513,,9424,9606.0,BAO_0000219,,,741.0,Intermediate,1,Homo sapiens,,1,,N,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,
5514,,9424,9606.0,BAO_0000219,,,741.0,Intermediate,1,Homo sapiens,,1,,N,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,
5515,,9424,9606.0,BAO_0000219,,,741.0,Intermediate,1,Homo sapiens,,1,,N,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,
5516,,9424,9606.0,BAO_0000219,,,741.0,Intermediate,1,Homo sapiens,,1,,N,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,
5517,,9424,9606.0,BAO_0000219,,,741.0,Intermediate,1,Homo sapiens,,1,,N,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,
5518,,9424,9606.0,BAO_0000219,,,741.0,Intermediate,1,Homo sapiens,,1,,N,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,
5519,,9424,9606.0,BAO_0000219,,,741.0,Intermediate,1,Homo sapiens,,1,,N,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,
5520,,9424,9606.0,BAO_0000219,,,741.0,Intermediate,1,Homo sapiens,,1,,N,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,
5521,,9424,9606.0,BAO_0000219,,,741.0,Intermediate,1,Homo sapiens,,1,,N,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,
5522,,9424,9606.0,BAO_0000219,,,741.0,Intermediate,1,Homo sapiens,,1,,N,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,
5523,,9424,9606.0,BAO_0000219,,,741.0,Intermediate,1,Homo sapiens,,1,,N,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,
5524,,9424,9606.0,BAO_0000219,,,741.0,Expert,1,Homo sapiens,,1,,N,,In vitro inhibition of human 8226 myeloma tumor cell line growth.,F,
5525,,11544,9606.0,BAO_0000219,,,741.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,F,
5526,,17378,9606.0,BAO_0000219,,,741.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity of compound against 8226/DOX1V cells,F,
5527,,17378,9606.0,BAO_0000219,,,741.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity of compound against 8226/S cells,F,
5528,,17079,9606.0,BAO_0000219,,,741.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory concentration against 8226 myeloma cancer cell line,F,
5529,,17079,9606.0,BAO_0000219,,,741.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,F,
5530,,13466,9606.0,BAO_0000219,,,854.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibition of cell growth was studied in human teratocarcinoma (833K).,F,
5531,,13466,9606.0,BAO_0000219,,,854.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',F,
5532,,2392,9606.0,BAO_0000219,,,854.0,Expert,1,Homo sapiens,,1,,N,,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,F,
5533,,2392,9606.0,BAO_0000219,,,854.0,Intermediate,1,Homo sapiens,,1,,N,,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,F,
5534,,6608,,BAO_0000019,,,,Autocuration,1,,,0,,U,,Inhibitory activity against caspase-1,B,
5535,,10199,1351.0,BAO_0000357,,,,Autocuration,1,Enterococcus faecalis,,8,,H,,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,B,
5536,,17749,9606.0,BAO_0000219,,,705.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,F,
5537,,17749,9606.0,BAO_0000219,,,705.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,F,
5538,,1229,,BAO_0000019,,,,Intermediate,1,,,0,,U,,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,F,
5539,,1229,,BAO_0000019,,,,Intermediate,1,,,0,,U,,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,F,
5540,,1229,,BAO_0000019,,,,Intermediate,1,,,0,,U,,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,F,
5541,,6390,,BAO_0000019,,,,Autocuration,1,,,0,,U,,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,B,
5542,,16219,1314.0,BAO_0000019,,,,Autocuration,1,Streptococcus pyogenes,,0,,U,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,F,
5543,,16219,1314.0,BAO_0000019,,,,Autocuration,1,Streptococcus pyogenes,,0,,U,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,F,
5544,,17043,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,B,
5545,,6929,9606.0,BAO_0000219,,,324.0,Intermediate,1,Homo sapiens,,1,,N,,Tested for in vitro cytotoxic potency of compound in 9KB assay,F,
5546,,6929,9606.0,BAO_0000219,,,324.0,Intermediate,1,Homo sapiens,,1,,N,,Tested for in vitro cytotoxic potency of compound in 9KB assay,A,
5547,,7083,9606.0,BAO_0000219,,,,Autocuration,1,Homo sapiens,,0,,U,,In vitro cytotoxicity of compound was tested against 9KB cells.,F,
5548,,12446,10116.0,BAO_0000219,,,392.0,Intermediate,1,Rattus norvegicus,,1,,N,,Cytotoxic concentration against 9L cells was determined on day 3,F,
5549,,15345,10116.0,BAO_0000219,,,392.0,Expert,1,Rattus norvegicus,,1,,N,,Tested in vitro for anticancer activity against 9L cells,F,
5550,,15345,10116.0,BAO_0000219,,,392.0,Expert,1,Rattus norvegicus,,1,,N,,Tested in vitro for anticancer activity against 9L cells; Not determined,F,
5551,,6301,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,F,
5552,,4833,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,F,
5553,,4833,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,F,
5554,,4833,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,F,
5555,,13330,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Cytotoxicity against human lung carcinoma A549 cell line,F,
5556,,17517,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,9,,D,,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,F,
5557,,17517,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,9,,D,,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",F,
5558,,14425,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,"In vitro growth inhibition of A549, lung carcinoma",F,
5559,,14425,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,"In vitro growth inhibition of A549, lung carcinoma.",F,
5560,,5228,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,
5561,,5351,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxic activity against human lung cancer A549 cell line was determined,F,
5562,,12198,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,F,
5563,,13891,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity concentration against human lung carcinoma A-549 cell line,F,
5564,,5677,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Cytotoxicity in A549 (human carcinoma) cell line.,F,
5565,,13788,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity on lung carcinoma (A-549) cell line,F,
5566,,13384,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,F,
5567,,6726,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Effective dose of compound against replication of A549 cell line was evaluated,F,
5568,,3455,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,F,
5569,,5726,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),F,
5570,,5726,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,F,
5571,,3936,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,The compound was evaluated for antiproliferative activity against A549 cell line,F,
5572,,14991,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,F,
5573,,5243,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Concentration required for growth inhibition of human lung carcinoma cell line A549,F,
5574,,12858,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,F,
5575,,6776,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Growth inhibition against A549 cell line was evaluated,F,
5576,,16558,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,F,
5577,,4583,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,F,
5578,,13514,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,F,
5579,,15166,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Chemosensitivity against DT-diaphorase rich A549 cell lines,F,
5580,,13873,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,F,
5581,,6447,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against human A549 (lung cancer) cell line.,F,
5582,,2068,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro antitumor activity against A549 (lung) human tumor cell lines.,F,
5583,,1863,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,In vitro cytotoxic activity against human lung carcinoma A549 cell line,F,
5584,,13873,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,F,
5585,,13873,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,F,
5586,,13873,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Tested against A549 lung carcinoma in the sulforhodamine B assay.,F,
5587,,579,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),F,
5588,,579,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,F,
5589,,4584,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,F,
5590,,5421,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,F,
5591,,5421,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,F,
5592,,5421,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,F,
5593,,5421,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,F,
5594,,14188,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,F,
5595,,14188,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,F,
5596,,15354,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for the growth inhibition of A549 lung tumor cell line,F,
5597,,14253,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Growth inhibition of human non-small-lung carcinoma (A549) cell line,F,
5598,,13873,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,F,
5599,,3043,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog (conscious),A,
5600,,3045,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Compound was evaluated for the oral bioavailability after oral administration in dog.,A,
5601,,3022,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,A,
5602,,4453,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog,A,
5603,,1696,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog,A,
5604,,5045,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog,A,
5605,,5356,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog (fasted),A,
5606,,17764,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,A,
5607,,6448,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog,A,
5608,,1475,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog,A,
5609,,3788,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Percent bioavailability in dog,A,
5610,,3639,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,A,
5611,,13397,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog,A,
5612,,2137,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,The compound was evaluated for bioavailability in dogs; 34-44,A,
5613,,2959,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability in dog (dose 4 mg/kg p.o.),A,
5614,,6448,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog,A,
5615,,6084,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,8 hour trough Blood level in dog was measured after administration of compound,A,
5616,1969.0,3639,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,A,Plasma
5617,,6316,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,C24 after oral administration at 5 mg/kg,A,
5618,,5238,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Clearance after oral and iv dosing in dogs,A,
5619,1969.0,17796,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Clearance of the drug was measured in the plasma of dog,A,Plasma
5620,,2652,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,A,
5621,,5654,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,
5622,,6621,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Clearance of compound was determined in dogs,A,
5623,,6505,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Clearance on i.v. administration of 2 mg/kg was measured in dog,A,
5624,,5802,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,
5625,,17267,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance in dog was determined,A,
5626,,4521,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,
5627,,6535,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance in dog after administration of 0.25 mg/kg iv,A,
5628,,6535,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance in dog after administration of 1 mg/kg iv,A,
5629,,6535,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance in dogs,A,
5630,,5542,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,A,
5631,,5199,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,A,
5632,,16907,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance after 15 mg/kg iv dose in Dogs,A,
5633,,16907,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance after 30 mg/kg po dose in Dogs,A,
5634,,16367,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma administration to dogs,A,
5635,,5505,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance was determined,A,
5636,,6215,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,A,
5637,,1466,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,A,
5638,2107.0,5007,9606.0,BAO_0000251,,,,Intermediate,1,Homo sapiens,In vitro,2,Microsomes,S,,Intrinsic clearance in human liver microsomes,A,Liver
5639,2107.0,5007,9606.0,BAO_0000251,,,,Intermediate,1,Homo sapiens,In vitro,2,Microsomes,S,,Intrinsic clearance in human liver microsomes,A,Liver
5640,,16452,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,
5641,,16452,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,
5642,,16452,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Clearance in dog (dose 1 mg/kg i.v.),A,
5643,,6221,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,A,
5644,,5007,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,
5645,,5668,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance after peroral administration at 10 mpk in dog,A,
5646,,5668,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance after peroral administration at 5 mpk in dog,A,
5647,,5668,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance after peroral administration at 5 mg/kg in dog,A,
5648,,15660,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance was measured in dog,A,
5649,,15660,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance was measured in dog,A,
5650,,5983,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,A,
5651,,5600,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Total clearance was determined after 0.1 mg/kg iv administration in dog,A,
5652,,17764,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,A,
5653,,6039,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,A,
5654,,6039,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,A,
5655,,6039,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Clearance after peroral administration of 0.2 mg/kg in dog was determined,A,
5656,,4368,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Clearance by intravenous administration of 1.2 mg/kg in dog,A,
5657,,4305,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Clearance by iv administration in dogs at a dose of 1 mg/kg,A,
5658,1969.0,1918,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Clearance value was evaluated in dog plasma,A,Plasma
5659,,6005,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,A,
5660,1969.0,4839,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Compound was tested for plasma clearance in dog,A,Plasma
5661,,4239,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Pharmacokinetic property (Plasma clearance) was measured in dog,A,
5662,,17729,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Area under curve when injected perorally in mice at a dose of 50 mg/kg,A,
5663,,17728,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,A,
5664,,5302,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Area under curve value in mouse at a dose of 10 mg/kg,A,
5665,,5506,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,A,
5666,,5506,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,A,
5667,,17764,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,F,
5668,,17764,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,F,
5669,,17764,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,F,
5670,,17764,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,F,
5671,,17764,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,A,
5672,,17753,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Area under curve was determined for the compound at 24 mg/Kg,A,
5673,,17753,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Area under curve was determined for the compound at 40 mg/Kg,A,
5674,,17753,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Area under curve was determined for the compound at 5 mg/Kg,A,
5675,,3132,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Area under the curve for the compound is obtained at dose 25 mg/kg,A,
5676,,3132,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Area under the curve for the compound was obtained when tested in mouse,A,
5677,,17837,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,A,
5678,,17837,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,A,
5679,,6062,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,A,
5680,,4066,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,A,
5681,,16597,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),A,
5682,,14239,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,A,
5683,,14239,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,A,
5684,,4890,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,"Compound was evaluated for the pharmacokinetic parameter, area under curve",A,
5685,,429,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),A,
5686,,429,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),A,
5687,,5969,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,A,
5688,,5969,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,A,
5689,,5969,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,
5690,,6091,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,A,
5691,,6091,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,A,
5692,,6091,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,A,
5693,,6091,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,A,
5694,,6178,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,A,
5695,,6178,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,A,
5696,,6619,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",A,
5697,,6619,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",A,
5698,,3760,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",A,
5699,,3760,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",A,
5700,,3760,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",A,
5701,,3760,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",A,
5702,,3192,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,A,
5703,,3192,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,A,
5704,,2675,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Area under the curve was evaluated in mice after intravenous administration,A,
5705,,2675,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Area under the curve was evaluated in mice after oral administration,A,
5706,1969.0,16597,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,A,Plasma
5707,1969.0,16597,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,AUC total value at a dose of 10 mg/kg peroral administration in mice.,A,Plasma
5708,,16597,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),A,
5709,,17734,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,AUMC after intraperitoneal administration of 100 mg/kg in mice,A,
5710,178.0,7767,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,A,Blood
5711,,15345,,BAO_0000219,,,392.0,Intermediate,1,,,1,,N,,The compound was tested in vitro for anticancer activity against 9L cells,F,
5712,,2181,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,0,,U,,Anti proliferation activity determined; Weak effect,F,
5713,,2181,10116.0,BAO_0000219,,,,Autocuration,1,Rattus norvegicus,,0,,U,,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,F,
5714,,2181,10116.0,BAO_0000219,,,,Autocuration,1,Rattus norvegicus,,0,,U,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,F,
5715,,2181,10116.0,BAO_0000219,,,,Autocuration,1,Rattus norvegicus,,0,,U,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,F,
5716,,10486,10090.0,BAO_0000019,,,,Autocuration,1,Mus musculus,,0,,U,,The cytotoxic activity was in vitro tested by 9PS assay method,F,
5717,,10486,10090.0,BAO_0000019,,,,Autocuration,1,Mus musculus,,0,,U,,The cytotoxic activity was in vitro tested by 9PS assay method.,F,
5718,,15508,,BAO_0000019,,,,Autocuration,1,,,0,,U,,Partition coefficient (logD6.5),A,
5719,,5242,9606.0,BAO_0000219,,,478.0,Expert,1,Homo sapiens,,1,,N,,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,F,
5720,,16167,9606.0,BAO_0000219,,,455.0,Intermediate,1,Homo sapiens,,1,,N,,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),F,
5721,,4782,9606.0,BAO_0000219,,,500.0,Expert,1,Homo sapiens,,1,,N,,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,F,
5722,,16093,9606.0,BAO_0000219,,,500.0,Expert,1,Homo sapiens,,9,,D,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,F,
5723,,2596,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,F,
5724,,2596,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,in vitro cytotoxicity against A 498 cancer cell line,F,
5725,,3239,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxic activity against renal (A 498) cancer cell line.,F,
5726,,1847,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxic activity against A 498 renal cancer cell lines.,F,
5727,,10553,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,F,
5728,,16219,1280.0,BAO_0000019,,,,Autocuration,1,Staphylococcus aureus,,0,,U,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,F,
5729,,16219,1280.0,BAO_0000019,,,,Autocuration,1,Staphylococcus aureus,,0,,U,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,F,
5730,,16219,1280.0,BAO_0000019,,,,Autocuration,1,Staphylococcus aureus,,0,,U,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,F,
5731,,16219,1280.0,BAO_0000019,,,,Autocuration,1,Staphylococcus aureus,,0,,U,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,F,
5732,,4782,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory concentration required against A 549 lung cancer cell line,F,
5733,,11805,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,F,
5734,,11805,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,F,
5735,,2007,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against lung cancer A 549 cell lines,F,
5736,,4594,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for its cytotoxicity against A 549 cell line,F,
5737,,6018,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",F,
5738,,6018,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",F,
5739,,3599,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,F,
5740,,2551,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,F,
5741,,16132,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,In vitro inhibition of A549 (human lung cancer) cell growth.,F,
5742,,16132,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,F,
5743,,2551,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,F,
5744,,2551,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),F,
5745,,11913,,BAO_0000218,,,,Autocuration,1,,,0,,U,,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,F,
5746,,12621,,BAO_0000218,,,,Autocuration,1,,In vivo,4,,H,,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,F,
5747,,12621,,BAO_0000218,,,,Autocuration,1,,In vivo,4,,H,,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,F,
5748,,12621,,BAO_0000218,,,,Autocuration,1,,In vivo,4,,H,,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,F,
5749,,12621,,BAO_0000218,,,,Autocuration,1,,In vivo,4,,H,,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,F,
5750,,12621,,BAO_0000218,,,,Autocuration,1,,In vivo,4,,H,,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,F,
5751,,3600,9606.0,BAO_0000219,,,624.0,Expert,1,Homo sapiens,,1,,N,,Inhibition of A-498 human Renal cell proliferation,F,
5752,,1796,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,0,,U,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",F,
5753,,1796,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,0,,U,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",F,
5754,,1796,10116.0,BAO_0000019,,,,Autocuration,1,Rattus norvegicus,,0,,U,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",F,
5755,,16464,9606.0,BAO_0000219,,,622.0,Expert,1,Homo sapiens,,1,,N,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,F,
5756,,16464,9606.0,BAO_0000219,,,622.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,
5757,,16464,9606.0,BAO_0000219,,,622.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,
5758,,13617,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,F,
5759,,4584,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,F,
5760,,13799,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Cytotoxic activity evaluated against A549 tumor cells,F,
5761,,16726,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,F,
5762,,16109,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,F,
5763,,16109,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,F,
5764,,15474,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,F,
5765,,6851,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity of compound against A549 cell line,F,
5766,,17534,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Cytotoxicity against human lung cell carcinoma A549 cell line,F,
5767,,2621,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,F,
5768,,830,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,F,
5769,,14255,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,F,
5770,,14255,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,F,
5771,,1590,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,F,
5772,,6146,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,F,
5773,,17427,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,
5774,,5280,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,F,
5775,,16786,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,F,
5776,,5895,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against A549 (human lung cancer),F,
5777,,14297,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,F,
5778,,17824,9606.0,BAO_0000218,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vivo antiproliferative activity against A549 cell line,F,
5779,,14368,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibition of non-small-cell lung adenocarcinoma (A549),F,
5780,,14368,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,F,
5781,,14254,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,F,
5782,,15897,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),F,
5783,,13866,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,F,
5784,,13370,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory activity of compound against human A549 lung carcinoma cell line.,F,
5785,,4862,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory activity against A549 lung cancer cell line,F,
5786,,4862,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,F,
5787,,4862,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,F,
5788,,15970,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory concentration against A549 (lung cancer) cell line,F,
5789,,17713,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,F,
5790,,4833,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,F,
5791,,13736,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Activity against A549 cancer cell line.,F,
5792,,4312,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,The compound was evaluated for cytotoxicity against A549 cell line,F,
5793,,5421,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,F,
5794,,5421,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,F,
5795,,14717,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Growth inhibitory activity was measured for human A549 tumor cell line.,F,
5796,,4634,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory activity against A549 lung cancer cell line,F,
5797,,1149,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory activity against A549 cell line; inactive,F,
5798,,5421,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,F,
5799,,5421,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,F,
5800,,5421,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,F,
5801,,3320,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),F,
5802,,3320,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),F,
5803,,3320,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),F,
5804,,3320,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),F,
5805,,3320,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),F,
5806,,5726,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,F,
5807,,17800,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance (in vivo) in mongrel dogs was determined,A,
5808,,5985,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance was measured in dog,A,
5809,,5530,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,A,
5810,,5530,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,A,
5811,1969.0,4839,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Tested for plasma clearance in dog,A,Plasma
5812,,3639,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,The compound was tested for clearance in dog plasma.,A,
5813,,4838,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",A,
5814,,4137,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,A,
5815,1969.0,5017,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),A,Plasma
5816,2107.0,17538,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vitro,1,Microsomes,N,,In vitro clearance in dog liver microsomes,A,Liver
5817,,6161,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,A,
5818,,6161,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,A,
5819,,1696,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance in dog,A,
5820,,6762,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Clearance rate in dog,A,
5821,1969.0,5932,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,A,Plasma
5822,,6305,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Clearance in dogs,A,
5823,,4942,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance in dogs,A,
5824,,4219,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance was determined,A,
5825,,17853,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Lower clearance in dog (i.v.) at 0.5 mpk,A,
5826,,4514,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance in Beagle dogs,A,
5827,,6448,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance (Clp) in dog,A,
5828,,6227,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,A,
5829,,6227,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance (pharmacokinetic parameter) in dog was determined,A,
5830,,6062,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,A,
5831,,6821,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance of compound was determined in dog,A,
5832,,4709,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance after intravenous administration of 1 mg/kg in dog,A,
5833,,4521,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,
5834,,5374,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance in dog was determined,A,
5835,,6057,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance was calculated in dog,A,
5836,,4727,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance at the dose of 2 mg/kg in dog,A,
5837,,5145,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance in dog,A,
5838,,17657,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance in dog,A,
5839,,17657,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance in dog; Unable to calculate,A,
5840,,5145,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance in rhesus monkey,A,
5841,,6642,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,
5842,,6641,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,
5843,,6642,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,
5844,,5472,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance was evaluated in dog,A,
5845,,5472,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance was evaluated in dog; Not tested,A,
5846,,5472,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance was evaluated in rhesus,A,
5847,,5472,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance was evaluated in rhesus; Not tested,A,
5848,,4257,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,A,
5849,,6679,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,
5850,,5546,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,
5851,,6348,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,
5852,,5474,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Clearance value at a dose of 0.2 mg/kg i.v.,A,
5853,1969.0,6316,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,A,Plasma
5854,,17594,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Cmax after oral dose of compound at 3 mg/kg in dogs,A,
5855,,17594,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Cmax after single intravenous bolus of 1 mg/kg in dogs,A,
5856,,5802,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,
5857,,6535,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,A,
5858,,6535,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Cmax in dog after administration of 1 mg/kg iv,A,
5859,1969.0,1466,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,A,Plasma
5860,,6505,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Cmax on p.o. administration of 10 mg/kg was measured in dog,A,
5861,,5668,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Cmax was determine after peroral administration at 10 mpk in dog,A,
5862,,5668,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Cmax was determine after peroral administration at 5 mpk in dog,A,
5863,,5668,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Cmax was determine after peroral administration at 5 mg/kg in dog,A,
5864,,5600,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Cmax after 0.3 mg/kg po administration in dog,A,
5865,,17764,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Cmax after peroral administration in dogs at 2.4 uM/kg,A,
5866,,6123,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Cmax in dog after oral administration at 1 mg/kg,A,
5867,,6123,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,A,
5868,,6757,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Cmax upon oral administration in male Beagle dog at 10 mg/kg,A,
5869,,16907,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Cmax value after 15 mg/kg iv dose in Dogs,A,
5870,178.0,7767,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,Blood
5871,178.0,7767,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,Blood
5872,10000001.0,7767,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,Bone
5873,10000001.0,7767,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,Bone
5874,10000001.0,7767,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,Bone
5875,,7767,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,
5876,,7767,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,
5877,,7767,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,
5878,948.0,7767,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,Heart
5879,948.0,7767,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,Heart
5880,948.0,7767,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,Heart
5881,2113.0,7767,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,Kidney
5882,2113.0,7767,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,Kidney
5883,2113.0,7767,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,Kidney
5884,160.0,7767,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,Intestine
5885,160.0,7767,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,Intestine
5886,160.0,7767,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,Intestine
5887,2107.0,7767,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,Liver
5888,2107.0,7767,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,Liver
5889,2107.0,7767,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,Liver
5890,2048.0,7767,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,Lung
5891,2048.0,7767,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,Lung
5892,2048.0,7767,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,Lung
5893,2385.0,7767,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,Muscle tissue
5894,2385.0,7767,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,Muscle tissue
5895,2385.0,7767,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,Muscle tissue
5896,,7767,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,
5897,,7767,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,
5898,,7767,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,
5899,160.0,7767,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,Intestine
5900,160.0,7767,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,Intestine
5901,160.0,7767,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,Intestine
5902,2106.0,7767,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,Spleen
5903,2106.0,7767,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,Spleen
5904,2106.0,7767,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,Spleen
5905,945.0,7767,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,Stomach
5906,945.0,7767,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,Stomach
5907,,2036,9606.0,BAO_0000219,,,622.0,Expert,1,Homo sapiens,,1,,N,,Cytotoxicity against A-172 human tumor cell lines,F,
5908,,2357,9606.0,BAO_0000219,,,622.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,F,
5909,,1457,9606.0,BAO_0000219,,,623.0,Intermediate,1,Homo sapiens,,1,,N,,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,F,
5910,,4379,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Tested for antiproliferative activity against A-2780 tumoral cell line,F,
5911,,1093,9606.0,BAO_0000219,,,455.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,F,
5912,,12152,9606.0,BAO_0000219,,,455.0,Intermediate,1,Homo sapiens,,1,,N,,Tested in vitro against A-375 cell line human melanoma,F,
5913,,16464,9606.0,BAO_0000219,,,797.0,Expert,1,Homo sapiens,,1,,N,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,F,
5914,,16464,9606.0,BAO_0000219,,,797.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,
5915,,16582,9606.0,BAO_0000219,,,797.0,Expert,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,F,
5916,,16464,9606.0,BAO_0000219,,,797.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,
5917,,10413,9606.0,BAO_0000219,,,797.0,Intermediate,1,Homo sapiens,,1,,N,,Antitumor activity on A-427 lung carcinoma cell lines,F,
5918,,6418,9606.0,BAO_0000219,,,797.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxic activity against human A-427 lung tumor cell line,F,
5919,,17134,9606.0,BAO_0000219,,,797.0,Expert,1,Homo sapiens,,1,,N,,In vitro antitumor effects against human A-427 cell lines.,F,
5920,,16132,9606.0,BAO_0000219,,,797.0,Expert,1,Homo sapiens,,1,,N,,In vitro inhibition of A-427 (human lung cancer) cell growth.,F,
5921,,16132,9606.0,BAO_0000219,,,797.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,F,
5922,,16780,9606.0,BAO_0000219,,,797.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxic activity of compound against A-427 lung human tumor cell line,F,
5923,,4085,9606.0,BAO_0000219,,,500.0,Expert,1,Homo sapiens,,1,,N,,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,F,
5924,,1276,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,F,
5925,,3498,9606.0,BAO_0000219,,,624.0,Expert,1,Homo sapiens,,1,,N,,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,F,
5926,,1169,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity against human kidney carcinoma A-498cell lines,F,
5927,,4450,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,F,
5928,,3311,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,F,
5929,,4461,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,Antitumor cytotoxic activity against A-498 cell line was determined,F,
5930,,3311,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,F,
5931,,3311,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,F,
5932,,1457,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,F,
5933,,3664,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro inhibitory activity against A-498 ovarian cancer cell lines,F,
5934,,15895,9606.0,BAO_0000219,,,624.0,Intermediate,1,Homo sapiens,,1,,N,,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",F,
5935,,11843,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibition of growth lung non-small cell carcinoma A-549 cell line,F,
5936,,11843,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,F,
5937,,17705,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro antiproliferative activity against human A-549 NSCL cell line,F,
5938,,17705,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,F,
5939,,4369,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,F,
5940,,4369,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,F,
5941,,4369,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,F,
5942,,4369,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,F,
5943,,4369,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,F,
5944,,4369,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,F,
5945,,4369,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,F,
5946,,4787,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,F,
5947,,4787,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,F,
5948,,6513,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxic activity against A-549 cell line,F,
5949,,6690,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,F,
5950,,6690,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,F,
5951,,12263,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",F,
5952,,1054,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),F,
5953,,1359,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),F,
5954,,3547,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxic activity against human lung carcinoma (A-549) cell line,F,
5955,,5771,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Cytotoxic activity towards A-549 cells,F,
5956,,14425,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,"In vitro percent inhibition of A549, lung carcinoma.",F,
5957,,14425,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,"In vitro percent inhibition of A549, lung carcinoma",F,
5958,,14425,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,"In vitro percent inhibition of A549, lung carcinoma.",F,
5959,,14425,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",F,
5960,,5280,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,F,
5961,,15176,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,F,
5962,,15300,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,F,
5963,,17824,9606.0,BAO_0000218,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,
5964,,17824,9606.0,BAO_0000218,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,
5965,,17824,9606.0,BAO_0000218,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,
5966,,17824,9606.0,BAO_0000218,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,
5967,,17824,9606.0,BAO_0000218,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,
5968,,17824,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",F,
5969,,17528,9606.0,BAO_0000218,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),F,
5970,,6870,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,F,
5971,,6870,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,F,
5972,,6870,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,F,
5973,,6870,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,F,
5974,,16726,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,F,
5975,,6170,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",F,
5976,,6583,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,F,
5977,,6583,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,F,
5978,,6583,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,F,
5979,,6583,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,F,
5980,,6583,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,F,
5981,,17321,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,F,
5982,,17528,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,F,
5983,,12888,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,F,
5984,,4312,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,F,
5985,,4312,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,F,
5986,,4312,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,F,
5987,,17737,10090.0,BAO_0000219,,,646.0,Intermediate,1,Mus musculus,,1,,N,,In vitro antiproliferative activity against A549 cell line,F,
5988,,6630,,BAO_0000219,,,646.0,Intermediate,1,,,1,,N,,Synergism with indomethacin in A549 cells,F,
5989,,6630,,BAO_0000219,,,646.0,Intermediate,1,,,1,,N,,Synergism with tolmetin in A549 cells,F,
5990,,6630,,BAO_0000219,,,646.0,Intermediate,1,,,1,,N,,Synergism with sulindac in A549 cells,F,
5991,,6630,,BAO_0000219,,,646.0,Intermediate,1,,,1,,N,,Antagonism of indomethacin in A549 cells,F,
5992,,6630,,BAO_0000219,,,646.0,Intermediate,1,,,1,,N,,Antagonism of sulindac in A549 cells,F,
5993,,6630,,BAO_0000219,,,646.0,Intermediate,1,,,1,,N,,Antagonism of tolmetin in A549 cells,F,
5994,,6630,,BAO_0000219,,,646.0,Intermediate,1,,,1,,N,,Synergism with indomethacin in A549 cells,F,
5995,,6630,,BAO_0000219,,,646.0,Intermediate,1,,,1,,N,,Synergism with sulindac in A549 cells,F,
5996,,6630,,BAO_0000219,,,646.0,Intermediate,1,,,1,,N,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,F,
5997,,16907,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Cmax value after 30 mg/kg po dose in Dogs,A,
5998,,5944,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),A,
5999,,5944,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,A,
6000,,5944,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),A,
6001,,5944,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,A,
6002,,2959,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Cmax value after administration of 4 mg/Kg oral dose in dog,A,
6003,,6241,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Cmax value in dog,A,
6004,,6241,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Cmax value in dogs after oral administration at 1 mg/kg,A,
6005,,2652,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,A,
6006,1969.0,1806,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,A,Plasma
6007,1969.0,1806,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,A,Plasma
6008,,1021,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Concentration maxima after oral dosing in dogs,A,
6009,,1021,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Concentration maxima after oral dosing in dogs; not available,A,
6010,,1021,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Concentration maxima after oral dosing in dogs; not available,A,
6011,,5444,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,A,
6012,,5444,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,A,
6013,,5444,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,In vivo maximal concentration was calculated at 1 mg/kg in dog,A,
6014,,5444,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,A,
6015,,5444,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,A,
6016,1969.0,5130,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Cmax in dog plasma after oral dose (1 mg/kg),A,Plasma
6017,1969.0,3249,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,A,Plasma
6018,1969.0,5473,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Maximal plasma concentration at a dose of 1 mg/kg,A,Plasma
6019,1969.0,5474,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Maximal plasma concentration at a dose of 1 mg/kg (oral),A,Plasma
6020,1969.0,4657,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,A,Plasma
6021,,3031,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Maximum concentration of compound in dog was evaluated.,A,
6022,,4527,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,A,
6023,,4186,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,A,
6024,,5007,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,
6025,1969.0,3132,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Maximum concentration obtained in dog plasma was determined,A,Plasma
6026,,5006,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Maximum concentration was determined,A,
6027,,4727,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Maximum concentration at the dose of 2 mg/kg in dog,A,
6028,,1916,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,
6029,1969.0,1918,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Maximum concentration was evaluated in dog plasma,A,Plasma
6030,,3045,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Maximum concentration was evaluated after 75 min after administration in dog,A,
6031,1969.0,9579,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Maximum plasma concentration determined in dog after oral administration of 17b,A,Plasma
6032,1969.0,9579,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Maximum plasma concentration determined in dog after oral administration of 2b,A,Plasma
6033,1969.0,933,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Maximum plasma concentration in dog,A,Plasma
6034,1969.0,17839,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,A,Plasma
6035,1969.0,17839,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,A,Plasma
6036,1969.0,17839,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,A,Plasma
6037,1969.0,17839,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,A,Plasma
6038,1969.0,6348,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,Plasma
6039,1969.0,16367,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,A,Plasma
6040,1969.0,1337,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,Plasma
6041,1969.0,1337,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,Plasma
6042,1969.0,5199,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,A,Plasma
6043,1969.0,17650,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,A,Plasma
6044,1969.0,6679,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,A,Plasma
6045,1969.0,5356,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,A,Plasma
6046,1969.0,5356,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,A,Plasma
6047,1969.0,6227,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,A,Plasma
6048,1969.0,6227,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,A,Plasma
6049,1969.0,6227,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,A,Plasma
6050,1969.0,6227,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,A,Plasma
6051,1969.0,3598,9615.0,BAO_0000218,,,,Expert,1,Canis lupus familiaris,In vivo,1,,N,,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,A,Plasma
6052,,4368,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,A,
6053,,6265,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,A,
6054,945.0,7767,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,Stomach
6055,1088.0,7767,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,Urine
6056,1088.0,7767,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,A,Urine
6057,1088.0,7767,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,A,Urine
6058,,17811,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,A,
6059,,17811,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,A,
6060,,17827,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),A,
6061,178.0,17827,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),A,Blood
6062,,17827,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),A,
6063,,17827,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),A,
6064,,17827,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),A,
6065,178.0,17827,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),A,Blood
6066,178.0,17827,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),A,Blood
6067,,17827,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Compound was evaluated for washout rate in mice (Radiolabeled compound),A,
6068,,17827,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,A,
6069,,17827,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,
6070,,17827,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,
6071,,17827,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,
6072,,17257,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,A,
6073,,17257,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,A,
6074,,17257,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,A,
6075,,17257,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,A,
6076,,17827,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Time at maximum activity in mice (Radiolabeled compound),A,
6077,,3760,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,A,
6078,,3760,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,A,
6079,,17409,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Binding towards mouse plasma protein at 10 uM,A,
6080,,17409,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Binding towards mouse plasma protein at 100 uM,A,
6081,,2675,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Bioavailability was evaluated in mice after intravenous administration,A,
6082,,2675,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Bioavailability was evaluated in mice after oral administration,A,
6083,,3132,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,A,
6084,,3132,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,A,
6085,,16597,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,A,
6086,,2862,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Oral bioavailability in mouse,A,
6087,,17764,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Oral bioavailability after intravenous administration in mice at 24 uM/kg,A,
6088,955.0,846,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,Brain
6089,955.0,846,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,Brain
6090,955.0,846,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,Brain
6091,955.0,846,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,Brain
6092,955.0,846,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,Brain
6093,955.0,846,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,Brain
6094,948.0,846,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,Heart
6095,948.0,846,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,Heart
6096,948.0,846,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,Heart
6097,948.0,846,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,Heart
6098,,1276,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),F,
6099,,3498,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,F,
6100,,1169,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity against human lung carcinoma A-549 cell lines,F,
6101,,4450,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,F,
6102,,358,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against human lung carcinoma cell line A-549,F,
6103,,358,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,F,
6104,,358,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,F,
6105,,358,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,F,
6106,,358,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,F,
6107,,358,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,F,
6108,,358,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,F,
6109,,15167,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against A-549 human lung cancer cells,F,
6110,,4139,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,F,
6111,,833,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,F,
6112,,15718,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,F,
6113,,12373,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Tested in vitro for cytotoxicity against A-549 lung cancer cells,F,
6114,,637,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,F,
6115,,14867,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,F,
6116,,4461,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Antitumor cytotoxic activity against A-549 cell line was determined,F,
6117,,5406,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",F,
6118,,4457,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,F,
6119,,1386,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,F,
6120,,3265,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Antitumoral activity was assayed against A-549 cell line,F,
6121,,2359,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,F,
6122,,4457,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,F,
6123,,12454,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,
6124,,1481,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for inhibition of cell growth of A-549 cells,F,
6125,,1750,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,F,
6126,,5065,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,F,
6127,,808,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against A549-human lung carcinoma cells.,F,
6128,,16364,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,F,
6129,,1847,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxic activity against A-549 cell lines.,F,
6130,,1747,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,F,
6131,,1003,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity against human A549 non small cell lung cell lines,F,
6132,,15313,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Inhibition of cell growth in (A-549) lung cell line,F,
6133,,3122,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,F,
6134,,16049,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro antitumor activity against A-549 tumor cells.,F,
6135,,17134,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,In vitro antitumor effects against human A-549 cell lines.,F,
6136,,6406,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxic activity of compound against A-549 cell line,F,
6137,,627,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against human lung carcinoma A-549 cell line,F,
6138,,12307,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against human non-small cell lung carcinoma A549,F,
6139,,17861,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,F,
6140,,6682,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,F,
6141,,6663,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory concentration of compound against A-549 cell line,F,
6142,,2454,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,F,
6143,,14709,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,cytotoxic activity against leukemia (A-549) cancer cell line,F,
6144,,15718,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,F,
6145,,15718,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,F,
6146,,17130,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),F,
6147,,17130,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),F,
6148,,17130,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),F,
6149,,17130,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),F,
6150,,6630,,BAO_0000219,,,646.0,Intermediate,1,,,1,,N,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,F,
6151,,16726,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,F,
6152,,17846,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity against A549 cells; No cytotoxicity,F,
6153,,3415,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Cytotoxicity against human lung carcinoma (A549) cell lines,F,
6154,,3415,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,F,
6155,,5609,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro anticancer activity against human lung (A549) cell line,F,
6156,,17206,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,F,
6157,,17206,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,F,
6158,,17206,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,F,
6159,,17206,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,F,
6160,,17206,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,F,
6161,,17206,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,F,
6162,,16295,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Inhibition of A549 human lung tumor cell proliferation,F,
6163,,16825,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",F,
6164,,3439,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against human tumor cell line A549,F,
6165,,10870,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,F,
6166,,4845,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,F,
6167,,5822,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,F,
6168,,5822,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,F,
6169,,5822,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,F,
6170,,16381,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,F,
6171,,16381,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,F,
6172,,16381,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,F,
6173,,5609,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro anticancer activity against human lung (A549) cell line,F,
6174,,4644,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,F,
6175,,4644,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,F,
6176,,4644,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,F,
6177,,4644,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,F,
6178,,5822,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,F,
6179,,3415,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Percentage inhibition of human lung carcinoma (A549) cell lines,F,
6180,,16726,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,F,
6181,,17206,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",F,
6182,,17206,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,F,
6183,,17206,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,F,
6184,,17206,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",F,
6185,,17206,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",F,
6186,,17206,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",F,
6187,,17206,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",F,
6188,,17206,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",F,
6189,,17206,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,F,
6190,,17206,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,F,
6191,,16726,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,F,
6192,,17206,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,F,
6193,,17206,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,F,
6194,,17206,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,F,
6195,,17206,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,F,
6196,,6084,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,A,
6197,,6084,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Pharmacokinetic activity (Cmax) in dog,A,
6198,,4809,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,
6199,,5983,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,A,
6200,,6251,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,A,
6201,1969.0,5932,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Cmax in dog plasma after 30mg/kg oral dose,A,Plasma
6202,178.0,4273,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Tested for the peak blood level in dog,A,Blood
6203,,5313,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",A,
6204,,5313,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",A,
6205,178.0,6221,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,A,Blood
6206,,4709,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,A,
6207,,167,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,A,
6208,1969.0,6241,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Final plasma concentration in dogs after oral administration at 1 mg/kg,A,Plasma
6209,,344,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,A,
6210,,344,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,A,
6211,,344,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,A,
6212,,2189,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,A,
6213,1088.0,2189,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,A,Urine
6214,1088.0,2189,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,A,Urine
6215,1088.0,2189,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,A,Urine
6216,,4257,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Absolute bioavailability was evaluated in dog,A,
6217,,6221,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,A,
6218,,6215,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability after peroral administration (1 mg/kg) was determined in dog,A,
6219,,17267,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability in dog,A,
6220,,6621,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability in dog,A,
6221,,3854,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability after intravenous administration in dogs,A,
6222,,3854,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability after peroral administration in dogs,A,
6223,,5007,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),A,
6224,,4333,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,A,
6225,1969.0,4333,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,A,Plasma
6226,,5006,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability,A,
6227,,5199,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability,A,
6228,,4368,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability by intravenous administration of 1.2 mg/kg in dog,A,
6229,,3771,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability in dog,A,
6230,,4953,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability in dog,A,
6231,,5064,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability in dog,A,
6232,,17657,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability in dog,A,
6233,,17796,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability in dog,A,
6234,,17853,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability in dog (p.o.) at 2.0 mpk,A,
6235,,4521,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),A,
6236,,4521,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,
6237,,5006,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability in dog,A,
6238,,16365,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability was evaluated after oral administration in dog,A,
6239,,1916,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,
6240,,1918,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability was evaluated in dog,A,
6241,,4239,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability in dog,A,
6242,,6505,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability in dog,A,
6243,,5334,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,
6244,,5334,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),A,
6245,,4809,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,
6246,,6348,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,
6247,,6005,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,A,
6248,,17804,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability of compound in dog was determined after peroral administration,A,
6249,,3184,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog,A,
6250,,1806,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,A,
6251,,1806,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,A,
6252,,1806,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Compound was evaluated for oral bioavailability in dogs; 37-38 %,A,
6253,,4839,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability in dog,A,
6254,,5017,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),A,
6255,948.0,846,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,Heart
6256,948.0,846,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,Heart
6257,2113.0,846,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,Kidney
6258,2113.0,846,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,Kidney
6259,2113.0,846,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,Kidney
6260,2113.0,846,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,Kidney
6261,2113.0,846,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,Kidney
6262,2113.0,846,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,Kidney
6263,2107.0,846,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,Liver
6264,2107.0,846,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,Liver
6265,2107.0,846,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,Liver
6266,2107.0,846,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,Liver
6267,2107.0,846,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,Liver
6268,2107.0,846,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,Liver
6269,2048.0,846,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,Lung
6270,2048.0,846,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,Lung
6271,2048.0,846,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,Lung
6272,2048.0,846,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,Lung
6273,2048.0,846,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,Lung
6274,2048.0,846,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,Lung
6275,,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,A,
6276,,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,A,
6277,,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,A,
6278,,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,A,
6279,,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,A,
6280,955.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,A,Brain
6281,955.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,A,Brain
6282,955.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,A,Brain
6283,955.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,A,Brain
6284,955.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,A,Brain
6285,948.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,A,Heart
6286,948.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,A,Heart
6287,948.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,A,Heart
6288,948.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,A,Heart
6289,948.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,A,Heart
6290,2113.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,A,Kidney
6291,2113.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,A,Kidney
6292,2113.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,A,Kidney
6293,,17130,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,F,
6294,,17130,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,F,
6295,,17130,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),F,
6296,,17130,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),F,
6297,,3263,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,F,
6298,,6663,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,F,
6299,,6663,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,F,
6300,,6663,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,F,
6301,,6663,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,F,
6302,,6663,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,F,
6303,,6663,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,F,
6304,,6663,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,F,
6305,,6663,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,F,
6306,,6663,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,F,
6307,,6663,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,F,
6308,,3983,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,The compound was evaluated for its cytotoxic potency against A-549 cell line,F,
6309,,11141,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,F,
6310,,5076,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxic activity of compound against A-549 tumor cell line.,F,
6311,,3311,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,F,
6312,,3311,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,F,
6313,,3311,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,F,
6314,,5076,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,F,
6315,,4150,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),F,
6316,,2150,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,F,
6317,,4644,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,F,
6318,,263,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,F,
6319,,11333,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxic concentration against A-549 tumor cells.,F,
6320,,11333,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,F,
6321,,15895,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",F,
6322,,16677,470.0,BAO_0000218,,,,Expert,1,Acinetobacter baumannii,,1,,N,,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,F,
6323,,10624,471.0,BAO_0000218,,,,Intermediate,1,Acinetobacter calcoaceticus,,1,,N,,Activity against Acinetobacter calcoaceticus (AC54),F,
6324,,16717,5059.0,BAO_0000218,,,,Expert,1,Aspergillus flavus,,1,,N,,In vitro antifungal activity against Aspergillus flavus CM74,F,
6325,,16717,5059.0,BAO_0000218,,,,Expert,1,Aspergillus flavus,,1,,N,,In vitro antifungal activity against Aspergillus flavus CM74,F,
6326,,5513,746128.0,BAO_0000218,,,,Intermediate,1,Aspergillus fumigatus,,1,,N,,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,F,
6327,,15962,746128.0,BAO_0000218,,,,Intermediate,1,Aspergillus fumigatus,,1,,N,,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),F,
6328,,15962,746128.0,BAO_0000218,,,,Intermediate,1,Aspergillus fumigatus,,1,,N,,Antimicrobial activity against Aspergillus fumigatus (MIC),F,
6329,,15962,746128.0,BAO_0000218,,,,Intermediate,1,Aspergillus fumigatus,,1,,N,,Antimicrobial activity against Aspergillus fumigatus (MIC),F,
6330,,15962,746128.0,BAO_0000218,,,,Intermediate,1,Aspergillus fumigatus,,1,,N,,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),F,
6331,,16717,746128.0,BAO_0000218,,,,Expert,1,Aspergillus fumigatus,,1,,N,,In vitro antifungal activity against Aspergillus fumigatus 48238E,F,
6332,,16717,746128.0,BAO_0000218,,,,Expert,1,Aspergillus fumigatus,,1,,N,,In vitro antifungal activity against Aspergillus fumigatus 48238E,F,
6333,,8117,1655.0,BAO_0000218,,,,Intermediate,1,Actinomyces naeslundii,,1,,N,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,F,
6334,,8117,1656.0,BAO_0000218,,,,Intermediate,1,Actinomyces viscosus,,1,,N,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,F,
6335,,15472,6277.0,BAO_0000218,,,,Intermediate,1,Acanthocheilonema viteae,,1,,N,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),F,
6336,,15472,6277.0,BAO_0000218,,,,Intermediate,1,Acanthocheilonema viteae,,1,,N,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),F,
6337,,16443,714.0,BAO_0000218,,,,Intermediate,1,Aggregatibacter actinomycetemcomitans,,1,,N,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,F,
6338,,16443,714.0,BAO_0000218,,,,Intermediate,1,Aggregatibacter actinomycetemcomitans,,1,,N,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,F,
6339,,16443,714.0,BAO_0000218,,,,Intermediate,1,Aggregatibacter actinomycetemcomitans,,1,,N,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,F,
6340,,17206,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,F,
6341,,17206,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,F,
6342,,16381,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,F,
6343,,16381,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,F,
6344,,16381,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,F,
6345,,16381,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,GI values against A549 cells (lung cancer),F,
6346,,17206,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,F,
6347,,16325,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory activity against A549 human adenocarcinoma,F,
6348,,10708,9606.0,BAO_0000218,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,F,
6349,,10708,9606.0,BAO_0000218,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,F,
6350,,17376,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory activity against A549 lung adenocarcinoma cell line,F,
6351,,17376,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,F,
6352,,17488,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity against human A549 lung cells,F,
6353,,17404,9606.0,BAO_0000218,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,F,
6354,,10958,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Growth inhibition of A549 (human lung carcinoma) cell line.,F,
6355,,17099,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Effective dose required for inhibitory activity against A549 human tumor cell line.,F,
6356,,17099,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,F,
6357,,4096,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,F,
6358,,4096,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,F,
6359,,4096,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,F,
6360,,2525,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro inhibitory activity against A549 tumor cell culture,F,
6361,,2525,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,F,
6362,,5302,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),F,
6363,,16325,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,F,
6364,,16939,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,F,
6365,,17229,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,F,
6366,,17380,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,F,
6367,,17380,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,F,
6368,,1903,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,F,
6369,,3838,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,F,
6370,,14696,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,F,
6371,,3838,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,F,
6372,,1522,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,F,
6373,,12400,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Tested in vitro for cytotoxicity in A549/ATCC cell lines,F,
6374,,14696,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,F,
6375,,14769,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),F,
6376,,14696,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,F,
6377,,1888,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,F,
6378,,12016,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,F,
6379,,6058,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,F,
6380,,17708,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,F,
6381,,12301,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Antitumor activity against A549/ATCC cell line,F,
6382,,11970,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,F,
6383,,11818,9606.0,BAO_0000219,,,646.0,Expert,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against A549/ATCC cell line.,F,
6384,,12400,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,F,
6385,,3381,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,F,
6386,,17376,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,F,
6387,,10708,9606.0,BAO_0000219,,,646.0,Intermediate,1,Homo sapiens,,1,,N,,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,F,
6388,,2964,9606.0,BAO_0000219,,,,Autocuration,1,Homo sapiens,,0,,U,,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,F,
6389,,5005,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,0,,U,,Compound was tested for oral bioavailability in dogs,A,
6390,,6229,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,A,
6391,,6229,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,A,
6392,,5374,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog,A,
6393,,5374,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Compound was tested for the oral bioavailability in dog; No availability,A,
6394,,6265,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog (dose 5 mg/kg),A,
6395,,5654,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,A,
6396,,5654,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,A,
6397,,16456,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),A,
6398,,5302,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog (dose 5 mg/kg),A,
6399,,3624,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),A,
6400,,16452,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability of active FTIs in dogs,A,
6401,,5802,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),A,
6402,,3598,9615.0,BAO_0000218,,,,Expert,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,A,
6403,,17839,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog,A,
6404,,6762,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog,A,
6405,,6821,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog,A,
6406,,6821,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability of compound was determined in dog; Not tested,A,
6407,,5210,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog,A,
6408,,6227,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability (10 mg/kg) was determined in dog,A,
6409,,761,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability,A,
6410,,761,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),A,
6411,,761,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability administered in solution in rats,A,
6412,,16907,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability after 30 mg/kg po dose in Dogs,A,
6413,,5474,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability at a dose of 1 mg/kg in dogs,A,
6414,,6535,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog (dose 1 mg/kg p.o.),A,
6415,,6535,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in Dog; ND = not determined,A,
6416,,3352,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog,A,
6417,,6168,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog,A,
6418,,5988,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog,A,
6419,,4942,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog,A,
6420,,4942,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dogs; No data,A,
6421,,14541,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability measured in dogs,A,
6422,,4449,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog,A,
6423,,6057,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability was calculated in dog,A,
6424,,5600,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability after 0.3 mg/kg po administration in dog,A,
6425,,5542,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog (i.v. dosing),A,
6426,,5542,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog,A,
6427,,5546,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,A,
6428,,4514,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in Beagle dogs,A,
6429,,3624,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog,A,
6430,,3854,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog,A,
6431,,5836,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog,A,
6432,,5940,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog,A,
6433,,6168,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog,A,
6434,,6227,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog,A,
6435,,6251,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog,A,
6436,,6448,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog,A,
6437,,6647,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog,A,
6438,,5940,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog,A,
6439,,933,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog,A,
6440,,5210,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog,A,
6441,,6642,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),A,
6442,,6641,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),A,
6443,,6642,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),A,
6444,,5472,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog,A,
6445,,5985,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog,A,
6446,,15660,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog,A,
6447,,5530,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),A,
6448,,5530,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog (dose 1 mg/kg i.v.),A,
6449,,6305,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability (F) in dogs,A,
6450,,5210,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog,A,
6451,,5238,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability in dog,A,
6452,,5668,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog (dose 10 mg/kg),A,
6453,,5668,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability after peroral administration at 5 mpk in Dog,A,
6454,,5668,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog (dose 5 mg/kg),A,
6455,,6084,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog (dose 10 mg/kg),A,
6456,2113.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,A,Kidney
6457,2113.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,A,Kidney
6458,2107.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,A,Liver
6459,2107.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,A,Liver
6460,2107.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,A,Liver
6461,2107.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,A,Liver
6462,2107.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,A,Liver
6463,2048.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,A,Lung
6464,2048.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,A,Lung
6465,2048.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,A,Lung
6466,2048.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,A,Lung
6467,2048.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,A,Lung
6468,,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,A,
6469,,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,A,
6470,,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,A,
6471,,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,A,
6472,,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,A,
6473,2106.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,A,Spleen
6474,2106.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,A,Spleen
6475,2106.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,A,Spleen
6476,2106.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,A,Spleen
6477,2106.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,A,Spleen
6478,,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,A,
6479,,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,A,
6480,,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,A,
6481,,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,A,
6482,,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,A,
6483,,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,A,
6484,,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,A,
6485,,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,A,
6486,,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,A,
6487,,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,A,
6488,948.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,A,Heart
6489,948.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,A,Heart
6490,948.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,A,Heart
6491,948.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,A,Heart
6492,948.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,A,Heart
6493,2107.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,A,Liver
6494,2107.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,A,Liver
6495,2107.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,A,Liver
6496,2107.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,A,Liver
6497,2107.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,A,Liver
6498,2048.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,A,Lung
6499,2048.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,A,Lung
6500,,12269,107673.0,BAO_0000218,,,,Intermediate,1,aeinetobacter anitrotap,,1,,N,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,
6501,,12269,107673.0,BAO_0000218,,,,Intermediate,1,Acinetobacter calcoaceticus subsp. anitratus,,1,,N,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,
6502,,12269,107673.0,BAO_0000218,,,,Intermediate,1,Acinetobacter calcoaceticus subsp. anitratus,,1,,N,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,
6503,,12269,107673.0,BAO_0000218,,,,Intermediate,1,aeinetobacter anitrotap,,1,,N,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,
6504,,10624,471.0,BAO_0000218,,,,Intermediate,1,Acinetobacter calcoaceticus,,1,,N,,Activity against Acinetobacter calcoaceticus (AC54),F,
6505,,17216,28377.0,BAO_0000218,,,,Intermediate,1,Anolis carolinensis,,1,,N,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,F,
6506,,17216,28377.0,BAO_0000218,,,,Intermediate,1,Anolis carolinensis,,1,,N,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,F,
6507,,9560,1655.0,BAO_0000218,,,,Intermediate,1,Actinomyces naeslundii,,1,,N,,Chlorohexidine coefficient for Actinomyces naeslundii 631,F,
6508,,9560,1655.0,BAO_0000218,,,,Intermediate,1,Actinomyces naeslundii,,1,,N,,Chlorohexidine coefficient for Actinomyces naeslundii B74,F,
6509,,9560,1655.0,BAO_0000218,,,,Intermediate,1,Actinomyces naeslundii,,1,,N,,Chlorohexidine coefficient for Actinomyces naeslundii N/3,F,
6510,,9560,1655.0,BAO_0000218,,,,Intermediate,1,Actinomyces naeslundii,,1,,N,,Chlorohexidine coefficient for Actinomyces naeslundii N/9,F,
6511,,9560,1655.0,BAO_0000218,,,,Intermediate,1,Actinomyces naeslundii,,1,,N,,Plaque bactericidal index against Actinomyces naeslundii 631,F,
6512,,9560,1655.0,BAO_0000218,,,,Intermediate,1,Actinomyces naeslundii,,1,,N,,Plaque bactericidal index against Actinomyces naeslundii N/9,F,
6513,,9560,1655.0,BAO_0000218,,,,Intermediate,1,Actinomyces naeslundii,,1,,N,,Plaque bactericidal index against Actinomyces naeslundii B74,F,
6514,,9560,1655.0,BAO_0000218,,,,Intermediate,1,Actinomyces naeslundii,,1,,N,,Plaque bactericidal index against Actinomyces naeslundii N/3,F,
6515,,114,85549.0,BAO_0000218,,,,Intermediate,1,Artemia salina,,1,,N,,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,F,
6516,,114,85549.0,BAO_0000218,,,,Intermediate,1,Artemia salina,,1,,N,,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",F,
6517,,10841,6253.0,BAO_0000218,,,,Intermediate,1,Ascaris suum,,1,,N,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,F,
6518,,10841,6253.0,BAO_0000218,,,,Intermediate,1,Ascaris suum,,1,,N,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,F,
6519,,10841,6253.0,BAO_0000218,,,,Intermediate,1,Ascaris suum,,1,,N,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,F,
6520,,10841,6253.0,BAO_0000218,,,,Intermediate,1,Ascaris suum,,1,,N,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,F,
6521,,10841,6253.0,BAO_0000218,,,,Intermediate,1,Ascaris suum,,1,,N,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,F,
6522,,10841,6253.0,BAO_0000218,,,,Intermediate,1,Ascaris suum,,1,,N,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,F,
6523,,10841,6253.0,BAO_0000218,,,,Intermediate,1,Ascaris suum,,1,,N,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,F,
6524,,10841,6253.0,BAO_0000218,,,,Intermediate,1,Ascaris suum,,1,,N,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,F,
6525,,10841,6253.0,BAO_0000218,,,,Intermediate,1,Ascaris suum,,1,,N,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,F,
6526,,10841,6253.0,BAO_0000218,,,,Intermediate,1,Ascaris suum,,1,,N,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,F,
6527,,10841,6253.0,BAO_0000218,,,,Intermediate,1,Ascaris suum,,1,,N,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,F,
6528,,10841,6253.0,BAO_0000218,,,,Intermediate,1,Ascaris suum,,1,,N,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,F,
6529,,8117,1656.0,BAO_0000218,,,,Intermediate,1,Actinomyces viscosus,,1,,N,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,F,
6530,,8117,1656.0,BAO_0000218,,,,Intermediate,1,Actinomyces viscosus,,1,,N,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,F,
6531,,9560,1656.0,BAO_0000218,,,,Intermediate,1,Actinomyces viscosus,,1,,N,,Chlorohexidine coefficient for Actinomyces viscosus 8A06,F,
6532,,9560,1656.0,BAO_0000218,,,,Expert,1,Actinomyces viscosus,,1,,N,,Chlorohexidine coefficient for Actinomyces viscosus M-100,F,
6533,,9560,1656.0,BAO_0000218,,,,Intermediate,1,Actinomyces viscosus,,1,,N,,Chlorohexidine coefficient for Actinomyces viscosus M-626,F,
6534,,9560,1656.0,BAO_0000218,,,,Intermediate,1,Actinomyces viscosus,,1,,N,,Chlorohexidine coefficient for Actinomyces viscosus T14V,F,
6535,,9560,1656.0,BAO_0000218,,,,Intermediate,1,Actinomyces viscosus,,1,,N,,Plaque bactericidal index against Actinomyces viscosus 8A06,F,
6536,,9560,1656.0,BAO_0000218,,,,Intermediate,1,Actinomyces viscosus,,1,,N,,Plaque bactericidal index against Actinomyces viscosus M-100,F,
6537,,9560,1656.0,BAO_0000218,,,,Expert,1,Actinomyces viscosus,,1,,N,,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,F,
6538,,9560,1656.0,BAO_0000218,,,,Intermediate,1,Actinomyces viscosus,,1,,N,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",F,
6539,,9560,1656.0,BAO_0000218,,,,Intermediate,1,Actinomyces viscosus,,1,,N,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",F,
6540,,9560,1656.0,BAO_0000218,,,,Intermediate,1,Actinomyces viscosus,,1,,N,,Plaque bactericidal index against Actinomyces viscosus 626,F,
6541,,9560,1656.0,BAO_0000218,,,,Intermediate,1,Actinomyces viscosus,,1,,N,,Plaque bactericidal index against Actinomyces viscosus T14V,F,
6542,,10986,6277.0,BAO_0000218,,,,Intermediate,1,Acanthocheilonema viteae,,1,,N,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,F,
6543,,10986,6277.0,BAO_0000218,,,,Intermediate,1,Acanthocheilonema viteae,,1,,N,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,F,
6544,,10986,6277.0,BAO_0000218,,,,Intermediate,1,Acanthocheilonema viteae,,1,,N,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,F,
6545,,10986,6277.0,BAO_0000218,,,,Intermediate,1,Acanthocheilonema viteae,,1,,N,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,F,
6546,,10986,6277.0,BAO_0000218,,,,Intermediate,1,Acanthocheilonema viteae,,1,,N,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,F,
6547,,10708,9606.0,BAO_0000219,,,165.0,Intermediate,1,Homo sapiens,,1,,N,,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,F,
6548,,10708,9606.0,BAO_0000219,,,645.0,Intermediate,1,Homo sapiens,,1,,N,,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,F,
6549,,416,10116.0,BAO_0000219,,,,Autocuration,1,Rattus norvegicus,,0,,U,,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,F,
6550,,14354,10090.0,BAO_0000219,,,625.0,Intermediate,1,Mus musculus,,1,,N,,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,F,
6551,,14354,10090.0,BAO_0000219,,,625.0,Intermediate,1,Mus musculus,,1,,N,,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,F,
6552,,5116,9606.0,BAO_0000219,,,625.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,F,
6553,,5116,9606.0,BAO_0000219,,,625.0,Intermediate,1,Homo sapiens,,1,,N,,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,F,
6554,,15694,9606.0,BAO_0000219,,,874.0,Expert,1,Homo sapiens,,1,,N,,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,F,
6555,,13038,10090.0,BAO_0000219,,,625.0,Expert,1,Mus musculus,,1,,N,,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",F,
6556,,13038,10090.0,BAO_0000219,,,625.0,Expert,1,Mus musculus,,1,,N,,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,F,
6557,,10923,10090.0,BAO_0000219,,,625.0,Expert,1,Mus musculus,,1,,N,,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,F,
6558,,10923,10090.0,BAO_0000219,,,625.0,Intermediate,1,Mus musculus,,1,,N,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,F,
6559,,10923,10090.0,BAO_0000219,,,625.0,Intermediate,1,Mus musculus,,1,,N,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,F,
6560,,10923,,BAO_0000019,,,,Expert,1,,,8,,H,,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",F,
6561,,10923,10090.0,BAO_0000219,,,625.0,Intermediate,1,Mus musculus,,1,,N,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,F,
6562,,10923,10090.0,BAO_0000219,,,625.0,Intermediate,1,Mus musculus,,1,,N,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,F,
6563,,8158,10029.0,BAO_0000219,,,975.0,Intermediate,1,Cricetulus griseus,,1,,N,,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,F,
6564,,15494,9606.0,BAO_0000219,,,,Autocuration,1,Homo sapiens,,0,,U,,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,F,
6565,,15494,9606.0,BAO_0000219,,,,Autocuration,1,Homo sapiens,,0,,U,,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",F,
6566,,12348,9606.0,BAO_0000219,,,974.0,Intermediate,1,Homo sapiens,,1,,N,,Anti -HIV activity was measured against AA5/HIV-1(IIIB),F,
6567,,12348,9606.0,BAO_0000219,,,974.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity was measured against AA5/HIV-1(IIIB),F,
6568,,2726,9606.0,BAO_0000219,,,974.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,F,
6569,,2726,9606.0,BAO_0000219,,,379.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,F,
6570,,10747,10029.0,BAO_0000219,,,274.0,Intermediate,1,Cricetulus griseus,,1,,N,,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,F,
6571,,11005,10029.0,BAO_0000219,,,185.0,Expert,1,Cricetulus griseus,,1,,N,,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",F,
6572,,12687,10029.0,BAO_0000219,,,185.0,Intermediate,1,Cricetulus griseus,,1,,N,,Average intracellular compound concentration when the hypoxic SER=1.6,F,
6573,,12687,10029.0,BAO_0000219,,,185.0,Intermediate,1,Cricetulus griseus,,1,,N,,Average intracellular compound concentration when the hypoxic SER=1.6.,F,
6574,,12687,10029.0,BAO_0000219,,,185.0,Intermediate,1,Cricetulus griseus,,1,,N,,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,F,
6575,,12687,10029.0,BAO_0000219,,,185.0,Intermediate,1,Cricetulus griseus,,1,,N,,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,F,
6576,,12687,10029.0,BAO_0000219,,,185.0,Intermediate,1,Cricetulus griseus,,1,,N,,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,F,
6577,,13436,10029.0,BAO_0000219,,,185.0,Intermediate,1,Cricetulus griseus,,1,,N,,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",F,
6578,,13435,10029.0,BAO_0000219,,,185.0,Intermediate,1,Cricetulus griseus,,1,,N,,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",F,
6579,,13302,10029.0,BAO_0000219,,,185.0,Intermediate,1,Cricetulus griseus,,1,,N,,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,F,
6580,,12687,10029.0,BAO_0000219,,,185.0,Intermediate,1,Cricetulus griseus,,1,,N,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,F,
6581,,12687,10029.0,BAO_0000219,,,185.0,Intermediate,1,Cricetulus griseus,,1,,N,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,A,
6582,,12687,10029.0,BAO_0000219,,,185.0,Intermediate,1,Cricetulus griseus,,1,,N,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,A,
6583,,12878,10029.0,BAO_0000219,,,185.0,Expert,1,Cricetulus griseus,,1,,N,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,A,
6584,,12878,10029.0,BAO_0000219,,,185.0,Intermediate,1,Cricetulus griseus,,1,,N,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,A,
6585,,14367,10029.0,BAO_0000219,,,185.0,Expert,1,Cricetulus griseus,,1,,N,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,F,
6586,,14367,10029.0,BAO_0000219,,,185.0,Intermediate,1,Cricetulus griseus,,1,,N,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,F,
6587,,12398,36483.0,BAO_0000219,,,185.0,Expert,1,hampster,,1,,N,,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,F,
6588,,12878,10029.0,BAO_0000219,,,185.0,Expert,1,Cricetulus griseus,,1,,N,,Aerobic growth inhibition in Chinese hamster cell line AA8,F,
6589,,13820,10029.0,BAO_0000219,,,185.0,Expert,1,Cricetulus griseus,,1,,N,,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,F,
6590,,13436,10029.0,BAO_0000219,,,185.0,Expert,1,Cricetulus griseus,,1,,N,,Inhibition of growth under aerobic conditions in AA8 cells,F,
6591,,6084,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog (dose 10 mg/kg),A,
6592,,5711,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog at 10 mg/kg of the compound,A,
6593,,4353,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog (dose 5 uM/kg),A,
6594,,4353,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog (dose 5 uM/kg),A,
6595,,17800,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog (mongrel),A,
6596,,3994,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog (dose 10 mg/kg),A,
6597,,3994,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog (dose 10 mg/kg),F,
6598,,5145,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability in dog,A,
6599,,16452,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability in dog (dose 1 mg/kg i.v.),A,
6600,,16452,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),A,
6601,,5983,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,A,
6602,,4273,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability in dog,A,
6603,,12500,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability in dog (dose 3-10 mg/kg),A,
6604,1969.0,12500,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,The compound was tested for bioavailability of compound in plasma of dog; Complete,A,Plasma
6605,,3639,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog,A,
6606,,3880,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog,A,
6607,,4838,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability in dog,A,
6608,,15600,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,oral bioavailability was measured in dogs,A,
6609,,17248,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Compound was tested for plasma protein binding in dog; Not determined,A,
6610,,17248,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Compound was tested for plasma protein binding of dog,A,
6611,,17248,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Compound was tested for plasma protein binding of dog; Not determined,A,
6612,,17443,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,A,
6613,,4186,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,A,
6614,,3749,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half life was determined,A,
6615,,3249,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,A,
6616,,3022,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half life was evaluated in dog,A,
6617,,3749,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half life was determined,A,
6618,,2517,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,
6619,948.0,2517,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,Heart
6620,2113.0,2517,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,Kidney
6621,2107.0,2517,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,Liver
6622,2048.0,2517,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,Lung
6623,2106.0,2517,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,Spleen
6624,,3639,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,LogP in dog,A,
6625,,6227,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Partition coefficient (logP),A,
6626,,6227,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Partition coefficient in dog,A,
6627,,17764,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,A,
6628,,4809,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),A,
6629,,5600,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,A,
6630,,14294,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),A,
6631,,14294,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),A,
6632,,14294,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Metabolism of compound in dog S9 microsomes; Trace,A,
6633,2107.0,6251,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,In vitro metabolic potential in dog liver microsomes,A,Liver
6634,,3748,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,A,
6635,,2713,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog,A,
6636,,6512,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog,A,
6637,,6679,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,
6638,,3749,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,The compound was tested for bioavailability in dogs,A,
6639,,3749,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,The compound was tested for oral bioavailability in dogs,A,
6640,,6742,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog,A,
6641,,6227,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Compound was tested for percent protein binding (PB) in dog,A,
6642,,6874,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,A,
6643,1969.0,2877,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Compound was evaluated for plasma clearance.,A,Plasma
6644,1969.0,12500,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,The compound was tested for plasma clearance in dog,A,Plasma
6645,1969.0,12500,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,A,Plasma
6646,,4709,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,A,
6647,2107.0,5542,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,In vitro relative rate of metabolism was determined in dog liver microsomes,A,Liver
6648,,17594,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,A,
6649,,2652,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,A,
6650,,17764,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life after intravenous administration in dogs at 1.2 uM/kg,A,
6651,2048.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,A,Lung
6652,2048.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,A,Lung
6653,2048.0,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,A,Lung
6654,,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,A,
6655,,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,A,
6656,,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,A,
6657,,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,A,
6658,,6599,10090.0,BAO_0000218,,,42.0,Intermediate,1,Mus musculus,,1,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,A,
6659,955.0,17641,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,C2 in brain of mice at the oral dose of 50 mg/kg,A,Brain
6660,2113.0,17641,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,C2 in kidney of mice at the oral dose of 50 mg/kg,A,Kidney
6661,2107.0,17641,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,C2 in liver of mice at the oral dose of 50 mg/kg,A,Liver
6662,2048.0,17641,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,C2 in lungs of mice at the oral dose of 50 mg/kg,A,Lung
6663,2106.0,17641,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,C2 in spleen of mice at the oral dose of 50 mg/kg,A,Spleen
6664,,17852,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Plasma clearance in mouse,A,
6665,,17764,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Clearance of compound after intravenous administration in mice at 24 uM/kg,A,
6666,,17837,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Clearance from mouse blood following i.v. administration of 10 mg/kg,A,
6667,,2675,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Clearance was evaluated in mice after intravenous administration,A,
6668,,2675,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Clearance was evaluated in mice after oral administration,A,
6669,,4239,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Pharmacokinetic property (Plasma clearance) was measured in mouse,A,
6670,,17753,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Plasma clearance of compound was determined at 40 mg/Kg,A,
6671,,17753,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Plasma clearance of at 24 mg/Kg,A,
6672,,17753,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Plasma clearance at 24 mg/Kg,A,
6673,,17753,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Plasma clearance at 5 mg/Kg,A,
6674,,5727,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Plasma clearance in mice,A,
6675,,2862,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Plasma clearance value upon iv administration in mouse,A,
6676,1969.0,5980,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Total plasma clearance in mice,A,Plasma
6677,,17592,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Clearance in mouse,A,
6678,,17718,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Clearance value was determined,A,
6679,,16597,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,A,
6680,,17384,,BAO_0000100,,,,Intermediate,1,,,0,,U,,Calculated partition coefficient (clogP),P,
6681,,6062,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,A,
6682,,17734,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,A,
6683,,6348,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,
6684,,5969,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,A,
6685,,5969,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,A,
6686,,5969,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,
6687,,16597,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,A,
6688,,5781,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Cmax after oral administration at 30 mg/kg in ICR mouse,A,
6689,,17764,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Cmax after peroral administration in mice at 2.4 uM/kg,A,
6690,955.0,17641,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Cmax in brain of mice at the oral dose of 50 mg/kg,A,Brain
6691,2113.0,17641,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Cmax in kidney of mice at the oral dose of 50 mg/kg,A,Kidney
6692,2107.0,17641,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Cmax in liver of mice at the oral dose of 50 mg/kg,A,Liver
6693,2048.0,17641,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Cmax in lungs of mice at the oral dose of 50 mg/kg,A,Lung
6694,,17764,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Cmax in mice at 18 uM/kg i.p. administration,F,
6695,,17764,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Cmax in mice at 23 uM/kg i.v. administration,F,
6696,,17764,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Cmax in mice at 24 uM/kg i.p. administration,F,
6697,,17764,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Cmax in mice at 25 uM/kg i.p. administration,F,
6698,,17764,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Cmax in mice at 26 uM/kg i.p. administration,F,
6699,2106.0,17641,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Cmax in spleen of mice at the oral dose of 50 mg/kg,A,Spleen
6700,,16597,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,A,
6701,,16597,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Cmax value at a dose of 10 mg/kg peroral administration in mice.,A,
6702,,5727,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Cmax value was determined,A,
6703,,5951,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Cmax value in IRC mice,A,
6704,,5506,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,A,
6705,,5506,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,A,
6706,1969.0,14239,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,A,Plasma
6707,1969.0,4890,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",A,Plasma
6708,,429,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,A,
6709,,10986,6277.0,BAO_0000218,,,,Intermediate,1,Acanthocheilonema viteae,,1,,N,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,F,
6710,,10986,6277.0,BAO_0000218,,,,Intermediate,1,Acanthocheilonema viteae,,1,,N,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,F,
6711,,10986,6277.0,BAO_0000218,,,,Intermediate,1,Acanthocheilonema viteae,,1,,N,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,F,
6712,,13227,9606.0,BAO_0000219,,,455.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory activity against human tumor cell line A0375 melanoma.,F,
6713,,4481,10116.0,BAO_0000249,,,,Expert,1,Rattus norvegicus,,9,Brain membranes,D,,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,B,
6714,,16931,9606.0,BAO_0000019,,,,Expert,1,Homo sapiens,,9,,D,,Forskolin-induced cAMP production at human A1 adenosine receptor,F,
6715,,3850,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,F,
6716,,3850,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,F,
6717,,3850,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,F,
6718,,3850,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,F,
6719,,3850,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,F,
6720,,3850,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,F,
6721,,3850,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,F,
6722,,3850,9606.0,BAO_0000219,,,449.0,Expert,1,Homo sapiens,,9,,D,,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,F,
6723,,3850,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,F,
6724,,3850,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,F,
6725,,3850,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,F,
6726,,3850,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,F,
6727,,3850,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,F,
6728,,3850,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,F,
6729,,3850,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,F,
6730,,3850,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,F,
6731,,3850,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,F,
6732,,3850,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,F,
6733,,3850,,BAO_0000219,,,449.0,Autocuration,1,,,8,,H,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,F,
6734,,3850,,BAO_0000219,,,449.0,Expert,1,,,8,,H,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,F,
6735,,12680,9986.0,BAO_0000219,,,164.0,Intermediate,1,Oryctolagus cuniculus,,1,,N,,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,F,
6736,,1313,10116.0,BAO_0000219,,,164.0,Autocuration,1,Rattus norvegicus,,0,,U,,In vitro potassium channel opening activity in A10 (smooth muscle) cells,F,
6737,,1313,10116.0,BAO_0000219,,,164.0,Autocuration,1,Rattus norvegicus,,0,,U,,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,F,
6738,,17567,10116.0,BAO_0000219,,,164.0,Intermediate,1,Rattus norvegicus,,1,,N,,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,F,
6739,,17567,10116.0,BAO_0000219,,,164.0,Intermediate,1,Rattus norvegicus,,1,,N,,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,F,
6740,,11819,10116.0,BAO_0000219,,,164.0,Intermediate,1,Rattus norvegicus,,1,,N,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,F,
6741,,13436,10029.0,BAO_0000219,,,185.0,Intermediate,1,Cricetulus griseus,,1,,N,,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,F,
6742,,12687,10029.0,BAO_0000219,,,185.0,Intermediate,1,Cricetulus griseus,,1,,N,,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,F,
6743,,12651,10029.0,BAO_0000219,,,185.0,Intermediate,1,Cricetulus griseus,,1,,N,,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,F,
6744,,13300,10029.0,BAO_0000219,,,185.0,Intermediate,1,Cricetulus griseus,,1,,N,,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,F,
6745,,15296,10029.0,BAO_0000219,,,185.0,Intermediate,1,Cricetulus griseus,,1,,N,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,F,
6746,,15328,10029.0,BAO_0000219,,,185.0,Intermediate,1,Cricetulus griseus,,1,,N,,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",F,
6747,,13302,10029.0,BAO_0000219,,,185.0,Intermediate,1,Cricetulus griseus,,1,,N,,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),F,
6748,,14367,10029.0,BAO_0000219,,,185.0,Expert,1,Cricetulus griseus,,1,,N,,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",F,
6749,,17002,10029.0,BAO_0000219,,,185.0,Expert,1,Cricetulus griseus,,1,,N,,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,F,
6750,,13436,10029.0,BAO_0000219,,,185.0,Intermediate,1,Cricetulus griseus,,1,,N,,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,F,
6751,,13435,10029.0,BAO_0000219,,,185.0,Intermediate,1,Cricetulus griseus,,1,,N,,Inhibitory activity against aerobic growth of AA8 cells.,F,
6752,,10503,10029.0,BAO_0000219,,,185.0,Intermediate,1,Cricetulus griseus,,1,,N,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,A,
6753,,10503,10029.0,BAO_0000219,,,185.0,Expert,1,Cricetulus griseus,,1,,N,,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,F,
6754,,10503,10029.0,BAO_0000219,,,185.0,Intermediate,1,Cricetulus griseus,,1,,N,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,F,
6755,,15090,10029.0,BAO_0000219,,,185.0,Expert,1,Cricetulus griseus,,1,,N,,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,F,
6756,,10368,10029.0,BAO_0000219,,,185.0,Expert,1,Cricetulus griseus,,1,,N,,Cytotoxicity against AA8 cell line,F,
6757,,12651,10029.0,BAO_0000219,,,185.0,Intermediate,1,Cricetulus griseus,,1,,N,,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),F,
6758,,12687,10029.0,BAO_0000219,,,185.0,Intermediate,1,Cricetulus griseus,,1,,N,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),A,
6759,,12687,10029.0,BAO_0000219,,,185.0,Intermediate,1,Cricetulus griseus,,1,,N,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),F,
6760,,12687,10029.0,BAO_0000219,,,185.0,Intermediate,1,Cricetulus griseus,,1,,N,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),A,
6761,,1890,10029.0,BAO_0000219,,,185.0,Intermediate,1,Cricetulus griseus,,1,,N,,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,F,
6762,,10747,10029.0,BAO_0000219,,,185.0,Intermediate,1,Cricetulus griseus,,1,,N,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,F,
6763,,10747,10029.0,BAO_0000219,,,185.0,Intermediate,1,Cricetulus griseus,,1,,N,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,F,
6764,,11616,10029.0,BAO_0000218,,,,Autocuration,1,Cricetulus griseus,,0,,U,,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),F,
6765,,11616,10029.0,BAO_0000219,,,185.0,Expert,1,Cricetulus griseus,,1,,N,,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,F,
6766,,3471,10029.0,BAO_0000219,,,185.0,Autocuration,1,Cricetulus griseus,,0,,U,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,F,
6767,,3471,10029.0,BAO_0000219,,,185.0,Autocuration,1,Cricetulus griseus,,0,,U,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,F,
6768,,3471,10029.0,BAO_0000219,,,185.0,Autocuration,1,Cricetulus griseus,,0,,U,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,F,
6769,,3471,10029.0,BAO_0000219,,,185.0,Autocuration,1,Cricetulus griseus,,0,,U,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,F,
6770,,3471,10029.0,BAO_0000219,,,185.0,Autocuration,1,Cricetulus griseus,,0,,U,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,F,
6771,,3471,10029.0,BAO_0000219,,,185.0,Autocuration,1,Cricetulus griseus,,0,,U,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,F,
6772,,3471,10029.0,BAO_0000219,,,185.0,Autocuration,1,Cricetulus griseus,,0,,U,,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,F,
6773,,11616,10029.0,BAO_0000219,,,185.0,Expert,1,Cricetulus griseus,,1,,N,,Concentration required to reduce AA8 cell survival by 10%,F,
6774,,2656,10029.0,BAO_0000219,,,185.0,Autocuration,1,Cricetulus griseus,,0,,U,,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",F,
6775,,10518,10029.0,BAO_0000219,,,185.0,Autocuration,1,Cricetulus griseus,,0,,U,,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,F,
6776,,10518,10029.0,BAO_0000219,,,185.0,Autocuration,1,Cricetulus griseus,,0,,U,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,F,
6777,,10518,10029.0,BAO_0000219,,,185.0,Autocuration,1,Cricetulus griseus,,0,,U,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,F,
6778,,10518,10029.0,BAO_0000219,,,185.0,Autocuration,1,Cricetulus griseus,,0,,U,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,F,
6779,,16156,10029.0,BAO_0000219,,,185.0,Autocuration,1,Cricetulus griseus,,0,,U,,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,F,
6780,,2656,10029.0,BAO_0000219,,,185.0,Autocuration,1,Cricetulus griseus,,0,,U,,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,F,
6781,,11005,10029.0,BAO_0000019,,,,Autocuration,1,Cricetulus griseus,,0,,U,,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",F,
6782,,11942,10029.0,BAO_0000219,,,185.0,Autocuration,1,Cricetulus griseus,,0,,U,,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,F,
6783,,2128,10029.0,BAO_0000219,,,185.0,Autocuration,1,Cricetulus griseus,,0,,U,,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,F,
6784,,16907,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life period after 15 mg/kg iv dose in Dogs,A,
6785,,16907,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life period after 30 mg/kg po dose in Dogs,A,
6786,,9579,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life was measured after oral 2b administration (tested in 6 dogs),A,
6787,,9579,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life was measured in dog after oral 17b administration,A,
6788,,9579,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,A,
6789,,9579,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,A,
6790,,16907,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Tmax value after 15 mg/kg iv dose in Dogs,A,
6791,,16907,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Tmax value after 30 mg/kg po dose in Dogs,A,
6792,,3184,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Compound was evaluated for its half life when administered intravenously in dog,A,
6793,1969.0,5017,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),A,Plasma
6794,,6821,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Elimination Half-life of compound was determined in dog,A,
6795,,17839,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life of compound in dog following oral administration,A,
6796,,17267,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half life of compound was determined in dog,A,
6797,178.0,4727,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half life of compound was determined in dog blood,A,Blood
6798,,5238,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life after oral and iv dosing in dogs,A,
6799,,4942,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half life in dogs in hours,A,
6800,,6505,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life on i.v. administration of 2 mg/kg was measured in dog,A,
6801,,5130,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,t1/2 in dog after oral dose (1 mg/kg),A,
6802,,1475,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half life was evaluated in dog,A,
6803,,17804,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life period of compound was determined after intravenous administration at 2 mg/kg,A,
6804,,17804,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life period of compound was determined after peroral administration at 2 mg/kg,A,
6805,,6084,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life period (10 mg/kg) was determined in dog,A,
6806,,6084,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life period (10 mg/kg) was determined in dog,A,
6807,,5542,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life period by iv administration in dog at a dose of 0.3 mg/kg,A,
6808,,5542,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life period by po administration in dog at a dose of 0.3 mg/kg,A,
6809,,6084,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half life period in dog,A,
6810,,6241,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life period in dogs after oral administration at 1 mg/kg,A,
6811,,1916,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,
6812,,6621,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half-life of compound was determined in dogs,A,
6813,1969.0,1696,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half-life in dog plasma,A,Plasma
6814,,17800,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half-life in mongrel dogs was determined,A,
6815,,17657,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half-life in dog upon oral administration,A,
6816,,17657,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half-life in dog upon oral administration; Unable to calculate,A,
6817,,4239,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half-life was measured in dog,A,
6818,,5985,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half-life was measured in dog,A,
6819,,9932,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,A,
6820,,5199,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral half life was determined,A,
6821,1969.0,5199,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,A,Plasma
6822,1969.0,1475,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Plasma half life was evaluated,A,Plasma
6823,1969.0,1475,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Plasma half life was evaluated in Dog,A,Plasma
6824,1969.0,1475,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Plasma half life was evaluated in dog,A,Plasma
6825,,6316,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,T1/2 (Half-life) was after oral administration at 5 mg/kg,A,
6826,,4883,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Tested for the half life value in dog,A,
6827,,4727,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Maximum time at the dose of 2 mg/kg in dog,A,
6828,,1916,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,
6829,178.0,1337,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,Blood
6830,178.0,1337,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,Blood
6831,,6265,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,A,
6832,,4809,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,
6833,,5983,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,A,
6834,,5313,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",A,
6835,,5313,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",A,
6836,1969.0,17650,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,A,Plasma
6837,1969.0,5199,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,A,Plasma
6838,1969.0,933,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Time taken for maximum plasma concentration in dog,A,Plasma
6839,,16367,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Time to reach Cmax after oral administration to dogs,A,
6840,1969.0,6348,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,Plasma
6841,,6316,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,A,
6842,,6215,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Tmax after peroral administration (1 mg/kg) was determined in dog,A,
6843,,3598,9615.0,BAO_0000218,,,,Expert,1,Canis lupus familiaris,In vivo,1,,N,,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,A,
6844,,4527,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,A,
6845,,17764,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Tmax after peroral administration in dogs at 2.4 uM/kg,A,
6846,,5969,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,In vivo Cmax in mice at dose of 100 mg/kg,A,
6847,,5969,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,In vivo Cmax in mice at dose of 50 mg/kg,A,
6848,,4573,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,A,
6849,1969.0,3277,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,Plasma
6850,1969.0,17734,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,A,Plasma
6851,1969.0,3132,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Maximum concentration obtained in mouse plasma was determined,A,Plasma
6852,1969.0,3132,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,A,Plasma
6853,1969.0,6348,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,Plasma
6854,1969.0,17729,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,A,Plasma
6855,1969.0,17729,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,A,Plasma
6856,1969.0,17729,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,A,Plasma
6857,1969.0,17728,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,A,Plasma
6858,1969.0,17728,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,A,Plasma
6859,1969.0,17728,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,A,Plasma
6860,,4066,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,A,
6861,,6178,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,A,
6862,,6178,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,A,
6863,,3760,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,A,
6864,,3760,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,A,
6865,,3760,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,A,
6866,,3760,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,A,
6868,,5961,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Cmax in male mice after 2 mg/kg oral dose,A,
6869,,6137,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,A,
6870,,3802,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,A,
6871,,3535,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,A,
6872,,3535,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,A,
6873,,3535,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,A,
6874,,3535,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,A,
6875,,3535,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,A,
6876,,3535,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,A,
6877,1969.0,2862,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Maximum concentration in plasma upon oral administration in mouse,A,Plasma
6878,1969.0,2675,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Maximum plasma concentration was evaluated in mice after oral administration,A,Plasma
6879,1969.0,2675,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,A,Plasma
6880,,5399,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Dose at which the compound induced fecal excretion in mice,A,
6893,,11819,10116.0,BAO_0000219,,,164.0,Expert,1,Rattus norvegicus,,1,,N,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,F,
6894,,11819,10116.0,BAO_0000219,,,164.0,Expert,1,Rattus norvegicus,,1,,N,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,F,
6895,,11819,10116.0,BAO_0000219,,,164.0,Expert,1,Rattus norvegicus,,1,,N,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,F,
6896,,11819,10116.0,BAO_0000219,,,164.0,Expert,1,Rattus norvegicus,,1,,N,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,F,
6897,,16361,10116.0,BAO_0000219,,,164.0,Intermediate,1,Rattus norvegicus,,1,,N,,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),F,
6898,,2288,9606.0,BAO_0000219,,,393.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,F,
6899,,10404,9606.0,BAO_0000219,,,393.0,Intermediate,1,Homo sapiens,,1,,N,,Anticancer activity against human ovarian carcinoma A121 cells,F,
6900,,14790,9606.0,BAO_0000219,,,393.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,F,
6901,,14790,9606.0,BAO_0000219,,,393.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,F,
6902,,14253,9606.0,BAO_0000219,,,393.0,Expert,1,Homo sapiens,,1,,N,,Growth inhibition of human ovarian carcinoma (A121) cell line,F,
6903,,13617,9606.0,BAO_0000219,,,393.0,Expert,1,Homo sapiens,,1,,N,,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,F,
6904,,1003,9606.0,BAO_0000219,,,393.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity against human A121 ovarian cells,F,
6905,,830,9606.0,BAO_0000219,,,393.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,F,
6906,,12307,9606.0,BAO_0000219,,,393.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against human ovarian carcinoma A21,F,
6907,,14254,9606.0,BAO_0000219,,,393.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,F,
6908,,13370,9606.0,BAO_0000219,,,393.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory activity of compound against human A121 ovarian cell line.,F,
6909,,14790,9606.0,BAO_0000219,,,393.0,Intermediate,1,Homo sapiens,,1,,N,,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,F,
6910,,3614,9606.0,BAO_0000219,,,393.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,F,
6911,,2664,9606.0,BAO_0000219,,,622.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,F,
6912,,2037,9606.0,BAO_0000219,,,622.0,Expert,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against A172 human tumor cell lines.,F,
6913,,14539,9606.0,BAO_0000219,,,622.0,Intermediate,1,Homo sapiens,,1,,N,,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,F,
6914,,2836,9606.0,BAO_0000219,,,622.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,F,
6915,,10708,9606.0,BAO_0000219,,,622.0,Intermediate,1,Homo sapiens,,1,,N,,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,F,
6916,,8975,9615.0,BAO_0000224,,,,Autocuration,1,Canis lupus familiaris,,4,,H,,Association constant against A2 adenosine receptor,B,
6917,,7645,,BAO_0000219,,,1085.0,Intermediate,1,fish,,1,,N,,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,F,
6918,,11377,10116.0,BAO_0000224,,,,Autocuration,1,Rattus norvegicus,,5,,D,,Ratio of Ki for adenosine A2 and A1 receptor binding,B,
6919,,13528,9606.0,BAO_0000219,,,623.0,Expert,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,F,
6920,,10160,9606.0,BAO_0000219,,,623.0,Expert,1,Homo sapiens,,1,,N,,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,F,
6921,,15144,9606.0,BAO_0000219,,,404.0,Intermediate,1,Homo sapiens,,1,,N,,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,F,
6922,,13160,9606.0,BAO_0000219,,,973.0,Intermediate,1,Homo sapiens,,1,,N,,Growth inhibition against Human squamous cell line(A 253),F,
6923,,12898,9606.0,BAO_0000219,,,973.0,Intermediate,1,Homo sapiens,,1,,N,,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,F,
6924,,13069,9606.0,BAO_0000219,,,973.0,Intermediate,1,Homo sapiens,,1,,N,,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,F,
6925,,15984,9606.0,BAO_0000219,,,973.0,Intermediate,1,Homo sapiens,,1,,N,,Growth inhibition of A253 cell lines.,F,
6926,,15564,9606.0,BAO_0000219,,,973.0,Intermediate,1,Homo sapiens,,1,,N,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),F,
6927,,15564,9606.0,BAO_0000219,,,973.0,Intermediate,1,Homo sapiens,,1,,N,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,F,
6928,,15564,9606.0,BAO_0000219,,,973.0,Intermediate,1,Homo sapiens,,1,,N,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,F,
6929,,4720,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,F,
6930,,16112,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,F,
6931,,16597,9606.0,BAO_0000219,,,478.0,Expert,1,Homo sapiens,,1,,N,,Cytotoxic activity against A2780 human ovarian carcinoma cell line,F,
6932,,16378,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity against human cancer cell lines A2780 (ovarian),F,
6933,,16085,9606.0,BAO_0000219,,,478.0,Expert,1,Homo sapiens,,1,,N,,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,F,
6934,,16317,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,F,
6935,,15748,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),F,
6936,,16597,9606.0,BAO_0000219,,,478.0,Expert,1,Homo sapiens,,1,,N,,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,F,
6937,,16597,9606.0,BAO_0000219,,,478.0,Expert,1,Homo sapiens,,1,,N,,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,F,
6938,,16597,9606.0,BAO_0000219,,,478.0,Expert,1,Homo sapiens,,1,,N,,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,F,
6939,,15608,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,F,
6940,,15608,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,F,
6941,,15608,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,F,
6942,,15296,10029.0,BAO_0000019,,,,Autocuration,1,Cricetulus griseus,,0,,U,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,F,
6943,,10251,10029.0,BAO_0000219,,,185.0,Autocuration,1,Cricetulus griseus,,0,,U,,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,A,
6944,,10251,10029.0,BAO_0000219,,,185.0,Autocuration,1,Cricetulus griseus,,0,,U,,Evaluated for growth inhibition of AA8 cells under aerobic conditions,F,
6945,,10251,10029.0,BAO_0000219,,,185.0,Autocuration,1,Cricetulus griseus,,0,,U,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,F,
6946,,10251,10029.0,BAO_0000219,,,185.0,Autocuration,1,Cricetulus griseus,,0,,U,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),F,
6947,,11858,10029.0,BAO_0000019,,,,Autocuration,1,Cricetulus griseus,,0,,U,,Growth inhibition against CHO-derived cell line AA8,F,
6948,,11858,10029.0,BAO_0000219,,,185.0,Autocuration,1,Cricetulus griseus,,0,,U,,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],F,
6949,,11616,36483.0,BAO_0000219,,,185.0,Expert,1,hampster,,1,,N,,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,F,
6950,,11616,10029.0,BAO_0000219,,,185.0,Expert,1,Cricetulus griseus,,1,,N,,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,F,
6951,,10518,10029.0,BAO_0000219,,,185.0,Autocuration,1,Cricetulus griseus,,0,,U,,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,F,
6952,,11396,10029.0,BAO_0000219,,,185.0,Autocuration,1,Cricetulus griseus,,0,,U,,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,F,
6953,,10518,10029.0,BAO_0000219,,,185.0,Autocuration,1,Cricetulus griseus,,0,,U,,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,F,
6954,,11616,10029.0,BAO_0000219,,,185.0,Expert,1,Cricetulus griseus,,1,,N,,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,F,
6955,,14837,,BAO_0000019,,,,Autocuration,1,,,8,,H,,compound was evaluated for association constant (Ka) of isolated serum protein AAG,F,
6956,,14837,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Number of binding sites (n) of isolated serum protein AAG,F,
6957,,16037,,BAO_0000225,,,,Intermediate,1,,,3,,M,,Association constant for binding to AATT duplex,B,
6958,,16597,9606.0,BAO_0000219,,,416.0,Expert,1,Homo sapiens,,1,,N,,Inhibition of ABAE human fibroblast cell proliferation,F,
6959,,8831,10090.0,BAO_0000218,,,1064.0,Intermediate,1,Mus musculus,,1,,N,,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",F,
6960,,13419,9986.0,BAO_0000218,,,,Expert,1,Oryctolagus cuniculus,,9,,D,,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,F,
6961,,13419,9986.0,BAO_0000218,,,,Expert,1,Oryctolagus cuniculus,In vivo,9,,D,,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,F,
6962,,15778,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Inhibitory activity against angiotensin-converting enzyme (ACE).,B,
6963,,15778,,BAO_0000357,,,,Autocuration,1,,,8,,H,,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,B,
6964,,12988,9606.0,BAO_0000219,,,978.0,Intermediate,1,Homo sapiens,,1,,N,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,F,
6965,,12988,9606.0,BAO_0000219,,,978.0,Intermediate,1,Homo sapiens,,1,,N,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),F,
6966,,12988,11676.0,BAO_0000219,,,998.0,Autocuration,1,Human immunodeficiency virus 1,,0,,U,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,F,
6967,,12988,11676.0,BAO_0000219,,,998.0,Autocuration,1,Human immunodeficiency virus 1,,0,,U,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),F,
6968,,12988,11676.0,BAO_0000219,,,998.0,Autocuration,1,Human immunodeficiency virus 1,,0,,U,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),F,
6969,,11843,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibition of growth of renal cancer ACHN cell line,F,
6970,,16939,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibition of growth of ACHN renal cancer cell line,F,
6971,,4782,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory concentration required against ACHN renal cancer cell line,F,
6972,,6310,9606.0,BAO_0000219,,,626.0,Expert,1,Homo sapiens,,1,,N,,Concentration required to inhibit growth of human renal (ACHN) cell line,F,
6973,,6310,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,F,
6974,,12858,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxic activity against ACHN Renal cancer cell line,F,
6975,,17380,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity evaluation against ACHN renal cancer cells,F,
6976,,5858,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro antitumor activity against human renal ACHN cell line,F,
6977,,3838,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,F,
6978,,3838,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,F,
6979,,5406,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",F,
6980,,4071,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,F,
6981,,4071,9606.0,BAO_0000219,,,626.0,Expert,1,Homo sapiens,,1,,N,,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,F,
6982,,4071,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,F,
6983,,15002,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,F,
6984,,14769,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),F,
6985,,13958,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",F,
6986,,1665,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,F,
6987,,15354,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for the growth inhibition of ACHN renal tumor cell line,F,
6988,,15354,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,F,
6989,,13978,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,F,
6990,,6798,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,F,
6991,,2959,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Tmax value after administration of 4 mg/Kg oral dose in dog,A,
6992,,9932,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",A,
6993,,5546,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,
6994,,16907,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Volume distribution after 15 mg/kg iv dose in Dogs,A,
6995,,16907,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Volume distribution after 30 mg/kg po dose in Dogs,A,
6996,,4257,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,A,
6997,,4305,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,A,
6998,,5472,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Volume of distribution was evaluated in dog,A,
6999,,6062,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,A,
7000,,3598,9615.0,BAO_0000218,,,,Expert,1,Canis lupus familiaris,,1,,N,,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,A,
7001,,12500,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,The compound was tested for volume of distribution in dog,A,
7002,,12500,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,A,
7003,,6227,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Vd (1 mg/kg) was determined in dog (in vivo),A,
7004,,6227,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Vd in dog,A,
7005,,4219,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Volume distribution was determined,A,
7006,,1696,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Volume of distribution in dog,A,
7007,,5542,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Volume of distribution by as 4 fold increase by iv administration in dogs,A,
7008,,5199,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,A,
7009,,6348,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,
7010,,4727,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Volume distribution at the dose of 2 mg/kg in dog,A,
7011,,16367,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Steady state volume of distribution was determined,A,
7012,,2652,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,A,
7013,,16452,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,
7014,,16452,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,
7015,,16452,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability in dog (dose 1 mg/kg i.v.),A,
7016,,5334,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,
7017,,4239,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Pharmacokinetic property (vdss) was measured in dog,A,
7018,,4709,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,A,
7019,,5600,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Vdss was determined after iv 0.1 mg/kg administration in dog,A,
7020,,6057,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Volume displacement was calculated in dog,A,
7021,,5654,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,
7022,,5505,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Volume distribution constant was determined,A,
7023,,4527,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Volume distribution at a dose of 1 uM/kg in dog was determined,A,
7024,,4521,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,
7025,,4521,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,
7026,,15660,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Volume distribution (Vdss) was measured in dog,A,
7027,,15660,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Volume distribution (Vdss) was measured in dog,A,
7028,,6679,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,
7029,,5145,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Volume of distribution in steady state was determined in dog,A,
7030,,6821,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Volume of distribution of compound was determined in dog,A,
7031,,4137,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,A,
7032,,5334,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),A,
7033,,15660,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Volume of distribution (Vdss) was measured in dog,A,
7034,,6642,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,
7035,,6641,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,
7036,,6642,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,
7037,,11659,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Maximum rate of depolarization of the upstroke of the action potential,A,
7038,,6448,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Steady state volume distribution in dog,A,
7039,,5474,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,A,
7040,,1466,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,A,
7041,,6535,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,A,
7042,,6535,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Volume distribution in dog after administration of 1 mg/kg iv,A,
7043,,17764,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,A,
7044,,6215,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Vss after intravenous administration (0.5 mg/kg) was determined in dog,A,
7045,,6505,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Vss on i.v. administration of 2 mg/kg was measured in dog,A,
7046,,3639,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Vss was determined,A,
7047,,3639,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Vss in dog,A,
7048,,6062,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,A,
7049,,4942,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Volume distribution in dogs,A,
7050,,17796,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Volume of distribution in dog,A,
7051,,4883,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Tested for the oral bioavailability in dog,A,
7060,,17837,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,A,
7061,,17729,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,A,
7062,,17729,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Bioavailability after peroral administration of 50 mg/kg of dose in mice,A,
7063,,4239,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Bioavailability was measured in mouse,A,
7064,,17592,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Bioavailability in mouse,A,
7065,,6348,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,
7066,,2801,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Bioavailability in mouse,A,
7067,,2801,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,A,
7068,,17718,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Oral bioavailability in mouse,A,
7069,,5727,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Oral availability at 50 mg/kg po in male mice,A,
7070,,5302,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Oral bioavailability in mouse (dose 10 mg/kg),A,
7071,,3598,10090.0,BAO_0000218,,,,Expert,1,Mus musculus,In vivo,1,,N,,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,A,
7072,,5961,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",A,
7074,,6091,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Oral bioavailability in mouse,A,
7075,,6091,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Oral bioavailability in vivo in mice;ND=Not determined,A,
7076,,5711,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Oral bioavailability in mouse at 10 mg/kg of the compound,A,
7077,,17728,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),A,
7078,,17728,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),A,
7079,,3802,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Tested for bioavailability of the compound,A,
7080,,3802,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Tested for half life at the dose of 10 mg/kg when administered intravenously,A,
7081,1969.0,14029,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,A,Plasma
7082,1969.0,14029,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,The plasma half life of compound was determined on heparin prepared by human plasma. ,A,Plasma
7083,1969.0,14029,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,A,Plasma
7084,1969.0,14029,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,A,Plasma
7085,1969.0,14029,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,A,Plasma
7086,,17753,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,F,
7087,,17753,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,A,
7088,,17753,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,,1,,N,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,A,
7089,178.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,Blood
7090,178.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,Blood
7091,178.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,Blood
7092,178.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,Blood
7093,178.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,Blood
7094,178.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,Blood
7095,178.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,Blood
7096,10000001.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,Bone
7097,10000001.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,Bone
7098,,15608,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,F,
7099,,3290,9606.0,BAO_0000219,,,478.0,Expert,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,F,
7100,,2859,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was evaluated for cytotoxicity against A2780 cell line,F,
7101,,15688,9606.0,BAO_0000219,,,478.0,Expert,1,Homo sapiens,,1,,N,,Inhibition of A2780 cell clonogenic assay,F,
7102,,5642,9606.0,BAO_0000219,,,478.0,Expert,1,Homo sapiens,,1,,N,,Cytotoxic effect on ovarian cancer cell line (A2780),F,
7103,,6633,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,F,
7104,,3906,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",F,
7105,,6788,9606.0,BAO_0000219,,,478.0,Expert,1,Homo sapiens,,1,,N,,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,F,
7106,,17582,9606.0,BAO_0000219,,,478.0,Expert,1,Homo sapiens,,1,,N,,Antiproliferative activity against human A2780 cells,F,
7107,,17764,9606.0,BAO_0000219,,,478.0,Expert,1,Homo sapiens,,1,,N,,Inhibition of human A2780 cell proliferation,F,
7108,,17764,9606.0,BAO_0000219,,,478.0,Expert,1,Homo sapiens,,1,,N,,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,F,
7109,,17764,9606.0,BAO_0000219,,,478.0,Expert,1,Homo sapiens,,1,,N,,Inhibition of human A2780 cell proliferation (No data),F,
7110,,2815,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,F,
7111,,16930,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was evaluated against human Ovarian carcinoma cell line A2780,F,
7112,,17777,9606.0,BAO_0000219,,,478.0,Expert,1,Homo sapiens,,1,,N,,Growth inhibition against A2780 wild-type ovarian cell lines,F,
7113,,17777,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,F,
7114,,16936,9606.0,BAO_0000019,,,,Autocuration,1,Homo sapiens,,5,,D,,Inhibition of tubulin polymerization in human ovarian cancer cell lines,F,
7115,,13759,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,F,
7116,,13759,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,F,
7117,,13759,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,F,
7118,,13759,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,F,
7119,,15292,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,F,
7120,,15292,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,F,
7121,,15069,9606.0,BAO_0000219,,,478.0,Expert,1,Homo sapiens,,1,,N,,In vitro inhibition of human ovarian cell line A2780,F,
7122,,15069,9606.0,BAO_0000219,,,478.0,Expert,1,Homo sapiens,,1,,N,,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",F,
7123,,14073,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),F,
7124,,14553,9606.0,BAO_0000219,,,478.0,Expert,1,Homo sapiens,,1,,N,,Concentration required to inhibit A2780-cell growth by 50%,F,
7125,,13040,9606.0,BAO_0000219,,,478.0,Expert,1,Homo sapiens,,1,,N,,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,F,
7126,,6891,9606.0,BAO_0000219,,,478.0,Expert,1,Homo sapiens,,1,,N,,Cytotoxic effect on human ovarian (A2780) cancer cell line,F,
7127,,15569,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,F,
7128,,14190,9606.0,BAO_0000219,,,478.0,Expert,1,Homo sapiens,,1,,N,,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,F,
7129,,15014,9606.0,BAO_0000219,,,478.0,Expert,1,Homo sapiens,,1,,N,,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,F,
7130,,15014,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,F,
7131,,17496,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity against human ovarian carcinoma A2780 cell line,F,
7132,,13617,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",F,
7133,,13617,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",F,
7134,,13617,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",F,
7135,,13617,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",F,
7136,,17672,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,F,
7137,,4544,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,F,
7138,,4544,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,F,
7139,,16317,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",F,
7140,,15099,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,F,
7141,,13978,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,F,
7142,,12989,9606.0,BAO_0000219,,,478.0,Expert,1,Homo sapiens,,1,,N,,In vitro antitumor activity against A2780 cell line.,F,
7143,,5574,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,F,
7144,,13528,9606.0,BAO_0000219,,,478.0,Expert,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against A2780 human ovarian cancer cell line,F,
7145,,12782,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory activity against kidney A-CHN tumor cell growth in culture,F,
7146,,14255,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,The IC50 value was measured on ACHN cell line in renal tumor type.,F,
7147,,16364,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,F,
7148,,17376,9606.0,BAO_0000219,,,626.0,Expert,1,Homo sapiens,,1,,N,,In vitro lethal concentration against most sensitive ACHN cell line,F,
7149,,12016,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,Tested for cytotoxic activity against renal cancer ACHN cell line,F,
7150,,6058,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,Compound tested for growth inhibition of renal cancer cell line ACHN,F,
7151,,17708,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,F,
7152,,15176,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,F,
7153,,2806,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro anticancer activity against ACHN renal cancer cell line,F,
7154,,15300,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,F,
7155,,16364,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,Percent selectivity was evaluated in renal ACHN cell lines,F,
7156,,13859,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro inhibitory activity against renal ACHN cancer cell line,F,
7157,,11970,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,Tested for cytotoxicity against ACHN cell lines in renal cancer,F,
7158,,2450,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,F,
7159,,12696,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,F,
7160,,12400,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,F,
7161,,12888,9606.0,BAO_0000219,,,626.0,Expert,1,Homo sapiens,,1,,N,,Cytotoxic effect on renal cancer line ACHN,F,
7162,,3156,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,F,
7163,,3381,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro inhibition of Renal Cancer ACHN cell lines,F,
7164,,16747,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,Antitumor activity against human renal adenocarcinoma ACHN cells,F,
7165,,16748,9606.0,BAO_0000219,,,626.0,Expert,1,Homo sapiens,,1,,N,,Antitumor activity against human renal adenocarcinoma ACHN cells.,F,
7166,,12062,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,F,
7167,,14769,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),F,
7168,,15895,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",F,
7169,,17376,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,F,
7170,,14882,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,F,
7171,,14882,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,F,
7172,,15661,9606.0,BAO_0000219,,,626.0,Intermediate,1,Homo sapiens,,1,,N,,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,F,
7173,,9680,,BAO_0000019,,,,Autocuration,1,,,0,,U,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,A,
7174,,14579,,BAO_0000019,,,,Autocuration,1,,,8,,H,,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,F,
7175,,17290,10358.0,BAO_0000218,,,468.0,Expert,1,Cytomegalovirus,,1,,N,,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,F,
7176,,17290,10358.0,BAO_0000218,,,,Intermediate,1,Cytomegalovirus,,1,,N,,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,F,
7177,,15891,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),B,
7178,,15890,,BAO_0000357,,,,Autocuration,1,,,8,,H,,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),B,
7179,,3801,9913.0,BAO_0000219,,,979.0,Intermediate,1,Bos taurus,,1,,N,,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,F,
7180,,9222,10090.0,BAO_0000219,,,980.0,Intermediate,1,Mus musculus,,1,,N,,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,F,
7181,,9222,10090.0,BAO_0000219,,,980.0,Intermediate,1,Mus musculus,,1,,N,,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,F,
7182,,7257,10090.0,BAO_0000219,,,980.0,Intermediate,1,Mus musculus,,1,,N,,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",F,
7183,,7257,10090.0,BAO_0000219,,,980.0,Intermediate,1,Mus musculus,,1,,N,,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,F,
7184,,7257,10090.0,BAO_0000219,,,980.0,Intermediate,1,Mus musculus,,1,,N,,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,A,
7185,,8084,10090.0,BAO_0000219,,,980.0,Intermediate,1,Mus musculus,,1,,N,,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,F,
7186,,14943,10090.0,BAO_0000019,,,,Autocuration,1,Mus musculus,,0,,U,,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,F,
7187,,14943,10090.0,BAO_0000019,,,,Autocuration,1,Mus musculus,,0,,U,,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,F,
7188,,14943,10090.0,BAO_0000019,,,,Autocuration,1,Mus musculus,,0,,U,,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,F,
7189,,10524,1423.0,BAO_0000218,,,,Autocuration,1,Bacillus subtilis,In vivo,0,,U,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),A,
7190,1969.0,3546,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,AUC value in dog after IV administration at a dose of 5 mg/kg,A,Plasma
7191,1969.0,3546,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,AUC value in dog after oral administration at a dose of 5 mg/kg,A,Plasma
7192,,3546,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Cmax value in dog after oral administration at a dose of 5 mg/kg,A,
7193,,3546,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability in dog after oral administration at a dose of 5 mg/kg,A,
7194,,3546,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Tmax value in dog after oral administration at a dose of 5 mg/kg,A,
7195,,3184,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Compound was evaluated for its clearance when administered intravenously in dog,A,
7196,,16456,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,
7197,,4809,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),A,
7198,,4219,,BAO_0000100,,,,Intermediate,1,,,0,,U,,Calculated partition coefficient (clogP),P,
7199,,3748,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half life in dog,A,
7200,,3132,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Time taken for EC90 was determined when tested in dog,A,
7201,,4219,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half life (iv) was determined,A,
7202,2107.0,16907,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,A,Liver
7203,,6057,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under the curve was calculated in dog after iv administration,A,
7204,,6057,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Area under the curve was calculated in dog after peroral administration,A,
7205,,17853,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,A,
7206,,3639,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,pKa was evaluated in dog,A,
7207,,14541,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,A,
7208,,16456,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,
7209,,16456,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,
7210,,2652,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,A,
7211,,3624,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Compound was evaluated for the half-life (t 1/2) in hours,A,
7212,178.0,1337,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,Blood
7213,178.0,1337,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,Blood
7214,,4709,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life after intravenous administration of 1 mg/kg in dog,A,
7215,,15660,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half life was measured in dog,A,
7216,,5302,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life period in dog after 5 mg/kg dose,A,
7217,,17791,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half life period was evaluated in dog; 4-4.8,A,
7218,,6348,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,
7219,,4257,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half-life was determined in dog after a3 mg/kg of iv dose,A,
7220,,3771,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half-life was determined,A,
7221,,6305,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half life in dogs,A,
7222,1969.0,13501,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,A,Plasma
7223,,17594,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,A,
7224,,3045,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Compound was evaluated for the half life period after iv administration in Beagle dog.,A,
7225,,3043,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Compound was evaluated for the half life period after oral administration in conscious dog.,A,
7226,,4839,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Compound was tested for half life in dog,A,
7227,,4839,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Compound was tested for its half life in dog,A,
7228,,5802,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,
7229,,17839,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half life of compound in dog was determined,A,
7230,,4219,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life (iv) was determined,A,
7231,178.0,13966,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),A,Blood
7232,1969.0,3994,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,A,Plasma
7233,1969.0,3994,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,F,Plasma
7234,,4453,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half life in dog,A,
7235,1969.0,6535,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half life in dog plasma,A,Plasma
7236,1969.0,6535,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life in dog plasma after administration of 0.25 mg/kg iv,A,Plasma
7237,1969.0,6535,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life in dog plasma after administration of 1 mg/kg iv,A,Plasma
7238,1969.0,3132,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life in dog plasma was determined at dose 10 mg/kg,A,Plasma
7239,,5374,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half life in dog was determined,A,
7240,,5007,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,
7241,1969.0,16907,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half life upon exposure to human plasma,A,Plasma
7242,,6057,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half life was calculated in dog,A,
7243,,5006,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half life was determined,A,
7244,,5473,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half life was determined,A,
7245,,4368,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life by intravenous administration of 1.2 mg/kg in dog,A,
7246,,6448,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half life in dog,A,
7247,,4353,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half life in dog after intra venous administration of the compound,A,
7248,,4353,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half life in dog after intra venous administration of the compound; ND means Not determined,A,
7249,,4353,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life in dog after po administration of the compound,A,
7250,,4353,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life in dog after po administration of the compound; ND means Not determined,A,
7251,,6265,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life in dog at the single oral dose of 1 mg/kg,A,
7252,,5006,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half life in dogs,A,
7253,,5356,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,A,
7254,,405,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half life in rat,A,
7255,,6642,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,
7256,10000001.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,Bone
7257,10000001.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,Bone
7258,10000001.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,Bone
7259,10000001.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,Bone
7260,10000001.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,Bone
7261,10000004.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,Gut
7262,10000004.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,Gut
7263,10000004.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,Gut
7264,10000004.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,Gut
7265,10000004.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,Gut
7266,10000004.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,Gut
7267,10000004.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,Gut
7268,948.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,Heart
7269,948.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,Heart
7270,948.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,Heart
7271,948.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,Heart
7272,948.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,Heart
7273,948.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,Heart
7274,948.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,Heart
7275,2113.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,Kidney
7276,2113.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,Kidney
7277,2113.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,Kidney
7278,2113.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,Kidney
7279,2113.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,Kidney
7280,2113.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,Kidney
7281,2113.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,Kidney
7282,2107.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,Liver
7283,2107.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,Liver
7284,2107.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,Liver
7285,2107.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,Liver
7286,2107.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,Liver
7287,2107.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,Liver
7288,2107.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,Liver
7289,2048.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,Lung
7290,,5895,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against A2780 (human ovarian cancer),F,
7291,,6338,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,F,
7292,,15163,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,F,
7293,,15163,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,F,
7294,,15000,9606.0,BAO_0000219,,,478.0,Expert,1,Homo sapiens,,1,,N,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,F,
7295,,15000,9606.0,BAO_0000219,,,478.0,Expert,1,Homo sapiens,,1,,N,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,F,
7296,,14729,9606.0,BAO_0000219,,,478.0,Expert,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,F,
7297,,17270,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity against A2780 cell line,F,
7298,,5685,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,F,
7299,,3563,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro inhibitory activity against human ovarian cancer A2780 cell line,F,
7300,,17753,9606.0,BAO_0000218,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,F,
7301,,16317,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",F,
7302,,16936,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibition of tubulin polymerization in analogy of ca.,F,
7303,,3801,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,F,
7304,,6181,9606.0,BAO_0000219,,,478.0,Expert,1,Homo sapiens,,1,,N,,Cytotoxic effect in ovarian cancer cell line (A2780),F,
7305,,5318,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,F,
7306,,4840,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Tested for the cytotoxicity in A2780 ovarian cell line,F,
7307,,15748,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),F,
7308,,15748,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,F,
7309,,15748,,BAO_0000219,,,481.0,Intermediate,1,,,1,,N,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,F,
7310,,15748,,BAO_0000219,,,481.0,Intermediate,1,,,1,,N,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),F,
7311,,15748,,BAO_0000219,,,481.0,Intermediate,1,,,1,,N,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,F,
7312,,15748,,BAO_0000219,,,481.0,Intermediate,1,,,1,,N,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),F,
7313,,17753,9606.0,BAO_0000218,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,In vivo log of cells killed after administration of compound in A2780 cell line,F,
7314,,17753,9606.0,BAO_0000218,,,478.0,Intermediate,1,Homo sapiens,In vivo,1,,N,,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,F,
7315,,16936,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,F,
7316,,16936,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,F,
7317,,16936,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,F,
7318,,16936,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,F,
7319,,17528,9606.0,BAO_0000218,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),F,
7320,,6633,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,F,
7321,,15000,9606.0,BAO_0000219,,,478.0,Expert,1,Homo sapiens,,1,,N,,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,F,
7322,,17528,9606.0,BAO_0000219,,,478.0,Expert,1,Homo sapiens,,1,,N,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,F,
7323,,16936,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,F,
7324,,16936,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,F,
7325,,16936,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,F,
7326,,16936,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",F,
7327,,16936,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),F,
7328,,16936,9606.0,BAO_0000219,,,478.0,Expert,1,Homo sapiens,,1,,N,,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",F,
7329,,16936,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,
7330,,16936,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,
7331,,16936,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,
7332,,17737,10090.0,BAO_0000219,,,478.0,Intermediate,1,Mus musculus,,1,,N,,In vitro antiproliferative activity against A2780 cell line,F,
7333,,17764,10090.0,BAO_0000219,,,478.0,Expert,1,Mus musculus,,1,,N,,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,F,
7334,,3830,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,F,
7335,,3829,9606.0,BAO_0000219,,,478.0,Intermediate,1,Homo sapiens,,1,,N,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,F,
7336,,3546,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Vc value in dog after IV administration at a dose of 5 mg/kg,A,
7337,,3546,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life period in dog after IV administration at a dose of 5 mg/kg,A,
7338,,5668,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,A,
7339,1969.0,3443,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,,0,,U,,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,Plasma
7340,1969.0,3443,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,,0,,U,,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,Plasma
7341,,4256,9541.0,BAO_0000218,,,,Autocuration,1,Macaca fascicularis,In vivo,0,,U,,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,A,
7342,,4256,9541.0,BAO_0000218,,,,Autocuration,1,Macaca fascicularis,In vivo,0,,U,,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,A,
7343,,4256,9541.0,BAO_0000218,,,,Autocuration,1,Macaca fascicularis,In vivo,0,,U,,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,A,
7344,,4256,10116.0,BAO_0000218,,,,Autocuration,1,Rattus norvegicus,In vivo,0,,U,,Oral Bioavailability in rat,A,
7345,,1916,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,,0,,U,,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,
7346,,5302,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,,0,,U,,Area under curve value in monkey at a dose of 5 mg/kg,A,
7347,,4257,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,,0,,U,,Area under curve was determined in monkey after a 3 mg/kg of oral dose,A,
7348,,5355,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,A,
7349,,5355,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,A,
7350,,5355,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,A,
7351,,6078,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,,0,,U,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,A,
7352,,6078,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,,0,,U,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,A,
7353,,6062,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,,0,,U,,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,A,
7354,,2661,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,,0,,U,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,
7355,,2661,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,
7356,,5394,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,,0,,U,,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,A,
7357,,4397,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,,0,,U,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,A,
7358,,17509,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,,0,,U,,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,A,
7359,,17509,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,,0,,U,,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,A,
7360,,6641,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Oral AUCN in monkey (dosed at 0.5 mpk iv ),A,
7361,,5355,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,,0,,U,,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),A,
7362,,3443,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,
7363,,3443,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,
7364,,17409,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Binding towards monkey plasma protein at 10 uM,A,
7365,,17409,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Binding towards monkey plasma protein at 100 uM,A,
7366,,1052,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Apparent bioavailability in squirrel monkey was determined,A,
7367,,13501,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,A,
7368,,17509,9443.0,BAO_0000218,,,,Autocuration,1,monkey,In vivo,0,,U,,Bioavailability in monkey (dose 2 mg/kg),A,
7369,,5394,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,A,
7370,,2661,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,
7371,,11219,9443.0,BAO_0000218,,,,Autocuration,1,monkey,In vivo,0,,U,,Bioavailability in monkey (i.d. dosing),A,
7372,,3045,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,A,
7373,,17796,9527.0,BAO_0000019,,,,Autocuration,1,Cercopithecidae,,0,,U,,Clearance of the drug was measured in cynomolgus,A,
7374,,1399,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,A,
7375,,2661,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,
7376,1969.0,5005,9544.0,BAO_0000218,,,,Autocuration,1,Macaca mulatta,In vivo,0,,U,,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,Plasma
7377,,17267,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Plasma clearance in rhesus monkey was determined,A,
7378,,6535,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Plasma clearance in monkey after administration of 1 mg/kg iv,A,
7379,,5922,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Plasma clearance in cynomolgus monkey,A,
7380,,6221,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,A,
7381,,5668,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Plasma clearance after peroral administration at 10 mpk in Rhesus,A,
7382,,5355,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,The total clearance was determined after intravenous administration in cynomolgus monkeys,A,
7383,,5355,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,A,
7384,,5355,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,A,
7385,,4578,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Tested for Clearance upon iv administration to african green monkey,A,
7386,,17592,9527.0,BAO_0000218,,,,Autocuration,1,Cercopithecidae,In vivo,0,,U,,Clearance in monkey,A,
7387,,6641,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,
7388,,6642,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,
7389,,16367,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life was evaluated after intravenous administration to dogs,A,
7390,,5472,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half life was evaluated in dog,A,
7391,,5474,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half life was evaluated in dog,A,
7392,,5654,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,
7393,,6227,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),A,
7394,,6227,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life period after intravenous administration in dog,A,
7395,,6221,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life period after oral administration (2.5 mg/kg) in dog was determined,A,
7396,,4527,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half life period at a dose of 1 uM/kg in dog was determined,A,
7397,,5668,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life period was determine after peroral administration at 10 mpk in dog,A,
7398,,5668,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life period was determine after peroral administration at 5 mpk in dog,A,
7399,,3854,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half life period was determined,A,
7400,,5505,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half life period was determined,A,
7401,,6251,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life period by iv administration in dog at a dose of 6 mg/kg,A,
7402,,1918,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half life period was evaluated in dog,A,
7403,,5546,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,
7404,,4809,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),A,
7405,,6215,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,A,
7406,,4527,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,A,
7407,,17594,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half-life after oral dose of compound at 3 mg/kg in dogs,A,
7408,,17839,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,A,
7409,,17839,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,A,
7410,,17839,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,A,
7411,,17839,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half-life of compound in dog following p.o. administration of 1 mg/kg,A,
7412,1969.0,5210,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half-life of compound in plasma of dog was determined,A,Plasma
7413,,5210,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half-life of compound was determined in dogs,A,
7414,,2959,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half-life after administration of 4 mg/Kg oral dose in dog,A,
7415,,4137,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half-life after intravenous administration of 1 mg/kg/h in dog,A,
7416,,5064,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half-life in Dog,A,
7417,,5147,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half-life in Dog,A,
7418,,5145,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half-life in dog,A,
7419,,6123,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half-life in dog after oral administration at 1 mg/kg,A,
7420,,6123,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,A,
7421,,4333,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half-life in dogs,A,
7422,,4333,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half-life in dogs; ND indicates not determined,A,
7423,1969.0,12500,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half-life in plasma of dog,A,Plasma
7424,1969.0,12500,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half-life in plasma of dog at dose of 3-10 mgkg,A,Plasma
7425,,6005,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,A,
7426,,6062,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half-life was measured in dog after an iv dose of 1 mg/kg,A,
7427,,17650,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half-life was measured in dogs after an oral dose of 10 uM/kg,A,
7428,,5530,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,A,
7429,,5530,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,A,
7430,,5600,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half-life of the compound after 0.3 mg/kg po administration in dog,A,
7431,,6039,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,A,
7432,,6039,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,A,
7433,,6039,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,A,
7434,,6227,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,t1/2 in dog,A,
7435,,14541,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,,1,,N,,Half-life period measured in dogs,A,
7436,,4521,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,
7437,,4521,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,
7438,,6679,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,
7439,1969.0,1116,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vitro,1,,N,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",A,Plasma
7440,,5444,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,In vivo half life period was calculated at 1 mg/kg in dog,A,
7441,,5444,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,A,
7442,,17853,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Longer half-life in dog (i.v.) at 0.5 mpk,A,
7443,,4353,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Oral bioavailability in dog (dose 5 uM/kg),A,
7444,,16452,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,
7445,,16452,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,
7446,,16452,9615.0,BAO_0000218,,,,Intermediate,1,Canis lupus familiaris,In vivo,1,,N,,Bioavailability in dog (dose 1 mg/kg i.v.),A,
7447,2048.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,Lung
7448,2048.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,Lung
7449,2048.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,Lung
7450,2048.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,Lung
7451,2048.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,Lung
7452,2048.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,Lung
7453,2385.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,Muscle tissue
7454,2385.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,Muscle tissue
7455,2385.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,Muscle tissue
7456,2385.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,Muscle tissue
7457,2385.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,Muscle tissue
7458,2385.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,Muscle tissue
7459,2385.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,Muscle tissue
7460,14.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,Zone of skin
7461,14.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,Zone of skin
7462,14.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,Zone of skin
7463,14.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,Zone of skin
7464,14.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,Zone of skin
7465,14.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,Zone of skin
7466,14.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,Zone of skin
7467,2106.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,Spleen
7468,2106.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,Spleen
7469,2106.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,Spleen
7470,2106.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,Spleen
7471,2106.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,Spleen
7472,2106.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,Spleen
7473,2106.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,Spleen
7474,945.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,Stomach
7475,945.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,Stomach
7476,945.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,Stomach
7477,945.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,Stomach
7478,945.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,Stomach
7479,945.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,Stomach
7480,945.0,10107,10090.0,BAO_0000218,,,,Intermediate,1,Mus musculus,In vivo,1,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,Stomach
7481,,4689,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,In vivo,1,,N,,Oral bioavailability in rat,A,
7482,,4950,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,In vivo,1,,N,,Tested for the bioavailability in rat,A,
7483,,5328,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,In vivo,1,,N,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),A,
7484,,406,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,In vivo,1,,N,,Bioavailability in rat,A,
7485,,12500,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,In vivo,1,,N,,Bioavailability in rat,A,
7486,,12500,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,In vivo,1,,N,,Bioavailability in rat (dose 3-10 mg/kg),A,
7487,,5247,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,In vivo,1,,N,,Bioavailability in rat,A,
7488,1969.0,4186,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,In vivo,1,,N,,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,Plasma
7489,1969.0,4186,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,In vivo,1,,N,,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,A,Plasma
7490,,6647,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,In vivo,1,,N,,Half life after oral administration was determined in rats at 6 mg/kg,A,
7491,,6484,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,,1,,N,,Half life was determined,A,
7492,,3249,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,In vivo,1,,N,,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,A,
7493,1969.0,6281,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,In vivo,1,,N,,Plasma half life in rat at oral dose 2.8 mg/mk body weight,A,Plasma
7494,,3307,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,,1,,N,,Half life in rats,A,
7495,178.0,12058,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,In vivo,1,,N,,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,A,Blood
7496,,8833,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,,1,,N,,Hill coefficient of the compound,A,
7497,178.0,3193,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,,1,,N,,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,A,Blood
7498,178.0,3193,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,,1,,N,,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,A,Blood
7499,178.0,3193,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,,1,,N,,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,A,Blood
7500,178.0,3193,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,,1,,N,,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,A,Blood
7501,178.0,3193,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,,1,,N,,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,A,Blood
7502,178.0,3193,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,,1,,N,,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,A,Blood
7503,178.0,3193,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,,1,,N,,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",A,Blood
7504,,5960,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,,1,,N,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,A,
7505,955.0,13950,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,In vivo,1,,N,,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,A,Brain
7506,955.0,13950,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,In vivo,1,,N,,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,A,Brain
7507,955.0,13950,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,In vivo,1,,N,,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,A,Brain
7508,955.0,13950,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,In vivo,1,,N,,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,A,Brain
7509,955.0,13950,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,In vivo,1,,N,,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,A,Brain
7510,2046.0,13950,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,In vivo,1,,N,,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,A,Thyroid gland
7511,2046.0,13950,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,In vivo,1,,N,,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,A,Thyroid gland
7512,2046.0,13950,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,In vivo,1,,N,,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,A,Thyroid gland
7513,2046.0,13950,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,In vivo,1,,N,,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,A,Thyroid gland
7514,2046.0,13950,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,In vivo,1,,N,,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,A,Thyroid gland
7515,178.0,9866,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,In vivo,1,,N,,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,Blood
7516,178.0,9866,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,In vivo,1,,N,,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,A,Blood
7517,178.0,9866,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,In vivo,1,,N,,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,A,Blood
7518,10000001.0,9866,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,In vivo,1,,N,,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,Bone
7519,10000001.0,9866,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,In vivo,1,,N,,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,A,Bone
7520,10000001.0,9866,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,In vivo,1,,N,,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,A,Bone
7521,948.0,9866,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,In vivo,1,,N,,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,Heart
7522,948.0,9866,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,In vivo,1,,N,,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,A,Heart
7523,948.0,9866,10116.0,BAO_0000218,,,,Intermediate,1,Rattus norvegicus,In vivo,1,,N,,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,A,Heart
